<SEC-DOCUMENT>0001171843-22-002875.txt : 20220427
<SEC-HEADER>0001171843-22-002875.hdr.sgml : 20220427
<ACCEPTANCE-DATETIME>20220427170048
ACCESSION NUMBER:		0001171843-22-002875
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		22
CONFORMED PERIOD OF REPORT:	20220608
FILED AS OF DATE:		20220427
DATE AS OF CHANGE:		20220427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Anika Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000898437
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				043145961
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14027
		FILM NUMBER:		22860705

	BUSINESS ADDRESS:	
		STREET 1:		32 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730
		BUSINESS PHONE:		(781) 457-9000

	MAIL ADDRESS:	
		STREET 1:		32 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA THERAPEUTICS INC
		DATE OF NAME CHANGE:	19970114

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA RESEARCH INC
		DATE OF NAME CHANGE:	19930309
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>def14a_042722.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; ">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-top: Black 4.5pt double; text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 13pt"><B>UNITED STATES
SECURITIES AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 16pt"><B>SCHEDULE 14A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 13pt"><B>Proxy Statement
Pursuant to<BR> Section 14(a) of the Securities Exchange Act of 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">Filed by the Registrant &#9746;</TD>
    <TD STYLE="text-align: right; width: 50%">Filed by a Party other than the Registrant &#9744;</TD></TR>
  </TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: justify">Check the appropriate box:</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; width: 3%; text-align: justify">&#9744;</TD>
    <TD STYLE="width: 97%; text-align: justify">Preliminary Proxy Statement</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; text-align: justify">&#9744;</TD>
    <TD STYLE="text-align: justify">Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; text-align: justify">&#9746;</TD>
    <TD STYLE="text-align: justify">Definitive Proxy Statement</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; text-align: justify">&#9744;</TD>
    <TD STYLE="text-align: justify">Definitive Additional Materials</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; text-align: justify">&#9744;</TD>
    <TD STYLE="text-align: justify">Soliciting Material Pursuant to &sect;240.14a-12</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><IMG SRC="logo.jpg" ALT="" STYLE="height: 56px; width: 300px"></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 13pt"><B>ANIKA THERAPEUTICS,
INC.</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <TR>
    <TD STYLE="width: 100%; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 8pt"><I>(Name of Registrant as Specified in Its Charter)</I></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="text-align: justify">Payment of Filing Fee (Check the appropriate box):</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&#9746;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">No fee required.</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#9744;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and&nbsp;0-11.</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 3%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; text-align: justify">(1)</TD>
    <TD STYLE="vertical-align: top; width: 92%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of each class of securities to which transaction
        applies:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(2)</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aggregate number of securities to which transaction
        applies:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(3)</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Per unit price or other underlying value of transaction
        computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(4)</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Proposed maximum aggregate value of transaction:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(5)</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total fee paid:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#9744;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify">Fee paid previously with preliminary materials.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#9744;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify">Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2) and
        identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or
        the Form or Schedule and the date of its filing.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(1)</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amount Previously Paid:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(2)</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Form, Schedule or Registration Statement No.:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(3)</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Filing Party:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(4)</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date Filed:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: Red"><IMG SRC="logo.jpg" ALT="" STYLE="height: 56px; width: 300px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">April 27, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">Dear Fellow Stockholder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">It is my pleasure to invite you to attend the Annual Meeting
of Stockholders of Anika Therapeutics, Inc. to be held on June 8, 2022, at 9:00 a.m., Eastern time. This year&rsquo;s Annual Meeting will
be a &ldquo;virtual meeting&rdquo; conducted via live audio webcast, consistent with our recent practice. Each holder of common stock
as of 5:00 p.m., Eastern time, on the record date of April 13, 2022 will be able to participate in the Annual Meeting by accessing a live
webcast at <I>virtualshareholdermeeting.com/ANIK2022 </I>and entering the control number included on the holder&rsquo;s Notice of Internet
Availability of Proxy Materials or proxy card. Stockholders will also be able to vote their shares and submit questions via the internet
during the meeting by participating in the webcast.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">During the Annual Meeting stockholders
will be asked to elect two Class II Directors, to approve an amendment to our 2017 Omnibus Incentive Plan, and to ratify the appointment
of Deloitte &amp; Touche LLP as our independent auditor for 2022. We will also be asking stockholders to approve, by an advisory vote,
our 2021 executive compensation as disclosed in the Proxy Statement for the Annual Meeting (a &ldquo;say-on-pay&rdquo; vote). Each of
these matters is important, and we urge you to vote in favor of the election of each of the director nominees, the approval of our 2017
Omnibus Incentive Plan amendment, the ratification of the appointment of our independent auditor, and the approval, on an advisory basis,
of our 2021 executive compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We are furnishing proxy materials to our stockholders over the internet. This process expedites the
delivery of proxy materials to our stockholders, lowers our costs, and reduces the environmental impact of the Annual Meeting. Today,
we are sending to each of our stockholders of record as of April 13, 2022, a Notice of Internet Availability of Proxy Materials containing
instructions on how to access our Proxy Statement for the Annual Meeting and our 2021 Annual Report to Stockholders, as well as instructions
on how to vote via proxy either by telephone or over the internet. Some stockholders will receive copies of the Proxy Statement, a proxy
card and the 2021 Annual Report by mail or e-mail. If you received a Notice of Internet Availability of Proxy Materials by mail and would
like to receive a printed copy of our proxy materials, you may request those materials by following the instructions included in your
Notice of Internet Availability of Proxy Materials.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">It is important that you vote your shares
of common stock virtually or by proxy, regardless of the number of shares you own. You will find the instructions for voting on your Notice
of Internet Availability of Proxy Materials and proxy card. We appreciate your prompt attention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The Board of Directors invites you to
participate in the Annual Meeting where Anika will address appropriate general questions about the business as time allows. Thank you
for your support, and we look forward to joining you at the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"><IMG SRC="crb.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Cheryl R. Blanchard, Ph.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">President and Chief Executive Officer</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center; color: #355E91"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center; color: #355E91"><FONT STYLE="font-size: 13pt">NOTICE
OF ANNUAL MEETING OF STOCKHOLDERS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Board of Directors of Anika
Therapeutics, Inc., a Delaware corporation (&ldquo;Anika&quot;), is soliciting proxies for use at Anika&rsquo;s 2022 Annual Meeting of
Stockholders being held on Wednesday, June 8, 2022, at 9:00 a.m., Eastern time (the &ldquo;Annual Meeting&rdquo;). You are receiving the
enclosed Proxy Statement because you were a holder of Anika&rsquo;s common stock as of 5:00 p.m., Eastern time, on the record date of
April 13, 2022, and therefore are entitled to vote at the Annual Meeting. You may participate in the Annual Meeting, including casting
votes and asking questions, by accessing a live webcast at <I>virtualshareholdermeeting.com/ANIK2022 </I>and entering the control number
included on the Notice of Internet Availability of Proxy Materials or proxy card. Online check-in to the Annual Meeting will begin at
8:45 a.m., Eastern time, and stockholders are encouraged to allow ample time to log in to the meeting webcast and test their computer
and audio system. There will be no physical location for the Annual Meeting.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">At the Annual Meeting the following matters will be considered:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">1.</TD>
    <TD>Election of two Class II Directors;</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">2.</TD>
    <TD>Amendment of Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan;</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">3.</TD>
    <TD>Ratification of appointment of Deloitte &amp; Touche LLP as Anika&rsquo;s independent auditor for 2022;</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">4.</TD>
    <TD>Advisory &ldquo;say-on-pay&rdquo; vote on executive compensation; and</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">5.</TD>
    <TD>Any other matters that properly come before the Annual Meeting.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.05pt">Each share
of common stock is entitled to one vote for each director position and other proposal. In accordance with rules of the Securities and
Exchange Commission, or SEC, we are providing stockholders with access to proxy materials on the internet, instead of mailing printed
copies. We are mailing to stockholders of record as of April 13, 2022, commencing on or about April 27, 2022, a Notice of Internet Availability
of Proxy Materials to provide:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="padding-right: 0pt">Directions for accessing and reviewing the proxy materials on the internet and submitting a proxy over the
        internet or by telephone;</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>Instructions for requesting copies of proxy materials in printed form or by email at no charge; and</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>A control number for use in submitting proxies and accessing the Annual Meeting webcast.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Some stockholders
will receive copies of the Proxy Statement, a proxy card and the 2021 Annual Report by mail or e-mail. If you received a Notice of Internet
Availability of Proxy Materials by mail and would like to receive a printed copy of our proxy materials, you may request those materials
by following the instructions included in the Notice of Internet Availability of Proxy Materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"><B>Your vote is important. </B>Whether
or not you plan to participate in the Annual Meeting, please complete and return your proxy card or vote by telephone or via the internet
by following the instructions on the Notice of Internet Availability of Proxy Materials. Returning a proxy card or otherwise submitting
your proxy does not deprive you of your right to access the Annual Meeting and vote during the webcast at that time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">Anika will maintain a list of stockholders
of record as of the record date at Anika&rsquo;s corporate headquarters, 32 Wiggins Avenue, Bedford, Massachusetts, for a period beginning
ten days prior to the Annual Meeting and ending at the close of the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">By Order of the Board of Directors,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: Red"><IMG SRC="dbc.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">David B. Colleran</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><I>Executive Vice President, General Counsel and Secretary</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">Bedford, Massachusetts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">April 27, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; color: Red">&nbsp;</P>

<TABLE CELLPADDING="5" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif;  width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border: Black 1.5pt solid; width: 100%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.4pt; text-align: center"><B><I>Important Notice Regarding Availability
        of Proxy Materials for Annual Meeting on June 8, 2022:</I></B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.4pt; text-align: center">The Notice of Annual Meeting of Stockholders,
        Proxy Statement and 2021 Annual Report to Stockholders are available at</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.4pt; text-align: center"><I>https://ir.anika.com/annual-meeting</I>.</P>
        </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: Red"><IMG SRC="logo.jpg" ALT="" STYLE="height: 56px; width: 300px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">32 Wiggins Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">Bedford, Massachusetts 01730</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt 0pt 57.15pt; text-align: center; color: #355E91"><FONT STYLE="font-size: 15pt"><B>Proxy
Statement dated April 27, 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt 0pt 57.15pt; text-align: center; color: #355E91"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt 0pt 57.2pt; text-align: center; color: #355E91"><FONT STYLE="font-size: 13pt">2022
Annual Meeting of Stockholders</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">Anika Therapeutics, Inc., a Delaware
corporation, is furnishing this Proxy Statement and the related proxy materials in connection with the solicitation by its Board of Directors
of proxies to be voted at its 2022 Annual Meeting of Stockholders and any postponements or adjournments thereof. Anika Therapeutics, Inc.
is providing these materials to the holders of record of its common stock as of the close of business on April 13, 2022 and is first making
available or mailing the materials on or about April 27, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 109.3pt; color: #355E91"><B>The Annual Meeting is scheduled to be
held as follows:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 25%; color: #355E91; font-weight: bold; font-style: italic; padding-left: 109.3pt">Date:</TD>
    <TD STYLE="width: 5%; color: #355E91; font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="width: 70%; color: #355E91; font-weight: bold; font-style: italic">Wednesday, June 8, 2022</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="color: #355E91; font-weight: bold; font-style: italic; padding-left: 109.3pt">Time:</TD>
    <TD STYLE="color: #355E91; font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="color: #355E91; font-weight: bold; font-style: italic; text-align: left">9:00 a.m., Eastern time</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="color: #355E91; font-weight: bold; font-style: italic; padding-left: 109.3pt">&nbsp;</TD>
    <TD STYLE="color: #355E91; font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="color: #355E91; font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; color: #355E91; font-weight: bold; font-style: italic; padding-left: 109.3pt"><B><I>Meeting Webcast Address:</I></B></TD>
    <TD STYLE="color: #355E91; font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="color: #355E91; font-weight: bold; font-style: italic; text-align: left">virtualshareholdermeeting.com/ANIK2022</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 109.3pt; color: #355E91"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center"><FONT STYLE="color: #355E91"><B>Your vote
is important.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center"><FONT STYLE="color: #355E91"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center"><FONT STYLE="color: #355E91"><B></B></FONT>Please see the detailed information that follows.</P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center"></P>

<P STYLE="font: 13pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center; color: #355E91"><B><I>Table of Contents</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%;  font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left; width: 90%"><A HREF="#a_001">2022 Proxy Summary</A></TD>
    <TD STYLE="text-align: center; width: 10%"><A HREF="#a_001">1</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left"><A HREF="#a_002">Proposal 1: Election of Directors</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_002">8</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_003">Information Regarding Directors</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_003">9</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left"><A HREF="#a_004">Governance</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_004">14</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_005">Corporate Governance and Board Matters</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_005">14</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_006">The Board&rsquo;s Leadership Structure</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_006">14</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_007">The Board&rsquo;s Role in Environmental, Social and Governance (ESG) Oversight</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_007">15</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_008">The Board&rsquo;s Role in Risk Oversight</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_008">15</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_009">Board Committees</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_009">15</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_059">Board
Membership Qualifications and Procedures</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_059">18</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_010">Communications with Directors</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_010">19</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_011">Our Code of Business Conduct and Ethics</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_011">19</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_012">Our Commitment to Compliance</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_012">19</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_013">Our Commitment to Corporate Social Responsibility &ndash; Focus on Environmental, Social, and Governance
(ESG)</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_013">20</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_014">Director Overboarding Guidelines</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_014">23</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_015">Prohibition on Employee, Officer, and Director Hedging and Pledging</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_015">24</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_016">Majority Voting in Uncontested Director Elections Policy</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_016">24</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_017">Transactions with Related Persons and Conflict of Interest Policy</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_017">24</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left"><A HREF="#a_018">Beneficial Ownership of Common Stock</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_018">25</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left"><A HREF="#a_019">Executive Officers</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_019">28</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left"><A HREF="#a_020">Compensation Discussion and Analysis</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_020">29</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_021">Executive Summary</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_021">29</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_022">Compensation Philosophy</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_022">31</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_023">Key Compensation Policies and Practices</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_023">32</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_024">2021 Compensation Decisions</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_024">34</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_025">Other Compensation Matters</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_025">37</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left"><A HREF="#a_026">Compensation Committee Report</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_026">40</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left"><A HREF="#a_027">Executive and Director Compensation</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_027">41</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_028">Summary Compensation Table</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_028">41</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_029">Grants of Plan-Based Awards in 2021</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_029">42</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_030">Outstanding Equity Awards at December 31, 2021</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_030">43</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_031">2021 Option Exercises and Stock Vested</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_031">44</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_032">Potential Payments Upon Termination or Change in Control</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_032">44</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_033">CEO Pay Ratio</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_033">45</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_034">Director Compensation</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_034">46</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_035">Director and Executive Officer Stock Retention Guidelines</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_035">47</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_036">Compensation Committee Interlocks and Insider Participation</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_036">48</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_057">Equity Compensation Plan Information
</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_057">48</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left"><A HREF="#a_037">Proposal 2: Amendment of 2017 Omnibus Incentive Plan</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_037">49</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_038">Overview</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_038">49</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_039">Shares Subject to the Plan</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_039">50</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_040">Historic Equity Usage</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_040">51</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_058">Key Features of the Fourth Amended Plan</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_058">51</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_041">Summary of the Fourth Amended Plan</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_041">52</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_042">Types of Awards</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_042">55</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_043">New Plan Benefits</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_043">56</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="padding-left: 20pt; text-align: left"><A HREF="#a_044">Federal Income Tax Information</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_044">56</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left"><A HREF="#a_045">Audit Committee Report</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_045">58</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left"><A HREF="#a_046">Proposal 3: Ratification of Appointment of Independent Auditor for 2022</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_046">60</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left"><A HREF="#a_047">Proposal 4: Advisory Vote on Executive Compensation</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_047">62</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left"><A HREF="#a_048">Participation in the Virtual Annual Meeting</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_048">63</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left"><A HREF="#a_049">Questions and Answers about the Annual Meeting</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_049">64</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left"><A HREF="#a_050">Other Matters</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_050">68</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left"><A HREF="#a_051">Solicitation Expenses</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_051">68</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left"><A HREF="#a_052">Stockholder Proposals</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_052">68</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left"><A HREF="#a_053">Cautionary Note Regarding Forward Looking Statements</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_053">68</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left"><A HREF="#a_054">Householding</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_054">69</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left"><A HREF="#a_055">Appendix A</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_055">A-1</A></TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left"><A HREF="#a_056">Appendix B</A></TD>
    <TD STYLE="text-align: center"><A HREF="#a_056">B-1</A></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-size: 8pt">References in this
Proxy Statement to &ldquo;Anika,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;our company&rdquo; and similar references
refer to Anika Therapeutics, Inc. and its subsidiaries, unless the context requires otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"><FONT STYLE="font-size: 8pt">Anika,
Anika Therapeutics, Arthrosurface, Parcus Medical, WristMotion, Tactoset, and Cingal are our registered trademarks. For convenience, these
registered trademarks appear in this Proxy Statement without &reg; symbols, but that practice does not mean we will not assert, to the
fullest extent under applicable law, our rights to the registered trademarks. This Proxy Statement also contains trademarks and service
marks that are the property of other companies, including certain trademarks licensed to us.</FONT></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center; color: #355E91"><FONT STYLE="font-size: 13pt"><A NAME="a_001"></A>2022
Proxy Summary</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><I>This summary highlights information contained elsewhere
in this Proxy Statement. This summary does not contain all of the information that you should consider, and you should read the entire
Proxy Statement carefully before voting.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; color: #355E91"><FONT STYLE="font-size: 11pt">Annual
Meeting of Stockholders</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; width: 20%; text-align: left">Time and Date</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 78%; text-align: left">9:00 a.m., Eastern time, on June 8, 2022</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="vertical-align: top; text-align: left">Meeting Webcast Address</TD>
    <TD STYLE="font-style: italic">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: left">virtualshareholdermeeting.com/ANIK2022 &mdash;To join, a stockholder will need the control
        number located on the stockholder&rsquo;s Notice of Internet Availability of Proxy Materials or proxy card</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">Record Date</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">5:00 p.m., Eastern time, on April 13, 2022</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left; vertical-align: top">Voting</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Stockholders will be entitled to one vote at the Annual Meeting for each outstanding share of common stock they
        hold of record as of the record date</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">Outstanding Common Stock</TD>
    <TD>&nbsp;</TD>
    <TD>14,519,284 shares as of the record date</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; color: #355E91"><FONT STYLE="font-size: 11pt">Annual
Meeting Agenda</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="5" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <TR STYLE="background-color: #365F91">
    <TD STYLE="width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: white"><B>Proposal</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 69%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: white"><B>Board <BR> Recommendation</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 0.15pt; text-indent: -0.15pt; text-align: center"><FONT STYLE="color: black">1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="color: black">Election of
        two Class II Directors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black"><B>FOR
        each nominee</B></FONT></TD></TR>
  <TR STYLE="background-color: #C8D7EA">
    <TD STYLE="vertical-align: top; padding-left: 0.15pt; text-indent: -0.15pt; text-align: center"><FONT STYLE="color: black">2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Amendment of 2017 Omnibus Incentive Plan</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black"><B>FOR</B></FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 0.15pt; text-indent: -0.15pt; text-align: center"><FONT STYLE="color: black">3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Ratification of independent auditor for
        2022</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>FOR</B></FONT></TD></TR>
  <TR STYLE="background-color: #C8D7EA">
    <TD STYLE="vertical-align: top; padding-left: 0.15pt; text-indent: -0.15pt; text-align: center"><FONT STYLE="color: black">4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Advisory &ldquo;say-on-pay&rdquo; vote</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black"><B>FOR</B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; color: #355E91"><FONT STYLE="font-size: 11pt">How
to Vote Prior to the Annual Meeting</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; color: #355E91"><FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; ">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; width: 32%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>By mailing your proxy card</B></P> </TD>
    <TD STYLE="border-top: Black 1pt solid; width: 2%">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; width: 32%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>By telephone</B></P> </TD>
    <TD STYLE="border-top: Black 1pt solid; width: 2%">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; width: 32%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>By Internet</B></P> </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-left: Black 1pt solid"><IMG SRC="envelope.jpg" ALT=""></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><IMG SRC="phone.jpg" ALT=""></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: Black 1pt solid"><IMG SRC="laptop.jpg" ALT=""></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">Cast your ballot,
        sign your proxy card and <BR> send by free post</FONT></P></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">Dial toll-free 24/7
        <BR> 1-800-690-6903</FONT></P></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">Visit 24/7 <BR> www.proxyvote.com</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt"><I>Mark, sign and
        date your proxy card and return it in the postage-paid envelope included in your proxy materials. Your proxy card must arrive by June
        7, 2022.</I></FONT>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 8pt"><I>Use
        a touch-tone telephone to transmit your voting instructions at any time up to 11:59 p.m., ET, on June 7, 2022. Follow the instructions
        on your Notice of Internet Delivery of Proxy Materials or proxy card.</I></FONT></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 8pt"><I>Use
        the Internet to transmit your voting instructions at any time up to 11:59 p.m., ET, on June 7, 2022. Follow the instructions on your Notice
        of Internet Delivery of Proxy Materials or proxy card.</I></FONT></P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><FONT STYLE="font-size: 11pt"><B>Proposal
1: Election of Two Class II Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Cheryl R. Blanchard, Ph.D. and Glenn R. Larsen,
Ph.D. serve as Class II Directors, with terms of office expiring at this year&rsquo;s Annual Meeting. Drs. Blanchard and Larsen are the
Board&rsquo;s nominees for election to the Board at the Annual Meeting. Each Class II Director will be elected to hold office until the
2025 Annual Meeting and until their successors are duly elected and qualified. Raymond J. Land, who also is currently a Class II Director,
notified us that he has decided not to stand for re-election. Anika is very thankful to Mr. Land for his 16 years of thoughtful leadership
and service to Anika.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" STYLE="font: 8pt Times New Roman, Times, Serif; width: 100%; ">
  <TR STYLE="vertical-align: top; background-color: #355E91">
    <TD STYLE="width: 17%"><FONT STYLE="font-size: 8pt; color: White"><B>Director Nominees</B></FONT></TD>
    <TD STYLE="text-align: center; width: 6%"><FONT STYLE="font-size: 8pt; color: White"><B>Age</B></FONT></TD>
    <TD STYLE="text-align: center; width: 7%"><FONT STYLE="font-size: 8pt; color: white"><B>Director <BR> Since</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 28%"><FONT STYLE="font-size: 8pt; color: White"><B>Occupation</B></FONT></TD>
    <TD STYLE="text-align: center; width: 18%"><FONT STYLE="font-size: 8pt; color: white"><B>Experience / <BR> Qualifications</B></FONT></TD>
    <TD STYLE="text-align: center; width: 9%"><FONT STYLE="font-size: 8pt; color: White"><B>Independent</B></FONT></TD>
    <TD STYLE="text-align: center; width: 15%"><FONT STYLE="font-size: 8pt; color: White"><B>Board Roles</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 8pt"><B>Cheryl R. Blanchard, Ph.D.</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">57</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2018</FONT></TD>
    <TD><P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt">President and Chief Executive Officer of</FONT></P>
        <P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt">Anika Therapeutics, Inc.</FONT></P></TD>
    <TD>
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt; color: #355E91">&bull;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
        </FONT></FONT><FONT STYLE="font-size: 8pt">Executive Leadership</FONT></P>
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt">&bull;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
        </FONT>Industry Experience</FONT></P>
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt; color: #355E91">&bull;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
        </FONT></FONT><FONT STYLE="font-size: 8pt">Research and Development</FONT></P>
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt; color: #355E91">&bull;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
        </FONT></FONT><FONT STYLE="font-size: 8pt">Commercialization</FONT></P></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">No</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">None</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD><FONT STYLE="font-size: 8pt"><B>Glenn R. Larsen, Ph.D.</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">67</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2015</FONT></TD>
    <TD><P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt">Chairman, President, Chief Executive Officer</FONT></P>
        <P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt">and Co&#45;Founder of Aquinnah Pharmaceuticals, Inc.</FONT></P></TD>
    <TD>
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt; color: #355E91">&bull;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
        </FONT></FONT><FONT STYLE="font-size: 8pt">Board and Executive Leadership</FONT></P>
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt"><FONT STYLE="color: #355E91">&bull;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
        </FONT></FONT>Industry Experience</FONT></P>
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt"><FONT STYLE="color: #355E91">&bull;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
        </FONT></FONT>Research and Development</FONT></P>
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 8pt"><FONT STYLE="color: #355E91">&bull;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;
        </FONT></FONT>Operations</FONT></P></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">Yes</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">Member of Compensation Committee and Governance and Nominating Committee</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; width: 20%; color: #355E91; font-weight: bold; font-style: italic; text-align: left">Board Recommendation:</TD>
    <TD STYLE="width: 1%; color: #355E91; font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="width: 79%; text-align: left">The Board of Directors recommends a vote &ldquo;FOR&rdquo; the reelection of each of Drs. Blanchard
        and Larsen.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; white-space: nowrap; color: #355E91; font-weight: bold; font-style: italic; text-align: left">Vote Required
        for Approval:</TD>
    <TD STYLE="color: #355E91; font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="text-align: left">Affirmative vote of a majority of the shares of common stock that are voting in the election of directors, meaning
        that, to be elected, the shares voted &ldquo;FOR&rdquo; a nominee must exceed the number of shares voted &ldquo;AGAINST&rdquo; that nominee.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Under our Majority Voting in Uncontested Director Elections Policy, if a director receives a greater
    number of votes &ldquo;AGAINST&rdquo; than &ldquo;FOR&rdquo; election, the director must promptly offer to resign, which resignation
    will be considered by the Governance and Nominating Committee. Please see the section captioned &ldquo;Majority Voting in
    Uncontested Director Elections Policy&rdquo; for more details on this policy and its impact on the election of director
    nominees.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Abstentions and broker non-votes will have no effect on the outcome of this proposal because they are not counted
        as &ldquo;votes cast.&rdquo;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11.25pt 0pt 120pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11.25pt 0pt 120pt; text-align: justify"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91">Board Representation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 30%; color: #003D63; font-weight: bold; padding-left: 0pt">DIVERSITY</TD>
    <TD STYLE="width: 5%; color: #003D63; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 30%; color: #003D63; font-weight: bold">INDEPENDENCE</TD>
    <TD STYLE="width: 5%; color: #003D63; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 30%; color: #003D63; font-weight: bold">TENURE</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-align: left; padding-left: 0pt">4 of our 7 continuing directors and director nominees voluntarily self-identify as having
        a diverse identity (gender, race/ethnicity, or LGBTQ+).</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">6 of our 7 continuing directors and director nominees qualify as independent under NASDAQ standards and SEC regulations.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">The tenure of our continuing director nominees (average
4.1 years) reflects experience and fresh perspective.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 0pt"><IMG SRC="p3a.jpg" ALT="" STYLE="height: 206px; width: 300px"></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><IMG SRC="p3b.jpg" ALT="" STYLE="height: 206px; width: 300px">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><IMG SRC="p3c.jpg" ALT="" STYLE="height: 206px; width: 300px">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91">Director Skills and Diversity</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The Board of Directors is
committed to maintaining a diverse and inclusive membership with varying experience, characteristics, and expertise that complement
our business strategy. The matrices below provide a summary of certain key skills, experience, and diversity disclosures of our
continuing directors and director nominees. Our directors, individually and as a group, possess a wide range of skills and
experiences that are highly relevant as we transform our company, expand our business into new treatment areas and develop,
manufacture, and launch new products. Our directors are strategic thinkers with high expectations for our performance and are
attuned to the value and importance of diversity in all of its forms and the demands of proper Board oversight and good governance
practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91"><I>Board of Directors Skills Matrix</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<TABLE BORDER="0" CELLPADDING="3" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <TR STYLE="vertical-align: middle">
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0pt; color: #16365C; font-weight: bold; text-align: justify; width: 30%">Skills and Experience</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: #16365C; font-weight: bold; text-align: center; width: 10%">Blanchard</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: #16365C; font-weight: bold; text-align: center; width: 10%">Conley</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: #16365C; font-weight: bold; text-align: center; width: 10%">Henneman</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: #16365C; font-weight: bold; text-align: center; width: 10%">Larsen</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: #16365C; font-weight: bold; text-align: center; width: 10%">Richard</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: #16365C; font-weight: bold; text-align: center; width: 10%">Thompson</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: #16365C; font-weight: bold; text-align: center; width: 10%">Vogt</TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-align: left">CEO/CFO Experience</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-align: left">Medical Devices/Pharmaceutical</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-align: left">Manufacturing</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-align: left">R&amp;D/Innovation</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-align: left">Regulatory</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-align: left">Financial Oversight/Accounting</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-align: left">Human Capital Management</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-align: left">Commercialization/Marketing</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-align: left">Public Company Governance/Corporate Responsibility</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-align: left">M&amp;A/Business Development</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-align: left">International/Global Business</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-align: left">Other Public Company Experience</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91"><I>Board of Directors Diversity Matrix</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE BORDER="0" CELLPADDING="3" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <TR STYLE="vertical-align: middle">
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0pt; color: #16365C; font-weight: bold; text-align: justify; width: 30%">Demographics</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: #16365C; font-weight: bold; text-align: center; width: 10%">Blanchard</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: #16365C; font-weight: bold; text-align: center; width: 10%">Conley</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: #16365C; font-weight: bold; text-align: center; width: 10%">Henneman</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: #16365C; font-weight: bold; text-align: center; width: 10%">Larsen</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: #16365C; font-weight: bold; text-align: center; width: 10%">Richard</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: #16365C; font-weight: bold; text-align: center; width: 10%">Thompson</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: #16365C; font-weight: bold; text-align: center; width: 10%">Vogt</TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-align: left">Age</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">57</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">61</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">60</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">67</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">59</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">56</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">68</TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-align: left">Gender Identity</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">F</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">F</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">M</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">M</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">M</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">M</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">F</TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-align: left">African American or Black</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: middle">
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-align: left">White</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; background-color: #C8D7EA">&bull;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91">Additional Board Governance Practices</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 18%"><FONT STYLE="font-size: 10pt; color: #003D63"><B><I>Elections:</I></B></FONT></TD>
    <TD STYLE="width: 62%"> Voting Standard</TD>
    <TD STYLE="width: 20%"> Majority <SUP>(1)</SUP></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Resignation Policy</TD>
    <TD>Yes</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Mandatory Retirement Age or Tenure</TD>
    <TD>No</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD><FONT STYLE="font-size: 10pt; color: #003D63"><B><I>Chair:</I></B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Separate Chair of the Board and Chief Executive Officer</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Yes</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Independent Chair of the Board</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Yes</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Robust Responsibilities and Duties Assigned to Independent Chair</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Yes</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt; color: #003D63"><B><I>Meetings:</I></B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Number of Board Meetings Held in 2021</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Each of the Directors Attended all of the Board Meetings in 2021</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Yes</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Independent Directors Meet without Management Present</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Yes</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Number of Standing Committee Meetings Held in 2021</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">13</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Each of the Members Attended all of the Committee Meetings in 2021</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Yes</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD><FONT STYLE="font-size: 10pt; color: #003D63"><B><I>Director Status:</I></B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">All Directors in Compliance with our Overboarding Guidelines</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Yes</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Material Related-Party Transactions with Directors</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">None</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Standing Board Committee Membership Independence</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">100%</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Board Oversight of Company Strategy and Risk</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Yes</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">All Directors in Compliance with Hedging and Pledging Prohibitions</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Yes</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">All Directors in Compliance with Stock Ownership Guidelines</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Yes</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt; color: #003D63"><B><I>Stockholder Rights:</I></B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Dual Class Common Stock</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">No</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Poison Pill</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">No</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Cumulative Voting</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">No</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(1)</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt; color: #003D63">P</FONT><FONT STYLE="font-size: 8pt">lurality carve out for contested elections</FONT></TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><FONT STYLE="font-size: 11pt">Proposal
2: Amendment of 2017 Omnibus Incentive Plan</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Board of Directors has approved the amendment,
subject to stockholder approval, of our 2017 Omnibus Incentive Plan (as amended June 16, 2021) to increase the number of shares of common
stock reserved by 950,000, from 4,600,000 to 5,550,000. As of April 13, 2022, a total of 934,089 shares of common stock remained available
for grant under the plan. Additionally, the Board approved an amendment, subject to stockholder approval, to allow all shares authorized
under the plan to be granted as incentive stock options. Please see the complete amendment attached hereto as <I>Appendix A</I>. No other
provisions of the plan are proposed to be amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In order to capitalize on the transformation our company has undertaken over the past two years,
including transformation in such key areas as leadership, technology, product portfolio expansion, commercial infrastructure enhancements,
and the expansion of our addressable market, it is crucial that we are able to remain competitive in our compensation offerings. Our ability
to grant equity awards to key employees is a fundamental part of our compensation program and integral to the success of our transformation.
We believe the request for 950,000 additional shares will be sufficient for us to grant equity awards to attract and incent newly hired
employees and to compensate existing employees and directors for approximately one year, based on our compensation philosophy and policies.
Our actual share usage will vary depending on a number of factors, including the number of employees receiving equity awards, the prevailing
price per share of our common stock, the methodology used to value and determine the size of equity awards, and the mix of award types
provided to participants.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">Without the ability to grant equity at a competitive level, our alternatives would be limited and would
likely include the need to increase the cash compensation of our employees to attract, motivate and retain the people with the skills
and experiences that we need to execute our long-term strategy. We believe equity-based compensation is an important feature of our compensation
program because it aligns the interests of our management team with those of our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The following table recaps key provisions of the
plan, after giving effect to the proposed amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top; background-color: #336699">
    <TD STYLE="width: 20%; padding-left: 2.2pt"><FONT STYLE="font-size: 10pt; color: white"><B>Key Provision</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 79%"><FONT STYLE="font-size: 10pt; color: white"><B>Summary Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD><FONT STYLE="font-size: 10pt">New share request</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">The 950,000 shares of common stock requested represents 6.5% of the fully diluted common stock
        outstanding as of April 13, 2022 and would increase the total shares of common stock available for grant under the plan from 934,089 to
        1,884,089.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Shares reserved</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Up to 1,884,089 shares of common stock, representing 13% of the fully diluted common stock
        outstanding as of April 13, 2022, would be available for grant, subject to adjustment by the plan administrator as set forth in the plan.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD><FONT STYLE="font-size: 10pt">Multiple award types</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Various types of awards may be granted as compensation tools to attract new employees and motivate our workforce,
        including incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards,
        and other types of share and cash-based awards.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Minimum vesting requirements</FONT></TD>
    <TD>&nbsp;</TD>
    <TD> Awards must have a vesting period of at least 1 year, except that:</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 22%">&nbsp;</TD>
    <TD STYLE="width: 3%">&bull;</TD>
    <TD STYLE="width: 75%">Up to 5% of the share pool can be granted without such minimum vesting period; and</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&bull;</TD>
    <TD>Awards may be accelerated due to a participant&rsquo;s retirement, death, disability or a change in control of Anika, if such term was
        included in the award agreement.</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD STYLE="width: 20%"><FONT STYLE="font-size: 10pt">Maximum award terms</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 79%"><FONT STYLE="font-size: 10pt">Awards may have terms of up to 10 years.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Board of Director limits</FONT></TD>
    <TD>&nbsp;</TD>
    <TD> The plan specifies the following annual limits on the value of awards that may be granted to non-employee directors:</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 22%">&nbsp;</TD>
    <TD STYLE="width: 3%">&bull;</TD>
    <TD STYLE="width: 75%">$500,000 limit for the non-employee Chair or Lead Director of the Board; and</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&bull;</TD>
    <TD>$425,000 limit for each non-employee director other than the Chair or Lead Director of the Board (not including awards to non-employee
        directors upon initial election to the Board)</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD STYLE="width: 20%"><FONT STYLE="font-size: 10pt">No repricing</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 79%"><FONT STYLE="font-size: 10pt">Awards may not be repriced without stockholder approval.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">No transferability</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Awards generally may not be transferred, except by will or laws of descent and
        distribution.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 120pt; text-align: justify; text-indent: -120pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 20%; color: #355E91; font-weight: bold; font-style: italic; text-align: left">Board
        Recommendation:</TD>
    <TD STYLE="width: 1%; color: #355E91; font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="width: 79%; text-align: left"><B>The Board recommends a vote &ldquo;FOR&rdquo; the amendment of our 2017 Omnibus Incentive
    Plan.</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; white-space: nowrap; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; vertical-align: top; color: #355E91; font-weight: bold; font-style: italic; text-align: left">Vote Required
        for Approval:</TD>
    <TD STYLE="color: #355E91; font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="text-align: left">Affirmative vote of the holders of a majority of the shares of common stock that are voting on the matter. Abstentions
        and broker non-votes will not be treated as votes cast and will have no impact on the proposal.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 120pt; text-align: justify; text-indent: -120pt">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 120pt; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><FONT STYLE="font-size: 11pt">Proposal
3: Ratification of Independent Auditor for 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Audit Committee has approved the retention of
Deloitte &amp; Touche LLP as our independent auditor with respect to our consolidated financial statements as of, and for the year ending,
December 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; width: 20%; color: #355E91; font-weight: bold; font-style: italic; text-align: left; text-indent: -120pt; padding-left: 120pt">Board
        Recommendation:</TD>
    <TD STYLE="width: 1%; color: #355E91; font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="width: 79%; text-align: left"><B>The Board of Directors recommends a vote &ldquo;FOR&rdquo; the ratification of Deloitte
    &amp; Touche LLP as our independent auditor for 2022.</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; color: #355E91; font-weight: bold; font-style: italic; text-align: left; text-indent: -120pt; padding-left: 120pt">Vote
        Required for Approval:</TD>
    <TD STYLE="color: #355E91; font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="text-align: left">Affirmative vote of the holders of a majority of the shares of common stock that are voting on the matter. Abstentions
        will not count as votes cast and will have no effect on the vote. Because this proposal is considered a routine matter, discretionary
        votes by brokers will be counted.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><FONT STYLE="font-size: 11pt">Proposal
4: Advisory &ldquo;Say-on-Pay&rdquo; Vote</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The overall objective of our executive compensation
policy is to attract and retain highly qualified executive officers and to incentivize them to provide superior performance
for the benefit of our company and stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91">2021 Executive
Total Compensation Mix</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The charts below show the annual
total direct compensation (actual base salary, grant date fair value of equity incentive compensation granted in 2021, and actual cash
bonuses received for the 2021 fiscal year) for our Chief Executive Officer and our other named executive officers, or NEOs, for 2021.
Of total direct compensation, 84% of our Chief Executive Officer&rsquo;s compensation, and on average 66% of our other NEOs&rsquo; compensation,
was variable, either because it was subject to performance goals, the fluctuations of our stock price, or both.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="p9.jpg" ALT="" STYLE="height: 329px; width: 800px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <TR STYLE="vertical-align: top; background-color: #355E91">
    <TD STYLE="padding-left: 2.2pt"><FONT STYLE="font-size: 10pt; color: white"><B>Compensation Element</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; color: white"><B>Description</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; color: white"><B>Objectives</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.2pt; width: 25%"><FONT STYLE="font-size: 10pt">Base salary</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 2%; vertical-align: top">&bull;</TD>
    <TD STYLE="text-align: justify; width: 33%"><FONT STYLE="font-size: 10pt">Fixed cash compensation</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 2%; vertical-align: top">&bull;</TD>
    <TD STYLE="text-align: justify; width: 34%"><FONT STYLE="font-size: 10pt">Provide appropriate level of fixed compensation based on role, responsibility, performance
        and competitive market practices</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.2pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD STYLE="padding-left: 2.2pt"><FONT STYLE="font-size: 10pt">Cash bonuses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&bull;</TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">Annual cash award based on the performance of our company and the individual</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&bull;</TD>
    <TD rowspan="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Reward the achievement of financial results, organizational development, business and technical development,
        individual goals and contributions to building long-term stockholder value</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD STYLE="padding-left: 2.2pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&bull;</TD>
    <TD STYLE="text-align: justify">Overall cash bonus capped at 200% of the target payout</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD STYLE="padding-left: 2.2pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.2pt"><FONT STYLE="font-size: 10pt">Equity-based grants</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&bull;</TD>
    <TD STYLE="text-align: justify">Grants of equity awards, including restricted stock unit awards and stock options, under our equity plan</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&bull;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Align interests of our executive officers with those of our stockholders in terms of long-term value generation</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&bull;</TD>
    <TD STYLE="text-align: justify">Includes performance-based and time-vesting equity awards</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&bull;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Provide executive officers with opportunity to be compensated based on meaningful and continued stock price
        appreciation over time</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&bull;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Encourage employee retention through long-term value creation</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additional detailed information regarding our compensation philosophy
and process and the compensation awarded to our named executive officers in 2021 is included in the Compensation Discussion and Analysis
beginning on page 29, the Executive and Director Compensation Tables beginning on page 41, and other related disclosures throughout this
Proxy Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; width: 20%; color: #355E91; font-weight: bold; font-style: italic; text-align: left; text-indent: -120pt; padding-left: 120pt">Board
        Recommendation:</TD>
    <TD STYLE="width: 1%; color: #355E91; font-weight: bold; font-style: italic">&nbsp;</TD>
    <TD STYLE="width: 79%; text-align: left"><B>The Board of Directors recommends a vote &ldquo;FOR&rdquo; the approval of NEO compensation
    for the 2021 fiscal year as set forth in this Proxy Statement.</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; color: #355E91; font-weight: bold; font-style: italic; text-align: left; text-indent: -120pt; padding-left: 120pt">Vote
        Required for Approval:</TD>
    <TD STYLE="color: #355E91">&nbsp;</TD>
    <TD STYLE="text-align: left">Affirmative vote of the holders of a majority of the shares of common stock that are voting on the matter. Abstentions
        and broker non-votes will not be treated as votes cast and will have no impact on the proposal. This vote is not binding on us, but will
        be given due consideration by the Compensation Committee and the Board.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.5pt 0pt 120pt; text-align: justify; text-indent: -120pt; color: #355E91"><B><I>&nbsp;</I></B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center; color: #355E91"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center; color: #355E91"><A NAME="a_002"></A><FONT STYLE="font-size: 13pt">Proposal
1: Election of Directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our company is managed under the oversight of the Board of Directors, which is led by an independent
chair. The directors utilize their deep experience in business and science, including biotech, pharmaceuticals, and medical devices, as
well as their diverse backgrounds to provide management with guidance and oversight in delivering innovative products to meet the needs
of clinicians and the patients that they treat, and in executing on our strategy for long-term value creation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Board sets high standards
for management and employees tied to our core values of principled and ethical behavior, and the Board applies those same standards to
itself, undertaking regular and rigorous reviews of each committee&rsquo;s and each director&rsquo;s performance, both collectively and
individually. This is evidenced in our ongoing approach to Board refreshment, having added three of our current eight directors in the
past three years. The current mix of longer-serving and recently added directors provides an appropriate balance of perspectives as the
Board holds management accountable for delivering long-term value and keeping the interests of our stockholders and stakeholders, including
clinicians and their patients, employees and business partners, at the center of our priorities.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The Board is currently comprised of
eight directors and is divided into three classes: Class I, Class II and Class III. Each class of directors serves for a three-year term,
with one class of directors being elected by our stockholders at each annual meeting. Cheryl R. Blanchard, Ph.D. and Glenn R. Larsen,
Ph.D. serve as Class II Directors, with terms of office expiring at the Annual Meeting. Raymond J. Land, who currently serves as a Class
II Director, will not stand for re-election at the Annual Meeting. John B. Henneman, III and Susan L. N. Vogt serve as Class III Directors,
with terms of office expiring at the 2023 Annual Meeting. Sheryl L. Conley, Stephen O. Richard and Jeffery S. Thompson serve as Class
I Directors, with terms of office expiring at the 2024 Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">Drs. Blanchard and Larsen are the Board&rsquo;s
nominees for election as Class II Directors at the Annual Meeting. Each Class II Director will be elected to hold office until the 2025
Annual Meeting and until a successor is duly elected and qualified. Unless otherwise instructed, the persons named in the accompanying
proxy will vote, as permitted by our bylaws, to elect Drs.&nbsp;Blanchard and Larsen as Class II Directors. The Board has no reason to
believe that either Dr. Blanchard or Dr. Larsen will be unable or unwilling to serve if elected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">There are no arrangements or understandings
between any nominee and any other person pursuant to which the nominee was selected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><FONT STYLE="font-size: 11pt">Vote
Required</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">At the Annual Meeting, the election of a director
requires the affirmative vote of a majority of the shares of common stock that are voting in the election of directors, meaning that,
to be elected, the shares voted &ldquo;FOR&rdquo; a nominee must exceed the number of shares voted &ldquo;AGAINST&rdquo; that nominee.
Abstentions and broker non-votes will not be treated as votes cast and will have no impact on the proposal. Under our Majority Voting
in Uncontested Director Elections Policy, if a director receives a greater number of votes &ldquo;AGAINST&rdquo; than &ldquo;FOR&rdquo;
election, the director must promptly offer the director&rsquo;s resignation for consideration by the Governance and Nominating Committee.
Please see the section captioned &ldquo;Majority Voting in Uncontested Director Elections Policy&rdquo; for more details on this policy
and its impact on the election of director nominees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><FONT STYLE="font-size: 11pt">Board
Recommendation</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS
A VOTE &ldquo;FOR&rdquo; THE ELECTION OF EACH OF CHERYL R. BLANCHARD, PH.D. AND GLENN R. LARSEN, PH.D., THE DIRECTOR NOMINEES.</P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><A NAME="a_003"></A><FONT STYLE="font-size: 11pt"><B>Information
Regarding Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The following table sets forth the name of our current
directors and includes the nominees for re-election as directors at the Annual Meeting, together with their ages (as of the record date)
and the years in which they became a director. As noted elsewhere, Raymond J. Land, who currently is a Class II Director, is not standing
for re-election at the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <TR STYLE="vertical-align: top; background-color: #355E91">
    <TD STYLE="width: 40%; border-bottom: black 1pt solid; padding-left: 2.2pt"><FONT STYLE="font-size: 10pt; color: white"><B>Director Name</B></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 20%; text-align: center"><FONT STYLE="font-size: 10pt; color: white"><B>Age</B></FONT></TD>
    <TD STYLE="width: 20%; border-bottom: black 1pt solid; padding-left: 30.55pt; text-align: center"><FONT STYLE="font-size: 10pt; color: white"><B>Director
        Since</B></FONT></TD>
    <TD STYLE="width: 20%; border-bottom: black 1pt solid; padding-left: 19.95pt; text-align: center"><FONT STYLE="font-size: 10pt; color: white"><B>Term
        Expires</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.2pt"><FONT STYLE="font-size: 10pt"><B><I>Class I Directors</I></B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD STYLE="padding-left: 0.15in"><FONT STYLE="font-size: 10pt">Sheryl L. Conley</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">61</FONT></TD>
    <TD STYLE="padding-left: 30.5pt; text-align: center"><FONT STYLE="font-size: 10pt">2021</FONT></TD>
    <TD STYLE="padding-left: 19.95pt; text-align: center"><FONT STYLE="font-size: 10pt">2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in"><FONT STYLE="font-size: 10pt">Stephen O. Richard</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">59</FONT></TD>
    <TD STYLE="padding-left: 30.5pt; text-align: center"><FONT STYLE="font-size: 10pt">2020</FONT></TD>
    <TD STYLE="padding-left: 19.95pt; text-align: center"><FONT STYLE="font-size: 10pt">2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD STYLE="padding-left: 0.15in"><FONT STYLE="font-size: 10pt">Jeffery S. Thompson</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">56</FONT></TD>
    <TD STYLE="padding-left: 30.5pt; text-align: center"><FONT STYLE="font-size: 10pt">2011</FONT></TD>
    <TD STYLE="padding-left: 19.95pt; text-align: center"><FONT STYLE="font-size: 10pt">2024</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.2pt"><FONT STYLE="font-size: 10pt"><B><I>Class II Directors</I></B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD STYLE="padding-left: 0.15in"><FONT STYLE="font-size: 10pt">Cheryl R. Blanchard Ph.D.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">57</FONT></TD>
    <TD STYLE="padding-left: 30.5pt; text-align: center"><FONT STYLE="font-size: 10pt">2018</FONT></TD>
    <TD STYLE="padding-left: 19.95pt; text-align: center"><FONT STYLE="font-size: 10pt">2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in"><FONT STYLE="font-size: 10pt">Glenn R. Larsen, Ph.D.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">67</FONT></TD>
    <TD STYLE="padding-left: 30.5pt; text-align: center"><FONT STYLE="font-size: 10pt">2015</FONT></TD>
    <TD STYLE="padding-left: 19.95pt; text-align: center"><FONT STYLE="font-size: 10pt">2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.2pt"><FONT STYLE="font-size: 10pt"><B><I>Class III Directors</I></B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD STYLE="padding-left: 0.15in"><FONT STYLE="font-size: 10pt">John B. Henneman, III</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">60</FONT></TD>
    <TD STYLE="padding-left: 30.5pt; text-align: center"><FONT STYLE="font-size: 10pt">2020</FONT></TD>
    <TD STYLE="padding-left: 19.95pt; text-align: center"><FONT STYLE="font-size: 10pt">2023</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in"><FONT STYLE="font-size: 10pt">Susan L. N. Vogt</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">68</FONT></TD>
    <TD STYLE="padding-left: 30.5pt; text-align: center"><FONT STYLE="font-size: 10pt">2018</FONT></TD>
    <TD STYLE="padding-left: 19.95pt; text-align: center"><FONT STYLE="font-size: 10pt">2023</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&nbsp;</P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<DIV><!-- Photos -->

<DIV STYLE="float: left; width: 49%"><!-- Photos_CB -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <TR>
    <TD STYLE="width: 100%; background-color: #4372B9; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt; color: white"><B>
        Cheryl R. Blanchard, Ph.D.</B></FONT></TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="background-color: White; vertical-align: top; text-align: left">
    <TD STYLE="width: 5%"><IMG SRC="blanchard.jpg" ALT=""></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 90%">
        <P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">Anika Board Service:</P>
        <P STYLE="text-align: left; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenure:
        3.5 years</P></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap; background-color: #C8D7EA; width: 5%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><FONT STYLE="font-size: 9pt"><B>PRESIDENT
        and CHIEF EXECUTIVE OFFICER</B></FONT></P></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 90%">Age: 57</TD></TR>
  </TABLE> </DIV>

<DIV STYLE="float: right; width: 49%"><!-- Photos_SC -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <TR>
    <TD STYLE="width: 100%; background-color: #4372B9; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt; color: white"><B>
        Sheryl L. Conley</B></FONT></TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="background-color: White; vertical-align: top; text-align: left">
    <TD STYLE="width: 5%"><IMG SRC="conley.jpg" ALT=""></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 90%">
        <P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">Anika Board Service:</P>
        <P STYLE="text-align: left; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenure:
        0.5 years</P>
        <P STYLE="text-align: left; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Symbol; color: #4372B9">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Committees:</P>
        <P STYLE="margin-left: 20pt; text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="color: #355E91">&#9675;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Audit</P></TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap; background-color: #C8D7EA; width: 5%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><FONT STYLE="font-size: 9pt"><B>INDEPENDENT</B></FONT></P></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 90%">Age: 61</TD></TR>
  </TABLE> </DIV> </DIV>

<div style='clear:both;'>&nbsp;</div>

<DIV><!-- Professional Experience -->

<DIV STYLE="float: left; width: 49%"><!-- Professional Experience_CB -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0pt; color: #355E91"><B>Professional Experience</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Director since August 2018</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">President and Chief Executive Officer of Anika since April 2020, and Interim Chief Executive Officer of Anika
        from February 2020 through April 2020</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Principal at Blanchard Consulting, LLC, a provider of scientific, regulatory, and business strategy consulting
        services to medical device companies and private equity clients, from 2012 to 2020</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">President and Chief Executive Officer of Microchips Biotech, Inc., a venture-backed biotechnology company
        developing regenerative medicine and drug delivery products, from 2014 until its sale to Dar&eacute; Bioscience, Inc. in November 2019</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Various offices, including Senior Vice President, Chief Scientific Officer, and general manager of Zimmer
        Biologics, of Zimmer, Inc., a medical device company focused on musculoskeletal products, from 2000 to 2012</TD></TR>
  </TABLE></DIV>

<DIV STYLE="float: right; width: 49%"><!-- Professional Experience_SC -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0pt; color: #355E91"><B>Professional Experience</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in">Director since October 2021</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in">President and Board Member of AcceLINX, Inc., a musculoskeletal health business accelerator,
        from March 2017 - present</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in">President and Chief Executive Officer of OrthoWorx, Inc., a community-based initiative
        that works strategically and collaboratively with the orthopedic industry, from September 2012 to May 2017</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in">Various management roles at Zimmer, Inc., a medical device company focused on musculoskeletal
        products, including Group President, Americas and Global Brand Management, and Chief Marketing Officer from December 2005 to May 2008</TD></TR>
  </TABLE> </DIV> </DIV>

<div style='clear:both;'>&nbsp;</div>

<DIV> <!-- Other Board Service -->

<DIV STYLE="float: left; width: 49%"> <!-- Other Board Service_CB -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><B>Other Current Public
Company Board Service</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Dar&eacute; Bioscience, Inc. (NASDAQ: DARE), a clinical-stage biopharmaceutical company committed to the
        advancement of innovative products for women's health, from November 2019 &ndash; present</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Vigil Neuroscience, Inc. (NASDAQ: VIGL), a clinical-stage biotechnology company that went public in January
        2022, committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, from November 2020 &ndash; present</TD></TR>
  </TABLE> </DIV>

<DIV STYLE="float: right; width: 49%"> <!-- Other Board Service_SC -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0pt; text-align: justify; color: #355E91"><B>Other Public Company
Board Service</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in">Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on developing
        products that improve the quality of life for patients suffering from psychiatric disorders, from October 2019 - present</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in">Surgalign Holdings, Inc. (NASDAQ: SRGA), a global medical technology company focused
        on elevating the standard of care by driving the evolution of digital surgery, from May 2021 - present</TD></TR>
  </TABLE> </DIV> </DIV>

<div style='clear:both;'>&nbsp;</div>

<DIV><!-- Former Board Service -->

<DIV STYLE="float: left; width: 49%"> <!-- Former Board Service_CB -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><B>Former Recent Public
Company Board Service</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on products for psychiatric
        disorders, from February 2019 to June 2020</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions
        for the treatment of spinal disorders, from June 2015 &ndash; May 2019</TD></TR>
  </TABLE> </DIV> </DIV>

<div style='clear:both;'>&nbsp;</div>

<div><!-- Education -->

<DIV STYLE="float: left; width: 49%"> <!-- Education_CB -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><B>Education</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Ph.D. and M.S. in Materials Science and Engineering from the University of Texas-Austin</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">B.S. in Ceramic Engineering from Alfred University</TD> </TR>
  </TABLE></DIV>

<DIV STYLE="float: right; width: 49%"><!-- Education_SC -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0pt; text-align: justify; color: #355E91"><B>Education</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in">M.B.A. from Ball State University</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in">B.S. in Biology and Chemistry from Ball State University</TD></TR>
  </TABLE> </DIV> </div>

<div style='clear:both;'>&nbsp;</div>

<div><!-- Relevant Skills -->

<DIV STYLE="float: left; width: 49%"><!-- Relevant Skills_CB -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><B>Relevant Skills</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Strong scientific and business background in biologics and regenerative medicine industry</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Extensive experience in management, including as a Chief Executive Officer, business development and developing
        and commercializing medical device and regenerative medicine and drug delivery products at multiple companies in the life science industry</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Significant experience in innovative research and product development and commercial development</TD></TR>
  </TABLE> </DIV>

<DIV STYLE="float: right; width: 49%"><!-- Relevant Skills_SC -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0pt; text-align: justify; color: #355E91"><B>Relevant Skills</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in">More than 35 years in the orthopedic medical device and healthcare industries</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in">Significant executive leadership experience running full profit-and-loss
    business segments, global brand management, marketing, sales, product development, and operations</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in">Extensive experience in global medical device development and commercialization</TD></TR>
  </TABLE> </DIV></DIV>

<div style='clear:both;'>&nbsp;</div>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV><!-- Photos -->

<DIV STYLE="float: left; width: 49%"><!-- Photos_JH -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <TR>
    <TD STYLE="width: 100%; background-color: #4372B9; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt; color: white"><B>
        John B. Henneman, III</B></FONT></TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="background-color: White; vertical-align: top; text-align: left">
    <TD STYLE="width: 5%"><IMG SRC="henneman.jpg" ALT=""></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 90%">
        <P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">Anika Board Service:</P>
        <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenure:
        1.5 years</P>
        <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Committees:</P>
        <P STYLE="margin-left: 20pt; text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="color: #355E91">&#9675;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compensation (Chair)</P>
        <P STYLE="margin-left: 20pt; text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="color: #355E91">&#9675;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Governance
        and Nominating</P></TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap; background-color: #C8D7EA; width: 5%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><FONT STYLE="font-size: 9pt"><B>INDEPENDENT</B></FONT></P></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 90%">Age: 60</TD></TR>
  </TABLE> </DIV>

<DIV STYLE="float: right; width: 49%"><!-- Photos_GL -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <TR>
    <TD STYLE="width: 100%; background-color: #4372B9; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt; color: white"><B>
        Glenn R. Larsen, Ph.D.</B></FONT></TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="background-color: White; vertical-align: top; text-align: left">
    <TD STYLE="width: 5%"><IMG SRC="larsen.jpg" ALT=""></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 90%">
        <P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">Anika Board Service:</P>
        <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenure:
        7 years</P>
        <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Committees:</P>
        <P STYLE="margin-left: 20pt; text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="color: #355E91">&#9675;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compensation</P>
        <P STYLE="margin-left: 20pt; text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="color: #355E91">&#9675;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Governance
        and Nominating</P></TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap; background-color: #C8D7EA; width: 5%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><FONT STYLE="font-size: 9pt"><B>INDEPENDENT</B></FONT></P></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 90%">Age: 67</TD></TR>
  </TABLE> </DIV> </DIV>

<div style='clear:both;'>&nbsp;</div>

<DIV><!-- Professional Experience -->

<DIV STYLE="float: left; width: 49%"><!-- Professional Experience_JH -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><B>Professional Experience</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Director since September 2020</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Senior Advisor to Prettybrook Partners, a private equity firm investing in medical technology and healthcare
        services companies, from May 2018 - present</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Consultant to SparkMed Advisors LLC, a provider of consulting and other services to start-up medical device
        and biotechnology companies, from January 2019 - present</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Executive Vice President and Chief Financial Officer of NewLink Genetics Corporation, a public biotechnology
        company, from October 2014 to July 2018 and Chief Administrative Officer of NewLink from July 2018 through his retirement in November
        2018</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Various offices of Integra LifeSciences Holdings Corp., a medical devices company, from 1998 to 2014, including
        Chief Financial Officer from 2007 to 2014 and earlier as General Counsel and Chief Administrative Officer</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><B>Other Public Company
Board Service</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Aprea Therapeutics Inc. (NASDAQ: APRE), a biotechnology company focused on novel cancer therapeutics, from
        August 2019 &ndash; present (lead independent director from September 2020 - present)</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">R1 RCM, Inc. (NASDAQ: RCM), a provider of revenue cycle management services to healthcare providers, from
        February 2016 &ndash; present (lead independent director from February 2022 &ndash; present)</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">SeaSpine Holdings Corporation (NASDAQ: SPNE), a spinal implant and orthobiologics company, from July 2015
        - present</TD></TR>
  </TABLE> </div>

<DIV STYLE="float: right; width: 49%"><!-- Professional Experience_GL -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91"><B>Professional Experience</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Director since February 2015</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Chairman, President, Chief Executive Officer and cofounder of Aquinnah Pharmaceuticals,
        Inc., a pharmaceutical company focused on the development of treatments for ALS, Alzheimer&rsquo;s and other neurodegenerative diseases,
        from February 2014 - present</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Chairman, President, and Chief Executive Officer of 180 Therapeutics L.P., a clinical
        stage musculoskeletal drug development company, from 2013 until its merger with NASDAQ-listed 180 LifeSciences in 2020</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Chief Scientific Officer and Executive Vice President of Research and Development of SpringLeaf
        Therapeutics, Inc., a producer of combination drug delivery devices, from 2010 to 2013</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Chief Operating Officer, Executive Vice President of Research and Development and director
        of Hydra Biosciences, Inc., a biopharmaceutical company focused on developing pain therapeutic drugs, from 2003 to 2010</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Series of drug discovery and development leadership positions, including Vice President
        Musculoskeletal Sciences, at Wyeth (now Pfizer)/Genetics Institute, where he directed Wyeth&rsquo;s second-largest therapeutic area with
        responsibility for Enbrel, an anti-TNF therapeutic for arthritic pain with multi-billion dollar annual sales, and the development of Infuse
        Bone Graft, the 1st regenerative biologic medicine approved for numerous orthopedic bone regeneration indications</TD></TR>
  </TABLE> </div> </div>

<div style='clear:both;'>&nbsp;</div>

<div><!-- Education -->

<DIV STYLE="float: left; width: 49%"> <!-- Education_JH -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><B>Education</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">J.D. from University of Michigan Law School</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">A.B. in Politics from Princeton University</TD></TR>
  </TABLE> </div>

<DIV STYLE="float: right; width: 49%"> <!-- Education_GL -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.0pt 0pt 0pt; text-align: justify; color: #355E91"><B>Education</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Ph.D. in Biochemistry from Stony Brook University</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">P.M.D. from Harvard University</TD></TR>
  </TABLE> </div> </div>

<div style='clear:both;'>&nbsp;</div>

<div><!-- Relevant Skills -->

<DIV STYLE="float: left; width: 49%"><!-- Relevant Skills_JH -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><B>Relevant Skills</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">More than 25 years of senior management experience in the medical technology and biotechnology industries</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Significant experience in serving on boards of directors, including boards of publicly held life science companies</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Extensive experience in the areas of finance, financial accounting, business transactions, law, and mergers
        and acquisitions</TD></TR>
  </TABLE> </div>

<DIV STYLE="float: right; width: 49%"><!-- Relevant Skills_GL -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.0pt 0pt 0pt; text-align: justify; color: #355E91"><B>Relevant Skills</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Strong scientific background in pharmaceuticals, biotech, orthopedics, pain management
        and regenerative medicine</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Extensive experience in management, product development and business development at multiple
        companies in the life science industry</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Significant experience in innovative research and product development and commercial development</TD></TR>
  </TABLE> </div> </div>

<div style='clear:both;'>&nbsp;</div>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV><!-- Photos -->

<DIV STYLE="float: left; width: 49%"><!-- Photos_JH -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <TR>
    <TD STYLE="width: 100%; background-color: #4372B9; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt; color: white"><B>
        Stephen O. Richard</B></FONT></TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="background-color: White; vertical-align: top; text-align: left">
    <TD STYLE="width: 5%"><IMG SRC="richard.jpg" ALT=""></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 90%">
        <P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">Anika Board Service:</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenure: 1.5 years</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Committees:</P>

<P STYLE="margin-left: 20pt; text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="color: #355E91">&#9675;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Audit (Financial Expert)</P>
	</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap; background-color: #C8D7EA; width: 5%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><FONT STYLE="font-size: 9pt"><B>INDEPENDENT</B></FONT></P></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 90%">Age: 59</TD></TR>
  </TABLE> </DIV>

<DIV STYLE="float: right; width: 49%"><!-- Photos_GL -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <TR>
    <TD STYLE="width: 100%; background-color: #4372B9; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt; color: white"><B>
        Jeffery
S. Thompson</B></FONT></TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="background-color: White; vertical-align: top; text-align: left">
    <TD STYLE="width: 5%"><IMG SRC="thompson.jpg" ALT=""></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 90%">
        <P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">Anika Board Service:</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenure: 11 years</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chair of the Board</P>
	</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap; background-color: #C8D7EA; width: 5%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><FONT STYLE="font-size: 9pt"><B>INDEPENDENT</B></FONT></P></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 90%">Age:
56</TD></TR>
  </TABLE> </DIV> </DIV>

<div style='clear:both;'>&nbsp;</div>


<DIV><!-- Professional Experience -->

<DIV STYLE="float: left; width: 49%"><!-- Professional Experience_SR -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91"><B>Professional Experience</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Director since September 2020</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Senior Vice President, Chief Risk Officer from May 2019 - present and Chief Audit Executive from 2016 to present
        of Becton, Dickinson and Company, a medical technology company</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Various offices in the areas of finance, operations and business development of the National Basketball Association
        organization from 1998 to 2016, including Senior Vice President, Business Development and Global Operations of NBA Properties, Inc. from
        2013 to 2016, Chief Financial Officer of NBA China from 2010 to 2013 and Interim Chief Executive Officer of NBA China from 2010 to 2011</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Earlier in his career, Mr. Richard served as, among other positions, Regional Audit Director, U.S. Consumer
        Businesses at Citigroup Inc., District Manager, Financial Planning and Analysis at AT&amp;T Corporation, and Senior Manager at Deloitte
        &amp; Touche LLP</TD></TR>
  </TABLE>
  </div>
<DIV STYLE="float: right; width: 49%"><!-- Professional Experience_GL -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91"><B>Professional Experience</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Director since January 2011</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Partner with HealthEdge Investment Partners, LLC, or HealthEdge, a private equity firm
        providing strategic capital exclusively to the healthcare industry, where he sits on the investment team and serves as a director for
        numerous HealthEdge affiliated companies, including ITRACs, Legacy Xspire Holdings, LifeSync and Westone, from 2008 - present</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Previously, Chairman, Chief Executive Officer and President of Advanced Bio-Technologies,
        Inc. and Enaltus LLC, both HealthEdge portfolio company specializing in skincare solutions sold to consumers and direct to physicians
        from 2008 to 2017</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Non-executive director of Sinclair Pharma, plc, a publicly traded international aesthetic
        dermatology company from September 2014 until its acquisition by China Grand in November 2018</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Director of Stiefel Laboratories, Inc., an independent pharmaceutical company specializing
        in dermatology, and President of Glades Pharmaceuticals, both of which were sold to GlaxoSmithKline in 2008</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Earlier in his career, Mr. Thompson held sales and business management positions at
        Bausch &amp; Lomb Pharmaceuticals and SmithKline Beecham</TD></TR>
  </TABLE>
</div>
</div>
<div style='clear:both;'>&nbsp;</div>

<div><!-- Education -->

<DIV STYLE="float: left; width: 49%"> <!-- Education_SR -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><B>Education</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">M.B.A. in Finance from Columbia Business School.</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">B.S. in Accounting from Northeastern University</TD></TR>
  </TABLE>
</div>
<DIV STYLE="float: right; width: 49%"> <!-- Education_JT -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.0pt 0pt 0pt; text-align: justify; color: #355E91"><B>Education</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">B.S. in General Science from University of Pittsburgh</TD></TR>
  </TABLE>
</div>
</div>
<div style='clear:both;'>&nbsp;</div>
<div><!-- Relevant Skills -->

<DIV STYLE="float: left; width: 49%"><!-- Relevant Skills_SR -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><B>Relevant Skills</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Education, training and experience in accounting and finance, reflected in status as a Certified Public Accountant,
        multiple senior accounting roles and the Chairman of the Committee on Governance, Risk and Compliance of Financial Executives International,
        an association of financial executives serving public and private companies</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Significant senior management experience, including in the medical technology industry</TD></TR>
  </TABLE></div>
<DIV STYLE="float: right; width: 49%"><!-- Relevant Skills_JT -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.0pt 0pt 0pt; text-align: justify; color: #355E91"><B>Relevant Skills</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Extensive experience serving on boards of directors of numerous life sciences, biotechnology,
        and healthcare services companies</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Significant experience as chief executive officer of life sciences and healthcare services
        companies</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">More than a decade of experience advising HealthEdge portfolio and other life science
        companies on business development strategies and transactions</TD></TR>
  </TABLE>
</div>
</div>
<div style='clear:both;'>&nbsp;</div>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<DIV><!-- Photos -->

<DIV STYLE="float: left; width: 49%"><!-- Photos_JH -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <TR>
    <TD STYLE="width: 100%; background-color: #4372B9; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt; color: white"><B>
        Susan L. N. Vogt</B></FONT></TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="background-color: White; vertical-align: top; text-align: left">
    <TD STYLE="width: 5%"><IMG SRC="vogt.jpg" ALT=""></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 90%">
        <P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">Anika Board Service:</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenure: 3.5 years</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Committees:</P>

<P STYLE="margin-left: 20pt; text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="color: #355E91">&#9675;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Audit (Financial Expert)</P>

<P STYLE="margin-left: 20pt; text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="color: #355E91">&#9675;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Governance and Nominating (Chair)</P>
	</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap; background-color: #C8D7EA; width: 5%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #365F91"><FONT STYLE="font-size: 9pt"><B>INDEPENDENT</B></FONT></P></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 90%">Age: 68</TD></TR>
  </TABLE>
  </DIV>
  </div>
  <div style='clear:both;'>&nbsp;</div>

<DIV><!-- Professional Experience -->

<DIV STYLE="float: left; width: 49%"><!-- Professional Experience_SV -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91"><B>Professional Experience</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Director since October 2018</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Chief Executive Officer and President of Aushon Biosystems, Inc., a developer of a
        multiplex immunoassay platform, from 2013 until its acquisition in January 2018</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Chief Executive Officer, President, and a director of SeraCare Life Sciences, Inc.,
        a NASDAQ-listed life sciences developer of products facilitating human diagnostics and therapeutics, from 2006 to 2011</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Former director of Andor Technology (LSE:AND) from 2010 to 2013</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">From 1981 to 2005, various management and officer positions at Millipore Corporation
        (now part of MilliporeSigma, the life science business of Merck KGaA), an NYSE-listed developer of technologies for life science research,
        drug development and manufacturing for the biotechnology and pharmaceutical industries, including, among other leadership roles, President
        of the Biopharmaceutical Division, Vice President and General Manager of the Laboratory Water Division, Vice President and General Manager
        of the Analytical Products Division.</TD></TR>
  </TABLE>
  </div>
  </div>
  <div style='clear:both;'>&nbsp;</div>

<DIV> <!-- Other Board Service -->

<DIV STYLE="float: left; width: 49%"> <!-- Other Board Service_SV -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91"><B>Other Public
Company Board Service</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Sharps Compliance, Inc. (NASDAQ: SMED) a leading full-service national provider of
        comprehensive waste management services, including medical, pharmaceutical, and hazardous, from October 2019 - present</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Charlotte&rsquo;s Web Holdings, Inc. (TSX: CWEB) a leading provider of CBD wellness
        products, from September 2020 - present</TD></TR>
  </TABLE>
  </div>
  </div>
  <div style='clear:both;'>&nbsp;</div>

<div><!-- Education -->

<DIV STYLE="float: left; width: 49%"> <!-- Education_SV -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91"><B>Education</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">M.B.A. from Boston University, concentration in Finance</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">A.B. in Art History from Brown University</TD></TR>
  </TABLE>
  </div>
  </div>
  <div style='clear:both;'>&nbsp;</div>
<div><!-- Relevant Skills -->

<DIV STYLE="float: left; width: 49%"><!-- Relevant Skills_SV -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91"><B>Relevant Skills</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">More than thirty-five years of experience in the global life science research, pharmaceutical,
        biotech and clinical diagnostics industries</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Proven record of driving operational efficiency and productivity, successfully scaling
        commercial operations, enhancing profitability by streamlining, restructuring and consolidating operations, and delivering sustained revenue
        and cash flow growth at multiple companies</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 10pt"><FONT STYLE="font-family: Symbol; color: #4271B9">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 7pt">Deep understanding of finance and accounting as a result of her education, financial-based
        roles during her career and serving on audit committees of several companies</TD></TR>
  </TABLE>
  </div>
  </div>
  <div style='clear:both;'>&nbsp;</div>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #355E91"><FONT STYLE="font-size: 13pt"><B><A NAME="a_004"></A><I>Governance</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><A NAME="a_005"></A><FONT STYLE="font-size: 11pt">Corporate
Governance and Board Matters</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The Board of Directors annually reviews
the independence of all non-employee directors. In April 2020, the Board established categorical standards consistent with the corporate
governance standards of NASDAQ to assist the Board in making determinations of the independence of Board members. A copy of our Standards
for Director Independence, which was adopted by the Board in April 2020, is available on the investor relations portion of our website
at <I>https://ir.anika.com/governance-documents</I>. These categorical standards require that, to be independent, a director may not have
a material relationship with our company. Even if a director meets all categorical standards for independence, the Board reviews other
relationships with Anika in order to conclude that each independent director has no material relationship with Anika either directly or
indirectly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The Board has determined that each of
the continuing directors and director nominees, other than our President and Chief Executive Officer, Cheryl R. Blanchard, Ph.D., is &ldquo;independent&rdquo;
within the meaning of the director independence standards of NASDAQ and the SEC. The Board based these determinations primarily on a review
of the responses of each director and director nominee to questions regarding employment and compensation history, affiliations, and family
and other relationships, and on other relevant discussions with the directors and director nominees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">Independent directors meet regularly
in executive sessions without management participation. The executive sessions generally occur in connection with regularly scheduled
meetings of the Board and committees of the Board, and at other times the independent directors deem appropriate. The executive sessions
are chaired either by the Chair of the Board or by the chair of the Board committee, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The Board and its committees review
matters related to our corporate governance annually at regularly scheduled meetings. The Board&rsquo;s review process includes an evaluation
of our bylaws, committee charters, diversity programs, corporate social and environmental responsibility initiatives, and other matters
related to our governance. During this review, the Board assesses input from management and outside consultants to discern whether any
actions should be taken on any of these topics. Furthermore, the Board conducts periodic evaluations that focus on the effectiveness of
the Board as a whole and of its committees. Board members complete a detailed questionnaire that provides for quantitative rankings in
key areas and seeks subjective comments in each of those areas. In addition, members of each Board committee complete a detailed questionnaire
to evaluate how well their committee is operating and to make suggestions for improvement. The evaluation process is managed by the Chair
of the Governance and Nominating Committee, with advice and assistance from outside counsel. Outside counsel may conduct separate, confidential
interviews with some or all of the directors to follow-up on responses and comments reflected in the questionnaires to the extent it is
determined helpful or necessary. An anonymized summary of the principal findings from the evaluation process is prepared by outside counsel
and is used as the basis for self-assessment discussions by the Board and its committees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The Board met 8 times during 2021. Each of the directors attended all of the Board meetings in 2021
during the director&rsquo;s term. The Board continued to make it a priority to oversee and support the senior management team in addressing
the challenges presented by the COVID-19 pandemic and its impact on the company&rsquo;s short and long-term strategic plans. The Board
discussions included continued focus on items such as key business updates, financial updates, including monitoring our liquidity and
cash position, recruitment and retention of employees, and support provided to the management team to ensure an appropriate and well-measured
response to the effects of the COVID-19 pandemic. The key goal, which we believe was achieved again in 2021, was to support employee health
and safety, while avoiding significant operational disruptions to the business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our annual meetings of stockholders
are generally held to coincide with one of the Board&rsquo;s regular quarterly meetings. Although we have no formal policy requiring attendance,
directors are encouraged to attend annual meetings of stockholders and each of the then-serving or nominated directors attended the 2021
Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><A NAME="a_006"></A><FONT STYLE="font-size: 11pt">The
Board&rsquo;s Leadership Structure</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">Jeffery S. Thompson has served as the
Chair of the Board since September 2020. Separating the roles of Chair of the Board and Chief Executive Officer allows our Chief Executive
Officer to focus on the strategic management of our day-to-day business, while allowing the Chair of the Board to focus on leading the
Board of Directors in its fundamental role of providing advice to, and independently overseeing, management. The Board recognizes the
time, effort, and energy that the Chief Executive Officer is required to devote to the position in the current business environment, as
well as the commitment required to serve as Chair of the Board, particularly as the Board&rsquo;s oversight responsibilities continue
to grow. The Board believes that having separate positions, with an independent, non-executive director serving as Chair of the Board,
is the appropriate leadership structure for our company at this time and allows the Board to fulfill its role with appropriate independence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; color: #355E91"><A NAME="a_007"></A><FONT STYLE="font-size: 11pt">The Board&rsquo;s
Role in Environmental, Social and Governance (ESG) Oversight</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Board of Directors believes that our company has a broad responsibility that takes into account
the positive effect we seek to have on the people we employ, serve and support, and the environment and the communities where we live
and work. The full Board has oversight of our Environmental, Social and Governance, or ESG, initiatives, which are the direct responsibility
of a cross-functional group comprised of members of our senior management team under the leadership of our Vice President, Investor Relations,
ESG and Corporate Communications. For additional detailed information regarding our ESG initiatives, please see the section captioned
&ldquo;<I>Our Commitment to Corporate Social Responsibility &ndash; Focus on Environmental, Social, and Governance (ESG)</I>&rdquo; below.</P>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; color: #355E91">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; color: #355E91"><A NAME="a_008"></A><FONT STYLE="font-size: 11pt">The
Board&rsquo;s Role in Risk Oversight</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The role of the Board of Directors in our risk oversight process includes receiving reports from management
and the Chairs of Board committees on areas of material risk to our company, including operational, financial, commercial, legal, regulatory,
strategic, cyber security and reputational risks. The Board has delegated primary responsibility to the Audit Committee to review these
reports and discuss with management the process by which management assesses and manages our risk exposure, risk management, and risk
mitigation strategies. The Audit Committee also works with other committees to assess areas of risk under the particular purview of those
committees. When the Audit Committee receives a report from management or another committee, the Chair of the Audit Committee reviews
the report and then summarizes the review results in a presentation to the full Board. This enables the Board and its committees to coordinate
the risk oversight role to ensure that all directors receive all significant risk-related information. The Board also administers its
risk oversight function through the required approval by the Board (or a committee of the Board) of significant transactions and other
material decisions and through regular periodic reports from our independent registered public accounting firm and other outside consultants
regarding various areas of potential risk, including, among others, those relating to our internal controls and financial reporting. In
addition, as part of its charter, the Audit Committee discusses with management significant financial and operational risks and exposures,
as well as the steps management has taken to minimize those risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><A NAME="a_009"></A><FONT STYLE="font-size: 11pt">Board
Committees</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">The Board of Directors currently has three
standing committees:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">&bull;</TD>
    <TD>Audit Committee;</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">&bull;</TD>
    <TD>Compensation Committee; and</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">&bull;</TD>
    <TD>Governance and Nominating Committee.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">The membership of each standing committees
was as follows as of April 13, 2022:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <TR STYLE="vertical-align: top; background-color: #355E91">
    <TD STYLE="vertical-align: bottom; text-align: left; width: 27%"><FONT STYLE="color: White"><B>Director</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 14%"><FONT STYLE="color: White"><B>Audit</B></FONT></TD>
    <TD STYLE="text-align: center; width: 16%"><FONT STYLE="color: White"><B>Committee <BR> Compensation</B></FONT></TD>
    <TD STYLE="text-align: center; width: 14%"><FONT STYLE="color: White"><B>Governance and <BR> Nominating</B></FONT></TD>
    <TD STYLE="text-align: center; width: 15%"><FONT STYLE="color: White"><B>Independent Under <BR> SEC Rules</B></FONT></TD>
    <TD STYLE="text-align: center; width: 14%"><FONT STYLE="color: White"><B>Financial Expert <BR> Under SEC Rules</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Sheryl L. Conley</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #355E91">&#10003;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #355E91">&#10003;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD><FONT STYLE="font-size: 10pt; color: black">John B. Henneman III</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: black">Chair</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #355E91">&#10003;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #355E91">&#10003;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Raymond J. Land</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Chair</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #355E91">&#10003;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #355E91">&#10003;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #355E91">&#10003;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD><FONT STYLE="font-size: 10pt; color: black">Glenn R. Larsen, Ph.D.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #355E91">&#10003;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #355E91">&#10003;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #355E91">&#10003;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Stephen O. Richard</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #355E91">&#10003;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #355E91">&#10003;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #355E91">&#10003;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD><FONT STYLE="font-size: 10pt; color: black">Jeffery S. Thompson<SUP>(1)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #355E91">&#10003;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Susan L. N. Vogt</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #355E91">&#10003;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Chair</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #355E91">&#10003;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #355E91">&#10003;</FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(1)</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">Mr. Thompson serves as our Chair of the Board of Directors and does not serve on any standing committees.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The Board has adopted a written charter
for each standing committee, which is reviewed yearly by that committee. You can find these charters on the investor relations portion
of our website at <I>https://ir.anika.com/board-committees</I>. The information contained on the website is not incorporated by reference
in, or considered to be a part of, this Proxy Statement.</P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91"><I>Audit Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I></I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="background-color: rgb(53,94,145); width: 100%"><FONT STYLE="color: White"><B>Role and Key Responsibilities&#9;</B></FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD>Overseeing accounting and financial reporting processes</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD>Overseeing audits of our financial statements and internal controls</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD STYLE="padding-right: 11.2pt">Taking, or recommending that the Board of Directors take, appropriate action to oversee the qualifications,
        independence and performance of our independent registered public accounting firm</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD>Leading the review of our risk management processes and exposure to financial and operational risks</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD>Preparing an Audit Committee report, as required by the SEC, for inclusion in our annual Proxy Statement</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD>Selecting, retaining, overseeing, and, when appropriate, terminating our independent registered public accounting firm</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD STYLE="padding-right: 11.05pt">Conferring with the independent registered public accounting firm and reporting to the Board regarding
        the scope, method, and result of the audit of our books and records</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD STYLE="padding-right: 11.25pt">Reviewing and discussing proposed earnings press releases and financial information and guidance proposed
        to be provided to investors</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD>Establishing, overseeing and periodically reviewing procedures for complaints regarding accounting or auditing matters</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD STYLE="padding-right: 11.25pt">Establishing and monitoring a policy relative to non-audit services provided by the independent registered
        public accounting firm in order to ensure the firm&rsquo;s independence</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The Audit Committee held 4 meetings
in 2021. Each of the members attended all of the Audit Committee meetings held in 2021 while the member served on the Audit Committee.
The Audit Committee holds separate sessions of its meetings, outside the presence of management, with our independent auditor in conjunction
with each regularly scheduled Audit Committee meeting in which the independent auditor participates. During 2021, the Audit Committee
regularly met privately with our management and held executive sessions with only non-employee directors in attendance as appropriate.
No director is eligible to serve on the Audit Committee if that director simultaneously serves on the audit committees of four or more
other public companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The current
members of the Audit Committee are Raymond J. Land, who serves as Chair, Sheryl L. Conley, Stephen O. Richard and Susan L. N. Vogt. The
Board has determined that each member is independent, as defined for purposes of the SEC and NASDAQ, is financially literate, and has
the requisite financial sophistication to serve on the Audit Committee. The Board has also determined that each of Messrs. Land and Richard
and Ms. Vogt qualifies under SEC rules as an &ldquo;audit committee financial expert,&rdquo; which designation is an SEC disclosure requirement
related to their experience and understanding of certain accounting and auditing matters. The designation does not impose upon any of
the three members any duties, obligations, or liabilities that are greater than those otherwise
imposed on them as members of the Audit Committee and the Board.</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91"><I>Compensation Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="background-color: rgb(53,94,145); width: 100%"><FONT STYLE="color: White"><B>Role and Key Responsibilities</B></FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD>Managing our overall compensation philosophy, structure, policies, processes, procedures, and programs</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD STYLE="padding-right: 11.25pt">Reviewing and approving corporate goals and objectives relevant to the compensation of our Chief Executive
        Officer and other executive officers</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD>Reviewing the performance of and determining the compensation of the Chief Executive Officer</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD STYLE="padding-right: 11.3pt">Reviewing the performance of and determining, with the advice and assistance of the Chief Executive Officer,
        the compensation of our executive officers other than the Chief Executive Officer</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD>Annually reviewing and recommending to the Board of Directors compensation for non-employee directors</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD>Overseeing our overall compensation programs, including the granting of awards under our omnibus incentive plan</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD>Preparing a report on executive compensation for inclusion in our annual Proxy Statement</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD STYLE="padding-right: 11.15pt">Reviewing, discussing with management and any compensation consultant, and recommending the inclusion of
        disclosures under &ldquo;Compensation Discussion and Analysis&rdquo; in our Proxy Statement</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 11.15pt">Periodically conducting a risk assessment to evaluate whether forms of pay encourage
        unnecessary or excessive risk taking and assisting the Audit Committee in assessing and managing potential risks created by our compensation
        practices, policies and programs</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 11.2pt">Reviewing, approving, recommending to the Board for approval, and considering the results
        of stockholder advisory &ldquo;say-on-pay&rdquo; and &ldquo;say-on-frequency&rdquo; votes and reviewing and recommending to the Board
        whether to submit a stockholder advisory vote on certain acquisition-related compensation arrangements</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 11.1pt">Appointing, retaining, compensating, terminating, and overseeing the work of any compensation
        consultant or other compensation adviser, as well as considering the independence of any compensation consultant or other compensation
        adviser</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The Compensation Committee held 4 meetings
in 2021. Each of the members attended all of the Compensation Committee meetings held in 2021 while the member served on the Compensation
Committee. During 2021, the Compensation Committee regularly held executive sessions with only non-employee directors in attendance as
appropriate, including when evaluating the performance of Dr. Cheryl R. Blanchard. The Compensation Committee continued to monitor and
discuss the impact of the COVID-19 pandemic and its impact on our organization in 2021, especially in light of the continued cancellation
or delay of many clinical procedures as the pandemic cases rose and fell unpredictably throughout the year, to ensure that there continued
to be strong engagement and appropriate motivation for our executives and other employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The current members of the Compensation
Committee are John B. Henneman, III, who serves as Chair, Raymond J. Land, and Glenn R. Larsen, Ph.D. The Board has determined that each
current member of the Compensation Committee is independent, as defined in the listing standards of NASDAQ.</P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91"><I>Governance and Nominating Committee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="background-color: rgb(53,94,145); width: 100%"><FONT STYLE="color: White"><B>Role and Key Responsibilities</B></FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD>Recommending to the Board of Directors the criteria for Board and committee membership</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD STYLE="padding-right: 11.15pt">Identifying, evaluating, and recommending nominees to stand for election as directors at each Annual Meeting
        of Stockholders, including incumbent directors and candidates recommended by stockholders</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD>Developing succession plans for the Board, the Chief Executive Officer and other executives</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD>Coordinating performance evaluations of the Board and its standing committees</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD STYLE="padding-right: 11.2pt">Recommending to the Board assignments of directors to each Board committee and monitoring compliance with
        Board and committee membership criteria</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD>Overseeing and administering Board education programs</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD>Overseeing corporate governance affairs of the Board and our company</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The Governance and Nominating Committee
held 5 meetings in 2021. Each of the members attended all of the of the Governance and Nominating Committee meetings held in 2021 while
the member served on the Governance and Nominating Committee. During 2021, the Governance and Nominating Committee regularly held executive
sessions with only non-employee directors in attendance as appropriate. In 2021, the Governance and Nominating committee focused on the
activities required to identify, recruit, and onboard our new director, Sheryl L. Conley, and reviewing the skill set of the Board members
as a whole to ensure that the Board represents a balanced skill set enabling appropriate Board oversight of our company in relation to
our industry, strategic plan and stockholder alignment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The current members of the Governance
and Nominating Committee are Susan L. N. Vogt, who serves as Chair, John B. Henneman, III, and Glenn R. Larsen, Ph.D. The Board has determined
that each current member of the Governance and Nominating Committee is independent, as defined in the listing standards of NASDAQ.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><A NAME="a_059"></A><FONT STYLE="font-size: 11pt">Board
Membership Qualifications and Procedures</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">When considering candidates for director, the Governance
and Nominating Committee takes into account a number of factors, including the following minimum qualifications: the nominee (a) shall
have the highest personal and professional integrity, (b) shall have demonstrated exceptional ability and judgment, and (c) shall be most
effective, in conjunction with the other members of the Board of Directors, in collectively serving the long-term interests of the stockholders.
In addition, the Governance and Nominating Committee takes into consideration such other factors as it deems appropriate, including any
direct experience in the biotechnology, pharmaceutical, medical device, and/or life sciences industries, or in the markets in which we
operate. The Governance and Nominating Committee may also consider, among other things, the skills of the candidate, his or her availability,
the candidate&rsquo;s depth and breadth of experience or other background characteristics, and his or her independence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">In addition to the considerations
above, the Board strongly believes that diversity is an important component of a successful and effective board of directors and
good corporate governance, including diversity of background, skills, experience, gender, race, and ethnicity. The Governance and
Nominating Committee, guided by its charter, assesses and considers the diversity of the Board prior to nominating candidates and
seeks to identify director candidates who will enhance the Board&rsquo;s overall diversity. The Governance and Nominating Committee
and the Board select candidates on the basis of qualifications and experience without discriminating on the basis of race, color,
national origin, gender, sex, sexual preference, or religion. Accordingly, it is the practice of the Governance and Nominating
Committee to include, and we request that the search firms we engage include, candidates with diversity in gender and demographic
backgrounds in any pool from which the Governance and Nominating Committee selects director candidates. We believe that our current
Board members collectively reflect a broad range of knowledge, expertise, and experience in the disciplines that impact our
business.</P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">Our bylaws include a procedure that
stockholders must follow to nominate a person for election as a director at an annual meeting of stockholders. The bylaws require that
timely notice of the nomination in proper written form, including all required information as specified in the bylaws, be mailed to the
Governance and Nominating Committee in care of our Chief Executive Officer, Anika Therapeutics, Inc., 32 Wiggins Avenue, Bedford, Massachusetts
01730. A copy of our bylaws can be viewed on the investor relations portion of our website at <I>https://ir.anika.com/governance-documents.
</I>The Governance and Nominating Committee will consider director nominees recommended by stockholders in accordance with the Anika Therapeutics,
Inc. Policy and Procedures for Stockholder Nominations to the Board adopted by the Governance and Nominating Committee and approved by
the Board in April 2020, a copy of which is available on the investor relations portion of our website at <I>https://ir.anika.com/governance-documents</I>.
Recommendations should be submitted to our Secretary in writing at Anika Therapeutics, Inc., 32 Wiggins Avenue, Bedford, Massachusetts
01730, along with additional required information about the nominee and the stockholder making the recommendation. Information on qualifications
for nominations to the Board and procedures for stockholder nominations to the Board is included below under &ldquo;Proposal 1. Election
of Directors&mdash;Board Membership Qualifications and Procedures&rdquo; and &ldquo;Stockholder Proposals.&rdquo; The Governance and Nominating
Committee may solicit recommendations for candidates for directors from non-management directors, the Chief Executive Officer, other executive
officers, third-party search firms, and such other sources as it deems appropriate, including stockholders. The Governance and Nominating
Committee will review and evaluate the qualifications of all such proposed candidates in the same manner and without regard to the source
of the recommendation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><A NAME="a_010"></A><FONT STYLE="font-size: 11pt">Communications
with Directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Board of Directors seeks input
from a wide variety of sources to inform their work, including from stockholders. The Board welcomes stockholder input via voting, via
participating in our annual meetings of stockholders, via our stockholder engagement program, and, more formally, via mail. If you wish
to communicate with any of our directors, or the Board as a group, you may do so by writing to the individual director or to the Board,
in care of our Chief Executive Officer, Anika Therapeutics, Inc., 32 Wiggins Avenue, Bedford, Massachusetts 01730. We recommend that all
correspondence be sent via certified U.S. mail, return receipt requested. All correspondence received by the Chief Executive Officer will
be forwarded to the appropriate addressee. Communications involving substantive accounting or auditing matters will be forwarded to the
Chair of the Audit Committee. Communications that pertain to non-financial matters will be forwarded to the relevant director.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><A NAME="a_011"></A><FONT STYLE="font-size: 11pt">Our
Code of Business Conduct and Ethics</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Board of Directors has adopted the Anika
Therapeutics, Inc. Code of Business Conduct and Ethics to clarify, disseminate, and enforce the requirement and expectation that all
of our officers, directors, and employees worldwide conduct our business in an honest and ethical manner and in compliance with all
applicable laws and regulations. The Code of Business Conduct and Ethics applies to all of our officers, directors, and employees
worldwide, including our Chief Executive Officer and Chief Financial Officer. It is our goal to aid our employees and Board members
in making ethical and legal decisions when conducting company business and performing daily duties. We cannot anticipate every
situation an employee or Board member may face when conducting business on behalf of our company, and we therefore encourage our
employees and Board members to speak with any one of several company representatives when he or she encounters situations giving
rise to a question or concern regarding compliance with our Code of Business Conduct and Ethics. The Code of Business Conduct and
Ethics can be viewed on the investor relations portion of our website at <I>https://ir.anika.com/governance-documents</I>. Please
note that the information contained on the website is not incorporated by reference in, or considered to be part of, this Proxy
Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><A NAME="a_012"></A><FONT STYLE="font-size: 11pt">Our
Commitment to Compliance</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We are committed to maintaining a strong
culture of compliance across our entire organization. We believe that a workplace with a culture of &ldquo;do the right thing,&rdquo;
guided by high standards and comprehensive policies, is the bedrock of our success as a healthcare company and our ability to deliver
life-changing solutions to the customers we serve and all of the patients they treat around the world. As part of setting this culture
and maintaining a strong tone at the top, the following quote from our President and Chief Executive Officer, Dr. Blanchard, is included
in our strategic plan as presented to the Board and at the beginning of each individual and annual compliance training session:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 80.2pt 0pt 80.35pt; text-align: justify"><I>&ldquo;At Anika, a commitment
to ethics and quality, as realized and demonstrated through personal integrity and accountability, forms the basis for everything we do
and forges the path to all that we can achieve. These foundational tenets of our company are non-negotiable and do not take a day off.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">In addition, in 2021, we continued to
build upon our previously expanded company-wide Compliance Program focused on healthcare fraud and abuse, anti-kickback, and foreign corrupt
practices act regulations, among others, and reinforced and updated processes to ensure that appropriate controls are in place for compliance
with these laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><A NAME="a_013"></A><FONT STYLE="font-size: 11pt">Our
Commitment to Corporate Social Responsibility &ndash; Focus on Environmental, Social, and Governance (ESG)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91"><B><I>Introduction</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">The Board of Directors and our senior management team believe that our company has a broad responsibility
to take into account the people we employ, serve and support, and the environment and the communities where we live and work. The full
Board has oversight of our environmental, social and governance, or ESG, initiatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">In 2021, we embarked on a process to develop
a foundational ESG framework for our company. This framework integrates our six key values:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red"><IMG SRC="p26.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><I>People</I>: We engage and invest in each other in a community that values diversity and inclusion.</TD></TR>

  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0pt"><I>Innovation</I>: We are agile and entrepreneurial in developing and delivering meaningful
        solutions to our healthcare stakeholders within our target markets.</TD></TR>

  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-right: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><I>Quality</I>: We strive for the highest quality and compliance in everything we do.</TD></TR>

  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><I>Teamwork</I>: We operate with mutual respect and trust and are collaborative as we grow together.</TD></TR>

  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><I>Integrity</I>: We live up to our promises and do the right thing, every day.</TD></TR>

  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><I>Accountability</I>: We are empowered and accountable to deliver results and value to all of our stakeholders.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">The initial step in our ESG journey
included the completion of a &ldquo;materiality assessment&rdquo; based on the Sustainability Accounting Standards Board, or SASB,
framework. Our materiality assessment was a research-intensive and stakeholder-inclusive process and included guidance and insight
from external advisors, while soliciting crucial feedback from key internal and external stakeholders, including investors,
customers, suppliers, employees and members of our Board. The materiality assessment, and the initiatives that have resulted from it,
have been undertaken with full support and oversight of the Board. Our senior management team owns, implements, and tracks our ESG
strategy and efforts in collaboration with every major business function, all under the leadership of our Vice President, Investor
Relations, ESG and Corporate Communications.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">As a result of the materiality assessment,
we identified the themes that are most important to our stakeholders and our business within traditional environmental, social and governance
pillars. Most immediately, our materiality assessment enabled us to select our current focus areas within ESG initiatives:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>Environmental</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.75in; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Climate, Energy Use and Emissions</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>Social</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.75in; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Diversity and Inclusion</TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.75in; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Safe and Healthy Workplace</TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.75in; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Product Quality and Safety</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>Governance</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.75in; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Business Ethics and Integrity</TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.75in; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Supply Chain Management</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">Each of our ESG focus areas will continue to have management team sponsorship and engagement with ongoing
oversight by the Board. We will continue to assess and update our ESG initiatives as our business grows and as we implement processes
and improvements over time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91"><B>Our Environmental Focus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91"><I>Environmental Climate: Climate, Energy Use
and Emissions </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">As a global company, we recognize the
importance of reducing the impact of our operations on the environment. Water is a precious resource, which we conserve and protect in
a number of ways. We employ deionization in our primary manufacturing facility in Bedford, Massachusetts to remove impurities in wastewater,
allowing it to be reused during the manufacturing process. In addition, because our Bedford facility is adjacent to wetlands, we take
measures to protect the wetlands through the use of state-of-the-art technology to trap sediment and other materials, maintain storm water
pollution plans, and ensure that harmful chemicals are not used on our company&rsquo;s grounds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Though we are not a significant
generator of greenhouse gases, we continually work to reduce energy consumption and evaluate ways to minimize greenhouse gases in our
atmosphere. In recent years, we have taken proactive steps to increase energy efficiency at our facilities. For example, we completed
a full transition to LED lighting at our Bedford facility in 2020, resulting in an energy reduction of 373,500 kilowatts over the prior
year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">In 2018, we began recycling packaging
used in the manufacture of our products, as well as paper goods used across our company. As a result of this program, in 2021 we diverted
more than 6,000 pounds of recyclable materials from landfills, saving the equivalent of 54 trees, nine cubic yards of landfill, six barrels
of oil and 21,000 gallons of water.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91"><B><I>Our Social Focus </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91"><I>Human Capital: Diversity and Inclusion</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Promoting diversity throughout
our company, including within the Board of Directors and our management team, has been a focal point of the Board, starting with the appointment
of Cheryl R. Blanchard, Ph.D. as our President and Chief Executive Officer in early 2020, and the additions to the Board of Stephen O.
Richard and Sheryl L. Conley in 2020 and 2021, respectively. As of April 27, 2022, women accounted for 36% of our senior management team
and 37.5% of our Board. As detailed under the &ldquo;Board Representation&rdquo; section on page 2 and our Board of Directors Diversity
Matrix on page 3 above, our eight-member Board currently includes three women and one person of color.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">In 2020, Dr. Blanchard, with the support
of the Board, joined other chief executive officers in signing the Massachusetts Biotechnology Council &ldquo;CEO Pledge for a More Equitable
and Inclusive Life Sciences Industry.&rdquo; The signers of this pledge &ldquo;recognize that racial inequity exists in [the life sciences]
industry and in [life sciences] companies, and [they] must take responsibility to fix that injustice through comprehensive equity, diversity,
and inclusion initiatives that are broad in scope, specific in action, and measurable in results.&rdquo; The full text of the pledge can
be found at: <I>https://www.massbio.org/initiatives/equity-diversity-and-inclusion/open-letter/</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">As part of our commitment to the
pledge, in 2021 we created an internal Diversity Dashboard to track diversity metrics throughout our company. The trends captured by the
Diversity Dashboard are shared and discussed with the Board, ensuring oversight and accountability at the highest level of our company.
Additionally, in 2021, we instituted a corporate Diversity, Equity and Inclusion, or DEI, policy statement and included it in our employee
handbook and onboarding program. The DEI policy statement clearly conveys our commitment:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;Anika is committed to an equitable,
diverse, and inclusive workplace where all employees, regardless of their gender, race, ethnicity, national origin, age, sexual orientation
or identity, education or disability are valued, respected, and supported. We will not discriminate based on these characteristics and
will provide equal opportunities for employment and advancement throughout our company. Anika respects and appreciates diverse life experiences
and heritages and will always work to ensure that all voices are heard and valued.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">To further reinforce our commitment to
DEI, we have begun to align management compensation and initiatives to specific DEI objectives, including: (i) implementation of a DEI
employee survey questionnaire, (ii) implementation of educational programs across our company, including, but not limited to, topics such
as unconscious bias and tone, and the importance of diversity at our company, (iii) establishment of employee resource groups, (iv) conducting
a diversity audit on our hiring processes, and (v) implementing metrics to drive continuous improvement around our DEI initiatives, processes
and objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Recognizing the value of employee
engagement and retention, we conduct regular company-wide employee engagement surveys. Our management team evaluates the results and identifies
opportunities for improvement. As a result of this feedback, in 2021, we established an employee Communications Task Force chartered with
improving communications across the business, and we launched a new e-learning program to expand employee development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Human Capital: Safe
and Healthy Workplace</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">We provide resources, programs and services
to support the physical, emotional and financial health of our employees. Additionally, specifically in regard to workplace safety, we
have a Health, Safety and Environmental Policy that all employees are required to be trained on, which can be viewed on our website at
<I>https://ir.anika.com/governance-documents.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">As part of our robust workplace safety
training, we have implemented interactive virtual learning systems. These systems are function-specific and ensure that all employees
have access to critical information to keep them and their co-workers safe. We also use an electronic management system, or EMS, to obtain
information on any accidents or other safety issues. Our EMS offers the ability for anyone at our company to submit information about
potential safety risks. All employees participate in annual training on workplace safety and the use of systems, including the EMS, to
ensure that the importance of workplace safety is top of mind for employees throughout our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>COVID-19 Pandemic Response</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">We have continually monitored the
impact of the COVID-19 pandemic and the public policy responses to it, with particular focus on the health and well-being of our
employees at all of our locations. We have taken a number of steps to promote the safety of our employees, and we
continue to review and adjust policies and procedures as needed to comply with the Centers for Disease Control and Prevention and
other country, state, and local guidelines in the rapidly changing COVID-19 environment. Some examples of the steps we have taken
and continue to evaluate include, but are not limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Created a global COVID-19 Pandemic Task Force that meets regularly to review current pandemic status and make
        recommendations to senior leadership to help ensure the health and safety of our employee population;</TD></TR>

  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Engaged a third-party firm to conduct a facility assessment and subsequently upgraded our air filtration systems
        to be more effective against COVID-19 transmission;</TD></TR>

  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">During peak infection periods, provided on-site COVID testing services through a third-party healthcare firm
        to make it easier for employees to receive testing if testing was otherwise unavailable or difficult to receive in the areas where they
        live;</TD></TR>

  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Transitioned a large portion of our employees to remote work to offer additional protections to our manufacturing
        team and others who must be onsite to enable the delivery of critical products to our customers, clinicians and their patients;</TD></TR>

  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Established and periodically update safety policies and protocols that are regularly communicated to employees
        as changes are made;</TD></TR>

  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Adjusted attendance policies to encourage those who may be ill or who have had a potential exposure to stay
        home; and</TD></TR>

  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Ensured our employees had resources and information to protect their physical, emotional and mental health,
        and that of those around them, including their families and co-workers.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Social Capital: Product
Quality and Safety</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Quality is integral to our business model
and our long-term success. To drive quality assurance, we maintain a robust Quality Management System, or QMS, that fosters continuous
improvement, drives manufacturing excellence and ensures compliance with global standards. Comprehensive annual training for employees
enables us to consistently produce safe, high-quality products that meet or exceed the expectations of our customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">As a medical device manufacturer, we adhere
to ISO 13485 standards supported by our QMS. Our QMS is aligned with regulations from the U.S. Food and Drug Administration and GMED,
an international reference body in the certification of health care and medical device quality management systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><B><I>Our Governance Focus
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Governance: Business
Ethics and Integrity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">A workplace
culture of &ldquo;do the right thing,&rdquo; guided by high standards and comprehensive policies, is the bedrock to our success as a life
science company. Our Code of Business Conduct and Ethics guides the Board of Directors and our employees in making ethical and legal decisions
when conducting business and fulfilling their roles and responsibilities as representatives of our company. We also have a Conflict of
Interest Policy and an Insider Trading Policy, as well as a channel for employees and Directors to report concerns through our Whistleblower
Policy. Please view our Corporate Governance documents webpage at <I>https://ir.anika.com/governance-documents </I>for a full list, and
access to copies, of our governance documents and policies.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Our Compliance Program is based on our
Code of Business Conduct and Ethics and is structured to help our company comply with the myriad of laws, guidelines and regulations
that impact our business by mirroring the recommendations of the U.S. Department of Health and Human Services, Office of Inspector General&rsquo;s
(OIG&rsquo;s) seven elements of an effective compliance program. We have established a Compliance Committee, made up of our Chief Executive
Officer and senior representatives from several other functions within our company, which oversees the operation of our healthcare Compliance
Program. In addition, we have established an Engagements Committee, which reviews and approves proposed interactions with healthcare
professionals and healthcare organizations, including consulting services, royalty arrangements, requests for grants and research engagements.
We are also a member of the Advanced Medical Technology Association, or AdvaMed, a global trade association of companies that develop,
produce, manufacture, and market medical technologies, and which are dedicated to advancing medical science, developing high quality,
innovative medical technology, and improving patient care. We follow AdvaMed&rsquo;s Code of Ethics on Interactions with U.S. Health
Care Professionals, or the AdvaMed Code of Ethics, which provides medical technology companies with guidance on ethical interactions
and relationships with health care professionals. To view the AdvaMed Code of Ethics, please visit <I>https://www.advamed.org/member-center/resource-library/advamed-code-of-ethics/</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">In 2021, we also expanded our focus on working to ensure that our international distributors are organizations
that operate in compliance with our policies and procedures and all laws and regulations. Using an independent screening process and third-party
service providers that focus on investigating the integrity, reputation and business practices of our potential distribution partners,
we attempt to gauge the level of risk posed by international distributors based on their geographic location and past corporate behavior,
among other factors, and tailor our due diligence efforts and our willingness to engage specific distributors accordingly. We recognize
that vigilant oversight of this aspect of our supply chain is foundational to our ability to grow our business with high ethical standards
and integrity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Business Model: Supply
Chain Management</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Supply chain management is a fundamental aspect of our business to ensure we have the raw materials and
equipment/parts available to manufacture our products in a timely fashion for our customers and their patients. During the past year,
we successfully took steps to navigate the challenges of the global supply chain crisis, including finding additional/alternative suppliers
and reengineering our manufacturing processes and supplies for a more streamlined procurement process. Many of these supply chain improvements
and the processes we initiated to develop and implement them, though born of near-term necessity, are now permanent and will enhance our
ability to procure supplies to satisfy the needs of our customers and their patients as we continue to grow and transform our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><B><I>Conclusion</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">The Board of Directors, our senior
management team and our global employees all recognize the importance of ESG matters in creating and maintaining an environment of
corporate accountability while striving to deliver high quality products that transform the lives of patients. As a result of our
2021 materiality assessment, which was based on the SASB framework, we have made significant progress in identifying and
establishing initiatives to address the ESG focus areas identified above, and we are committed to the ongoing assessment,
development and continuous improvement required in these important areas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><A NAME="a_014"></A><FONT STYLE="font-size: 11pt">Director
Overboarding Guidelines</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Board of Directors recognizes that its members benefit from service on the boards of other companies
and it encourages such service. The Board also believes, however, that it is critical that directors are able to dedicate sufficient time
to their service on the Board. The Board adopted our Commitment to the Board; Service on Other Boards; Change in Status Guidelines in
March 2021. Pursuant to these guidelines, unless the Board determines that such service would not impair the ability of a director to
effectively serve on the Board or the Audit Committee of the Board:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="padding-right: 0pt">No director who serves as the chief executive officer of any public company, including Anika, may serve on
        the boards of directors of more than three public companies, including Anika;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>No other director may serve on the board of directors of more than five public companies, including Anika; and</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="padding-right: 0pt">No member of the Audit Committee should serve simultaneously on the audit committees of more than four public
        companies, including Anika.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">Directors must notify the Chair of the
Governance and Nominating Committee and our Corporate Secretary before accepting a seat on the board of directors of, or any assignment
to the audit committee of, another public company so that the potential for conflicts or other factors compromising the director&rsquo;s
ability to perform his or her duties may be fully assessed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><A NAME="a_015"></A><FONT STYLE="font-size: 11pt">Prohibition
on Employee, Officer, and Director Hedging and Pledging</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">It is our policy that all employees and directors, as well as their family members, must not hedge
or pledge any Anika securities they hold directly. An exception to this prohibition may be granted where a person wishes to pledge Anika
securities as collateral for a loan, upon approval by our Chief Financial Officer, if certain other conditions are met. The prohibition
on hedging is included in our Insider Trading Policy, which was implemented by the Board of Directors in December 2016 and most recently
amended in December 2021. A copy of our Insider Trading Policy can be viewed on the investor relations portion of our website at <I>https://ir.anika.com/governance-documents</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><A NAME="a_016"></A><FONT STYLE="font-size: 11pt">Majority
Voting in Uncontested Director Elections Policy</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Board of Directors adopted our
&ldquo;Majority Voting in Uncontested Director Elections Policy&rdquo; in December 2015. An uncontested election occurs when the
number of director nominees is equal to the number of Board positions to be filled through election and proxies are being solicited
for such election of directors solely by our company. Pursuant to our policy in such an election, if a director receives a greater
number of votes &ldquo;AGAINST&rdquo; than &ldquo;FOR&rdquo; election, such director must promptly offer to resign. The Governance
and Nominating Committee then will consider all of the relevant facts and circumstances and recommend to the Board whether or not to
accept the offer of resignation. The final decision of whether or not to accept such resignation shall be made by the Board, and, if
required or determined by the Board to be desirable, we will disclose the decision of the Board along with the rationale for the
decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><A NAME="a_017"></A><FONT STYLE="font-size: 11pt">Transactions
with Related Persons and Conflict of Interest Policy</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">It is our policy that all employees and directors,
as well as their family members, must avoid any activity that is, or has the appearance of, conflicting with our business interests.
This policy is included in our Code of Business Conduct and Ethics, and it is supplemented by our Conflict of Interest Policy, which
was implemented by the Board of Directors in October 2015, and can be viewed on the investor relations portion of our website at <I>https://ir.anika.com/governance-documents</I>.
Both the Code of Business Conduct and Ethics and the Conflict of Interest Policy are reviewed at least every three years, or more often
as necessary or advisable. Among other things, this policy requires each director and officer to provide to the Chair of the Board (or
to the Chief Executive Officer, if such transaction involves the Chair of the Board) written notice of any potential related party transaction,
defined by our policy to mirror the definition of Item 404 of Regulation S-K under the Securities Exchange Act of 1934, or the Exchange
Act, (with the exception that our policy includes a monetary threshold of $100,000 as opposed to the threshold of $120,000 set by Item
404 of Regulation S-K under the Exchange Act). Any such notice must include all information requested by the Chair of the Board (or the
Chief Executive Officer). Upon receiving all relevant information, the disinterested members of the Board may approve the transaction
if they determine that the transaction is in the best interests of, and fair to, Anika, may require modifications to the transaction
to make it acceptable for approval, or may reject it. The Board may also establish guidelines for ongoing management of a specific related
party transaction. The policy requires continuing related party transactions to be reviewed on at least an annual basis. Additionally,
the policy requires all of our executives and directors to complete a director and officer questionnaire in connection with each of our
annual proxy statements, which asks them to disclose family relationships and other related party transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">From January 1, 2021 through April 27,
2022, we had no reportable related party transactions.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center; color: #355E91"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center; color: #355E91"><FONT STYLE="font-size: 13pt"><A NAME="a_018"></A>Beneficial
Ownership of Common Stock</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">The following table sets forth the beneficial
ownership of common stock as of April 13, 2022, by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>Each current director and director nominee;</TD></TR>

  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="padding-right: 0pt">Each of the named executive officers named in the Summary Compensation Table set forth under &ldquo;Executive
        Compensation&rdquo;;</TD></TR>

  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>Each other person who is known by us to beneficially own 5% or more of our common stock; and</TD></TR>

  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>Current directors, director nominees and executive officers as a group.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The number of shares of common stock
owned by each person is determined under the rules of the SEC. Under these rules, beneficial ownership includes any shares as to which
the individual has sole or shared voting power or investment power and any shares that the individual has the right to acquire by June
12, 2022 (sixty days after April 13, 2022) through the conversion of a security or other right. Unless otherwise indicated, each person
has sole investment and voting power, or shares such power with a family member, with respect to the shares set forth in the following
table. The inclusion in this table of any shares deemed beneficially owned does not constitute an admission of beneficial ownership of
those shares for any other purpose. As of April 13, 2022, there were 14,519,284 shares of common stock outstanding. Shares not outstanding,
but deemed beneficially owned by virtue of the right of a person to acquire those shares, are treated as outstanding only for purposes
of determining the number and percent of shares of common stock owned by such person or group. Unless otherwise noted below, the address
of each person listed on the table is in care of Anika Therapeutics, Inc., 32 Wiggins Avenue, Bedford, Massachusetts 01730.</P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%;  font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="background-color: #1F497D">
    <TD STYLE="color: white; font-weight: bold; vertical-align: bottom; border-bottom: Black 0.5pt solid; width: 54%">Beneficial Owner</TD>
    <TD STYLE="color: white; font-weight: bold; vertical-align: bottom; border-bottom: Black 0.5pt solid; width: 2%">&nbsp;</TD>
    <TD STYLE="color: white; font-weight: bold; vertical-align: bottom; border-bottom: Black 0.5pt solid; text-align: center; width: 20%">Amount
        and Nature <BR> of Beneficial <BR> Ownership</TD>
    <TD STYLE="color: white; font-weight: bold; vertical-align: top; border-bottom: Black 0.5pt solid; text-align: center; width: 4%">&nbsp;</TD>
    <TD STYLE="color: white; font-weight: bold; vertical-align: bottom; border-bottom: Black 0.5pt solid; text-align: center; width: 20%">Percentage
        of <BR> Common Stock <BR> Outstanding</TD></TR>
  <TR>
    <TD STYLE="font-weight: bold; font-style: italic; vertical-align: bottom">Directors and Named Executive officers<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: 700">:</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="padding-left: 10pt; text-align: left">Sheryl L. Conley</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD>&nbsp;<SUP>(1)</SUP></TD>
    <TD STYLE="text-align: right">-&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-align: left; background-color: white">John B. Henneman, III</TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: right">12,379</TD>
    <TD>&nbsp;<SUP>(2)</SUP></TD>
    <TD STYLE="text-align: right; background-color: white">&nbsp;*&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="padding-left: 10pt; text-align: left">Raymond J. Land</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">12,125</TD>
    <TD>&nbsp;<SUP>(3)</SUP></TD>
    <TD STYLE="text-align: right">&nbsp;*&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-align: left">Glenn R. Larsen, Ph.D.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">15,869</TD>
    <TD>&nbsp;<SUP>(4)</SUP></TD>
    <TD STYLE="text-align: right">&nbsp;*&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="padding-left: 10pt; text-align: left">Stephen O. Richard</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">10,379</TD>
    <TD>&nbsp;<SUP>(5)</SUP></TD>
    <TD STYLE="text-align: right">&nbsp;*&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-align: left; background-color: white">Jeffery S. Thompson</TD>
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: right">17,121</TD>
    <TD>&nbsp;<SUP>(6)</SUP></TD>
    <TD STYLE="text-align: right; background-color: white">&nbsp;*&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="padding-left: 10pt; text-align: left">Susan L. N. Vogt</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">15,824</TD>
    <TD>&nbsp;<SUP>(7)</SUP></TD>
    <TD STYLE="text-align: right">&nbsp;*&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-align: left">Cheryl R. Blanchard, Ph.D.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">187,466</TD>
    <TD>&nbsp;<SUP>(8)</SUP></TD>
    <TD STYLE="text-align: right">1.29%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="padding-left: 10pt; text-align: left">David B. Colleran</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">40,927</TD>
    <TD>&nbsp;<SUP>(9)</SUP></TD>
    <TD STYLE="text-align: right">&nbsp;*&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-align: left">Michael L. Levitz</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">46,093</TD>
    <TD>&nbsp;<SUP>(10)</SUP></TD>
    <TD STYLE="text-align: right; background-color: white">&nbsp;*&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="padding-left: 10pt; text-align: left">Thomas Finnerty</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">57,557</TD>
    <TD>&nbsp;<SUP>(11)</SUP></TD>
    <TD STYLE="text-align: right">&nbsp;*&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-align: left">James Loerop</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">23,592</TD>
    <TD>&nbsp;<SUP>(12)</SUP></TD>
    <TD STYLE="text-align: right">&nbsp;*&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 30pt; vertical-align: middle">Current directors and executive officers as a group (12 persons)</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">439,332</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;<SUP>(13)</SUP></TD>
    <TD STYLE="vertical-align: bottom; text-align: right">3.03%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="font-weight: bold; font-style: italic">5% and Above Stockholders:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="padding-left: 10pt; text-align: left">BlackRock, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="padding-left: 20pt; text-align: left">55 East 52<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: 400"><SUP>nd</SUP>
        Street</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="padding-left: 20pt; text-align: left">New York, NY 10055</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">2,358,617</TD>
    <TD>&nbsp;<SUP>(14)</SUP></TD>
    <TD STYLE="text-align: right">16.30%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-align: left">Kayne Anderson Rudnick Investment Management LLC</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 20pt; text-align: left">1800 Avenue of the Stars, 2nd Floor</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 20pt; text-align: left">Los Angeles, CA 90067</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">1,467,510</TD>
    <TD>&nbsp;<SUP>(15)</SUP></TD>
    <TD STYLE="text-align: right">10.17%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="padding-left: 10pt; text-align: left">Ameriprise Financial, Inc.&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="padding-left: 20pt; text-align: left">145 Ameriprise Financial Center</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="padding-left: 20pt; text-align: left">Minneapolis, MN 55474</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">987,733</TD>
    <TD>&nbsp;<SUP>(16)</SUP></TD>
    <TD STYLE="text-align: right">6.84%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-align: left">The Vanguard Group</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 20pt; text-align: left">100 Vanguard Blvd.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 20pt; text-align: left">Malvern, PA 19355</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">965,913</TD>
    <TD>&nbsp;<SUP>(17)</SUP></TD>
    <TD STYLE="text-align: right">6.69%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="padding-left: 10pt; text-align: left">Dimensional Fund Advisors LP</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="padding-left: 20pt; text-align: left">6300 Bee Cave Road, Building One&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="padding-left: 20pt; text-align: left">Austin, TX 78746</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">856,124</TD>
    <TD>&nbsp;<SUP>(18)</SUP></TD>
    <TD STYLE="text-align: right">5.90%</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-align: left">State Street Corporation</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 20pt; text-align: left">State Street Financial Center</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 20pt; text-align: left">One Lincoln Street</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="color: red">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 20pt; text-align: left">Boston, MA 02111</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">798,568</TD>
    <TD>&nbsp;<SUP>(19)</SUP></TD>
    <TD STYLE="text-align: right">5.53%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"><B>&nbsp;</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">* Indicates less than 1%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(1)</FONT></TD><TD><FONT STYLE="font-size: 8pt">Ms. Conley was appointed to the Board of
                                            Directors on October 28, 2021, and does not currently beneficially own any shares of our
                                            common stock.</FONT></TD></TR></TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(2)</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">This amount includes 7,276 shares subject to restricted stock units vesting within sixty days of April 13,
        2022.</FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(3)</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">This amount includes 4,172 shares subject to restricted stock units vesting within sixty days of April 13,
        2022.</FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(4)</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">This amount includes 4,172 shares subject to restricted stock units vesting within
        sixty days of April 13, 2022.</FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(5)</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">This amount includes 7,276 shares subject to restricted stock units vesting within sixty days of April 13,
        2022.</FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(6)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">This amount includes 4,172 shares subject to restricted
        stock units vesting within sixty days of April 13, 2022.</FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(7)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">This amount includes 4,172 shares subject to restricted
        stock units vesting within sixty days of April 13, 2022.</FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(8)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">This
amount includes 102,898 shares subject to stock options that are exercisable within sixty days of April 13, 2022, 24,576 shares of restricted
stock units expected to vest within 60 days of April 13, 2022, and 11,724 shares held by The Cheryl R. Blanchard Amended and Restated
Revocable Trust dated December 19, 2014, of which Dr. Blanchard is a beneficiary and the sole trustee.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD><FONT STYLE="font-size: 8pt">(9)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">This amount includes 32,560 shares subject to
    stock options that are exercisable within sixty days of April 13, 2022.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(10)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">This amount includes 30,169 shares subject to stock options
        that are exercisable within sixty days of April 13, 2022.</FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(11)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Mr. Finnerty retired from our company as of March 11,
        2022. This amount reflects the number of shares beneficially owned by Mr. Finnerty as of his last date of service to our company and includes
        32,959 shares subject to stock options that are exercisable within 60 days of April 13, 2022.</FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(12)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Mr. Loerop resigned from our company as of January 27,
        2022. This amount reflects the number of shares beneficially owned by Mr. Loerop as of his last date of service to our company and includes:
        (i) 18,000 shares subject to stock options that are exercisable within 60 days of April 13, 2022, and (ii) 1,567 deferred stock units
        that vested on February 25, 2021, and were settled in a lump sum within 60 days of Mr. Loerop's &quot;separation from service,&quot; as
        that term is defined in Section 409A of the Internal Revenue Code.</FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(13)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">This amount includes 216,586 shares subject to stock
        options that are exercisable within sixty days of April 13, 2022, and 55,816 shares of restricted stock units expected to vest within 60
        days of April 13, 2022.</FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(14)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Such information is provided based on amended Schedule
        13G filed with the SEC on behalf of BlackRock, Inc. on January 27, 2022. BlackRock, Inc. has sole voting power with respect to 2,325,024
        shares and sole dispositive power with respect to 2,358,617 shares.</FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(15)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Such information is provided based on amended Schedule
        13G filed with the SEC on behalf of Kayne Anderson Rudnick Investment Management LLC on February 14, 2022. Kayne Anderson Rudnick Investment
        Management LLC has sole voting power with respect to 712,759 shares, shared voting power with respect to 507,117 shares, sole dispositive
        power with respect to 960,393 shares, and shared dispositive power with respect to 507,117 shares.</FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(16)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Such information is provided based on Schedule 13G filed
        with the SEC on behalf of Ameriprise Financial, Inc. and its subsidiaries, Columbia Management Investment Advisers, LLC and Columbia Wanger
        Asset Management, LLC, on February 14, 2022. Ameriprise Financial, Inc. beneficially owns 987,733 shares, has shared voting power with
        respect to 987,733 shares, and shared dispositive power with respect to 987,733 shares. Columbia Management Investment Advisers, LLC beneficially
        owns 987,361 shares, has shared voting power with respect to 950,771 shares, and shared dispositive power with respect to 987,361 shares.
        Columbia Wanger Asset Management, LLC beneficially owns 766,289 shares, has shared voting power with respect to 766,289 shares, and shared
        dispositive power with respect to 766,289 shares.</FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(17)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Such information is provided based on amended Schedule
        13G filed with the SEC on behalf of The Vanguard Group on February 9, 2022. The Vanguard Group has shared voting power with respect to
        10,965 shares, sole dispositive power with respect to 944,329 shares, and shared dispositive power with respect to 21,584 shares.</FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(18)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Such information is provided based on amended Schedule
        13G filed with the SEC on behalf of Dimensional Fund Advisors LP on February 8, 2022. Dimensional Fund Advisors LP has sole voting power
        with respect to 833,946 shares and sole dispositive power with respect to 856,124 shares.</FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(19)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Such information is provided based on amended Schedule
        13G filed with the SEC on behalf of State Street Corporation on February 10, 2022. State Street Corporation has shared voting power with
        respect to 767,671 shares and shared dispositive power with respect to 798,568 shares.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center; color: #355E91"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center; color: #355E91"><A NAME="a_019"></A><FONT STYLE="font-size: 13pt">Executive
Officers</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Board
of Directors elects our executive officers annually at a regular meeting held immediately preceding an annual meeting of stockholders.
The Board also elects executive officers throughout the year as such individuals are hired by us. Executive officers hold office until
the next annual meeting of stockholders or until their successors are duly elected and qualified, unless they sooner resign or are removed
from office. There are no family relationships between any of our directors (including director nominees) or executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The following table lists our executive
officers and their offices and ages, all as of April 27, 2022. It is currently expected that each of these officers will be re-appointed
to their current offices by the Board immediately preceding the Annual Meeting:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <TR STYLE="vertical-align: top; background-color: #355E91">
    <TD STYLE="width: 24%; padding-left: 2.2pt"><FONT STYLE="font-size: 10pt; color: white"><B>Name</B></FONT></TD>
    <TD STYLE="width: 67%"><FONT STYLE="font-size: 10pt; color: white"><B>Position</B></FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt; color: white"><B>Age</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.3pt"><FONT STYLE="font-size: 10pt">Cheryl R. Blanchard, Ph.D.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">57</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD STYLE="padding-left: 2.3pt"><FONT STYLE="font-size: 10pt">Michael L. Levitz</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Executive Vice President, Chief Financial Officer and Treasurer</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">48</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.3pt"><FONT STYLE="font-size: 10pt">David B. Colleran</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Executive Vice President, General Counsel and Secretary</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">50</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: -0.05pt"><I>Dr. Blanchard&rsquo;s</I>
biography is included above in the section titled &ldquo;Proposal 1: Election of Directors &ndash; Information Regarding the Directors.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"><I>Michael L. Levitz </I>was appointed
Executive Vice President, Chief Financial Officer and Treasurer in August 2020. Mr. Levitz served as the Senior Vice President, Chief
Financial Officer and Treasurer of Insulet Corporation, a publicly traded, global medical device and drug delivery company, from 2015
to May 2019. From 2009 to 2015, Mr. Levitz was the Senior Vice President, Chief Financial Officer and Treasurer of Analogic Corporation,
a global provider of medical guidance, diagnostic imaging, and threat detection equipment. Previously, during his seven years with Hologic,
Inc. and Cytyc Corporation (which merged with Hologic), Mr. Levitz served in various capacities including Vice President and Corporate
Controller. Mr. Levitz began his career in the high technology audit practice at Arthur Andersen LLP. Mr. Levitz earned his Bachelor of
Arts in Business Economics, with emphasis in Accounting, from the University of California Santa Barbara and is a certified public accountant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"><I>David B. Colleran </I>was appointed
Executive Vice President, General Counsel and Secretary in March 2020. Most recently, Mr. Colleran served as Senior Vice President, General
Counsel, Secretary and Chief Compliance Officer at Insulet Corporation, a publicly traded, global medical device and drug delivery company,
from July 2015 through March 2019. Prior to that, from 2010 to 2015, he held the role of Vice President and General Counsel of the Medical
Supplies segment, and from 2006 to 2010, he held the role of Associate General Counsel, both at Covidien, a global manufacturer of medical
devices and supplies acquired by Medtronic in 2015. Prior to that, he was Corporate Counsel at Ocean Spray Cranberries. Mr. Colleran began
his career as a corporate attorney at the law firm Choate, Hall &amp; Stewart. Mr. Colleran holds a B.A. in Political Science from Boston
College and a J.D. from Boston College Law School.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center; color: #355E91"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center; color: #355E91"><FONT STYLE="font-size: 13pt"><A NAME="a_020"></A>Compensation
Discussion and Analysis</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center; color: #355E91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">This section describes and analyzes the material elements of
the 2021 compensation for our named executive officers, or NEOs, determined in accordance with SEC rules, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="3" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif;  width: 100%">
  <TR STYLE="vertical-align: top; background-color: #355E91">
    <TD STYLE="width: 30%"><FONT STYLE="font-size: 10pt; color: white"><B>Name</B></FONT></TD>
    <TD STYLE="width: 1%"><B>&nbsp;</B></TD>
    <TD STYLE="width: 69%; text-align: center"><FONT STYLE="font-size: 10pt; color: white"><B>Title (as of December 31, 2021)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">Cheryl R. Blanchard, Ph.D.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">President and Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="font-weight: bold; text-align: left">Michael L. Levitz</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: left">EVP, Chief Financial Officer, and Treasurer</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">David B. Colleran</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: left">EVP, General Counsel, and Secretary</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="font-weight: bold; text-align: left">Thomas Finnerty*</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: left">EVP, Human Resources</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">James Loerop**</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: left">EVP, Business Development and Strategic Planning</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">*</FONT></TD>
    <TD STYLE="padding-right: 0pt"><FONT STYLE="font-size: 8pt">Mr. Finnerty retired as of March 11, 2022.</FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0pt; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">**</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Mr. Loerop resigned as of January 27, 2022.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; color: #355E91"><A NAME="a_021"></A><FONT STYLE="font-size: 11pt">Executive
Summary</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91"><I>Our Fiscal Year 2021 Business Performance</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In 2021, we extended our transformation initiative that began in 2020 with our acquisitions of Parcus
Medical, LLC, or Parcus Medical, and Arthrosurface, Inc., or Arthrosurface. Those acquisitions expanded our overall technology portfolio
and product pipeline, enhanced our global footprint and commercial infrastructure, diversified our revenue streams in faster growing segments,
and grew our overall market opportunity from the over $1 billion global osteoarthritis, or OA, pain management market to an over $8 billion
joint preservation market (which includes faster growing regenerative, sports medicine and bone preserving extremities markets). Following
these acquisitions, and with the COVID-19 pandemic continuing to create uncertainty, we managed our business to prioritize the health
and safety of our employees while delivering high-quality products and support for our customers and their patients without significant
operational interruptions. We also achieved other important accomplishments in talent acquisition, commercial organization integration,
and new product launches. While the COVID-19 environment and staffing constraints periodically limited elective procedures, and have presented
supply chain and staffing challenges, we drove 13% revenue growth in 2021, having made significant progress on our operational transformation
as we established the foundation for our multi-year growth strategy. Our 2021 key accomplishments included:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Market launch of our Tactoset Injectable Bone Substitute for augmentation of suture anchor fixation in the
        fourth quarter, a new indication that allows surgeons to use Tactoset for hardware fixation due to insufficient bone quality, increasing
        pull-out strength of suture anchors;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Market launch in the third quarter of our WristMotion Total Wrist Arthroplasty, or TWA, system focused on
        alleviating pain and restoring full range of motion for patients with arthritic wrist joints (WristMotion TWA, along with our WristMotion
        Hemiarthroplasty System, provides surgeons with multiple innovative and bone preserving treatment options for different stages and severities
        of wrist arthritis);</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Received 510(k) clearance from the U.S. Food and Drug Administration in the third quarter for our reverse
        shoulder implant system, which sets the stage for the development and expansion of our company&rsquo;s shoulder implant portfolio targeted
        for ambulatory surgical centers;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Completed
 enrollment in the fourth quarter of the U.S. pilot clinical trial of Cingal, our combination viscosupplement/steroid product for OA
pain management;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Launched a focused effort to advance our ESG strategy in the fourth quarter by completing an in-depth &ldquo;materiality
assessment&rdquo; validating key environmental, social and governance issues of greatest importance to our stakeholders;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: right"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Rolled out our SAP enterprise resource planning system to legacy Parcus Medical and Arthrosurface
operations in the third quarter, providing additional operational capabilities in support of our growth strategy; and</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: right"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Added key members to our management team and Board of Directors, including Kevin Stone, Vice
President and General Manager of Sports Medicine, Anne Nunes, Vice President &nbsp;of Operations, and Sheryl L. Conley, a new independent
director, each bringing deep knowledge and decades of orthopedic industry experience.</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 0">For other business and financial highlights, please see
our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.</P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91"><I>Compensation Decisions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">As described more fully below, we made compensation decisions
for our NEOs for 2021 that were generally linked to our performance. In particular, the Compensation Committee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: right"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Determined
                                            Cash Bonuses </I>&ndash; Paid the NEOs annual cash bonuses, generally at 100% of target,
                                            based on our business performance results as described above, including the strong stewardship
                                            of our company through the unprecedented circumstances associated with the COVID-19 pandemic
                                            and supply chain and staffing challenges, and a review of each NEO&rsquo;s individual accomplishments;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Awarded
                                            Long-Term Incentive Equity </I>&ndash; Granted the NEOs, including the Chief Executive Officer,
                                            equity awards in early 2021 evenly split between time-vesting restricted stock units and
                                            performance-based, time-vesting stock options in the form of premium priced stock options,
                                            as further described below;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: right"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Revised
                                            the Form of Long-Term Incentive Equity Awarded as Compared to Prior Years</I> &ndash; Reviewed
                                            the effectiveness of performance-based restricted stock unit awards and determined that three
                                            (3) year vesting premium priced stock options priced at 110% of fair market value on the
                                            grant effective date were the most effective performance-based long-term equity incentive
                                            for our NEOs to continue to align with stockholder interests; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: right"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Certified
                                            Achievement Under our 2019 Performance Restricted Unit Awards</I> &ndash; In connection with
                                            the end of the 3-year performance period, ended December 31, 2021, certified achievement
                                            and subsequent vesting of 112.5% of the shares granted at target under our 2019 Performance
                                            Restricted Unit awards.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Stockholder Outreach</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In 2021, we reached out to stockholders
holding a majority of our common stock as part of our practice to provide updates on our performance and to solicit their feedback,
including outreach specifically on our executive compensation program. As part of our annual outreach program, in May 2021, we contacted
our top stockholders holding approximately 70% of our outstanding common stock and held meetings with stockholders representing approximately
40% of our outstanding common stock. The remaining stockholders, representing approximately 30% of our outstanding common stock, either
did not respond to our outreach efforts or expressed no concerns. During those meetings, we typically discussed our compensation philosophy,
performance, strategy, capital allocation, corporate governance and ESG initiatives. Some general themes arising from those conversations
were that our investors would like to better understand: (i) how we align performance and compensation, (ii) our approach to, and progress
on, our ESG initiatives, and (iii) our progress on our transformational strategy and how we expect to drive increased stockholder value.</P>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">In response to the feedback received
through our stockholder outreach communications in 2021, and in prior years, we have implemented changes to our compensation programs,
including: (i) maintaining an even split between time-based and performance-based equity grants made to our Chief Executive Officer, (ii)
utilizing a relative metric based on total stockholder return in our Chief Executive Officer&rsquo;s 2020 new-hire performance-based stock
option grant, and (iii) in 2021, awarding premium-priced stock options with an exercise price that is 10% above the closing price of our
common stock on the grant date, all of which we believe further aligns the goals and objectives of our executive officers with those of
our stockholders. In 2021, we also completed our ESG materiality assessment, which included direct feedback from our outreach to certain
stockholders, and we began to incorporate and plan for expanded ESG-related disclosures regarding our values, approach to, and progress
on, ESG issues, including disclosures made during our June 2021 Investor Day and above in this Proxy Statement.</P>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">At our 2021 Annual Meeting, we
presented our stockholders with a proposal to approve, on an advisory basis, the 2020 compensation of our named executive officers as
disclosed in our 2021 proxy statement. 77% of the shares voted on this proposal were cast in support of our 2020 named executive officer
compensation. The Compensation Committee does, and will continue to, consider the results of stockholders advisory votes on executive
compensation when making future decisions relating to our executive compensation programs and compensation for named executive officers.
We welcome, appreciate and will continue to solicit feedback from our stockholders, and will continue to consider this feedback as we
seek to enhance our compensation program and related narrative disclosure, including the information provided in the following discussion.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><A NAME="a_022"></A><FONT STYLE="font-size: 11pt">Compensation
Philosophy</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Compensation Committee oversees our overall
compensation program and approves our compensation policies. The overriding goal of our compensation program is to drive long-term high
performance and increase stockholder value through our pay programs and corporate culture. As a result, the Compensation Committee incorporates
performance into many aspects of our compensation program, including pay levels, incentive payouts, and pay opportunities. Corporate and
individual goals are set through our yearly budgeting and strategic planning processes and these goals are ultimately reviewed and approved
by the Board of Directors prior to, or at the beginning of, each year.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Compensation Committee, utilizing the structure
of our compensation program and, as appropriate, its discretion, implements our executive compensation program to reward our NEOs when
their performance meets or exceeds established goals. A significant portion of each NEO&rsquo;s incentive compensation is weighted towards
the management team&rsquo;s achievement against targeted goals (rather than individual performance), so that if we meet or exceed our
goals, the team earns awards at or above target levels. Conversely, if the team fails to meet the minimum thresholds, they will not be
awarded the targeted components of the performance-based compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As a general matter, the Compensation Committee
uses compensation data from the annual compensation study of competitive peer companies to inform its decisions about overall compensation
opportunities and specific compensation elements. Additionally, the Compensation Committee uses multiple reference points when establishing
targeted compensation levels, and it does not benchmark specific elements or total compensation to a specific level or percentile relative
to peer companies or the broader market. Rather than rely on a specific formula-based model, the Compensation Committee applies judgment
and discretion in establishing targeted pay levels, taking into account not only competitive market data, but also factors such as company,
business, and individual performance, scope of responsibility, critical needs and skill sets, leadership potential, and succession planning.
The Compensation Committee believes that retaining this discretion gives the Compensation Committee the ability to more accurately reflect
factors and individual contributions that cannot be absolutely quantified. The Compensation Committee also considers our primary physical
locations near Boston, Massachusetts, the high level of competition for highly qualified life sciences employees in that geographic area,
and the need to remain competitive with the compensation offered by other life sciences companies to ensure the successful recruitment
and retention of top performing executives and employees, all of which have become more challenging in recent years. We have designed
our compensation program to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Motivate and reward our executives to achieve or exceed our financial and operating performance objectives;</TD>
        </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Propel our business forward through a focus on operational excellence and execution of our business strategy;</TD>
        </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Link each NEO&rsquo;s compensation with specific business objectives;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="padding-right: 10.5pt">Align each NEO&rsquo;s compensation with the interests of long-term stockholders by tying a significant
        portion of total compensation opportunity to the value of our stock;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 10.5pt">&nbsp;</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="padding-right: 10.65pt">Reinforce accountability and cooperation by tying a significant portion of total NEO compensation to overall
        company performance;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 10.65pt">&nbsp;</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Attract and retain talented leaders who can drive and implement our growth, transformation, and operational
        excellence strategies;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Reward individual performance and accomplishments; and</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="padding-right: 0pt">Keep the compensation packages competitive with those of our peers and other companies with whom we compete
        for talented employees.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><A NAME="a_023"></A><FONT STYLE="font-size: 11pt">Key
Compensation Policies and Practices</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Key Features</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">We believe that our executive compensation
program includes key features that align the performance and objectives of the NEOs and our company with the interests of our stockholders
and does not include features that misalign NEO and corporate objectives with stockholder interests. During 2021, we arranged our compensation
program in accordance with the practices set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="background-color: rgb(53,94,145); vertical-align: top; text-align: left">
    <TD STYLE="width: 100%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 182.95pt; text-align: center; color: white"><B>What We Do</B></P> </TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD>Link a significant portion of NEO compensation to company performance</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD STYLE="padding-right: 19.25pt">Align a significant portion of NEO compensation with stockholders&rsquo; interests through
    long-term incentives, including historical grants of performance-based awards with exclusively multi-year performance metrics and
    made grants of 2021 performance-based awards in the form of premium priced stock options with a 3-year vesting period</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD STYLE="padding-right: 20pt">Structure our equity grants to NEOs to be evenly divided between time-vesting and performance-based awards
        (excepting certain new- hire awards of time-vesting stock options)</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD>Balance short-term and long-term incentives</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD STYLE="padding-right: 10pt">Require NEOs to own significant amounts of stock through robust stock ownership guidelines (see page
47 of this Proxy Statement)</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD>Include minimum vesting requirements for equity awards in our equity compensation plan, subject to certain exceptions</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD>Incorporate double-trigger vesting upon a change in control for all equity awards to NEOs</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD>Cap annual cash bonus payouts at 2x target</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD>Utilize an independent compensation consultant annually to assist our assessment of our compensation program</TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; color: #355E91">&uuml;</FONT></TD>
    <TD>Solicit say-on-pay votes annually</TD></TR>
  </TABLE>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; color: Red">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="background-color: rgb(53,94,145); vertical-align: top; text-align: left">
    <TD STYLE="width: 100%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 182.95pt; text-align: center; color: white"><B>What We Don&rsquo;t Do</B></P> </TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0pt; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; color: #355E91">&Auml;</FONT></TD>
    <TD STYLE="text-align: justify">No automatic or guaranteed annual salary increases</TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0pt; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; color: #355E91">&Auml;</FONT></TD>
    <TD STYLE="text-align: justify">No guaranteed short-term or long-term incentive awards</TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0pt; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; color: #355E91">&Auml;</FONT></TD>
    <TD STYLE="text-align: justify">No repricing of stock options or SARs without stockholder approval</TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0pt; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; color: #355E91">&Auml;</FONT></TD>
    <TD STYLE="text-align: justify">No hedging/pledging of our stock per our Insider Trading Policy</TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0pt; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; color: #355E91">&Auml;</FONT></TD>
    <TD STYLE="text-align: justify">No &ldquo;golden parachute&rdquo; excise tax gross-ups</TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0pt; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; color: #355E91">&Auml;</FONT></TD>
    <TD STYLE="text-align: justify">No granting of stock options or SARs at a per share exercise price less than fair market value on the grant
        date</TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0pt; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; color: #355E91">&Auml;</FONT></TD>
    <TD STYLE="text-align: justify">No pension or other special benefits</TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0pt; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; color: #355E91">&Auml;</FONT></TD>
    <TD STYLE="text-align: justify">No perquisites</TD> </TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.6pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91"><I>Key Performance Factors</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">In setting the compensation for our
executive officers, the Compensation Committee relies primarily on our overall financial performance and an assessment of each individual&rsquo;s
performance and contribution to the achievement of our goals. The Compensation Committee seeks to align the metrics it uses in evaluating
our executive compensation with the metrics that we use to evaluate our performance more generally, including those metrics that we publicly
disclose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2021, the Compensation Committee
began to use premium priced stock options as a performance-based equity award to further align individual performance with our goals for
growth and stockholder value appreciation. The Compensation Committee balances corporate goals and objectives, including certain financial
metrics, product development, share price performance and revenue growth, and individual performance, including, but not limited to, completion
of strategic projects/transactions and new product releases, in making decisions on annual cash bonus payments. Additionally, the Compensation
Committee considers the recommendations of the Chief Executive Officer in its review with regard to other NEO performance (other than
the Chief Executive Officer) and resulting compensation decisions. In 2021, decisions on annual cash bonus payments also included as a
key component the Compensation Committee&rsquo;s consideration of the role the NEOs played in guiding our company through the challenges
of the COVID-19 pandemic with no significant operational disruption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Peer Group and Role
of Compensation Consultant</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">In addition to corporate and individual
performance metrics, the Compensation Committee weighs other quantitative factors, such as general compensation trends, in making compensation
decisions. In this regard, the Compensation Committee periodically reviews surveys of executive compensation and information concerning
compensation at similarly situated companies. In 2021, as in prior years, the Compensation Committee engaged Aon&rsquo;s Human Capital
Solutions practice, a division of Aon plc (formerly known as Radford), to provide executive compensation consulting services to the Compensation
Committee, to assist the Compensation Committee in selecting an appropriate peer group for compensation comparisons, and to perform an
executive compensation review. The Compensation Committee has assessed the independence of Aon under the applicable SEC and NASDAQ Listing
Rules and concluded that the continued engagement of Aon did not raise any conflicts of interest and did not adversely affect Aon&rsquo;s
independence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The Compensation Committee, with the
assistance of Aon, has performed this analysis each year from 2015 through 2021, and currently intends to continue the practice of performing
this analysis yearly. In completing its analysis for 2021, the Compensation Committee reviewed competitive data compiled by Aon from a
peer group comprised of 20 companies in related businesses at similar stages of development and of similar size in terms of market capitalization
and employee population. The Compensation Committee also reviewed market data from the 2020 Radford Global Life Sciences Survey (the &ldquo;Radford
Survey&rdquo;) covering 101 public biopharmaceutical and medical device companies. The Compensation Committee uses competitive compensation
data from these peer company and industry reviews to inform its decisions about overall compensation opportunities and specific compensation
elements. Additionally, the Compensation Committee uses multiple reference points when establishing targeted compensation levels. While
the Compensation Committee considers benchmarking data and may factor certain benchmarking data elements into its compensation decisions,
it does not generally seek to benchmark specific compensation elements or total compensation to a specific level or percentile relative
to the peer companies or the broader United States market. Rather than rely on a specific formula-based model, the Compensation Committee
applies judgment and discretion in establishing targeted pay levels, considering not only competitive market data, but also factors such
as company, business, and individual performance, scope of responsibility, critical needs and skill sets, leadership potential, and succession
planning. The Compensation Committee believes that retaining this discretion gives the Compensation Committee the ability to more accurately
reflect factors and individual contributions that cannot be absolutely quantified. The Compensation Committee also considers our primary
locations near Boston, Massachusetts, the high level of competition for highly qualified life sciences employees in that area, and the
need to remain competitive with the compensation offered by other life sciences companies to ensure the successful recruitment and retention
of top performing executives and employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">With Radford&rsquo;s assistance, we
review and adjust our peer group annually to ensure that the industry data we review is relevant to our current and near-term future activities
and goals. We believe that the adjustments we made to our 2021 peer group are appropriate to better reflect changes in our company over
time, based on our history of strong financial performance, growing product pipeline, commercial strategies, and our Global Industrial
Classification System (GICS) Code as a Biotechnology company. Given this dynamic, we felt it appropriate to blend biotechnology companies
with medical device companies in a ratio of approximately 2/3 to 1/3, as we did in 2020. The Compensation Committee adopted the following
peer group in September 2020 for use in 2021 compensation decisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="background-color: rgb(53,94,145); border-bottom: Black 1pt solid; color: #355E91; font-style: italic; text-align: center"><FONT STYLE="color: White"><B>Peer
        Group Companies</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 25%">&nbsp;</TD>
    <TD STYLE="width: 24%; color: #355E91; font-style: italic; text-align: left"><U>Biotechnology Companies</U></TD>
    <TD STYLE="width: 2%; color: #355E91; font-style: italic">&nbsp;</TD>
    <TD STYLE="width: 24%; color: #355E91; font-style: italic; text-align: left"><U>Medical Device Companies</U></TD>
    <TD STYLE="width: 25%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">AMAG Pharmaceuticals, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">AtriCure, Inc.</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Avid Biosciences, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Atrion Corporation</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Collegium Pharmaceutical, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">AxoGen, Inc.</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Flexion Therapeutics, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">CryoLife, Inc.</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">MacroGenics, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Glaukos Corporation</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Momenta Pharmaceuticals, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Orthofix, Inc.</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Omeros Corporation</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">SurModics, Inc.</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Organogenesis Holdings Inc.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Radius Health, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Retrophin, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Spectrum Pharmaceuticals, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Vanda Pharmaceuticals, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Vericel Corporation</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 110.6pt">&nbsp;</P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 110.6pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; color: #355E91"><A NAME="a_024"></A><FONT STYLE="font-size: 11pt">2021
Compensation Decisions</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">Our 2021 NEO compensation was made up of three key components:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Base salary;</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Discretionary annual bonuses; and</TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="padding-right: 0pt">Equity-based long-term incentive awards, generally in the form of time-based and performance-based stock options
        and restricted stock units.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10pt; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Aside from Cheryl R. Blanchard, Ph.D., each of
the NEOs is an at-will employee with terms of employment documented on our standard form of offer letter. For additional detailed information
regarding the compensation of Dr. Blanchard resulting from her employment agreement with us, please see the section captioned &ldquo;<I>Other
Compensation Matters &ndash; Dr. Blanchard&rsquo;s Employment Agreement</I>&rdquo; below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Base Salary</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The first principal component of compensation
for our executive officers is base salary, which is paid to our NEOs in recognition of their talents and the unique skills each NEO possesses
and which are required to drive our company toward achievement of its goals and objectives. Base salaries for our NEOs are subject to
annual review by the Compensation Committee. For this purpose, the Compensation Committee considers a number of factors, including the
individual&rsquo;s level of responsibility, experience, and performance. The Compensation Committee also considers market practices as
described above, taking into account any contractual obligations. Salaries are reviewed and determined at the discretion of the Compensation
Committee on an annual basis, and there is no guaranteed year-over-year increase to any of the NEOs&rsquo; salaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">For 2021, base salaries and compensation
increases, as applicable, for the NEOs are set forth below. We hired Dr. Blanchard, Mr. Levitz, and Mr. Colleran in 2020, and their 2020
salaries reflect the annualized salaries approved by the Compensation Committee at the time of their hire (in the case of Dr. Blanchard,
her appointment as President and Chief Executive Officer on April 26, 2020). With the exception of Dr. Blanchard, all NEOs received a
3.5% salary increase, which was largely in line with the rest of our employees. Dr. Blanchard&rsquo;s salary increase was determined following
a review of competitive market compensation for her position as president and chief executive officer against companies within our peer
group, and in recognition of the contributions made by Dr. Blanchard in implementing the early stages of our business transformation while
simultaneously managing the challenges of the COVID-19 pandemic.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt; color: #2F5496"><B>2021
Base Salary</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt; color: #2F5496"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <TR STYLE="vertical-align: top; background-color: #355E91">
    <TD STYLE="width: 40%; text-align: center"><FONT STYLE="font-size: 10pt; color: white"><B>Name</B></FONT></TD>
    <TD STYLE="text-align: center; width: 20%"><FONT STYLE="font-size: 10pt; color: white"><B>2020 Salary</B></FONT></TD>
    <TD STYLE="text-align: center; width: 20%"><FONT STYLE="font-size: 10pt; color: white"><B>2021 Salary</B></FONT></TD>
    <TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-size: 10pt; color: white"><B>% Change</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Cheryl R. Blanchard, Ph.D.</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$625,000</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$668,400</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">6.9%</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD><FONT STYLE="font-size: 10pt"><B>Michael L. Levitz</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$450,000</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$456,400</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">3.5%</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>David B. Colleran</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$420,000</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$432,400</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">3.5%</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD><FONT STYLE="font-size: 10pt"><B>Thomas Finnerty</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$353,505</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$365,900</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">3.5%</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>James Loerop</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$381,563</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$394,900</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">3.5%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91"><I>Annual Cash Bonus</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.75pt 0pt 0pt">The second principal component of our compensation policy
for executive officers consists of cash bonuses, which are generally paid to our NEOs to motivate attainment of our near-term goals that
are consistent with our long-term strategic plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">Each NEO has a target annual bonus amount
established by the Compensation Committee at the beginning of each year that is expressed as a percentage of the NEO&rsquo;s base salary.
In 2021, these targets were unchanged from the targets from the prior year for individuals in similar positions. The Compensation Committee
establishes the target bonus amounts consistent with the compensation philosophy described above, including consideration of market practices,
and to provide, in its view, an appropriate balance between fixed (salary) and variable (bonus) cash compensation. The 2021 target bonus
amounts for the NEOs were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center; color: #2F5496"><B>2021 Annual Cash Bonus
Targets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <TR STYLE="vertical-align: top; background-color: #355E91">
    <TD STYLE="width: 40%; padding-left: 50.25pt"><FONT STYLE="font-size: 10pt; color: white"><B>Name</B></FONT></TD>
    <TD STYLE="width: 30%; padding-left: 65.75pt; text-align: center"><FONT STYLE="font-size: 10pt; color: white"><B>% of Salary</B></FONT></TD>
    <TD STYLE="width: 30%; padding-left: 44pt; text-align: center"><FONT STYLE="font-size: 10pt; color: white"><B>Amount at Target</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 4pt"><FONT STYLE="font-size: 10pt"><B>Cheryl R. Blanchard, Ph.D.</B></FONT></TD>
    <TD STYLE="padding-left: 65.75pt; text-align: center"><FONT STYLE="font-size: 10pt">85%</FONT></TD>
    <TD STYLE="padding-left: 44pt; text-align: center"><FONT STYLE="font-size: 10pt">$568,140</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD STYLE="padding-left: 4pt"><FONT STYLE="font-size: 10pt"><B>Michael L. Levitz</B></FONT></TD>
    <TD STYLE="padding-left: 65.75pt; text-align: center"><FONT STYLE="font-size: 10pt">45%</FONT></TD>
    <TD STYLE="padding-left: 44pt; text-align: center"><FONT STYLE="font-size: 10pt">$205,380</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 4pt"><FONT STYLE="font-size: 10pt"><B>David B. Colleran</B></FONT></TD>
    <TD STYLE="padding-left: 65.75pt; text-align: center"><FONT STYLE="font-size: 10pt">45%</FONT></TD>
    <TD STYLE="padding-left: 44pt; text-align: center"><FONT STYLE="font-size: 10pt">$194,580</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD STYLE="padding-left: 4pt"><FONT STYLE="font-size: 10pt"><B>Thomas Finnerty</B></FONT></TD>
    <TD STYLE="padding-left: 65.75pt; text-align: center"><FONT STYLE="font-size: 10pt">45%</FONT></TD>
    <TD STYLE="padding-left: 44pt; text-align: center"><FONT STYLE="font-size: 10pt">$164,655</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 4pt"><FONT STYLE="font-size: 10pt"><B>James Loerop</B></FONT></TD>
    <TD STYLE="padding-left: 65.75pt; text-align: center"><FONT STYLE="font-size: 10pt">45%</FONT></TD>
    <TD STYLE="padding-left: 44pt; text-align: center"><FONT STYLE="font-size: 10pt">$177,705</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.0pt 0pt 0pt; text-align: justify">Actual bonus amounts awarded are not
formulaic and depend on the Compensation Committee&rsquo;s assessment of both our business and individual NEO performance after the completion
of each year. The Compensation Committee considers our financial performance, our overall operational performance, and our contribution
to increasing stockholder value at its discretion to determine an appropriate level of baseline cash bonus compensation for our NEOs.
Once the Compensation Committee has established this baseline, it considers the applicable individual performance with respect to individual
goals and contribution to overall company performance in its discretion to adjust each individual NEO&rsquo;s cash bonus award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.95pt 0pt 0pt; text-align: justify">After the completion of the 2021
fiscal year, the Compensation Committee, with the assistance of our Chief Executive Officer, reviewed our performance, as well as the
individual performance of each executive officer (other than her own performance). The accomplishments set forth in the Executive Summary
section titled &ldquo;<I>Our Fiscal Year 2021 Business Performance</I>&rdquo; were considered in this review. For the year, the Compensation
Committee determined that we continued to make strong overall business progress transforming our organization and integrating our 2020
acquisitions, especially in light of the ongoing challenges presented by the unpredictable rise and fall of cases of COVID-19 during 2021.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.95pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.95pt 0pt 0pt; text-align: justify">While the COVID-19 pandemic, including
related supply chain and staffing challenges, had an impact on the financial results delivered by the organization, we achieved significant
strategic and operational goals as set forth in the section captioned &ldquo;<I>Our Fiscal Year 2021 Business Performance</I>&rdquo; above,
including new product launches of our Tactoset product for suture anchor augmentation and our WristMotion Total Wrist Arthroplasty system,
as well as completion of enrollment in our Cingal pilot study. In addition, we: (i) received 510(k) clearance from the U.S. Food and Drug
Administration for our reverse shoulder system, which paves the way for expansion of our shoulder implant portfolio, (ii) integrated Parcus
Medical and Arthrosurface into our global enterprise resource planning system, (iii) launched a focused plan to advance ESG initiatives
throughout our company, (iv) continued to strengthen our management team and Board of Directors with two key senior management team additions
and one new Board member, and (v) continued successful guidance of our company through the COVID-19 pandemic with no significant operational
disruptions or reductions in workforce.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.95pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.95pt 0pt 0pt; text-align: justify">These achievements, combined with
our efforts in 2020, continued to transform our company and allowed us to continue to focus on execution of our multi-year strategy and
value creation for our stakeholders over the coming years. As a result, the Compensation Committee, using its informed judgment in considering
our performance in relation to 2021 corporate objectives and macroeconomic business factors, such as the COVID-19 pandemic, and related
supply chain and staffing challenges, and without any pre-established formulas or target levels, set a cash bonus payment baseline of
100% of the target for each NEO, subject to adjustment based on individual performance achievement with respect to individual goals, which
included goals and objectives in the financial, R&amp;D pipeline/new product development, clinical program, and employee engagement categories,
and contributions to overall company performance. Overall, each NEO had a strong performance during the year and significantly contributed
to our business and financial highlights outlined above. The bonus targets based on annualized salary and final, individual actual bonus
amounts paid are included in the table below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center; color: #2F5496"><B>2021 Cash Bonus Decisions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <TR STYLE="vertical-align: top; background-color: #355E91">
    <TD STYLE="width: 40%; padding-left: 60.6pt; text-align: center"><FONT STYLE="font-size: 10pt; color: white"><B>Name</B></FONT></TD>
    <TD STYLE="width: 20%; text-align: right"><FONT STYLE="font-size: 10pt; color: white"><B>Bonus Target</B></FONT></TD>
    <TD STYLE="width: 20%; text-align: right"><FONT STYLE="font-size: 10pt; color: white"><B>% Achieved</B></FONT></TD>
    <TD STYLE="width: 20%; text-align: right"><FONT STYLE="font-size: 10pt; color: white"><B>Bonus Paid</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 4pt"><FONT STYLE="font-size: 10pt"><B>Cheryl R. Blanchard, Ph.D.</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">$568,140</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100%</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">$568,140</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD STYLE="padding-left: 4pt"><FONT STYLE="font-size: 10pt"><B>Michael L. Levitz</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">$205,380</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100%</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">$205,362</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 4pt"><FONT STYLE="font-size: 10pt"><B>David B. Colleran</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">$194,580</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100%</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">$194,597</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD STYLE="padding-left: 4pt"><FONT STYLE="font-size: 10pt"><B>Thomas Finnerty</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">$164,655</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100%</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">$164,600</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 4pt"><FONT STYLE="font-size: 10pt"><B>James Loerop*</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">$177,705</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">n/a</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">n/a</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 8pt">* Mr. Loerop resigned as of January 27, 2022 and was not eligible for a 2021 bonus payment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Equity-Based Grants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The third principal component
of our compensation policy for executive officers consists of grants under our equity incentive plan, which are generally provided to
our NEOs to align their goals and objectives with the interests of our stockholders, to motivate attainment of our long-term strategic
vision, and for retention purposes. Under our equity compensation plan, NEOs may be granted stock options or other forms of equity awards,
including restricted stock awards and units, performance-based equity awards, and stock appreciation rights. Equity awards typically are
approved at regularly scheduled Compensation Committee meetings, generally during the first quarter of each year given the meeting&rsquo;s
proximity to the beginning of the performance period for performance-based awards, and generally granted effective on the third full business
day following our announcement of financial and business results for the completed prior fiscal year. During 2019, we implemented a deferred
stock program that allows our directors and executives, at their discretion, to defer settlement of restricted stock unit awards granted
to them in 2020 and thereafter. We implemented this program, and continue to maintain it, to remain competitive with market practices
and to encourage our NEOs to hold shares of our common stock, thereby aligning their long-term incentives with those of our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">This year, we are seeking
stockholder approval to make an additional 950,000 shares available for issuance under our equity incentive plan. As discussed
further in Proposal 2, as we refine our strategic objectives and initiatives and position our company for future growth, and as we
attempt to attract, incent and retain key employees in a rapidly changing and challenging hiring market within an already
geographically competitive life sciences landscape, we are seeking stockholder approval for an amount of additional shares which,
based on our estimates, would support our equity compensation program over the course of the next year based on our current share
price, recent burn rate history, and new-hire and annual grant practices. These additional shares will help ensure that we are able
to appropriately recruit, motivate, and retain our employees over the next year. Furthermore, in connection with this approval and
our multi-year business strategy, we will continue to review our compensation strategy as a whole, including an ongoing analysis and
use of the most appropriate equity tools, which are selected in order to maintain performance-based compensation that will
competitively incentivize our management team and employees while also driving long-term stockholder value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The amount and form of equity-based
grants each year are determined by the Compensation Committee using the compensation philosophy described above, including the Compensation
Committee&rsquo;s informed judgment, and taking into account our performance, competitive market practices, past and expected individual
performance achievements, past and expected contributions to overall company performance, and the need to attract and retain talented
executives in an extremely competitive environment who can drive and implement our transformation, growth and operational excellence strategies.
For the last several years, the Compensation Committee has increasingly used performance-based equity awards to align the interests of
our NEOs with those of our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In 2021, each of our NEOs, including our Chief Executive Officer, was granted equity awards, the value
of which was generally evenly split between time-vesting restricted stock units and performance based, time-vesting stock options in the
form of premium priced stock options. The restricted stock units vest in three equal annual installments beginning one year from the grant
date. The premium priced stock options vest in three equal annual installments beginning one year from the grant date, with an exercise
price that is 110% of the fair market value on the grant date. We believe premium priced stock options granted with an exercise price
of 110% of the fair market value of our common stock on the grant date inherently drive individual and company performance, while strongly
aligning executive interests with stockholder interests by generating stockholder value through increased stock performance over time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">For 2021, the Compensation Committee
awarded the following balanced mix of time-vesting restricted stock units and premium priced stock options:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <TR STYLE="vertical-align: top; background-color: #355E91">
    <TD STYLE="width: 40%; padding-left: 60.6pt; text-align: center"><FONT STYLE="font-size: 10pt; color: white"><B>Name</B></FONT></TD>
    <TD STYLE="width: 30%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right; color: white"><B>Time-Vesting
        RSUs</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right; color: white"><B>(#
        of Shares)</B></P></TD>
    <TD STYLE="width: 30%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right; color: white"><B>Premium
        Priced Stock Options</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right; color: white"><B>(#
        of Shares)</B></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 4pt"><FONT STYLE="font-size: 10pt"><B>Cheryl R. Blanchard, Ph.D.</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">43,259</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">108,398</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD STYLE="padding-left: 4pt"><FONT STYLE="font-size: 10pt; color: black"><B>Michael L. Levitz</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: black">13,315</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: black">33,363</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 4pt"><FONT STYLE="font-size: 10pt"><B>David B. Colleran</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">11,047</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">27,681</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD STYLE="padding-left: 4pt"><FONT STYLE="font-size: 10pt; color: black"><B>Thomas Finnerty</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: black">7,645</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt; color: black">19,158</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 4pt"><FONT STYLE="font-size: 10pt"><B>James Loerop</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6,705</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">16,802</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Vesting of 2019 Performance
Restricted Unit Awards</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">In 2019, we issued performance
restricted unit (PSU) awards with a three-year performance period ending on December 31, 2021. Payouts under these PSU awards were based
on our achievement of metrics regarding our vitality index (55% of total award), Tactoset product launch, and implementation of a hybrid
sales team (30% of total award), and Adjusted EBITDA margin (15% of total award). During the performance period, we exceeded our vitality
index metric with a vitality index of greater than 30% and launched Tactoset and staffed a new hybrid sales team model, but our Adjusted
EBITDA of over 11% in 2021 did not achieve the established Adjusted EBITDA margin metric. Based upon these achievements, the Compensation
Committee certified payouts pursuant to the 2019 PSU awards at 112.5%. Only Mr. Finnerty and Mr. Loerop received the 2019 PSU grants as the other NEOs were not yet at
the company in their current positions.</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; color: #355E91">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; color: #355E91"><A NAME="a_025"></A><FONT STYLE="font-size: 11pt">Other
Compensation Matters</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Employment and Executive
Retention Agreements Effective at December 31, 2021</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">Prior to 2021, we had entered into
an employment agreement with Cheryl R. Blanchard (as described below under &ldquo;Dr. Blanchard&rsquo;s Employment Agreement&rdquo;)
and executive retention agreements with each of the other NEOs. While the NEOs remain employed at-will, these agreements are intended
to provide market-level severance compensation to be competitive with our peer group of comparable companies and to promote retention.
We believe that these agreements are fair to the executives and to our stockholders because they provide relatively modest severance
in exchange for the restrictive covenants that help protect our company. These restrictive covenants include standard non-competition,
non-solicitation, non-disparagement, and confidentiality restrictions. The agreements are discussed in connection with the &ldquo;Potential
Payments Upon Termination or Change in Control&rdquo; table on page 44 below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Each agreement provides for severance
benefits that may be triggered by an involuntary termination of employment by us without &ldquo;cause&rdquo; or by the executive for &ldquo;good
reason&rdquo; (as defined in each agreement), or a qualifying termination. The level of severance benefits depends on whether the involuntary
termination occurs during or outside of a change in control protected period that runs from three months before until 12 months after
a change in control (as defined in each agreement). In addition, the agreements provide for full vesting of outstanding equity awards
upon a qualifying termination occurring during the period from three months before until 12 months after a change in control for awards
granted after January 29, 2019. Equity awards granted prior to January 29, 2019 will continue to vest in full upon the occurrence of a
change in control in accordance with the award terms. Except as described in this paragraph and for certain equity grants made to Dr.
Blanchard upon her appointment as our President and Chief Executive Officer, none of the equity grants made to our NEOs provide for accelerated
vesting upon termination of their employment by us without &ldquo;cause&rdquo; or by the executive for &ldquo;good reason.&rdquo; If &ldquo;golden
parachute&rdquo; excise taxes would be triggered by payments due in connection with termination during a change in control protected period,
the agreements provide for a cut-back in the payments to avoid the excise tax, if the cut-back would result in a greater after-tax benefit
to the executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The following summarizes the cash and
health benefits (i.e., company payment of premiums under our health plans) severance provided to the NEOs as of December 31, 2021:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="background-color: rgb(53,94,145); vertical-align: bottom">
    <TD STYLE="text-align: left"><FONT STYLE="color: White"><B>Trigger</B></FONT></TD>
    <TD><FONT STYLE="color: White"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: White"><B>Type of Severance</B></FONT></TD>
    <TD><FONT STYLE="color: White"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: White"><B>CEO</B></FONT></TD>
    <TD><FONT STYLE="color: White"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="color: White"><B>Other NEOs</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 25%; text-align: left">Termination without cause or with</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 24%; text-align: left">Cash severance</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 24%; text-align: left">18 months&rsquo; salary</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 24%; text-align: left">12 months&rsquo; salary</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">good reason, not in connection with a</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Health benefits</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">18 months at active</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">12 months at active</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD> change in control</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> employee rates</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"> employee rates</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left">Termination without cause or with</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Cash severance</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">2x the sum of 12 months&rsquo;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">12 months&rsquo; salary plus target</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left">good reason, within 3 months before</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">salary plus target bonus</TD>
    <TD>&nbsp;</TD>
    <TD>bonus</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left">or 12 months after a change in control</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Health benefits</TD>
    <TD>&nbsp;</TD>
    <TD>18 months at active</TD>
    <TD>&nbsp;</TD>
    <TD>12 months at active</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">employee rates</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">employee rates</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 26.4pt 0pt 111.2pt; text-indent: -107.35pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.0pt 0pt 111.2pt; text-indent: -107.35pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 26.4pt 0pt 111.2pt; text-indent: -107.35pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 49.0pt 0pt 12.85pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11.8pt 0pt 12.0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 49.85pt 0pt 12.0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">In addition, in accordance with the terms of Dr. Blanchard&rsquo;s employment agreement, if Dr. Blanchard&rsquo;s
employment had been terminated &ldquo;without cause&rdquo; or Dr. Blanchard terminated her employment with us for &ldquo;good reason&rdquo;
not due to disability prior to December 31, 2021, she would have been entitled to pro rata vesting of the time-vesting restricted stock
unit grant and the time-vesting stock option grant awarded to her on April 26, 2020 in conjunction with the commencement of her employment
as President and Chief Executive Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Dr. Blanchard&rsquo;s
Employment Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.95pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In early 2020, our then current Chief
Executive Officer, Mr. Joseph Darling, unexpectedly passed away. Following Mr. Darling&rsquo;s passing, the Board of Directors briefly
activated an interim Office of the President to provide leadership and oversight of day-to-day affairs before appointing Dr. Blanchard
as our interim Chief Executive Officer, effective February 10, 2020, pursuant to the terms of a letter agreement executed between her
and our company. Dr. Blanchard was later appointed our President and Chief Executive Officer effective April 26, 2020. In connection with
Dr. Blanchard&rsquo;s transition to President and Chief Executive Officer, we and Dr. Blanchard entered into an employment agreement effective
as of April 23, 2020 (the &ldquo;Agreement&rdquo;). The Agreement has an initial term of April 26, 2020 through December 31, 2021, which
automatically renews for successive 1-year periods unless either party elects nonrenewal in accordance with the Agreement. The Agreement
provided for an initial annual base salary of $625,000 and a target annual bonus opportunity equal to 85% percent of annual base salary.
In addition, the Agreement provided for the following initial equity awards: (i) a time-based restricted stock unit grant covering 73,726
shares, eligible to vest in equal annual installments over three years; (ii) a performance-based restricted stock unit grant covering
80,620 shares at target, eligible to vest up to 150% of the target shares on February 25, 2023; (iii) a time-based stock option grant
covering 104,638 shares, eligible to vest in equal annual installments over three years; and (iv) a performance-based stock option grant
covering 104,638 shares at target, eligible to vest up to 150% of the target shares based on our total stockholder return relative to
a comparison group of companies set forth in the Agreement through December 31, 2022. In each case, vesting generally requires Dr. Blanchard&rsquo;s
continued employment through the relevant vesting date. The Agreement provides for (i) reimbursement of reasonable business expenses,
(ii) the payment of up to $10,000 in legal fees incurred by Dr. Blanchard in connection with the Agreement, (iii) participation in our
benefit plans, and (iv) 30 paid vacation days per year. Under the Agreement, if Dr. Blanchard&rsquo;s employment is terminated due to
death, disability (as defined in the Agreement), by us without &ldquo;cause&rdquo; (as defined in the Agreement and including our nonrenewal
of the term of the Agreement), or by Dr. Blanchard for &ldquo;good reason&rdquo; (as defined in the Agreement), Dr. Blanchard would become
entitled to (i) 18 months of base salary, (ii) continued payment of company premiums under our benefit plans for 18 months and (iii) if
such termination is not due to disability and occurs prior to December 31, 2021, pro rata vesting of the time-based restricted stock unit
grant and the time-based option grant described above. Notwithstanding the foregoing, if such a termination without cause or for good
reason occurs within 3 months prior to or 12 months after a change in control (as defined in the Agreement), Dr. Blanchard would become
entitled to (i) 2 times the sum of her base salary and her target annual bonus, (ii) continued payment of company premiums under our benefit
plans for 18 months and (iii) vesting of her equity awards. The performance-based restricted stock unit grant and each other award with
a performance metric-based vesting condition (other than a total stockholder return-based vesting condition) would vest based on the greater
of assumed target performance or actual performance measured through the date of termination. For the total stockholder return-based
option grant (and any other award with a total stockholder return-based vesting condition), the applicable performance period would be
shortened to end as of immediately prior to the change in control and performance would be measured at such time. Any such severance benefits
under the Agreement are contingent on Dr. Blanchard entering into and not revoking a general release of claims in favor of our company,
our affiliates, and our service providers. Finally, the Agreement contains customary covenants related to non-competition and non-solicitation
for 12 months following termination of employment, as well as customary covenants related to confidentiality, inventions and intellectual
property rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In addition to the Agreement, we
entered into a letter agreement with Dr. Blanchard in connection with her appointment as our interim Chief Executive Officer under which
she was employed at will and we: (i) paid her base salary compensation at an annualized rate of $600,000, which resulted in base salary
payments of $115,385, (ii) paid her a cash retention bonus of $127,500, (iii) provided additional monthly payments of $3,448.28 in lieu
of her participation in our company&rsquo;s health plans, (iv) granted her 4,231 restricted stock units on February 25, 2020, and (v)
provided for the payment of up to $3,000 in legal fees incurred by Dr. Blanchard in connection with the letter agreement. The letter agreement
was executed on February 25, 2020 and covered the period from her appointment as interim Chief Executive Officer on February 10, 2020
through her appointment as our President and Chief Executive Officer on April 26, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Other Compensation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The NEOs are eligible to participate
in our health and welfare programs, 401(k) plan with company matching, and other benefit programs on the same basis as other employees.
This includes our Employee Stock Purchase Plan, or ESPP, which stockholders approved at our 2021 Annual Meeting. Our ESPP provides the
opportunity for all eligible U.S. based employees, including our NEOs, to purchase company stock, further aligning management and stockholder
interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Deductibility of Executive
Compensation and Accounting Considerations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">Section 162(m) of the Internal Revenue
Code generally limits our annual corporate tax deduction for compensation paid to each of our &ldquo;covered employees&rdquo; to $1 million.
&ldquo;Covered employees&rdquo; include anyone who served as chief executive officer or chief financial officer during any part of a year
and the next three most highly compensated named executive officers for that year. In addition, once a person is considered a &ldquo;covered
employee,&rdquo; that person remains a covered employee in all subsequent years (including after the person leaves our service or changes
roles). The American Rescue Plan Act of 2021 updated Section 162(m) of the Internal Revenue Code, effective in 2026, to expand the number
of &ldquo;covered employees&rdquo; subject to the $1 million deduction limit to include the next five highest compensated employees; however
this new group of employees will not retain the perpetual &ldquo;covered employee&rdquo; status and will be determined annually. Consequently,
we generally will not be entitled to a U.S. tax deduction for compensation paid in any year to our named executive officers and our other
&ldquo;covered employees&rdquo; in excess of $1 million. While considering tax deductibility as only one of several considerations in
determining compensation, we believe that the tax deduction limitation should not compromise our ability to structure compensation programs
that provide benefits to us that outweigh the potential benefit of a tax deduction and, therefore, may approve compensation that is not
deductible for tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">We follow the Financial Accounting Standard
Board&rsquo;s Accounting Standards Codification Topic 718 for our stock-based compensation awards, which requires us to measure the compensation
expense for all share-based awards based on the grant date &ldquo;fair value&rdquo; of these awards. This calculation is performed for
accounting purposes and reported in the executive compensation tables required by the federal securities laws, even though the recipient
of the awards may realize no value from their awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We have not provided or committed
to provide any NEO with a gross-up or other reimbursement for tax amounts the executive might pay pursuant to Section 280G or Section
409A of the Internal Revenue Code. Section 280G and related sections of the Internal Revenue Code provide that an executive officer and
certain persons who hold significant stockholder interests and certain other service providers could be subject to significant additional
taxes if they receive payments or benefits in connection with a change in control that exceeds certain limits, and that we or our successor
could lose a deduction on the amounts subject to the additional tax. Section 409A of the Internal Revenue Code also imposes additional
significant taxes on the individual in the event that an executive officer, director or service provider of certain types receives &ldquo;deferred
compensation&rdquo; that does not meet the requirements of Section 409A of the Internal Revenue Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Role of Management
in Determining Compensation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The Compensation Committee, which is
comprised entirely of independent directors, is responsible for establishing and implementing our executive compensation philosophy and
for ensuring that the total compensation paid to our NEOs and other executives is fair, competitive and motivates high performance. The
Compensation Committee is solely responsible for compensation decisions regarding our Chief Executive Officer. When making compensation
recommendations for NEOs other than the Chief Executive Officer, the Compensation Committee expects to seek and consider the advice and
counsel of the Chief Executive Officer, given her direct day-to-day working relationship with those executives. Taking this feedback into
consideration, the Compensation Committee will engage in discussions and make final determinations related to compensation paid to the
NEOs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Risk Considerations
in Our Compensation Programs</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The Compensation Committee believes
that risks arising from our policies and practices for compensating employees are not reasonably likely to have a material adverse effect
on our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Compensation Clawback</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">All awards, amounts or benefits received
or outstanding under the Plan by the NEOs are subject to clawback, cancellation, recoupment, rescission, payback, reduction or other similar
action in accordance with the terms of any clawback or similar policy or any applicable law related to such actions, as may be in effect
from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91"><I>Prohibition on Hedging, Pledging, and Short
Sales</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">Our Insider Trading Policy prohibits the NEOs from hedging
or pledging our stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91"><I>Stock Retention Guidelines</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">Our stock retention guidelines generally
require each NEO to beneficially own certain amounts of our common stock. Generally, these guidelines require the Chief Executive Officer
to beneficially own, at a minimum, either (a) 50,000 outstanding shares of common stock or (b) a number of shares (or vested share equivalents)
of common stock having a market value equal to three times the amount of his or her base salary. They require any other NEO to beneficially
own, at a minimum, either (a) 10,000 outstanding shares of common stock or (b) a number of shares (or vested share equivalents) of common
stock having a market value equal to the amount of his or her base salary. Any individual initially designated as an executive officer has
five years to achieve compliance. Each NEO is currently in compliance or within the five-year grace period. See the section captioned
&ldquo;<I>Director and Executive Officer Stock Retention Guidelines</I>&rdquo; elsewhere in this Proxy Statement for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0.8in; text-align: center; color: #355E91"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0.8in; text-align: center; color: #355E91"><FONT STYLE="font-size: 13pt"><A NAME="a_026"></A>Compensation
Committee Report</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Compensation Committee of the Board of Directors
of Anika Therapeutics, Inc., or Anika, has reviewed and discussed with the management of Anika Therapeutics, Inc. the section entitled
&ldquo;Compensation Discussion and Analysis&rdquo; contained in this Proxy Statement. Based on its review and discussions with management,
the Compensation Committee recommended to the Board that the section entitled &ldquo;Compensation Discussion and Analysis&rdquo; be included
in Anika&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, and this Proxy Statement for the 2022 Annual
Meeting of Stockholders. This report is submitted by the following independent directors who comprise the Compensation Committee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 33%; text-align: center">John B. Henneman, III, Chair</TD>
    <TD STYLE="text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 33%; text-align: center">Raymond J. Land</TD>
    <TD STYLE="text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center">Glenn R. Larsen, Ph.D.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">THE FOREGOING REPORT SHOULD NOT
BE DEEMED INCORPORATED BY REFERENCE INTO ANY FILING UNDER THE SECURITIES ACT OF 1933 OR UNDER THE SECURITIES EXCHANGE ACT OF 1934 BY ANY
GENERAL STATEMENT INCORPORATING BY REFERENCE THIS PROXY STATEMENT, EXCEPT TO THE EXTENT THAT ANIKA THERAPEUTICS, INC. SPECIFICALLY INCORPORATES
THIS INFORMATION BY REFERENCE, AND SHALL NOT OTHERWISE BE DEEMED FILED UNDER EITHER OF SUCH ACTS.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt 0pt 57.2pt; text-align: center; color: #355E91"><B><I></I></B></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt 0pt 57.2pt; text-align: center; color: #355E91"><FONT STYLE="font-size: 13pt"><B><I><A NAME="a_027"></A>Executive
and Director Compensation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91"><A NAME="a_028"></A><FONT STYLE="font-size: 11pt"><B>Summary Compensation
Table</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 44.35pt">The following table summarizes the compensation information
in respect of our NEOs for the year ended December 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: Red">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: #1F497D">
    <TD STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Name and Principal Position</TD><TD STYLE="color: white; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap; color: white; font-weight: bold">Year</TD><TD STYLE="color: white; font-weight: bold; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1pt solid">Salary ($)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: 700; color: white"><SUP>(1)</SUP></FONT></TD><TD STYLE="color: white; font-weight: bold; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1pt solid">Bonus <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: 700; color: white">($)<SUP>(2)</SUP></FONT></TD><TD STYLE="color: white; font-weight: bold; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1pt solid">Stock Awards <BR>
($)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: 700; color: white"><SUP>(3)</SUP></FONT></TD><TD STYLE="color: white; font-weight: bold; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1pt solid">Option Awards <BR>
($) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: 700; color: white"><SUP>(3)</SUP></FONT></TD><TD STYLE="color: white; font-weight: bold; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; font-style: normal; text-align: center; border-bottom: Black 1pt solid">All Other <BR>
Compensation <BR>
($) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: 700; color: white"><SUP>(4)</SUP></FONT></TD><TD STYLE="color: white; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total ($)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="width: 37%; text-align: left">Cheryl R. Blanchard, Ph.D.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 6%; text-align: center">2021</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">668,400</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">568,140</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">1,470,806</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">1,471,831</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">23,431</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">4,202,608</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left">President and Chief</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2020</TD><TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">548,077</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(5)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">458,510</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(6)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,335,439</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(7)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,659,450</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(8)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">27,958</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(9)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,029,434</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left">Executive Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2019</TD><TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Michael L. Levitz</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2021</TD><TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">456,400</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">205,362</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">452,710</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">453,004</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">21,380</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,588,856</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">EVP, Chief Financial Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2020</TD><TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">173,077</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">73,601</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">799,971</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">799,993</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">11,318</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,857,960</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">and Treasurer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2019</TD><TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left">David B. Colleran</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2021</TD><TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">432,400</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">194,597</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">375,598</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">375,853</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">22,064</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,400,513</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left">EVP, General Counsel</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2020</TD><TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">344,077</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">143,931</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">645,900</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">553,445</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">18,263</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,705,616</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left">and Secretary</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2019</TD><TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Thomas Finnerty</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2021</TD><TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">365,900</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">164,600</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">259,930</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">260,128</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">25,052</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,075,610</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">EVP, Human Resources</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2020</TD><TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">353,505</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">143,169</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">626,367</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">20,746</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,143,787</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2019</TD><TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">341,550</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">184,437</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">585,540</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">24,352</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,135,879</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left">James Loerop</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2021</TD><TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">394,900</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">227,970</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">228,138</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">23,396</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">874,404</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left">EVP, Business Development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2020</TD><TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">381,563</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">171,703</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">464,449</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">22,156</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,039,871</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left">and Strategic Planning</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2019</TD><TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">165,865</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">202,500</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">732,060</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">377,772</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,429</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,479,626</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: Red">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">The amounts in this column represent the annual base salary
        approved for the executive by the Board of Directors. The 2020 base salaries for Dr. Blanchard and Messrs. Levitz and Colleran were prorated
        based upon the date of commencement of employment in that year.</FONT></TD></TR>
  </TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">The
                                            amounts in this column represent discretionary cash bonuses earned in the indicated year,
                                            but paid in the following year. The 2020 bonus amounts for Dr. Blanchard and Messrs. Levitz
                                            and Colleran were prorated based on the date of commencement of employment during 2020. Mr.
                                            Loerop resigned as of January 27, 2022 and was not eligible for a 2021 bonus payment. See
                                            the section in the Compensation Discussion and Analysis titled &ldquo;Annual Cash Bonus&rdquo;
                                            for additional details regarding the cash bonuses earned for 2021.</FONT></TD></TR></TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">The
                                            amounts in this column reflect the grant date fair value computed with respect to the equity
                                            stock and option awards issued during the indicated year calculated in accordance with Financial
                                            Accounting Standards Board Accounting Standards Codification Topic 718, or ASC 718. See the
                                            information appearing in Note 14 to our consolidated financial statements included as part
                                            of our Annual Report on Form 10-K for the year ended December 31, 2021 for certain assumptions
                                            made in the valuation of stock and option awards. Unless otherwise noted, the Board granted
                                            equity awards on March 9, 2021, February 25, 2020, and February 26, 2019, respectively. Time-vesting
                                            awards granted in 2021, 2020, and 2019 vest ratably over 3 years beginning one year from the grant date. For 2020 and 2019 performance-based restricted stock units, the fair value
                                            on the grant date was determined at the probable outcome level of the &quot;target,&quot;
                                            or 100%, attainment level pursuant to ASC 718. If the grant date fair value of the 2020 performance-based
                                            restricted stock units had been determined at the &quot;maximum,&quot; or 150%, attainment
                                            level, the fair value on the grant date for the awards would have been valued at $4,039,062
                                            for Dr. Blanchard, $599,978 for Mr. Levitz, $484,425 for Mr. Colleran, and $396,273 for Messrs.
                                            Finnerty and Loerop. These values represent incremental increases over the amounts set forth
                                            in this column for 2020 of $1,346,354 for Dr. Blanchard, $199,993 for Mr. Levitz, $161,475
                                            for Mr. Colleran, and $132,091 for Messrs. Finnerty and Loerop. If the grant date fair value
                                            of the 2019 performance-based restricted stock units had been determined at the &quot;maximum,&quot;
                                            or 135%, attainment level, the grant date fair value of the awards would have been valued
                                            at $395,240 for Mr. Finnerty, $494,141 and for Mr. Loerop, $2,766,677. These values represent
                                            incremental increases over the amounts set forth in this column for 2019 of $102,470 for
                                            Mr. Finnerty and $128,111for Mr. Loerop. See the section in the Compensation Discussion and
                                            Analysis titled &ldquo;Equity-Based Grants&rdquo; for additional details regarding the stock
                                            and option awards issued in 2021.</FONT></TD></TR></TABLE>






<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Unless
                                            otherwise noted, these amounts constitute matching contributions to our Employee Savings
                                            and Retirement Plan, or 401(k) Plan, and group term life insurance premiums. Matching contributions
                                            to the 401(k) Plan in the indicated year were $20,300 to each of Dr. Blanchard and Messrs.
                                            Levitz, Colleran, Finnerty, and Loerop.</FONT></TD></TR></TABLE>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">This amount represents $115,385 in salary and $10,345
        in lieu of participation in our company's health plans paid to Dr. Blanchard during her service as the interim Chief Executive Officer
        from February 10, 2020 to April 25, 2020, and $432,692 in Dr. Blanchard's prorated 2020 base salary upon her appointment on April 26,
        2020 as President and Chief Executive Officer. See the section in the Compensation Discussion and Analysis titled &rdquo;Dr. Blanchard&rsquo;s
        Employment Agreement&quot; for additional details.</FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(6)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">This amount reflects the discretionary prorated cash bonus
        earned for the indicated year of $331,010 and a cash retention bonus of $127,500 provided under the terms of the interim Chief Executive
        Officer letter agreement entered into between our company and Dr. Blanchard.</FONT></TD></TR>
  </TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(7)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">In
                                            addition to the time-vesting and performance-based restricted stock units granted to her
                                            under her employment agreement (see the section in the Compensation Discussion and Analysis
                                            titled &quot; Dr. Blanchard&rsquo;s Employment Agreement&quot; for additional details regarding
                                            such awards), this amount includes the grant date fair value of the restricted stock unit
                                            award granted to Dr. Blanchard by the Board on February 10, 2020 in connection with her appointment
                                            as interim Chief Executive Officer. This award vests ratably on annual basis over 3 years
                                            beginning one year from the grant date.</FONT></TD></TR></TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(8)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">This
                                            amount includes the performance-based stock option award made by the Board to Dr. Blanchard
                                            on February 25, 2020. The 2020 performance-based stock option award fair value on the grant
                                            date was determined at the &quot;target,&quot; or 100%, attainment level pursuant to ASC
                                            718. If the fair value of the 2020 performance-based stock option award had been determined
                                            at the &quot;maximum,&quot; or 150%, attainment level, the award would have been valued at
                                            $5,242,364. The value represents an additional incremental increase over the amount set forth
                                            in this column of $2,948,699.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(9)</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">This amount includes $6,868 in fees earned as an independent director prior
        to Dr. Blanchard's appointment as our interim Chief Executive Officer.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><A NAME="a_029"></A><FONT STYLE="font-size: 11pt"><B>Grants
of Plan-Based Awards in 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The following table sets forth each grant of equity
awards under the Plan made to the NEOs during the year ended December 31, 2021. All such equity awards vest over a three-year period commencing
on the first anniversary of the grant date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(31,73,125)">
    <TD STYLE="white-space: nowrap"><FONT STYLE="color: White"><B>Name</B></FONT></TD>
    <TD><FONT STYLE="color: White"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="color: White"><B>Grant Date</B></FONT></TD>
    <TD><FONT STYLE="color: White"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="color: White"><B>Approval Date</B></FONT></TD>
    <TD><FONT STYLE="color: White"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="color: White"><B>All other <BR> stock awards:&nbsp;&nbsp;<BR>
        Number of <BR> shares of <BR> stock or <BR> units (#)</B></FONT></TD>
    <TD><FONT STYLE="color: White"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; text-align: center"><FONT STYLE="color: White"><B>All other <BR> option awards: <BR> Number of
        <BR> securities <BR> underlying <BR> options (#)</B></FONT></TD>
    <TD STYLE="font-style: normal"><FONT STYLE="color: White"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-style: normal; text-align: center"><FONT STYLE="color: white"><B>Exercise or <BR> base price
        of <BR> option awards <BR> ($/Sh) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal"><SUP>(1)</SUP></FONT></B></FONT></TD>
    <TD STYLE="font-style: normal"><FONT STYLE="color: White"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-style: normal; text-align: center"><FONT STYLE="color: white"><B>Grant date <BR> fair value
        of <BR> stock and <BR> option awards <BR> ($)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal"><SUP>(2)</SUP></FONT></B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="width: 32%; text-align: left">Cheryl R. Blanchard, Ph.D.</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: center">March 9, 2021</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: center">February 10, 2021</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: right">43,259</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 6%; text-align: right">1,470,806</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2021</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">February 10, 2021</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">108,398</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">37.40</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">1,471,831</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Michael L. Levitz</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2021</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">February 10, 2021</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">13,315</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">452,710</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2021</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">February 10, 2021</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">33,363</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">37.40</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">453,004</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left">David B. Colleran</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2021</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">February 10, 2021</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">11,047</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">375,598</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2021</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">February 10, 2021</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">27,681</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">37.40</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">375,853</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; background-color: white">Thomas Finnerty</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2021</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">February 10, 2021</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: right; background-color: white">7,645</TD>
    <TD STYLE="white-space: nowrap; text-align: left; background-color: white">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: right; background-color: white">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left; background-color: white">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">259,930</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2021</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">February 10, 2021</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: right; background-color: white">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left; background-color: white">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: right; background-color: white">19,158</TD>
    <TD STYLE="white-space: nowrap; text-align: left; background-color: white">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">37.40</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: white">$</TD>
    <TD STYLE="text-align: right; background-color: white">260,128</TD>
    <TD STYLE="white-space: nowrap; text-align: left; background-color: white">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left">James Loerop</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2021</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">February 10, 2021</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">6,705</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">227,970</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2021</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">February 10, 2021</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">16,802</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">37.40</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">228,138</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: Red"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">The option awards granted to our NEOs in 2021
    are premium priced stock options with an exercise price or base price of each option award equal to 110% of the grant date closing
    stock price, as reported on the NASDAQ stock exchange.</FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">This column represents the full grant date fair value
        of stock options and restricted stock unit awards under ASC 718 granted to each of the NEOs in the fiscal year ended December 31, 2021.
        Generally, the full grant date fair value is the amount that we will expense in our financial statements over the award's vesting period.
        For time-vesting restricted stock units, fair value was calculated using the closing price of our common stock on the grant date. For
        stock options, the fair value was calculated using the Black-Scholes value on the grant date. See the information appearing in Note 14
        to our consolidated financial statements included as part of our Annual Report on Form 10-K for the year ended December 31, 2021 for certain
        assumptions made in the valuation of these awards.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; color: #355E91"><A NAME="a_030"></A><FONT STYLE="font-size: 11pt">Outstanding
Equity Awards at December 31, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">The following table provides information on the holdings of
outstanding stock options and unvested stock awards held by the NEOs as of December 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 8pt Times New Roman, Times, Serif;  width: 100%">
  <TR STYLE="vertical-align: bottom; background-color: #1F497D">
    <TD STYLE="white-space: nowrap; color: white">&nbsp;</TD>
    <TD STYLE="color: white; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="17" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option Awards</TD>
    <TD STYLE="color: white; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="15" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock Awards</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #1F497D">
    <TD STYLE="color: white; font-weight: bold; text-align: center">&nbsp;Name</TD>
    <TD STYLE="text-align: center; color: white; font-weight: bold; font-style: normal">&nbsp;</TD>
    <TD STYLE="color: white; font-weight: bold; font-style: normal; text-align: center">&nbsp;</TD>
    <TD STYLE="color: white; font-weight: bold; font-style: normal; text-align: center">Number of <BR> securities <BR> underlying <BR> unexercised
        <BR> options (#) <BR> exercisable<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: 700; color: white"><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="color: white; font-weight: bold; font-style: normal; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; color: white; font-weight: bold; font-style: normal">&nbsp;</TD>
    <TD STYLE="color: white; font-weight: bold; font-style: normal; text-align: center">&nbsp;</TD>
    <TD STYLE="color: white; font-weight: bold; font-style: normal; text-align: center">Number of <BR> securities <BR> underlying <BR> unexercised
        <BR> options (#)<BR> unexercisable<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: 700; color: white"><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="color: white; font-weight: bold; font-style: normal; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; color: white; font-weight: bold">&nbsp;</TD>
    <TD STYLE="color: white; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="color: white; font-weight: bold; text-align: center">Equity <BR> incentive plan <BR> awards: <BR> number of <BR> securities <BR>
        underlying <BR> unexercised <BR> unearned <BR> options (#)</TD>
    <TD STYLE="color: white; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; color: white; font-weight: bold">&nbsp;</TD>
    <TD STYLE="color: white; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="color: white; font-weight: bold; text-align: center">Option <BR> exercise <BR> price ($)</TD>
    <TD STYLE="color: white; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; color: white; font-weight: bold">&nbsp;</TD>
    <TD STYLE="color: white; font-weight: bold; text-align: center">Option <BR> expiration <BR> date</TD>
    <TD STYLE="text-align: center; color: white; font-weight: bold; font-style: normal">&nbsp;</TD>
    <TD STYLE="color: white; font-weight: bold; font-style: normal; text-align: center">&nbsp;</TD>
    <TD STYLE="color: white; font-weight: bold; font-style: normal; text-align: center">Number of <BR> shares or <BR> units of <BR> stock that
        <BR> have not <BR> vested (#)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: 700; color: white"><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="color: white; font-weight: bold; font-style: normal; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; color: white; font-weight: bold; font-style: normal">&nbsp;</TD>
    <TD STYLE="color: white; font-weight: bold; font-style: normal; text-align: center">&nbsp;</TD>
    <TD STYLE="color: white; font-weight: bold; font-style: normal; text-align: center">Market value <BR> of shares or <BR> units of <BR> stock
        that <BR> have not <BR> vested (#)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: 700; color: white"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="color: white; font-weight: bold; font-style: normal; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; color: white; font-weight: bold; font-style: normal">&nbsp;</TD>
    <TD STYLE="color: white; font-weight: bold; font-style: normal; text-align: center">&nbsp;</TD>
    <TD STYLE="color: white; font-weight: bold; font-style: normal; text-align: center">Equity <BR> incentive plan <BR> awards: <BR> number of
        <BR> unearned <BR> shares, units or <BR> other rights <BR> that have not <BR> vested (#)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: 700; color: white"><SUP>(3)</SUP></FONT></TD>
    <TD STYLE="color: white; font-weight: bold; font-style: normal; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; color: white; font-weight: bold; font-style: normal">&nbsp;</TD>
    <TD STYLE="color: white; font-weight: bold; font-style: normal; text-align: center">&nbsp;</TD>
    <TD STYLE="color: white; font-weight: bold; font-style: normal; text-align: center">Equity <BR> incentive plan <BR> awards: market <BR> or
        payout value <BR> of unearned <BR> shares, units or <BR> other rights <BR> that have not <BR> vested ($)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: 700; color: white"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="color: white; font-weight: bold; font-style: normal; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="width: 19%; text-align: left">Cheryl R. Blanchard, Ph.D.</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: right">31,885</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: right">69,759</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 6%; text-align: right">33.40</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 8%; text-align: right">4/26/2030</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: right">49,151</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 6%; text-align: right">1,761,080</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">52,319</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(4)</SUP></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">33.40</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">4/26/2030</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">8,062</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">288,861</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">108,398</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">37.40</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(5)</SUP></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">3/9/2031</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">43,259</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">1,549,970</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left">Michael L. Levitz</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">19,048</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">38,097</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">34.55</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">8/10/2030</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">7,718</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">276,536</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,157</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">41,455</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">33,363</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">37.40</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(5)</SUP></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">3/9/2031</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">13,315</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">477,076</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left">David B. Colleran</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">11,667</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">23,333</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">43.06</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">3/4/2030</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">5,000</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">179,150</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">750</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">26,873</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">27,681</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">37.40</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(5)</SUP></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">3/9/2031</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">11,047</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">395,814</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left">Thomas Finnerty</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">17,000</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">54.09</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">10/30/2027</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">7,180</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">61.47</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">1/24/2028</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">19,158</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">37.40</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(5)</SUP></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">3/9/2031</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">7,645</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">273,920</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">13,125</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(6)</SUP></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">470,269</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">5,667</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">203,049</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">620</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">22,215</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left">James Loerop</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">18,000</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">40.67</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">7/8/2029</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">13,125</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(6)</SUP></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">470,269</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">16,802</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">37.40</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(5)</SUP></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">3/9/2031</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">6,705</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">240,240</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">620</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">22,215</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: Red"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Vesting of equity awards commences on the first anniversary
        of the grant date and continues on each subsequent grant date anniversary until the equity award is fully vested, except as otherwise
        noted below. Except as otherwise noted, equity awards are subject to a three-year vesting period, in each case subject to the holder's
        continued employment with us. The expiration date of each equity award is ten years after its grant date.</FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Based on the closing price of our common stock on the NASDAQ stock exchange on
        December 31, 2021 of $35.83 per share.</FONT></TD></TR>
  </TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Except
                                            as otherwise noted, these amounts are based on performance-based restricted stock units granted
                                            at target in 2020. The performance measurement date for these awards and the date on which
                                            the shares underlying the award will vest (if any) is generally the date on which the Compensation
                                            Committee reviews our financial and business achievements for the fiscal year ending December
                                            31, 2022, including our audited financial statements for such period, and determines and
                                            specifies, at the Compensation Committee's sole discretion, the percentage of the shares
                                            that have been earned by each individual NEO. See the sections in the Compensation Discussion
                                            and Analysis of the 2021 Proxy Statement titled &ldquo;Equity-Based Grants&rdquo; and &quot;The
                                            Death of Mr. Darling and the Appointment of Dr. Blanchard&quot; for additional details regarding
                                            the restricted stock units issued in 2020.</FONT></TD></TR></TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">This
                                            amount includes performance-based stock options granted at threshold in 2020, which, due
                                            to administrative error, was mistakenly reported as 8,062 in the 2021 Proxy Statement. The
                                            performance measurement date for this award and the date on which the shares underlying the
                                            awards will vest (if any) is generally the date on which the Compensation Committee reviews
                                            our Total Shareholder Return (as defined in the grant agreement) against the Comparison Group
                                            (as defined in the grant agreement), and determines and specifies, at the Compensation Committee's
                                            sole discretion, the percentage of the shares that have been earned by Dr. Blanchard. See
                                            the section in the Compensation Discussion and Analysis titled &ldquo;Dr. Blanchard&rsquo;s
                                            Employment Agreement&quot; for additional details regarding the option award.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Represents an exercise price of 110% of the grant date closing
        stock price, as reported on the NASDAQ stock exchange.</FONT></TD></TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(6)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">These amounts include 10,125 performance-based restricted
        stock units granted in 2019 and deemed earned upon the Compensation Committee's certification on February 9, 2021. The 10,125 performance-based
        restricted stock units reflect achievement at 112.5% of target.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; color: #355E91"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; color: #355E91"><A NAME="a_031"></A><FONT STYLE="font-size: 11pt">2021
Option Exercises and Stock Vested</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">The following table provides information regarding options
exercised and stock awards vested for the NEOs during the year ended December 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: #1F497D">
    <TD STYLE="white-space: nowrap; color: white; text-align: right">&nbsp;</TD>
    <TD STYLE="color: white; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option Awards</TD>
    <TD STYLE="color: white; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock Awards</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #1F497D">
    <TD STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Name</TD>
    <TD STYLE="color: white; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of
        <BR> shares acquired <BR> on exercise (#)</TD>
    <TD STYLE="color: white; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Value realized
        <BR> on exercise ($)</TD>
    <TD STYLE="color: white; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of
        <BR> shares acquired <BR> on vesting (#)</TD>
    <TD STYLE="color: white; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Value realized
        <BR> on vesting ($)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="width: 48%; text-align: left">&nbsp;Cheryl R. Blanchard, Ph.D.</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right">2,994</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 10%; text-align: right">27,964</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right">24,575</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 10%; text-align: right">1,010,278</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: left">&nbsp;Michael L. Levitz</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">3,859</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">155,826</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left">&nbsp;David B. Colleran</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">2,500</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">95,325</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: left">&nbsp;Thomas Finnerty</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">5,833</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">216,026</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left">&nbsp;James Loerop</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">3,000</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">129,720</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><A NAME="a_032"></A><FONT STYLE="font-size: 11pt">Potential
Payments Upon Termination or Change in Control</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our President and Chief Executive Officer, our
Chief Financial Officer, and our other NEOs have certain termination or change in control benefits described in the Compensation
Discussion and Analysis sections captioned &ldquo;Other Compensation Matters &ndash; <I>Employment and Executive Retention
Agreements Effective at December 31, 2021</I>&rdquo; and &ldquo;Other Compensation Matters &ndash;<I> Dr. Blanchard&rsquo;s
Employment Agreement</I>.&rdquo; The following table provides estimates of the potential payments and other post-termination
benefits these individuals would receive assuming a change in control occurred and/or their employment was terminated as of December
31, 2021:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; color: Red">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: #1F497D">
    <TD STYLE="color: white; font-weight: bold; text-align: center">Name</TD><TD STYLE="color: white; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="color: white">&nbsp;</TD><TD STYLE="color: white; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; color: white; font-weight: bold; text-align: center">Termination <BR>
without cause or <BR>
for good reason</TD><TD STYLE="color: white; font-weight: bold; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; color: white; font-weight: bold; font-style: normal; text-align: center">Termination
    <BR>
    upon change in <BR>
    control without <BR>
    cause or for good <BR>
    reason <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: 700; color: white"><SUP>(1)(2)</SUP></FONT></TD><TD STYLE="color: white; font-weight: bold; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; color: white; font-weight: bold; font-style: normal; text-align: center">Change
    in control <BR>
    without termination <BR>
    or death or <BR>
    disability <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: 700; color: white"><SUP>(1)(2)</SUP></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="width: 40%; text-align: left">Cheryl R. Blanchard, Ph.D.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 20%; text-align: left">Salary Continuation</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,002,600</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,336,800</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Additional Cash Payment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,136,280</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Equity Awards Vesting</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,623,788</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(3)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6,623,450</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(4)</SUP></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">Health Care Benefits</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">25,884</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">25,884</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">2,652,272</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">9,122,414</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left">Michael L. Levitz</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Salary Continuation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">456,400</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">456,400</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Additional Cash Payment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">205,380</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Equity Awards Vesting</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,217,180</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">Health Care Benefits</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,256</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,256</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">473,656</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">1,896,216</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left">David B. Colleran</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Salary Continuation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">432,400</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">432,400</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Additional Cash Payment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">194,580</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Equity Awards Vesting</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">843,689</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">Health Care Benefits</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,256</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,256</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">449,656</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">1,487,925</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left">Thomas Finnerty</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Salary Continuation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">365,900</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">365,900</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Additional Cash Payment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">164,655</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Equity Awards Vesting</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,129,075</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">Health Care Benefits</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13,351</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13,351</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">379,251</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">1,672,981</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left">James Loerop</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Salary Continuation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">394,900</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">394,900</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Additional Cash Payment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">177,705</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Equity Awards Vesting</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,004,602</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">Health Care Benefits</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,256</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,256</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">412,156</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">1,594,462</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; text-align: right">-</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; color: Red">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Termination
                                            for the purposes of this column is limited to termination without cause or termination for
                                            good reason within a period three months prior to, or twelve months after, a change in control.
                                            The indicated values for the accelerated vesting of stock options reflect the number of equity
                                            award shares that would vest on an accelerated basis, multiplied by the excess, if any, of
                                            the $35.83 closing price for our common stock as reported by NASDAQ on December 31, 2021,
                                            over the applicable exercise price for each option. This calculation assumes equity awards
                                            with an exercise price higher than the closing price of our common stock on December 31,
                                            2021 will not be exercised.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">The indicated
                                            values for the accelerated vesting of performance-based restricted stock units are included
                                            at target.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">According
                                            to the terms of Dr. Blanchard's employment agreement as in place at December 31, 2021, if
                                            Dr. Blanchard&rsquo;s employment is terminated &ldquo;without cause&rdquo; or Dr. Blanchard
                                            terminates her employment with us for &ldquo;good reason&rdquo; not due to disability prior
                                            to December 31, 2021, she would be entitled to pro rata vesting of the time-vesting restricted
                                            stock unit grant and the time-vesting stock option grant awarded to her on April 26, 2020
                                            in conjunction with the commencement of her employment as President and Chief Executive Officer.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Includes
                                            the 2020 grant at target of performance-based restricted stock units and the 2020 grant at
                                            target of performance-based stock options. If the stock options were valued at maximum, the
                                            equity award&rsquo;s vesting value would be $6,750,585. If the stock options were valued
                                            at threshold, the equity award&rsquo;s vesting value would be $6,326,800. See the section
                                            in the Compensation Discussion and Analysis titled &ldquo;Dr. Blanchard&rsquo;s Employment
                                            Agreement&rdquo; for additional details regarding the equity grants to Dr. Blanchard in 2020
                                            and her employment agreement with us.</FONT></TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 10.7pt 0pt 36.55pt">&nbsp;</P>



<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><A NAME="a_033"></A><FONT STYLE="font-size: 11pt">CEO
Pay Ratio</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As required by applicable SEC rules, we are providing
the following information about the relationship of the annual total compensation of our employees and the annual total compensation of
Dr. Blanchard, our year-end Chief Executive Officer or CEO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">For 2021, our last completed fiscal year:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">The median of the annual total compensation of all our employees (other than our CEO) was $115,858; and</TD>
        </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">The annual total compensation of our CEO, for the purposes of this disclosure, was $4,202,608.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">Based on this information, for 2021
the ratio of the annual total compensation of Dr. Blanchard, our year-end Chief Executive Officer, to the median of the annual total compensation
of all our employees was 36 to 1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">We took the following steps to identify
the median of the annual total compensation of all our employees, as well as to determine the annual total compensation of our median
employee and our CEO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">1.</TD>
    <TD STYLE="text-align: justify">We determined that, as of December 31, 2021, our employee population consisted of 296
        individuals. This population consisted of our full-time employees employed with us as of the determination date, excluding our CEO.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">2.</TD>
    <TD STYLE="text-align: justify">To identify the &ldquo;median employee&rdquo; from our employee population, we aggregated
        for each applicable employee, other than our CEO, (a) annual base salary (or hourly rate multiplied by estimated work schedule, for hourly
        employees), (b) the bonus amount earned for 2021, which was paid out in early 2022, and (c) the grant date fair value of equity granted
        in 2021. Once aggregated, we ranked this compensation measure for our employees from lowest to highest and selected the median employee.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">3.</TD>
    <TD STYLE="text-align: justify">For the annual total compensation of our median employee, we identified and calculated
        the elements of that employee&rsquo;s compensation for 2021 in accordance with the requirements of Item 402(c)(2)(x), resulting in annual
        total compensation of $115,858.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The pay ratio reported above is a reasonable
estimate calculated in a manner consistent with SEC rules based on our internal records and the methodology described above. The SEC rules
for identifying the median-compensated employee and calculating the pay ratio based on that employee&rsquo;s annual total compensation
allow companies to adopt a variety of methodologies, to apply certain exclusions, and to make reasonable estimates and assumptions that
reflect their employee populations and compensation practices. Therefore, the pay ratio reported by other companies may not be comparable
to the pay ratio reported above, as other companies have different employee populations and compensation practices and may utilize different
methodologies, exclusions, estimates and assumptions in calculating their own pay ratios.</P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; color: #355E91"><A NAME="a_034"></A><FONT STYLE="font-size: 11pt">Director
Compensation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91"><I>Cash Compensation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">For 2021, each of our non-employee directors
was entitled to annual retainers per the following schedule, with such amounts to be prorated based on the actual number of days served
if a director&rsquo;s service to us commenced after January 1, 2021 or ended prior to the end of 2021:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; background-color: #355E91"><FONT STYLE="font-size: 10pt; color: white"><B>Compensation
        Element</B></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; background-color: #355E91; text-align: center"><FONT STYLE="font-size: 10pt; color: white"><B>2021
        Cash Compensation</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>Board of Directors</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Board Chair Retainer</FONT></TD>
    <TD STYLE="padding-left: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">$80,000<SUP>1</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Other Directors Retainer</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">$50,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>Audit Committee</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Committee Chair Retainer</FONT></TD>
    <TD STYLE="padding-left: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">$20,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Other Committee Members Retainer</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">$10,000</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>Compensation Committee</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Committee Chair Retainer</FONT></TD>
    <TD STYLE="padding-left: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">$15,000</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">Other Committee Members Retainer</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">$7,500</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>Governance and Nominating Committee</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Committee Chair Retainer</FONT></TD>
    <TD STYLE="padding-left: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">$10,000</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #C8D7EA">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Other Committee Members Retainer</FONT></TD>
    <TD STYLE="padding-left: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">$5,000</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%">
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">(1)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">On February 9, 2022, the Board of Directors amended the Anika Therapeutics, Inc. Director Compensation
        Policy to increase the Board Chair Retainer from $80,000 to $87,500, effective February 9, 2022.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 48%">&nbsp;</TD>
    <TD STYLE="padding-left: 39.4pt; text-align: center; width: 50%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Board of Directors approved a grant of 4,172
restricted stock units to each non-employee director, valued at $174,974 under the Plan, based on the fair market value of our common
stock on June 16, 2021, the date of grant for our then-current directors. These restricted stock units granted to each then-current non-employee
director in 2021 vests in one installment on the earlier of the date that is immediately prior to the Annual Meeting and one year from
the date of grant. On October 28, 2021, Ms. Conley joined the Board of Directors as a non-employee director, and was granted 8,179
restricted stock units, valued at $349,979 based on the fair market value of our common stock as of that day. The restricted stock units
granted to Ms. Conley vest in three equal annual installments beginning one year from the date of grant. Each non-employee director is
eligible for an annual equity award grant with a value and vesting provisions as may be determined by the Board based on their review
of our compensation policies and general compensation trends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">The following table summarizes the compensation
earned by non-employee directors in 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: #1F497D">
    <TD STYLE="white-space: nowrap; color: white; font-weight: bold">Name</TD>
    <TD STYLE="color: white; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center">Fees earned <BR> in cash ($)</TD>
    <TD STYLE="color: white; font-weight: bold; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; font-style: normal; text-align: center">Stock awards <BR> ($)
        <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: 700; color: white"><SUP>(1)
        (2)</SUP></FONT></TD>
    <TD STYLE="color: white; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center">Total ($)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="width: 55%; text-align: left">Joseph L. Bower</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right">30,000</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;<SUP>(3)</SUP></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right">-</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;<SUP>(4)</SUP></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right">30,000</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Sheryl L. Conley</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">10,598</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(5)</SUP></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">349,979</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;<SUP>(6)</SUP></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">360,577</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left">John B. Henneman, III</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">66,559</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">174,974</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">241,533</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Raymond J. Land</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">77,500</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">174,974</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">252,474</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left">Glenn R. Larsen, Ph.D.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">62,500</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">174,974</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">237,474</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stephen O. Richard</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">60,000</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">174,974</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">234,974</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left">Jeffery S. Thompson</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">80,000</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">174,974</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">254,974</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Susan L. N. Vogt</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">70,000</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">174,974</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">244,974</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; color: Red"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 8pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Except
                                            as otherwise noted, an amount of 4,172 restricted stock units were awarded per director on
                                            June 16, 2021, based on the closing price of $41.94 per share, and vests on the earlier of
                                            the 2022 Annual Meeting or the one year anniversary of the grant date. The amounts in this
                                            column reflect the grant date fair value computed with respect to the restricted stock units,
                                            made during 2021 in accordance with ASC 718. See the information appearing in Note 14 to
                                            our consolidated financial statements included as part of our Annual Report on Form 10-K
                                            for the year ended December 31, 2021 for certain assumptions made in the valuation of these
                                            restricted stock unit awards.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 8pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">The
                                            aggregate number of shares outstanding for each director as of December 31, 2021 were: 4,172
                                            for each of Messrs. Land, and Thompson, Dr. Larsen and Ms. Vogt, 10,379 for each of Messrs.
                                            Henneman and Richard and 8,179 for Ms. Conley.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 8pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Represents
                                            fees earned by Mr. Bower prior to his retirement from the Board as of the Annual Meeting
                                            on June 16, 2021.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 8pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Mr. Bower
                                            retired from the Board as of the Annual Meeting on June 16, 2021 and did not receive a 2021
                                            annual award.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 8pt">(5)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Represents
                                            prorated fees earned in 2021 based on Ms. Conley's appointment to the Board and the Audit
                                            Committee on October 28, 2021.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font-size: 8pt">(6)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">8,179
                                            restricted stock units were awarded to Ms. Conley upon her appointment to the Board on October
                                            28, 2021, based on the closing price of $42.79 per share. Such awards vest ratably over 3
                                            years beginning on the first anniversary of the grant date.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><A NAME="a_035"></A><FONT STYLE="font-size: 11pt">Director
and Executive Officer Stock Retention Guidelines</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Effective October 6, 2015, the Board of Directors
adopted stock retention guidelines that generally require each of our directors and executive officers to beneficially own certain amounts
of our common stock. We believe that ownership of shares of common stock by directors and executive officers helps align the financial
interests of these individuals with the interests of stockholders, promotes sound corporate governance, and evidences a commitment to
our company. These stock retention guidelines supersede the director stock retention guidelines previously adopted by the Board on April
22, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify">Generally,
these guidelines require each director to beneficially own, at a minimum, either (a) 3,000 outstanding shares of common stock or (b) a
number of shares (or vested share equivalents) of common stock having a market value equal to three times the amount of our annual Board
retainer for the non-lead or non-chairman directors. The minimum shareholding requirement became effective immediately, except that any
director has three years from the date of their initial election to achieve compliance. Compliance by each director will be reviewed annually
by the Board&rsquo;s Governance and Nominating Committee, which is authorized to approve exceptions upon a showing of serious hardship.
A non-complying director must retain at least 75% of the shares (net of shares sold or offset to pay the exercise price and taxes) the
director subsequently acquires through exercise of equity grants, until the director complies with the guidelines. As of December 31,
2021, each of the following directors had met their minimum shareholding requirement: John B. Henneman, III, Raymond J. Land, Glenn R.
Larsen, Ph.D., Jeffery S. Thompson, and Susan L. N. Vogt. Sheryl L. Conley and Stephen O. Richard are within the three-year phase-in period
for directors to meet their required ownership threshold, such phase-in period to be completed on October 28, 2024 and September 3, 2023,
respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="p59.jpg" ALT="" STYLE="height: 250px; width: 400px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">Generally, the stock retention guidelines require the Chief Executive Officer to beneficially own, at a minimum,
either (a) 50,000 outstanding shares of common stock or (b) a number of shares (or vested share equivalents) of common stock having a
market value equal to three times the amount of his or her base salary. The guidelines require any other executive officer to beneficially
own, at a minimum, either (a) 10,000 outstanding shares of common stock or (b) a number of shares (or vested share equivalents) of common
stock having a market value equal to the amount of his or her base salary. The minimum shareholding requirement became effective immediately
upon adoption of the stock retention guidelines, except that any individual has five years after initial delegation to achieve compliance.
Compliance by each executive officer is reviewed annually by the Governance and Nominating Committee, which is authorized to approve exceptions
upon a showing of serious hardship. A non-complying executive officer must retain at least 75% of the shares (net of shares sold or offset
to pay the exercise price and taxes) he or she subsequently acquires through exercise of equity grants, until he or she complies with
the guidelines. Each of our executive officers is within the five-year phase-in period to meet his or her required shareholding requirement,
such period to be completed on April 26, 2025 for Cheryl R. Blanchard, Ph.D., our President and Chief Executive Officer; August 10, 2025
for Michael L. Levitz, our Executive Vice President, Chief Financial Officer and Treasurer; and March 4, 2025 for David B. Colleran, our
Executive Vice President, General Counsel, and Secretary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><A NAME="a_036"></A><FONT STYLE="font-size: 11pt">Compensation
Committee Interlocks and Insider Participation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Compensation Committee as of December 31, 2021 consisted of John B. Henneman, III, Raymond J. Land,
and Glenn R. Larsen, Ph.D. None of these individuals is or formerly was an officer or employee of our company, nor have they engaged in
any transactions involving our company that would require disclosure as a transaction with a related person. There are no Compensation
Committee interlocks between our company and any other entity involving our or such entity&rsquo;s executive officers or directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">During the fiscal year ended December
31, 2021, none of our executive officers served as: (1) a member of the compensation committee (or other committee of the board of directors
performing equivalent functions or, in the absence of any such committee, the entire board) of another entity, one of whose executive
officers served on the Compensation Committee; (2) a director of another entity, one of whose executive officers served on the Compensation
Committee; or (3) a member of the compensation committee (or other committee of the board of directors performing equivalent functions
or, in the absence of any such committee, the entire board) of another entity, one of whose executive officers served as one of our directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><A NAME="a_057"></A><FONT STYLE="font-size: 11pt">Equity
Compensation Plan Information</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">The following table sets forth information
concerning our equity compensation plan as of December 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: #1F497D">
    <TD COLSPAN="13" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center">Equity Compensation Plan Information</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #1F497D">
    <TD COLSPAN="13" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #1F497D">
    <TD COLSPAN="13" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #1F497D">
    <TD STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center">Plan category</TD>
    <TD STYLE="color: white; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center">Number of securities to be issued <BR> upon
        exercise of outstanding options, <BR> warrants and rights</TD>
    <TD STYLE="color: white; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center">Weighted Average exercise price <BR> of outstanding
        options, <BR> warrants and rights</TD>
    <TD STYLE="color: white; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center">Number of securities remaining <BR> available
        for future issuance <BR> under equity compensation plans</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 55%; text-align: left; background-color: white">Equity compensation plans approved by security holders</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; background-color: white">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right; background-color: white">1,174,924</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left; background-color: white">&nbsp;<SUP>(1)</SUP></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 12%; text-align: right">39.56</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; background-color: white">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right; background-color: white">2,112,518</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left; background-color: white">&nbsp;<SUP>(2)</SUP></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Equity compensation plans not approved by security holders</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,069</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;<SUP>(3)</SUP></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">38.53</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">123,463</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">1,175,993</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">39.56</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">2,235,981</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Includes our 2017 Omnibus Incentive Plan, as amended, and our 2007
    Omnibus Incentive Plan, as amended (collectively, the &quot;Incentive Plans&quot;). Outstanding restricted stock units convert to
    common stock without payment consideration. As of December 31, 2021, we also had 570,989 shares to be issued upon vesting of
    restricted stock units and performance restricted stock units granted at target.</FONT></TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">The number of shares remaining available for future issuance under the Incentive
        Plans includes 1,924,940 shares of common stock that may be awarded pursuant to the 2017 Omnibus Incentive Plan, as amended, and 200,000
        shares of common stock that may be issued pursuant to our 2021 Employee Stock Purchase Plan.</FONT></TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">Includes our 2021 Inducement Plan (the &ldquo;Inducement Plan&rdquo;). Outstanding
        restricted stock units convert to common stock without payment consideration. As of December 31, 2021, we also had 468 shares to be issued
        upon vesting of restricted stock units granted.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center; color: #355E91"><B><I></I></B></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center; color: #355E91"><A NAME="a_037"></A><FONT STYLE="font-size: 13pt"><B><I>Proposal
2: Amendment of 2017 Omnibus Incentive Plan</I></B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><A NAME="a_038"></A><FONT STYLE="font-size: 11pt">Overview</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>History of the Anika
Therapeutics, Inc. 2017 Omnibus Incentive Plan (as amended June 16, 2021)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify">On March 31, 2017, the Board of Directors,
upon the recommendation of the Compensation Committee, adopted the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, or the Original
Plan, for officers, employees, non-employee directors and other key persons of Anika Therapeutics, Inc. and its subsidiaries, subject
to the approval of our stockholders. Our stockholders approved the Original Plan at the 2017 Annual Meeting of Stockholders, and the Original
Plan has been previously amended, with the approval of our stockholders, as follows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.95pt 0pt 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">On March 19, 2019, the Board, upon the recommendation of the Compensation Committee,
        approved the amendment and restatement of the Original Plan (the First Amended Plan), to increase the number of shares of common stock
        reserved by 1,500,000, from 1,200,000 to 2,700,000 shares, subject to the approval of our stockholders. Additionally, the Board approved
        certain clarifying amendments to the sections governing minimum vesting and tax withholding to facilitate plan administration. Our stockholders
        approved the First Amended Plan on June 18, 2019.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">On April 23, 2020, the Board, upon the recommendation of the Compensation Committee,
        approved the amendment and restatement of the First Amended Plan (the Second Amended Plan), to increase the number of shares of common
        stock reserved by 800,000, from 2,700,000 to 3,500,000 shares, subject to the approval of our stockholders. The Board also approved an
        amendment to the First Amended Plan to allow for all 3,500,000 shares authorized under the Second Amended Plan to be issued as Incentive
        Stock Options under Section 422 of the Internal Revenue Code of 1986, or the Code. No other provisions of the First Amended Plan were
        proposed to be amended. Our stockholders approved the Second Amended Plan on June 16, 2020.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">On March 17, 2021, the Board, upon the recommendation of the Compensation Committee,
        approved the amendment and restatement of the Second Amended Plan (the Third Amended Plan), to increase the number of shares of common
        stock reserved by 1,100,000, from 3,500,000 to 4,600,000 shares, subject to the approval of our stockholders. The Board also approved
        an amendment to the Second Amended Plan to allow for all 4,600,000 shares authorized under the Third Amended Plan to be issued as Incentive
        Stock Options under Section 422 of the Code. No other provisions of the Second Amended Plan were proposed to be amended. Our stockholders
        approved the Third Amended Plan on June&nbsp;16, 2021.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">On April 18, 2022, the Board, upon the
recommendation of the Compensation Committee, approved the amendment and restatement of the Third Amended Plan (the Fourth Amended Plan),
to increase the number of shares of common stock reserved by 950,000 from 4,600,000 to 5,550,000 shares, subject to the approval of our
stockholders. The Board also approved an amendment to the Third Amended Plan to allow for all 5,550,000 shares authorized under the Fourth
Amended Plan to be issued as Incentive Stock Options under the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #355E91"><I>Plan Amendment  Provides Adequate
Shares to Attract,  Motivate and Retain Employees Needed to Execute Strategic Plan and Drive Stockholder Value</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.05pt">The Board
recommends that stockholders approve the Fourth Amended Plan, a copy of which is attached as <I>Appendix A</I> to this Proxy Statement
and is incorporated herein by reference. The overall purposes of the Fourth Amended Plan continue to be to ensure our ability to attract,
incentivize and retain highly qualified officers, non-employee directors, key employees, and consultants, and to motivate those individuals
to expend maximum effort to execute our strategic plan and drive increased stockholder value, by providing those individuals with an opportunity
to acquire or increase a direct ownership interest in our company and to share in its future success.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #355E91"><I>Strategic Transformation of Our Company
Provides New Opportunities in $8 Billion Global Joint Preservation Market</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.05pt">In early 2020, we fundamentally transformed
our company from primarily a manufacturer of a small number of products sold to a single large customer, which represented over 70% of
our total revenues, to a diversified medical device company with a broad base of products and its own sales and distribution channel.
To accomplish this, we expanded our overall technology platform and product portfolio, and significantly enhanced our commercial infrastructure,
especially in the United States, through our strategic acquisitions of Parcus Medical and Arthrosurface. We expanded our addressable market
from the over $1 billion global OA pain management market to the over $8 billion global joint preservation market (which includes the
faster growing regenerative, sports medicine and extremities markets), advanced our commercial capabilities, instituted systems and processes
to support our transformation, and expanded our product pipeline and research and development expertise in our target markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #355E91"><I>Transformation into a Global Commercial
Joint Preservation Company Requires Employees with Expanded Skills, Capabilities and Experiences</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.05pt">Following the appointment of Cheryl
R. Blanchard, Ph.D., as President and Chief Executive Officer following the acquisitions of Parcus Medical and Arthrosurface in early
2020, we established strategic priorities that continue to guide the next phase of our transformation into a more diversified and faster
growing global commercial joint preservation company. This transformation requires employees with new, expanded skills and capabilities,
and under Dr. Blanchard&rsquo;s leadership, within the last two years, approximately 80% of Anika&rsquo;s senior leaders, possessing decades
of experience and proven success leading orthopedic, regenerative medicine and medical device companies, were appointed to their respective
positions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #355E91"><I>Equity-based Compensation is a Critical
Component of Our Ability to Attract, Motivate and Retain Experienced and Talented Employees</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As we continue to transform our business in a highly competitive
life sciences sector, we believe that our future success depends in large part upon our ability to attract, incentivize and retain highly
skilled and experienced executive, managerial, professional, and technical employees. The ability to offer competitive compensation packages
with a meaningful equity component is an important element in achieving our success, especially as we compete to recruit exceptional
leadership and key employees with companies, research and academic institutions, government entities, and other organizations in proximity
to our corporate headquarters near Boston, Massachusetts, and more broadly. We remain dependent on the members of our senior leadership,
technical and commercial teams, and other key employees, to execute on our plan, the loss of any one of whom could have a material adverse
effect on our ability to achieve our strategic priorities. In this fast changing market where proven leaders and key employees are in
high demand and are receiving lucrative compensation packages from competitors, it is important that we have the ability to issue equity
to targeted individuals at all levels of our organization to help attract them to our company, retain their services, and align their
interests to those of our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #355E91"><I>Equity-based Compensation is Preferable
to Cash or Other Compensation Vehicles to Align Management Incentives with Those of Our Stockholders</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In the judgement
of the Board, our future growth and success is directly correlated to our ability to maintain a competitive position in attracting, motivating,
and retaining key employees. The Board believes that approval of the Fourth Amended Plan, including the authorization of the additional
shares for issuance thereunder, is in the best interests of our stockholders given our current expectations regarding hiring, the extremely
competitive environment in which we attempt to recruit and retain high value employees, and our historical burn rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We are, therefore, seeking stockholder
approval to make an additional 950,000 shares available for issuance under the Fourth Amended Plan, which would increase the number of
available shares under the plan from 934,089 shares as of April 13, 2022, to 1,884,089 shares in total, pending stockholder approval.
The 950,000 shares requested reflects our estimate of the number of shares we would grant under the Fourth Amended Plan over the course
of the next year based on our recent burn rate history and new-hire and annual grant practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">If the proposed Fourth Amended
Plan is not approved by our stockholders, we currently anticipate that we will exhaust the 934,089 shares that remain available for issuance
under the Third Amended Plan by early 2023. Not only would we then be unable to attract experienced and talented employees through competitive
and meaningful equity-based long-term incentive plans, it is possible we would not be able to maintain our competitive annual equity grant
practices to current key employees during the 2023 annual compensation cycle due to lack of shares available. Without the ability to grant
share-based compensation, our alternative would be to increase the cash compensation of our employees in order to execute our long-term
strategy. We believe share-based equity compensation is preferable to cash or other compensation vehicles from an incentive standpoint
as it better aligns our management team with our stockholders in driving increased stockholder value over both the short-term and the
long-term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our Compensation Committee will carefully review and consider
all proposed grants under the Fourth Amended Plan. We continue to be in a transition period and are seeking stockholder approval only
for an amount of additional shares which we believe is necessary to carry us through the upcoming new hire period and our next annual
grant cycle in early 2023 to ensure that we are able to appropriately incentivize our key employees. We believe our strategy to accelerate
revenue growth and profitability over the coming years through commercial execution and new product development will deliver superior
value to our stockholders and other stakeholders over time, and we look forward to continuing to engage with our stockholders as we strive
to achieve our goals and transform and grow our company. Our compensation programs are a part of, and tie directly into, our strategic
plan, and we anticipate seeking stockholder approval at next year&rsquo;s annual meeting for the additional shares needed to continue
to fund an equity incentive program designed to align closely with the goals of our comprehensive strategic plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><A NAME="a_039"></A><FONT STYLE="font-size: 11pt">Shares
Subject to the Plan</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The following table summarizes information regarding
awards outstanding and shares of our common stock remaining available for grant under the Third Amended Plan as of April 13, 2022:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 85%; text-align: left; background-color: white">Stock Options Outstanding</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right">1,504,596</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left">Weighted Average Exercise Price of Stock Options Outstanding</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">36.76</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Weighted Average Remaining Term of Stock Options Outstanding</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">8.6</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left">Full Value Awards Outstanding (RSAs, RSUs and PSUs)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">808,407</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Shares Available for Grant under the Third Amended Plan*</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">934,089</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 8pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">The Fourth Amended Plan will continue to employ a &ldquo;fungible&rdquo;
    plan design that assigns a higher cost to &ldquo;full-value&rdquo; awards (all awards other than stock options and stock appreciation
    rights) by reducing the share pool on a greater than one-for-one basis when full-value shares are granted. Consistent with the terms
    of the Original Plan and each of the First, Second, and Third Amended Plans, we have maintained a fungible rate of 2.0 common shares
    per full-value award in the Fourth Amended Plan.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The number of shares remaining available for grant under
the Third Amended Plan as noted in the previous table differs from those reported as of December 31, 2021 because the information at December
31, 2021 does not take into account year-to-date grants for our annual grant cycle and grants to new-hires who started after January 1,
2022. Information regarding the number of shares remaining available for grant as required by SEC disclosure rules are discussed in detail
under &ldquo;Equity Compensation Plan Information&rdquo; on page 48. In addition, we historically have made equity grants to directors
in the first quarter of each year to align to the annual grant cycle that we utilize for employees. In 2021, we revised this approach
to align the annual grant cycle for directors to our annual meeting cycle. As a result, we expect to make our annual equity grant to directors
immediately following the Annual Meeting, and shares granted to our directors in 2022, along with shares granted to new hires and to existing
employees as a part of our annual grant cycle between now and our next annual meeting, will further reduce the shares available for grant
under the Third Amended Plan.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><A NAME="a_040"></A><FONT STYLE="font-size: 11pt">Historic
Equity Usage</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As part of our ongoing review of our compensation plans,
we calculate our annual equity &ldquo;burn rate&rdquo; to help us determine, among other things, the expected remaining life of our equity
incentive plans based on the current number of outstanding shares. Burn rate is calculated by dividing the aggregate number of stock options
and full-value awards (as adjusted by the fungible rate as described above) granted during the year by our basic weighted average common
shares outstanding during the year. The following table provides detailed information regarding the activity related to our equity incentive
plans and weighted average ordinary shares outstanding for the each of the three fiscal years ending on December 31, 2021:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 0pt; color: Red">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="white-space: nowrap; font-weight: bold; text-align: left; border-bottom: Black 1pt solid">Award Type</TD>
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">FY 2019</TD>
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">FY 2020</TD>
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">FY 2021</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="width: 55%; text-align: left">Stock Options Granted</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right">254,517</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right">598,815</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right">530,574</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock Settled Restricted Stock/RSUs Granted</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">712,464</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">924,499</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">656,514</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">Basic Weighted. Avg. Common Shares Outstanding</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">14,121,000</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">14,222,000</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">14,263,825</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Annual Burn Rate</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">6.85</TD>
    <TD STYLE="white-space: nowrap; text-align: left">%</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">10.71</TD>
    <TD STYLE="white-space: nowrap; text-align: left">%</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">8.32</TD>
    <TD STYLE="white-space: nowrap; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Three Year Avg. Burn Rate (FY 2019-2021)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">8.63</TD>
    <TD STYLE="white-space: nowrap; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Based on the recent range of our stock price, our current
compensation practices, our anticipated future awards, as well as our three-year burn rate experience, we are requesting an additional
950,000 shares to be added to the 4,600,000 shares already authorized under the Third Amended Plan. We believe this request for additional
shares will be sufficient for us to grant equity awards for approximately one year based on our stock price and compensation philosophy
and policies. Our actual share usage will vary depending on a number of factors, including the number of employees receiving equity awards,
the prevailing price per share of our common stock, the methodology used to value and determine the size of equity awards, and the mix
of award types provided to participants. We believe that our requested number of common shares will give us the flexibility we need to
respond to these changes and other unanticipated circumstances that may arise during the life of the Fourth Amended Plan. As stated above,
we anticipate that we will be seeking stockholder approval at next year&rsquo;s annual meeting for an additional number of shares to fund
an equity program in line with our comprehensive strategic plan. As of April 13, 2022, the closing price of a share of common stock on
the NASDAQ Global Select Market was $24.47.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">A copy of the Fourth Amended Plan as approved by the Board
on April 18, 2022, marked to show the amendments to the existing Third Amended Plan, is attached as <I>Appendix A </I>to this Proxy Statement
and is incorporated herein by reference. The following discussion summarizes certain features and effects of the Third Amended Plan as
proposed to be amended by the Fourth Amended Plan, and it is qualified in its entirety by reference to the terms of Fourth Amended Plan
set forth in <I>Appendix A</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><A NAME="a_058"></A><FONT STYLE="font-size: 11pt">Key
Features of the Fourth Amended Plan</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The following is a summary of key features of the
Fourth Amended Plan, which are intended to protect the interests of our stockholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><I>Limitation on terms of stock options and stock appreciation rights</I>. The maximum
        term of each stock option and Stock Appreciation Right, or SAR, is 10 years.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><I>Minimum vesting requirement</I>. The Fourth Amended Plan includes minimum vesting
        requirements that were updated in the First Amended Plan to reflect current administrative practices. Equity-based awards generally cannot
        vest earlier than one year after grant. Certain limited exceptions are permitted.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><I>No repricing or grant of discounted stock options. </I>The Fourth Amended Plan does
        not permit the repricing of options or SARs either by amending an existing award or by substituting a new award at a lower price without
        stockholder approval. The Fourth Amended Plan prohibits the granting of stock options or SARs with an exercise price less than the fair
        market value of the common stock on the date of grant.</TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><I>No transferability</I>. Awards generally may not be transferred, except by will
        or the laws of descent and distribution, unless approved by the plan administrator.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><I>No single-trigger vesting on a change in control</I>. In the event of a change in
        control of our company, the plan administrator may provide for accelerated vesting of outstanding awards, but there is no automatic acceleration
        of awards upon a change in control.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><I>No dividends on options, SARs or unvested share awards</I>. The Fourth Amended
        Plan prohibits the payment of dividends or dividend equivalents on stock options and SARs, or on any other awards that have not vested.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><I>Multiple award types</I>. The Fourth Amended Plan permits the issuance of incentive
        stock options, non-qualified stock options, SARs, restricted stock units, restricted stock awards, and other types of share and cash-based
        awards, subject to the share limits of the Fourth Amended Plan. This gives us the flexibility to grant different types of awards as compensation
        tools to motivate our workforce.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><I>Independent oversight</I>. The Fourth Amended Plan is administered by the Compensation
        Committee, which is comprised of independent members of the Board of Directors.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><I>Director limits</I>. The Fourth Amended Plan contains annual limits on the value
        of awards that may be granted to non-employee directors.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><A NAME="a_041"></A><FONT STYLE="font-size: 11pt">Summary
of the Fourth Amended Plan</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The following description of certain
features of the Fourth Amended Plan is intended to be a summary only, and it is qualified in its entirety by reference to the terms of
the Fourth Amended Plan set forth in <I>Appendix A</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Plan Administration</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">As with the Third Amended Plan, the
Fourth Amended Plan may be administered by the Board of Directors or the Compensation Committee. The Board or Compensation Committee so
acting is referred to below as the Administrator. The Administrator, in its discretion, selects the individuals to whom awards may be
granted, the time or times at which such awards are granted and the terms and conditions of such awards. In addition, the Administrator
may not reprice outstanding options or cancel stock options or SARs for cash without prior stockholder approval, other than to appropriately
reflect changes in our capital structure. The Administrator may delegate to the Chief Executive Officer the authority to grant stock options
to employees who are not subject to the reporting and other provisions of Section 16 of the Exchange Act, subject to certain limitations
and guidelines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91"><I>Eligibility</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">As with the Third Amended Plan, all
full-time and part-time officers, employees, non-employee directors, and other key persons of our company and subsidiaries are eligible
to participate in the Fourth Amended Plan, subject to the discretion of the Administrator. The number of individuals potentially eligible
to participate in the Fourth Amended Plan is currently approximately 313 persons (all employees of our company and subsidiaries), including
3 executive officers and 7 non-employee directors. The Administrator will use its discretion to select individuals to participate in the
Fourth Amended Plan who are responsible for, or contribute to, our management, growth, or profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91"><I>Plan Limits</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The number of shares of common
stock authorized for issuance under the Fourth Amended Plan is 5,550,000 shares comprised of the 4,600,000 shares approved under the Third
Amended Plan and 950,000 additional shares if the amendment to the Third Amended Plan is approved by the stockholders. These additional
shares represent 6.5% of the fully diluted common stock outstanding as of April 13, 2022. In addition, any shares subject to outstanding
awards under the Third Amended Plan that subsequently expire, terminate, or are surrendered or forfeited for any reason without issuance
of shares will automatically become available for issuance under the Fourth Amended Plan. As well, under the Fourth Amended Plan, up to
5,550,000 shares may be granted as incentive stock options under Code Section 422. The shares of common stock issuable under the Fourth
Amended Plan will consist of authorized and unissued shares, treasury shares, or shares purchased on the open market or otherwise.</P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Fourth Amended Plan makes no changes
to the share counting and share recycling provisions under the Third Amended Plan. For purposes of determining the number of shares available
for issuance under the Fourth Amended Plan, the grant of any &ldquo;full value award&rdquo; (<I>i.e.</I>, a restricted stock award, deferred
stock award, unrestricted stock award, or performance share) shall be deemed an award of two shares for each share subject to such full
value award. For purposes of determining the number of shares available for issuance under the Fourth Amended Plan, the grant of any option
or SAR shall be deemed an award of one share for each share subject to such option or SAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">If any award expires, terminates, is
settled in cash, or is surrendered or forfeited, the shares subject to such awards will not count against the aggregate number of shares
of common stock available for grant under the Fourth Amended Plan. Additionally, awards granted in assumption of or in substitution for
awards previously granted by an acquired company will not count against the shares available for grant. Shares issuable upon exercise,
vesting, or settlement or an award, or shares surrendered or tendered to pay the exercise price or taxes required to be withheld with
respect to an award, shall not be available again for the grant of awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The Fourth Amended Plan makes no changes
to the individual award limits included in the Third Amended Plan, although these award limits are no longer needed as the result of changes
in the federal tax laws effective in 2018. The maximum award of stock options or SARs granted to any one individual will not exceed 400,000
shares of common stock (subject to adjustment for stock splits and similar events) for any calendar-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Awards to Non-Employee
Directors</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As under the Third Amended Plan,
the maximum value of plan awards granted during any calendar year to any non-employee director, taken together with any cash fees paid
to such non-employee director during the calendar year and the value of awards granted to the non-employee director under any other equity
compensation plan of our company or an affiliate during the calendar year, may not exceed the following in total value (calculating the
value of any equity compensation plan awards based on the grant date fair market value for financial reporting purposes): (a) $500,000
for the Chair of the Board; and (b) $425,000 for each non-employee director other than the Chair of the Board. However, awards granted
to non-employee directors upon their initial election to the Board of Directors or the board of directors of an affiliate will not be
counted towards this limit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Tax Withholding</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: -0.05pt">Participants under
the Fourth Amended Plan are responsible for the payment of any federal, state, or local taxes that we are required by law to withhold
upon any option or SAR exercise or vesting or payment of other awards. Subject to approval by the Administrator, participants may elect
to have the tax withholding obligations satisfied either by authorizing us to withhold shares of common stock to be issued pursuant to
an option exercise or other award, or by transferring to us shares of common stock having a value equal to the amount of such taxes. Such
share withholding may be made at up to maximum statutory tax rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Change of Control Provisions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">As under the Third Amended Plan, the
Fourth Amended Plan provides that upon the effectiveness of a &ldquo;change in control&rdquo; as defined in the Fourth Amended Plan, the
Administrator may take any one or more of the following actions, with or without the consent of a participant: (a) accelerate the vesting
or settlement of awards on the terms and conditions determined by the Administrator (including upon a participant&rsquo;s separation from
service following the change in control); (b) permit the assumption or substitution of outstanding awards by the acquiror in the change
in control, and cancel any awards that are not assumed or substituted for; or (c) cancel outstanding vested awards in exchange for cash,
the stock of the acquiror, or other property having a fair market value equal to the consideration paid for shares in the change in control
(reduced by the exercise price of an award, if necessary).</P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Adjustments for Stock
Dividends, Mergers, etc.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As under the Third Amended Plan,
subject to any required action by our stockholders, in the event of any change in our common stock effected without receipt of consideration
by us, whether through merger, consolidation, reorganization, reincorporation, recapitalization, reclassification, stock dividend, stock
split, reverse stock split, split-up, split-off, spin-off, combination of shares, exchange of shares, or similar change in our capital
structure, or in the event of payment of a dividend or distribution to our stockholders in a form other than our common stock (excepting
normal cash dividends) that has a material effect on the fair market value of our common stock, appropriate and proportionate adjustments
will be made in the number and class of shares subject to the Fourth Amended Plan and to any outstanding awards, and in the option exercise
price, SAR exercise price, or purchase price per share of any outstanding awards in order to prevent dilution or enlargement of participant
rights under the Fourth Amended Plan. If a majority of our common shares are exchanged for, converted into, or otherwise become shares
of another corporation, the Administrator may unilaterally amend outstanding awards under the Fourth Amended Plan to provide that such
awards are for new shares. In the event of any such amendment, the number of shares subject to, and the option exercise price, SAR exercise
price, or purchase price per share of, the outstanding awards will be adjusted in a fair and equitable manner as determined by the Administrator.
The Administrator may also make such adjustments in the terms of any award to reflect, or related to, such changes in our capital structure
or distributions as it deems appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>No Repricing</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">Without stockholder approval, the Administrator
is not authorized to (a) lower the exercise or grant price of a stock option or SAR after it is granted, except in connection with certain
adjustments to our corporate or capital structure permitted by the Fourth Amended Plan, such as stock splits, (b) take any other action
that is treated as a repricing under generally accepted accounting principles or (c) cancel a stock option or SAR at a time when its exercise
or grant price exceeds the fair market value of the underlying stock, in exchange for cash, another stock option or SAR, restricted stock,
restricted stock units or other equity award, unless the cancellation and exchange occur in connection with a change in capitalization
or other similar change. These provisions are unchanged from the Third Amended Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Minimum Vesting Provisions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">Equity-based awards granted under the
Fourth Amended Plan will have a one-year minimum vesting requirement. This requirement does not apply to (1) substitute awards resulting
from acquisitions, (2) shares delivered in lieu of fully vested cash awards, or (3) awards to non-employee directors that vest on the
earlier of the one-year anniversary of the date of grant or the next annual meeting of stockholders (but not sooner than 50 weeks after
the grant date). Also, the Compensation Committee may grant equity-based awards without regard to the minimum vesting requirement with
respect to a maximum of five percent of the available share reserve authorized for issuance under the Fourth Amended Plan. In addition,
the minimum vesting requirement does not apply to the Administrator&rsquo;s discretion to provide for accelerated exercisability or vesting
of any award, including in cases of retirement, death, disability or a change in control, in the terms of the award or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Amendments and Termination</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">Unless earlier terminated by the Board
of Directors, the Fourth Amended Plan will terminate, and no further awards may be granted, 10 years after the date on which the Original
Plan was approved by stockholders. The Board may amend, suspend, or terminate the Fourth Amended Plan at any time, except that, if required
by applicable law, regulation, or stock exchange rule, stockholder approval will be required for any amendment. The amendment, suspension,
or termination of the Fourth Amended Plan or the amendment of an outstanding award generally may not, without a participant&rsquo;s consent,
materially impair the participant&rsquo;s rights under an outstanding award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91"><I>Transferability</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">Awards are not transferable other than
by will or the laws of descent and distribution, except that in certain instances transfers may be made to or for the benefit of designated
family members of the participant for no value.</P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><A NAME="a_042"></A><FONT STYLE="font-size: 11pt">Types
of Awards</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Fourth Amended Plan makes no changes to the
types of awards as authorized under the Third Amended Plan, which are summarized below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Stock Options</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">Options granted under the Fourth Amended
Plan may be either incentive stock options, which must comply with Code Section 422, or non-qualified stock options. Incentive stock options
may be granted only to employees of our company or any subsidiary. Options granted under the Fourth Amended Plan will be non-qualified
stock options if they (a) fail to qualify as incentive stock options, (b) are granted to a person not eligible to receive incentive stock
options under the Code, or (c) otherwise so provide. Non-qualified stock options may be granted to persons eligible to receive incentive
stock options and to non-employee directors and other key persons. The Administrator has authority to determine the terms and conditions
of options at the time of grant, including quantity of shares covered, exercise price, method of exercise, vesting conditions, the term
(which cannot exceed 10 years), and other conditions on exercise. Stock options must be granted with an exercise price not less than 100%
of the fair market value of our common stock on the date of grant (excluding stock options granted in connection with assuming or substituting
stock options in acquisition transactions). The Fourth Amended Plan prohibits the payment of dividends or dividend equivalent rights on
unvested stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Stock Appreciation
Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The Administrator may award SARs, with
a term not to exceed 10 years. Upon exercise of an SAR, the holder will be entitled to receive an amount equal to the excess of the fair
market value on the date of exercise of one share of common stock over the exercise price per share specified in such right times the
number of shares of common stock with respect to which the SAR is exercised. This amount may be paid in cash, common stock, or a combination
thereof, as determined by the Administrator. The exercise price is the fair market value of the common stock on the date of grant. The
Fourth Amended Plan prohibits the payment of dividends or dividend equivalent rights on SARs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Restricted Stock and
Restricted Stock Unit Awards</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Administrator may grant shares
of restricted stock, which are shares of common stock subject to specified restrictions, and restricted stock units or RSUs, which represent
the right to receive shares of our common stock in the future. These awards may be made subject to repurchase, forfeiture, or vesting
restrictions at the Administrator&rsquo;s discretion. The restrictions may be based on continuous service with us or the attainment of
specified performance goals, as determined by the Administrator. RSUs may be paid in stock or cash or a combination of stock and cash,
as determined by the Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Other Share-Based and Cash-Based Awards</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The Administrator may also grant awards
based on shares of stock, either alone or in addition to or in conjunction with other awards. Such awards may be granted in lieu of other
cash or other compensation to which a participant is entitled from us or may be used in the settlement of amounts payable under any of
our other compensation plans or arrangements. The Administrator shall have the authority to determine the persons to whom and the time
or times at which such Awards will be made, the number of shares to be granted pursuant to such Awards, and all other terms of such Awards.
The Administrator may grant cash bonuses under the Fourth Amended Plan. The cash bonuses may be subject to achievement of certain performance
goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Performance Awards</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: -0.05pt">At the time of
grant, the Administrator may condition the grant, exercise, vesting, or settlement of any award on such performance conditions as it may
specify. We refer to these awards as &ldquo;performance awards.&rdquo; The Administrator may select such business criteria or other performance
measures as it may deem appropriate in establishing any performance conditions.</P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><A NAME="a_043"></A><FONT STYLE="font-size: 11pt">New
Plan Benefits</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">A new plan benefits table for the Fourth Amended
Plan and the benefits or amounts that would have been received by or allocated to participants for the last completed fiscal year under
the Fourth Amended Plan if the Fourth Amended Plan was then in effect, as described in the SEC proxy rules, are not provided because all
awards made under the Fourth Amended Plan will be made at the Administrator&rsquo;s discretion, subject to the terms and conditions of
the Fourth Amended Plan. Therefore, the benefits and amounts that will be received or allocated under the Fourth Amended Plan are not
determinable at this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><A NAME="a_044"></A><FONT STYLE="font-size: 11pt">Federal
Income Tax Information</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><I>The following is a brief summary of the U.S.
federal income tax consequences of the Fourth Amended Plan generally applicable to us and to participants in the Fourth Amended Plan who
are subject to U.S. federal taxes. The summary is based on the Code, applicable Treasury Regulations, and administrative and judicial
interpretations thereof, each as in effect on the date of this Proxy Statement, and is, therefore, subject to future changes in the law,
possibly with retroactive effect. The summary is general in nature and does not purport to be legal or tax advice. Furthermore, the summary
does not address issues relating to any U.S. gift or estate tax consequences or the consequences of any state, local or foreign tax laws.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Non-qualified Stock
Options</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">A participant generally will not recognize
taxable income upon the grant or vesting of a non-qualified stock option with an exercise price at least equal to the fair market value
of the common stock on the date of grant and no additional deferral feature. Upon the exercise of a non-qualified stock option, a participant
generally will recognize compensation taxable as ordinary income in an amount equal to the difference between the aggregate fair market
value of the exercised shares underlying the stock option on the date of exercise and the aggregate exercise price of the exercised shares.
When a participant sells the shares, the participant will have short-term or long-term capital gain or loss, as the case may be, equal
to the difference between the amount the participant received from the sale and the tax basis of the shares sold. The tax basis of the
shares generally will be the fair market value of the shares on the exercise date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Incentive Stock Options</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">A participant generally will not recognize
taxable income upon the grant of an incentive stock option. If a participant exercises an incentive stock option during employment or
within three months after employment ends (one year in the case of permanent and total disability), the participant will not recognize
taxable income at the time of exercise for regular U.S. federal income tax purposes (although the participant generally will have taxable
income for alternative minimum tax purposes at that time as if the stock option were a non-qualified stock option). If a participant sells
or otherwise disposes of the shares acquired upon exercise of an incentive stock option after the later of (a) one year from the date
the participant exercised the option and (b) two years from the grant date of the stock option, the participant generally will recognize
long-term capital gain or loss equal to the difference between the amount the participant received in the disposition and the exercise
price of the stock option. If a participant sells or otherwise disposes of shares acquired upon exercise of an incentive stock option
before these holding period requirements are satisfied, the disposition will constitute a &ldquo;disqualifying disposition,&rdquo; and
the participant generally will recognize taxable ordinary income in the year of disposition equal to the excess of the fair market value
of the shares on the date of exercise over the exercise price of the stock option (or, if less, the excess of the amount realized on the
disposition of the shares over the exercise price of the stock option). The balance of the participant&rsquo;s gain on a disqualifying
disposition, if any, will be taxed as short-term or long-term capital gain, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">With respect to both non-qualified stock
options and incentive stock options, special rules apply if a participant uses shares of common stock already held by the participant
to pay the exercise price or if the shares received upon exercise of the stock option are subject to a substantial risk of forfeiture
by the participant.</P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Stock Appreciation
Rights</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">A participant generally will not recognize
taxable income upon the grant or vesting of a SAR with a grant price at least equal to the fair market value of common stock on the date
of grant and no additional deferral feature. Upon the exercise of a SAR, a participant generally will recognize compensation taxable as
ordinary income in an amount equal to the difference between the aggregate fair market value of the exercised shares underlying the SAR
on the date of exercise and the aggregate grant price of the exercised shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Restricted Stock Awards,
Restricted Stock Units, and Performance Awards</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">A participant generally will not have
taxable income upon the grant of restricted stock, restricted stock units or performance awards. Instead, the participant will recognize
ordinary income at the time of vesting or payout equal to the fair market value (on the vesting or payout date) of the shares or cash
received minus any amount paid. For restricted stock only, a participant may instead elect to be taxed at the time of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Other Stock or Cash-Based
Awards</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The U.S. federal income tax consequences
of other stock or cash-based awards will depend upon the specific terms of each award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Tax Consequences to
Us</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">In the foregoing cases, we generally
will be entitled to a deduction at the same time, and in the same amount, as a participant recognizes ordinary income, subject to limitations
imposed under the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Section 409A</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">We intend that awards granted under
the Fourth Amended Plan comply with, or otherwise be exempt from, Code Section 409A, but make no representation or warranty to that effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><I>Tax Withholding</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">We are authorized to deduct or withhold
from any award granted or payment due under the Fourth Amended Plan, or require a participant to remit to us, the amount of any withholding
taxes due in respect of the award or payment and to take such other action as may be necessary to satisfy all obligations for the payment
of applicable withholding taxes. We are not required to issue any shares of common stock or otherwise settle an award under the Fourth
Amended Plan until all tax withholding obligations are satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><FONT STYLE="font-size: 11pt">Vote
Required</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">At the Annual Meeting, the approval of the amendment
to the Third Amended Plan, in the form of the Fourth Amended Plan attached as <I>Appendix A</I> to this Proxy Statement, requires the
affirmative vote of the holders of a majority of the shares of common stock that are voting on the matter. Abstentions and broker non-votes
will not be treated as votes cast and will have no impact on the proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><FONT STYLE="font-size: 11pt">Board
Recommendation</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">THE BOARD OF DIRECTORS UNANIMOUSLY
RECOMMENDS A VOTE &ldquo;FOR&rdquo; THE AMENDMENT OF THE THIRD AMENDED PLAN IN THE FORM OF THE FOURTH AMENDED PLAN ATTACHED AS <I>APPENDIX
A</I> TO THIS PROXY STATEMENT.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center; color: #355E91"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center; color: #355E91"><A NAME="a_045"></A><FONT STYLE="font-size: 13pt"><B><I>Audit
Committee Report</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Audit Committee of the Board of Directors consists
entirely of members who meet the independence requirements of the listing standards of NASDAQ and the rules and regulations of the SEC,
as determined by the Board. The Audit Committee is responsible for providing independent, objective oversight of the financial reporting
processes and internal controls of Anika Therapeutics, Inc., or Anika. The Audit Committee operates under a written charter approved by
the Board. A copy of the current charter is available on the investor relations portion of Anika&rsquo;s website at <I>https://ir.anika.com/board-committees</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">Management is responsible for Anika&rsquo;s
system of internal control and financial reporting processes, for the preparation of consolidated financial statements in accordance with
U.S. generally accepted accounting principles and for the annual report on Anika&rsquo;s internal control over financial reporting. The
independent auditor is responsible for performing an integrated audit of Anika&rsquo;s consolidated financial statements in accordance
with the standards of the Public Company Accounting Oversight Board, or PCAOB, and for issuing a report on the financial statements and
the effectiveness of Anika&rsquo;s internal control over financial reporting. The Audit Committee&rsquo;s responsibility is to monitor
and oversee these processes. In performing its functions, the Audit Committee acts only in an oversight capacity and necessarily relies
on the work and assurances of management, the internal audit group, and the independent auditor. Audit Committee members do not serve
as professional accountants or auditors for Anika, and their functions are not intended to duplicate or certify the activities of Anika&rsquo;s
management or independent auditor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">Consistent with its monitoring and oversight
responsibilities, the Audit Committee met with management and Deloitte &amp; Touche LLP, or Deloitte, Anika&rsquo;s independent auditor,
to review and discuss the December 31, 2021 audited consolidated financial statements. Management represented that Anika had prepared
the consolidated financial statements in accordance with accounting principles generally accepted in the U.S. The Audit Committee discussed
with Deloitte the matters required by the PCAOB in accordance with Auditing Standard No. 1301, &ldquo;Communications with Audit Committees.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The Audit Committee received from Deloitte
the written communication that is required by PCAOB Rule 3526, &ldquo;Communication with Audit Committees Concerning Independence,&rdquo;
and the Audit Committee discussed with Deloitte that firm&rsquo;s independence. The Audit Committee also considered whether Deloitte&rsquo;s
provision of non-audit services and the audit and non-audit fees paid to Deloitte were compatible with maintaining that firm&rsquo;s independence.
On the basis of these reviews, the Audit Committee determined that Deloitte has the requisite independence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">Management completed the documentation,
testing, and evaluation of Anika&rsquo;s system of internal control over financial reporting as of December 31, 2021 as required by Section
404 of the Sarbanes-Oxley Act of 2002. The Audit Committee received periodic updates from management and Deloitte at Audit Committee meetings
throughout the year and provided oversight of the process. Prior to the filing of Anika&rsquo;s Annual Report on Form 10-K for the fiscal
year ended December 31, 2021, or the Form 10-K, with the Securities and Exchange Commission, the Audit Committee also reviewed management&rsquo;s
report on the effectiveness of Anika&rsquo;s internal control over financial reporting contained in the Form 10-K, as well as the Report
of Independent Registered Public Accounting Firm provided by Deloitte and also included in the Form 10-K. Deloitte&rsquo;s reports included
in the Form 10-K related to its audit of Anika&rsquo;s consolidated financial statements and the effectiveness of Anika&rsquo;s internal
control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">Based upon the Audit Committee&rsquo;s
discussions with management and Deloitte and the Audit Committee&rsquo;s review of the information provided by, and the representations
of, management and Deloitte, the Audit Committee recommended to the Board that the audited consolidated financial statements as of and
for the year ended December 31, 2021 be included in the Annual Report. The Audit Committee selected Deloitte as Anika&rsquo;s independent
auditor for the fiscal year ending December 31, 2022 and recommended that the selection be submitted for ratification by the stockholders
of Anika.</P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">This report is submitted by the following
independent directors who comprise the Audit Committee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 25%; text-align: left; padding-left: 44.7pt">Sheryl L. Conley</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 24%; text-align: left">Raymond J. Land, Chair</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 24%; text-align: left">Stephen O. Richard</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 24%; text-align: left">Susan L. N. Vogt</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">THE FOREGOING REPORT SHOULD NOT
BE DEEMED INCORPORATED BY REFERENCE INTO ANY FILING UNDER THE SECURITIES ACT OF 1933 OR THE SECURITIES EXCHANGE ACT OF 1934 BY ANY GENERAL
STATEMENT INCORPORATING BY REFERENCE THIS PROXY STATEMENT, EXCEPT TO THE EXTENT THAT ANIKA SPECIFICALLY INCORPORATES THIS INFORMATION
BY REFERENCE, AND SHALL NOT OTHERWISE BE DEEMED FILED UNDER SUCH ACTS.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52.65pt; color: #355E91"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #355E91"><A NAME="a_046"></A><FONT STYLE="font-size: 13pt"><B><I>Proposal
3: Ratification of Appointment of Independent Auditor for 2022</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><FONT STYLE="font-size: 11pt"><B>Appointment
of Independent Auditor by Audit Committee</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Audit Committee annually evaluates the performance
of our independent auditor, including the senior audit engagement team, and determines whether to reengage the current independent auditor
or consider other audit firms. The Audit Committee&rsquo;s initial appointment of Deloitte &amp; Touche LLP, or Deloitte, as independent
auditor of our consolidated financial statements for 2017, was ratified by a vote of stockholders at our 2017 Annual Meeting of Stockholders.
The Audit Committee again appointed Deloitte as our independent auditor for each of 2018, 2019, 2020, and 2021, which appointments were
ratified by votes of our stockholders at our 2018, 2019, 2020, and 2021 Annual Meetings of Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">This year the Audit Committee has approved
the retention of Deloitte as our independent auditor to report on our consolidated financial statements and the effectiveness of our internal
control over financial reporting for the year ending December 31, 2022. Factors considered by the Audit Committee in deciding whether
to retain Deloitte included:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>Deloitte&rsquo;s global capabilities;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>Deloitte&rsquo;s technical expertise and knowledge of our global operations and industry;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>The quality and candor of Deloitte&rsquo;s communications with the Audit Committee and management;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="padding-right: 10pt">The quality and efficiency of the services provided by Deloitte, including input from management on Deloitte&rsquo;s
        performance;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>Deloitte&rsquo;s objectivity and professional skepticism;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>External data on audit quality and performance, including recent PCAOB reports on Deloitte and its peer firms;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>Deloitte&rsquo;s use of technology to aid in audit efficiency;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="padding-right: 0.15in">Deloitte&rsquo;s independence, how effectively Deloitte demonstrated its independent judgment, and the controls
        and processes in place that help ensure Deloitte&rsquo;s independence; and</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>The appropriateness of Deloitte&rsquo;s fees.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><FONT STYLE="font-size: 11pt">Proposed
Ratification of Independent Auditor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The Audit Committee is responsible for
the appointment, retention, termination, compensation, and oversight of the work of our independent registered public accounting firm
for the purpose of preparing or issuing an audit report or related work. Although ratification of the appointment of our independent auditor
is not required by our bylaws or otherwise, the Board of Directors is submitting the appointment of Deloitte to our stockholders for ratification
because we value the views of our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Audit Committee considers Deloitte to be well qualified.
In the absence of contrary specification, the proxy holders will vote proxies received in response to this solicitation in favor of ratification
of the appointment. In the event that stockholders fail to ratify the appointment of Deloitte, the Audit Committee will reconsider the
appointment of Deloitte. Even if the appointment is ratified, the ratification is not binding and the Audit Committee may in its discretion
select a different independent auditor at any time during the year if it determines that such a change would be in the best interests
of our company and stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">Representatives of Deloitte are expected
to be present at the Annual Meeting. They will have an opportunity to make a statement, if they desire, and will be available to respond
to appropriate questions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><FONT STYLE="font-size: 11pt">Vote
Required</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">At the Annual Meeting, the ratification
of our independent auditor for 2022 requires the affirmative vote of the holders of a majority of the shares of common stock that are
voting on the matter. Abstentions will not be treated as votes cast and will have no effect on the vote. Because this proposal is considered
a routine matter, discretionary votes by brokers will be counted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><FONT STYLE="font-size: 11pt">Board
Recommendation</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">THE BOARD OF DIRECTORS UNANIMOUSLY
RECOMMENDS A VOTE &ldquo;FOR&rdquo; THE RATIFICATION OF THE APPOINTMENT OF DELOITTE &amp; TOUCHE LLP AS OUR INDEPENDENT AUDITOR FOR THE
YEAR ENDING DECEMBER 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><FONT STYLE="font-size: 11pt"><B>Fees
Paid to Our Independent Auditor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The following table summarizes the fees
that we paid or accrued for audit and other services provided by Deloitte, our independent auditor, for the years ended December 31, 2021
and 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" align="center" STYLE=" width: 60%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: #1F497D">
    <TD STYLE="white-space: nowrap; color: white; font-weight: bold; border-bottom: Black 1pt solid">Fee Category</TD>
    <TD STYLE="color: white; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021</TD>
    <TD STYLE="color: white; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="white-space: nowrap; color: white; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 70%; text-align: left">Audit fees</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 12%; text-align: right">1,108,421</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 12%; text-align: right">1,314,815</TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left">Audit-related fees</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">20,000</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: left">Tax fees</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">301,705</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">196,269</TD>
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C8D7EA">
    <TD STYLE="text-align: left; padding-bottom: 1pt">All other fees</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,685</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,685</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 2.25pt">Total fees</TD>
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: right">1,435,811</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; text-align: right">1,516,769</TD>
    <TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">For purposes of the preceding table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Audit fees consist of fees for the audit of our consolidated financial statements,
        the review of the interim financial statements included in our Quarterly Reports on Form 10-Q, and other professional services provided
        in connection with statutory and regulatory filings or engagements for those years, inclusive of fees related to work performed with respect
        to our acquisitions of Arthrosurface and Parcus Medical in early 2020. In addition, Audit fees include: fees for comfort letters, consents,
        assistance with and review of documents filed with the SEC, Section 404 attest services, other attest services that generally only the
        principal independent auditor can provide, work done by tax professionals in connection with the audit or quarterly review, and accounting
        consultations billed as audit services, as well as other accounting and financial reporting consultation research work necessary to comply
        with the standards of the PCAOB.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">Audit-related fees consist of the aggregate fees billed by the principal accountant
        in each of the last two fiscal years for assurance and related services reasonably related to the performance of the audit or review.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>Tax fees consist of fees for tax compliance, tax advice, and tax planning services for those years.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">All other fees consist of the aggregate fees billed by the principal accountant in
        each of the last two fiscal years for products and services other than the services reported herein.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">In considering the nature of the services
provided by a principal independent auditor, the Audit Committee determined that such services are compatible with the provision of independent
audit services. The Audit Committee discussed these services with the independent auditor and management to determine that they are permitted
under the rules and regulations concerning auditor independence promulgated by the SEC to implement the Sarbanes-Oxley Act of 2002, as
well as the American Institute of Certified Public Accountants. In accordance with its charter, the Audit Committee has procedures for
pre-approving audit and non-audit services to be provided by the independent auditor. These procedures are designed to ensure the continued
independence of the independent auditor. More specifically, the use of the independent auditor to perform either audit or non-audit services
is prohibited unless specifically approved in advance by the Audit Committee. As a result of this approval process, the Audit Committee
has pre-approved specific categories of services and associated fee budgets. All services outside of the specified categories and all
amounts exceeding the approved fee budgets are approved by the Chair of the Audit Committee, who has been delegated the authority to review
and approve audit and non-audit related services during the year. A listing of the audit and non-audit services and associated fees approved
by the Chair outside the scope of the services and fees initially approved by the full Audit Committee is reported to the full Audit Committee
no later than its next meeting. The Audit Committee also regularly receives updates from Deloitte and management about the services actually
performed and the associated fees and expenses actually incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">In addition, the Audit Committee evaluates
other known potential engagements of the independent auditor, including the scope of audit-related services, tax services, and other services
proposed to be performed and the proposed fees, and approves or rejects each service, taking into account whether the services are permissible
under applicable law and the possible impact of each non-audit service on the independent auditor&rsquo;s independence from management.
All such services were approved by the Audit Committee pursuant to Rule 2-01 of Regulation S-X under the Exchange Act to the extent that
rule was applicable. Since May 2003 each new engagement of a principal independent auditor has been approved in advance by the Audit Committee.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center; color: #355E91"></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center; color: #355E91"><FONT STYLE="font-size: 13pt"><A NAME="a_047"></A>Proposal
4: Advisory Vote on Executive Compensation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">In accordance with Section 14A of the
Exchange Act, we are providing our stockholders with the opportunity to vote on a non-binding, advisory resolution to approve the compensation
of our NEOs for the year ended December 31, 2021, which is described in the section titled &ldquo;Compensation Discussion and Analysis&rdquo;
in this Proxy Statement. At our 2017 Annual Meeting of Stockholders, we asked our stockholders to indicate if we should hold a &ldquo;say-on-pay&rdquo;
vote every one, two or three years. Consistent with the recommendation of the Board of Directors, our stockholders indicated by advisory
vote their preference to hold a &ldquo;say-on-pay&rdquo; vote annually. After consideration of the 2017 voting results, and based upon
its prior recommendation, the Board elected to hold a stockholder &ldquo;say-on-pay&rdquo; vote annually.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">As described in the section titled &ldquo;Compensation
Discussion and Analysis&rdquo; of this Proxy Statement, our executive compensation program is designed to attract and retain highly qualified
executive officers and motivate them to provide a high level of performance for the benefit of our company and stockholders. Stockholders
are urged to read the section titled &ldquo;Compensation Discussion and Analysis,&rdquo; which more thoroughly discusses how our compensation
policies and procedures implement our compensation philosophy and objectives. The Compensation Committee and the Board believe that these
policies and procedures are effective in implementing our compensation philosophy and in achieving our objectives. This vote is not intended
to address any specific item of compensation, but rather the overall compensation of our NEOs and the policies and practices described
in this Proxy Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Accordingly, the following resolution
is submitted for a stockholder vote at the Annual Meeting:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 26.1pt 0pt 90pt; text-align: justify; text-indent: -1in">&ldquo;RESOLVED:
That the stockholders of Anika Therapeutics, Inc. approve, on an advisory basis, the compensation paid to the named executive officers
of Anika Therapeutics, Inc. as disclosed pursuant to Item 402 of Regulation S-K under the Securities Exchange Act of 1934, including the
Compensation Discussion and Analysis, compensation tables, and narrative discussion set forth in the Proxy Statement for the 2022 Annual
Meeting of Stockholders.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">This vote is advisory and
will not be binding upon us, the Compensation Committee or the Board. However, the Board and its Compensation Committee value the opinions
of our stockholders and to the extent there is any significant vote against the NEO compensation as disclosed in this Proxy Statement,
we will consider our stockholders&rsquo; concerns, and the Compensation Committee will evaluate whether any actions are necessary to address
those concerns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><FONT STYLE="font-size: 11pt">Vote
Required</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">At the Annual Meeting, approval of our
2021 executive compensation requires the affirmative vote of the holders of a majority of the shares of common stock that are voting on
the matter. Abstentions and broker non-votes will not be treated as votes cast and will have no impact on the proposal. While this vote
is required by law, it will not be binding on us, the Compensation Committee, or the Board of Directors, nor will it create or imply any
change in the fiduciary duties of, or impose any additional fiduciary duty on, our company, the Compensation Committee or the Board. However,
the Compensation Committee and the Board will take into account the outcome of the vote when considering future executive compensation
decisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; color: #355E91"><FONT STYLE="font-size: 11pt">Board
Recommendation</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">THE BOARD OF DIRECTORS UNANIMOUSLY
RECOMMENDS THAT STOCKHOLDERS VOTE TO APPROVE THE OVERALL COMPENSATION OF THE NAMED EXECUTIVE OFFICERS IN 2021 BY VOTING &ldquo;FOR&rdquo;
THIS RESOLUTION.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt 0pt 57.2pt; text-align: center; color: #355E91"></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt 0pt 57.2pt; text-align: center; color: #355E91"><FONT STYLE="font-size: 13pt"><A NAME="a_048"></A>Participation
in the Virtual Annual Meeting</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The Board of Directors considers the
appropriate format of our annual meeting of stockholders on an annual basis. This year, the Board again chose a virtual meeting format
for the Annual Meeting The virtual meeting format will allow our stockholders to engage with us at the Annual Meeting from any geographic
location, using any convenient internet connected devices, including smart phones and tablets, and laptop or desktop computers. The virtual
format allows stockholders to submit questions during the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The live audio webcast of the Annual
Meeting will be available for listening by the general public, but participation in the Annual Meeting, including voting shares and submitting
questions, will be limited to stockholders. To ensure they can participate, stockholders and proxyholders should visit <I>virtualshareholdermeeting.com/ANIK2022</I>
and enter the control number included on their Notice of Internet Availability of Proxy Materials or proxy card. If you wish to participate
in the meeting and your shares are held in street name, you must obtain, from the broker, bank or other organization that holds your shares,
the information required, including a control number, in order for you to be able to participate in, and vote at, the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">Stockholders can vote their shares and
submit questions via the internet during the Annual Meeting by accessing the annual meeting website at <I>virtualshareholdermeeting.com/ANIK2022</I>.
We will answer any timely submitted and relevant questions on a matter to be voted on at the Annual Meeting before voting is closed on
the matter. Following adjournment of the formal business of the Annual Meeting, we will address appropriate general questions from stockholders
regarding Anika as time allows. Questions relating to stockholder proposals or Anika may be submitted in the field provided in the web
portal at or before the time the questions are to be discussed. If we receive substantially similar questions, we may group those questions
together and provide a single response to avoid repetition. Additional information regarding the submission of questions during the Annual
Meeting can be found in our 2022 Annual Meeting of Stockholders Rules of Conduct and Procedure, a copy of which is attached hereto as
<I>Appendix B</I>. Any material changes or updates to the 2022 Rules of Conduct and Procedure will be posted on our website and disclosed
in a Current Report on Form 8-K filed with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">Online check-in to the Annual Meeting
webcast will begin at 8:45 a.m., Eastern time, and you should allow ample time to log in to the meeting webcast and test your computer
audio system. During online check-in and continuing through the length of the Annual Meeting, we will have technicians standing by to
assist you with any technical difficulties you may have accessing the virtual meeting. If you encounter any difficulties accessing the
virtual meeting during the check-in or meeting time, please call the technical support number that will be posted on the Virtual Shareholder
Meeting log in page.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">We have designed our virtual format
to enhance, rather than constrain, stockholder access, participation and communication. For example, stockholders will be able to communicate
with us during the Annual Meeting so they can ask questions. An audio replay of the Annual Meeting will be made publicly available at
<I>https://ir.anika.com/annual-reports-and-proxies</I> for ninety (90) days after the Annual Meeting. This audio replay will include each
stockholder question addressed during the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">We are utilizing technology from Broadridge
Financial Solutions, Inc., or Broadridge, the leading virtual meeting solution. The Broadridge platform is expected to accommodate most,
if not all, stockholders. Both we and Broadridge will test the platform technology before going &ldquo;live&rdquo; for the Annual Meeting.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt 0pt 57.2pt; text-align: center; color: #355E91"></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt 0pt 57.2pt; text-align: center; color: #355E91"><FONT STYLE="font-size: 13pt"><A NAME="a_049"></A>Questions
and Answers about the Annual Meeting</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; color: #355E91">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #355E91">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0; color: #355E91; font-weight: bold; font-style: normal"></TD>
    <TD STYLE="text-align: left; width: 0.5in; color: #355E91; font-weight: bold; font-style: normal"><I>Q:</I></TD>
    <TD STYLE="color: #355E91; font-weight: bold; font-style: normal; text-align: left"><I>When and where will the Annual Meeting be held?</I></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 0.5in"><B>A:</B></TD>
    <TD STYLE="text-align: justify">This year the Annual Meeting of Stockholders of Anika Therapeutics, Inc., which we
        refer to throughout this Proxy Statement as the Annual Meeting, will be held exclusively by webcast at <I>virtualshareholdermeeting.com/ANIK2022
        </I>on Wednesday, June 8, 2022, beginning at 9:00 a.m., Eastern time. We encourage you to access the Annual Meeting webcast prior to the
        start time.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #355E91">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0; color: #355E91; font-weight: bold; font-style: italic; padding-left: 0pt"></TD>
    <TD STYLE="width: 0.5in; color: #355E91; font-weight: bold; font-style: italic">Q:</TD>
    <TD STYLE="color: #355E91; font-weight: bold; font-style: italic; text-align: left">Who may join the Annual Meeting?</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 0.5in"><B>A</B>:</TD>
    <TD STYLE="text-align: justify">The live audio webcast of the Annual Meeting will be available for listening by the
        general public, but participation in the Annual Meeting, including voting shares and submitting questions, will be limited to stockholders.
        To ensure they can participate, stockholders and proxyholders should visit <I>virtualshareholdermeeting.com/ANIK2022 </I>and enter the
        control number included on their Notice of Internet Availability of Proxy Materials or proxy card.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">Online
check-in to the Annual Meeting webcast will begin at 8:45 a.m., Eastern time. We encourage you to allow ample time to log in to the meeting
webcast and test your computer audio system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #355E91">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0; color: #355E91; font-weight: bold; font-style: normal; padding-left: 0pt"></TD>
    <TD STYLE="width: 0.5in; color: #355E91; font-weight: bold; font-style: normal"><I>Q:</I><I>&nbsp;</I></TD>
    <TD STYLE="color: #355E91; font-weight: bold; font-style: normal; text-align: left"><I>What materials have been prepared for stockholders
        in connection with the Annual Meeting?</I></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0pt; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><B>A:</B></TD>
    <TD STYLE="text-align: justify">We are furnishing stockholders of record with access to, or copies of, the following proxy materials:</TD>
        </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">&bull;</TD>
    <TD STYLE="text-align: justify">Our 2021 Annual Report to Stockholders, which includes our audited consolidated financial statements;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">&bull;</TD>
    <TD STYLE="text-align: justify">This Proxy Statement for the 2022 Annual Meeting, which also includes a Notice of Annual
        Meeting of Stockholders;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">&bull;</TD>
    <TD STYLE="text-align: justify">For most stockholders, a Notice of Internet Availability of Proxy Materials; and</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">&bull;</TD>
    <TD STYLE="text-align: justify">For other stockholders who are receiving printed copies of the 2021 Annual Report
        and Proxy Statement by mail, a proxy card for the Annual Meeting.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">These
materials were first made available on the internet or mailed to stockholders on or about April 27, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #355E91">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0; color: #355E91; font-weight: bold; font-style: normal; padding-left: 0pt"></TD>
    <TD STYLE="width: 0.5in; color: #355E91; font-weight: bold; font-style: normal"><I>Q:</I><I>&nbsp;</I></TD>
    <TD STYLE="color: #355E91; font-weight: bold; font-style: normal; text-align: left"><I>Why was I mailed a Notice of Internet Availability
        of Proxy Materials rather than a printed set of proxy materials?</I></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 0.5in"><B>A:</B></TD>
    <TD STYLE="text-align: justify">In accordance with rules and regulations adopted by the Securities and Exchange Commission
        or SEC, we are furnishing the proxy materials to most stockholders by providing access via the internet, instead of mailing printed copies.
        This e-proxy process expedites our stockholders&rsquo; receipt of proxy materials, lowers our costs, and reduces the environmental impact
        of the Annual Meeting.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">The
Notice of Internet Availability of Proxy Materials tells you how to access and review the proxy materials on the internet and how to vote
on the internet. The Notice also provides instructions you may follow to request paper or e-mailed copies of our proxy materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #355E91">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0; color: #355E91; font-weight: bold; font-style: normal; padding-left: 0pt"></TD>
    <TD STYLE="width: 0.5in; color: #355E91; font-weight: bold; font-style: normal"><I>Q:</I><I>&nbsp;</I></TD>
    <TD STYLE="color: #355E91; font-weight: bold; font-style: normal; text-align: left"><I>Are the proxy materials available via the Internet?</I></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 0.5in"><B>A:</B></TD>
    <TD STYLE="text-align: justify">You can access and review the proxy materials for the Annual Meeting at <I>https://ir.anika.com/annual-meeting
        </I>or <I>www.proxyvote.com</I>. In order to submit your proxies or access the Annual Meeting webcast, however, you will need to refer
        to the Notice of Internet Availability of Proxy Materials or proxy card to obtain your control number and other personal information needed
        to vote by proxy or virtually<I>.</I></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #355E91">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0; color: #355E91; font-weight: bold; font-style: normal; padding-left: 0pt"></TD>
    <TD STYLE="width: 0.5in; color: #355E91; font-weight: bold; font-style: normal"><I>Q:</I><I>&nbsp;</I></TD>
    <TD STYLE="color: #355E91; font-weight: bold; font-style: normal; text-align: left"><I>What is a proxy?</I></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 0.5in"><B>A:</B></TD>
    <TD STYLE="text-align: justify">Because it is important that as many stockholders as possible be represented at the
        Annual Meeting, the Board of Directors asks that you review this Proxy Statement carefully and then vote by following the instructions
        set forth on the Notice of Internet Availability of Proxy Materials or proxy card. In voting prior to the Annual Meeting, you will deliver
        your proxy to Cheryl R. Blanchard, Ph.D., David B. Colleran, and Michael L. Levitz, which means you will&nbsp;authorize each of Dr. Blanchard
        and Messrs. Colleran and Levitz to vote your shares at the Annual Meeting in the way you instruct. All shares represented by valid proxies
        will be voted in accordance with the stockholder&rsquo;s specific instructions. Please see the section captioned &ldquo;Executive Officers&rdquo;
        for the titles and roles of Dr. Blanchard and Messrs. Colleran and Levitz with our company.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #355E91">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><I>Q:</I></TD>
    <TD STYLE="text-align: justify"><I>What matters will the stockholders vote on at the Annual Meeting?</I></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0.5in; font-weight: bold; padding-left: 0pt">A:</TD>
    <TD STYLE="width: 0.5in; font-weight: bold">&bull;</TD>
    <TD STYLE="text-align: left">Proposal 1. Election of two Class II Director nominees: Cheryl R. Blanchard, Ph.D. and Glenn R. Larsen, Ph.D.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">&bull;</TD>
    <TD>Proposal 2. Amendment of our 2017 Omnibus Incentive Plan.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">&bull;</TD>
    <TD>Proposal 3. Ratification of the appointment of our independent auditor for 2022.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">&bull;</TD>
    <TD>Proposal 4. Approval, as an advisory vote, of 2021 executive compensation as disclosed in this Proxy Statement.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #355E91">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0; text-align: right"></TD>
    <TD STYLE="width: 0.5in">Q:</TD>
    <TD STYLE="text-align: justify"><I>Who can vote at the Annual Meeting?</I></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 0.5in"><B>A:</B></TD>
    <TD STYLE="text-align: justify">Stockholders of record of common stock at the close of business on April 13, 2022, the
        record date, will be entitled to vote at the Annual Meeting. A total of 14,519,284 shares of common stock were outstanding as of the record
        date. Each share outstanding on the record date will be entitled to one vote on each proposal.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #355E91">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0; color: #355E91; font-weight: bold; font-style: normal; padding-left: 0pt"></TD>
    <TD STYLE="width: 0.5in; color: #355E91; font-weight: bold; font-style: normal"><I>Q:</I></TD>
    <TD STYLE="color: #355E91; font-weight: bold; font-style: normal; text-align: left"><I>What is a stockholder of record?</I></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 0.5in"><B>A:</B></TD>
    <TD STYLE="text-align: justify">A stockholder of record is a stockholder whose ownership of our common stock is reflected
        directly on the books and records of our transfer agent, American Stock Transfer &amp; Trust Co.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #355E91">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0; color: #355E91; font-weight: bold; font-style: normal; padding-left: 0pt"></TD>
    <TD STYLE="width: 0.5in; color: #355E91; font-weight: bold; font-style: normal"><I>Q:</I></TD>
    <TD STYLE="color: #355E91; font-weight: bold; font-style: normal; text-align: left"><I>What does it mean for a broker or other nominee to
        hold shares in &ldquo;street name&rdquo;?</I></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 0.5in"><B>A:</B></TD>
    <TD STYLE="text-align: justify">If you beneficially own shares held in an account with a broker, bank, or similar organization,
        that organization is the stockholder of record and is considered to hold those shares in &ldquo;street name.&rdquo;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">An organization
that holds your beneficially owned shares in street name will vote in accordance with the instructions you provide. If you do not provide
the organization with specific voting instructions with respect to a proposal, under the rules of the NASDAQ Stock Market, Inc., or NASDAQ,
the organization&rsquo;s authority to vote your shares will depend upon whether the proposal is considered a &ldquo;routine&rdquo; or
non-routine matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">&bull;</TD>
    <TD STYLE="text-align: justify">The organization generally may vote your beneficially owned shares on routine items for
        which you have not provided voting instructions to the organization. The only routine matter expected to be voted on at the Annual Meeting
        is the ratification of the appointment of our independent auditor for 2022 (Proposal 3).</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">&bull;</TD>
    <TD STYLE="text-align: justify">The organization generally may not vote on non-routine matters, including Proposals 1,
        2, and 4. Instead, it will inform the inspector of election that it does not have the authority to vote on those matters. This is referred
        to as a &ldquo;broker non-vote.&rdquo;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">For the purpose of determining a quorum, we will treat
as present at the Annual Meeting any proxies that are voted on any of the proposals to be acted upon by the stockholders, including abstentions
or proxies containing broker non-votes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #355E91">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0; color: #355E91; font-weight: bold; font-style: normal; padding-left: 0pt"></TD>
    <TD STYLE="width: 0.5in; color: #355E91; font-weight: bold; font-style: normal"><I>Q:</I></TD>
    <TD STYLE="color: #355E91; font-weight: bold; font-style: normal; text-align: left"><I>How do I vote my shares if I do not attend the Annual
        Meeting?</I></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0pt; font-weight: bold; padding-left: 0pt"></TD>
    <TD STYLE="width: 0.5in; font-weight: bold">A:</TD>
    <TD STYLE="text-align: left"><B><I>If you are a stockholder of record,</I></B> you may vote prior to the Annual Meeting as follows:</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify"><I><U>Via the Internet</U></I>: You may vote via the internet at <I>www.proxyvote.com</I>,
in accordance with the voting instructions printed on the Notice of Internet Availability of Proxy Materials and the proxy card. Internet
voting is available 24 hours a day until 11:59 p.m., Eastern time, on June 7, 2022. You will be given the opportunity to confirm that
your instructions have been recorded properly. If you vote via the internet, you do not need to return a proxy card.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">&bull;</TD>
    <TD STYLE="text-align: justify"><I><U>By Telephone</U></I>: If you receive a proxy card by mail, you may vote by calling
        1-800-690-6903 and following the instructions provided on the telephone line. Telephone voting is available 24 hours a day until 11:59
        p.m., Eastern time, on June 7, 2022. Easy-to-follow voice prompts allow you to vote your shares and confirm that your instructions have
        been recorded properly. If you vote by telephone, you do not need to return a proxy card.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 62.4pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">&bull;</TD>
    <TD STYLE="text-align: justify"><I><U>By Mail</U></I>: If you receive a proxy card by mail, you may vote by returning
        the dated and signed proxy card in the postage-paid return envelope provided with the proxy card. Your proxy card must arrive by June
        7, 2022.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><B><I>If you hold shares
in street name, </I></B>you may vote by following the voting instructions provided by your bank, broker, or other nominee. In general,
you may vote prior to the Annual Meeting as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">&bull;</TD>
    <TD STYLE="text-align: justify"><I><U>Via the Internet</U></I>: You may vote at <I>www.proxyvote.com</I>, in accordance
        with the voting instructions printed on the Notice of Internet Availability of Proxy Materials and the proxy card. Internet voting is
        available 24 hours a day until 11:59 p.m., Eastern time, on June 7, 2022. You will be given the opportunity to confirm that your instructions
        have been recorded properly.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">&bull;</TD>
    <TD STYLE="text-align: justify"><I><U>By Telephone</U></I>: If you receive a proxy card by mail, you may vote by calling
        1-800-690-6903 and following the instructions provided on the telephone line. Telephone voting is available 24 hours a day until 11:59
        p.m., Eastern time, on June 7, 2022. Easy-to-follow voice prompts allow you to vote your shares and confirm that your instructions have
        been recorded properly.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">&bull;</TD>
    <TD STYLE="text-align: justify"><I><U>By Mail</U></I>: You may vote by returning a completed and signed proxy card
        in accordance with instructions provided by your bank, broker, or other nominee. Your proxy card must arrive by June 7, 2022.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">For
your information, voting via the internet is the least expensive to us, followed by telephone voting, with voting by mail being the most
expensive. Also, you may help us to save the expense of a second mailing if you vote promptly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #355E91">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0; color: #355E91; font-weight: bold; font-style: italic; padding-left: 0pt"></TD>
    <TD STYLE="width: 0.5in; color: #355E91; font-weight: bold; font-style: italic">Q:</TD>
    <TD STYLE="color: #355E91; font-weight: bold; font-style: italic; text-align: left">Can I vote at the Annual Meeting?</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 0.5in"><B>A:</B></TD>
    <TD STYLE="text-align: justify">If you are a stockholder of record, you may vote virtually at the Annual Meeting, whether
        or not you previously voted. If your shares are held in street name, you must obtain a written proxy, executed in your favor, from the
        stockholder of record to be able to vote at the Annual Meeting.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #355E91">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0; color: #355E91; font-weight: bold; font-style: italic; padding-left: 0pt"></TD>
    <TD STYLE="width: 0.5in; color: #355E91; font-weight: bold; font-style: italic">Q:</TD>
    <TD STYLE="color: #355E91; font-weight: bold; font-style: italic; text-align: left">Can I ask questions at the Annual Meeting?</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 0.5in"><B>A:</B></TD>
    <TD STYLE="text-align: justify">You may submit questions via the internet during the Annual Meeting by participating
        in the webcast at <I>virtualshareholdermeeting.com/ANIK2022</I>. We will answer any timely submitted questions on a matter to be voted
        on at the Annual Meeting before voting is closed on the matter. Following adjournment of the formal business of the Annual Meeting, we
        will address appropriate general questions from stockholders regarding Anika in the order in which the questions are received as time
        allows. Questions relating to the stockholder proposals or Anika may be submitted in the field provided in the web portal at or before
        the time the questions are to be discussed. If we receive substantially similar questions, we may group those questions together and provide
        a single response to avoid repetition. Additional information regarding the submission of questions during the Annual Meeting can be found
        in our 2022 Annual Meeting of Stockholders Rules of Conduct and Procedure, attached hereto as <I>Appendix B </I>and also available at
        <I>https://ir.anika.com/annual-meeting</I>.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #355E91">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0; color: #355E91; font-weight: bold; font-style: italic; padding-left: 0pt"></TD>
    <TD STYLE="width: 0.5in; color: #355E91; font-weight: bold; font-style: italic">Q:</TD>
    <TD STYLE="color: #355E91; font-weight: bold; font-style: italic; text-align: left">Why is the Annual Meeting being conducted as a virtual
        meeting?</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 0.5in"><B>A:</B></TD>
    <TD STYLE="text-align: justify">The Board considers the appropriate
format of our annual meeting of stockholders on an annual basis. This year, as in 2020 and 2021, the Board chose a virtual meeting format
for the Annual Meeting in an effort to facilitate stockholder attendance and participation. The virtual meeting format will allow our
stockholders to engage with us at the Annual Meeting from any geographic location, using any convenient internet-connected devices, including
smart phones and tablets, and laptop or desktop computers.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">The
virtual format allows stockholders to submit questions during the meeting. We are utilizing technology from Broadridge, the leading virtual
meeting solution. The Broadridge platform is expected to accommodate most, if not all, stockholders. Both we and Broadridge will test
the platform technology before going &ldquo;live&rdquo; for the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #355E91">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0; color: #355E91; font-weight: bold; font-style: italic; padding-left: 0pt"></TD>
    <TD STYLE="width: 0.5in; color: #355E91; font-weight: bold; font-style: italic">Q:</TD>
    <TD STYLE="color: #355E91; font-weight: bold; font-style: italic; text-align: left">If I am unable to participate in the live audio webcast
        of the Annual Meeting, may I listen at a later date?</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 0.5in"><B>A:</B></TD>
    <TD STYLE="text-align: justify"><P STYLE="text-align: justify">An audio replay of the Annual Meeting will be posted and publicly available at <I>https://ir.anika.com/annual-reports-and-proxies</I>
following the Annual Meeting and will remain publicly available for ninety (90) days after the Annual Meeting. This audio replay will
cover the entire Annual Meeting, including each stockholder question addressed during the Annual Meeting.</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #355E91">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0; color: #355E91; font-weight: bold; font-style: normal; padding-left: 0pt"></TD>
    <TD STYLE="width: 0.5in; color: #355E91; font-weight: bold; font-style: normal"><I>Q:</I></TD>
    <TD STYLE="color: #355E91; font-weight: bold; font-style: normal; text-align: left"><I>May I change my vote or revoke my proxy?</I></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0pt; font-weight: bold; padding-left: 0pt"></TD>
    <TD STYLE="width: 0.5in; font-weight: bold">A:</TD>
    <TD STYLE="text-align: left">If you are a stockholder of record, you may later change or revoke your proxy at any time before it is exercised
        by:</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">&bull;</TD>
    <TD>Voting via the internet or telephone at a later time;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">&bull;</TD>
    <TD>Submitting a completed and signed proxy card with a later date; or</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">&bull;</TD>
    <TD>Voting via the internet at the Annual Meeting.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">If you
are a beneficial owner of shares held in street name, you should contact your bank, broker, or other nominee for instructions as to whether,
and how, you can change or revoke your proxy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #355E91">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0; color: #355E91; font-weight: bold; font-style: normal; padding-left: 0pt"></TD>
    <TD STYLE="width: 0.5in; color: #355E91; font-weight: bold; font-style: normal"><I>Q:</I></TD>
    <TD STYLE="color: #355E91; font-weight: bold; font-style: normal; text-align: left"><I>What happens if I do not give specific voting instructions?</I></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 0.5in"><B>A:</B></TD>
    <TD STYLE="text-align: justify"><P STYLE="text-align: justify">If you are a stockholder of record and you return a proxy card without giving specific voting
instructions, the proxy holders will vote your shares in the manner recommended by the Board on all proposals presented in this Proxy
Statement and as they may determine in their discretion on any other matters properly presented for a vote at the Annual Meeting.</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify">If you
are a beneficial owner of shares held in street name and do not provide specific voting instructions to the broker, bank, or other organization
that is the stockholder of record of your shares, the organization generally may not vote on some proposals. Instead, the organization
will inform the inspector of election that it does not have the authority to vote on the specific matter. As a result, beneficial owners
of shares held in street name that do not provide specific voting instructions may not have an effect on the outcome of certain proposals.
See &ldquo;Q. <I>What does it mean for a broker or other nominee to hold shares in &lsquo;street name&rsquo;?</I>&rdquo; above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #355E91">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">Q:</TD>
    <TD STYLE="text-align: justify">What should I do if, during check-in or the meeting, I have technical difficulties
        or trouble accessing the virtual meeting website?</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 0.5in"><B>A:</B></TD>
    <TD STYLE="text-align: justify">Online check-in to the Annual Meeting webcast will begin at 8:45 a.m., Eastern time.
        You should allow ample time to log in to the meeting webcast and test your computer audio system. During online check-in and continuing
        through the length of the Annual Meeting, we will have technicians standing by to assist you with any technical difficulties you may have
        accessing the Annual Meeting. If you encounter any difficulties accessing the virtual meeting during the check-in or meeting time, please
        call the technical support number that will be posted on the Virtual Shareholder Meeting log in page.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0; color: #355E91; font-weight: bold; font-style: normal"></TD>
    <TD STYLE="width: 0.5in; color: #355E91; font-weight: bold; font-style: normal"><I>Q:</I></TD>
    <TD STYLE="color: #355E91; font-weight: bold; font-style: normal; text-align: left"><I>What if other matters are presented at the Annual Meeting?</I></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0pt"></TD>
    <TD STYLE="width: 0.5in"><B>A:</B></TD>
    <TD STYLE="text-align: justify"><P STYLE="text-align: justify">If a stockholder of record provides a proxy by voting in any manner described in this Proxy
Statement, the proxy holders will have the discretion to vote on any matters, other than the proposals presented in this Proxy Statement,
that are properly presented for consideration at the Annual Meeting. We do not know of any other matters to be presented for consideration
at the Annual Meeting.</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #355E91"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt 0pt 57.2pt; text-align: center; color: #355E91"><B></B></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt 0pt 57.2pt; text-align: center; color: #355E91"><FONT STYLE="font-size: 13pt"><B><A NAME="a_050"></A><I>Other
Matters</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The Board of Directors does not know
of any other matters that will come before the Annual Meeting. However, if any other matters are properly presented at the Annual Meeting,
it is the intention of the persons named in the accompanying proxy card to vote, or otherwise act, in accordance with their judgment on
such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt 0pt 57.2pt; text-align: center; color: #355E91"><A NAME="a_051"></A><FONT STYLE="font-size: 13pt">Solicitation
Expenses</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">All costs of solicitation of proxies will be borne
by us. In addition to solicitation by mail, our directors, officers, and employees, without additional remuneration, may solicit proxies
in person or by telephone, e-mail, and facsimile. We will reimburse banks, brokerage firms, and other custodians, nominees, trustees,
and fiduciaries for reasonable out-of-pocket expenses incurred by them in sending proxy materials to and soliciting proxies from beneficial
holders of our shares. We have retained Georgeson LLC to assist in the solicitation of proxies for a fee of $17,500, plus reimbursement
of expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt 0pt 57.3pt; text-align: center; color: #355E91"><FONT STYLE="font-size: 13pt"><A NAME="a_052"></A>Stockholder
Proposals</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In order for stockholder proposals for the 2023
Annual Meeting of Stockholders to be eligible for inclusion in the proxy statement and form of proxy card for that meeting, we must receive
the proposals before December 23, 2022. These proposals must also comply with the rules of the SEC governing the form and content of proposals
in order to be included in our proxy statement and form of proxy, and proposals should be directed to: Secretary, Anika Therapeutics,
Inc., 32 Wiggins Avenue, Bedford, Massachusetts 01730. All proposals will need to comply with Rule 14a-8 of the Exchange Act, which sets
forth the requirements for the inclusion of stockholder proposals in our sponsored proxy materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">Our bylaws and Policy and Procedures
for Stockholder Nominations to the Board set forth the procedures you must follow in order to nominate a director for election or make
a proposal at an annual meeting of our stockholders, other than proposals intended to be included in our sponsored proxy materials. In
addition to any other applicable requirements, in order for business to be properly brought before the 2023 Annual Meeting by a stockholder,
the stockholder must have given us timely notice thereof in proper written form, including all required information, at our corporate
headquarters, 32 Wiggins Avenue, Bedford, Massachusetts 01730, directed to the attention of the Secretary, between February 16, 2023 and
March 18, 2023. The proposal must also comply with the other requirements contained in the bylaws, including supporting documentation
and other information. Proxies solicited by the Board of Directors will confer discretionary voting authority with respect to these proposals,
subject to SEC rules governing the exercise of this authority. We have posted copies of our bylaws and our Policy and Procedures for Stockholders
to the Board in the investor relations section of our website at <I>https://ir.anika.com/governance-documents</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">The chair of the meeting has the power
and duty to (a) determine whether a nomination or any business proposed to be brought before the meeting was made or proposed, as the
case may be, in accordance with the procedures set forth in our bylaws and (b) declare that a proposed nomination shall be disregarded
or that proposed business shall not be transacted if such proposed nomination or business was not made or proposed in compliance our bylaws.
Additionally, unless otherwise required by law, if the stockholder (or a qualified representative of the stockholder) does not appear
at the Annual Meeting to present a nomination or proposed business, such nomination shall be disregarded and such proposed business shall
not be transacted, notwithstanding that proxies in respect of such vote may have been received by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt 0pt 57.3pt; text-align: center; color: #355E91"><FONT STYLE="font-size: 13pt"><A NAME="a_053"></A>Cautionary
Note Regarding Forward Looking Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; background-color: white">This Proxy Statement
contains forward-looking statements that involve a number of risks and uncertainties, many of which are outside our control. All statements
other than statements of historical facts included in this Proxy Statement are forward-looking statements and may include, among others,
statements relating to: our business, business strategy and anticipated operating initiatives and results, including potential ongoing
impacts of the COVID-19 pandemic; our corporate governance; our stockholder engagement; our executive compensation plans; our ESG programs
and initiatives; our corporate culture; and our human capital management policies, practices and initiatives. Forward-looking statements
are based upon the current beliefs and expectations of our management. Our actual results could differ materially from any anticipated
future results, performance or achievements described in forward-looking statements as the result of a number of factors, including those
described in our Annual Reports on Form&nbsp;10-K, Quarterly Reports on Form 10-Q and other filings with the SEC, which filings are available
on our investor relations website at <I>https:</I>//<I>ir.anika.com/sec-filings</I> and the SEC&rsquo;s website at <I>www.sec.gov</I>.
Any forward-looking statement made in this Proxy Statement is based only on information currently available to us and speaks only as of
the date on which it is made, and we undertake no obligation to publicly update any forward-looking statement other than as required by
law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt 0pt 57.3pt; text-align: center; color: #355E91"></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt 0pt 57.3pt; text-align: center; color: #355E91"><FONT STYLE="font-size: 13pt"><A NAME="a_054"></A>Householding</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">SEC rules permit us to deliver a single copy of
our 2021 Annual Report to Stockholders and this Proxy Statement, or one Notice of Internet Availability of Proxy Materials, to two or
more stockholders who share an address, unless we have received contrary instructions from one or more of the security holders. This delivery
method, which is known as &ldquo;householding,&rdquo; can reduce our expenses for printing and mailing. Any stockholder of record at a
shared address to which a single copy of the documents was delivered may request a separate copy of the 2021 Annual Report to Stockholders
and this Proxy Statement, or a separate Notice of Internet Availability of Proxy Materials, as applicable, by sending us a written request
made to Anika Therapeutics, Inc., 32 Wiggins Avenue, Bedford, Massachusetts 01730, Attention: Secretary or by calling (781) 457-9000.
Stockholders of record who wish to receive separate copies of these documents in the future may also contact us as stated above. Stockholders
of record who share an address and are receiving multiple copies of our annual reports to stockholders and Proxy Statements, or of our
Notices of Internet Availability of Proxy Materials, may contact us as stated above to request delivery of a single copy of such documents.
Stockholders who hold their shares in &ldquo;street name&rdquo; and who wish to obtain copies of these proxy materials should follow the
instructions on their voting instruction forms or contact the holders of record. STOCKHOLDERS MAY OBTAIN, WITHOUT CHARGE, A COPY OF OUR
ANNUAL REPORT ON FORM 10-K, INCLUDING THE FINANCIAL STATEMENTS CONTAINED THEREIN, FILED WITH THE SEC FOR THE YEAR ENDED DECEMBER 31, 2021,
BY WRITING TO OUR SECRETARY AT ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD, MASSACHUSETTS 01730.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center; color: #2E5396"><B></B></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center; color: #2E5396"><FONT STYLE="font-size: 13pt"><B><I><A NAME="a_055"></A>Appendix
A</I></B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 184.3pt 0pt 184.35pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 184.3pt 0pt 184.35pt; text-align: center">ANIKA THERAPEUTICS, INC.
2017</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 184.3pt 0pt 184.35pt; text-align: center">OMNIBUS INCENTIVE PLAN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center"><U>(Marked to Show 2022 Amendment)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Anika Therapeutics, Inc. sets forth herein the terms of its
2017 Omnibus Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">1.</TD>
    <TD><FONT STYLE="font-size: 10pt">PURPOSE</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The
Plan is intended to enhance the ability of the Company and its Affiliates to attract and retain highly qualified officers, Non-employee
Directors, employees, consultants and advisors, and to motivate such individuals to serve the Company and its Affiliates and to expend
maximum effort to improve the business results and earnings of the Company, by providing to such persons an opportunity to acquire or
increase a direct proprietary interest in the operations and future success of the Company. To this end, the Plan provides for the grant
of stock options, stock appreciation rights (&ldquo;<B>SARs</B>&rdquo;), restricted stock, restricted stock units (&ldquo;<B>RSUs</B>&rdquo;),
unrestricted stock, other share-based awards and cash awards. Any of these awards may, but need not, be made as performance incentives
to reward attainment of performance goals in accordance with the terms hereof. Upon the Plan becoming effective, no further awards shall
be made under the Prior Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">2.</TD>
    <TD><FONT STYLE="font-size: 10pt">DEFINITIONS</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">For
purposes of interpreting the Plan and related documents (including Award Agreements), the following definitions shall apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Acquiror</B>&rdquo;
shall have the meaning set forth in <B>Section 15.2.1</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Affiliate</B>&rdquo;
means any company or other trade or business that &ldquo;controls,&rdquo; is &ldquo;controlled by&rdquo; or is &ldquo;under common control
with&rdquo; the Company within the meaning of Rule 405 of Regulation C under the Securities Act, including any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Annual
Incentive Award</B>&rdquo; means a cash-based Performance Award with a performance period that is the Company&rsquo;s fiscal year or other
12-month (or shorter) performance period as specified under the terms of the Award as approved by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Award</B>&rdquo;
means a grant under the Plan of an Option, SAR, Restricted Stock, RSU, Other Share-based Award or cash</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Award
Agreement</B>&rdquo; means a written agreement between the Company and a Participant, or notice from the Company or an Affiliate to a
Participant that evidences and sets out the terms of an Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Board</B>&rdquo;
means the Board of Directors of the Company<B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Business
Combination</B>&rdquo; shall have the meaning set forth in <B>Section 15.2.2</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Cause</B>&rdquo;
shall be defined as that term is defined in the Participant&rsquo;s offer letter or other applicable employment agreement; or, if there
is no such definition, &ldquo;Cause&rdquo; means, as determined by the Company in its sole discretion and unless otherwise provided in
the applicable Award Agreement: (i) any material breach by the Participant of any agreement between the Participant and the Company; (ii)
the conviction of or plea of nolo contendere by the Participant to a felony or a crime involving moral turpitude; or (iii) any material
misconduct or willful and deliberate non-performance (other than by reason of disability) by the Participant of the Participant&rsquo;s
duties to the Company. A Separation from Service for Cause shall be deemed to include a determination by the Company in its sole discretion
following a Participant&rsquo;s Separation from Service that circumstances existing prior to such Separation from Service would have entitled
the Company or an Affiliate to have terminated the Participant&rsquo;s service for Cause. All rights a Participant has or may have under
the Plan shall be suspended automatically during the pendency of any investigation by the Company, or during any negotiations between
the Company and the Participant, regarding any actual or alleged act or omission by the Participant of the type described in the applicable
definition of Cause.</P>

<!-- Field: Page; Sequence: 75; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Change
in Control</B>&rdquo; shall have the meaning set forth in <B>Section 15.2.2</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Code</B>&rdquo;
means the Internal Revenue Code of 1986.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Committee</B>&rdquo;
means the Compensation Committee of the Board, or such other committee as determined by the Board. The Compensation Committee of the Board
may designate a subcommittee of its members to serve as the Committee (to the extent the Board has not designated another person, committee
or entity as the Committee). The Board will cause the Committee to satisfy the applicable requirements of any securities exchange on which
the Common Stock may then be listed. For purposes of Awards to Covered Employees intended to qualify as Performance-Based Compensation,
to the extent required by Section 162(m), Committee means all of the members of the Compensation Committee who are &ldquo;outside directors&rdquo;
within the meaning of Section 162(m). For purposes of Awards to Participants who are subject to Section 16 of the Exchange Act, Committee
means all of the members of the Compensation Committee who are &ldquo;non-employee directors&rdquo; within the meaning of Rule 16b-3 adopted
under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Company</B>&rdquo;
means Anika Therapeutics, Inc., a Massachusetts corporation, or any successor corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Common
Stock</B>&rdquo; means the common stock of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Consultant</B>&rdquo;
means a consultant or advisor that provides bona fide services to the Company or any Affiliate and who qualifies as a consultant or advisor
under Form S-8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Covered
Employee</B>&rdquo; means a Participant who is a &ldquo;covered employee&rdquo; within the meaning of Section 162(m) as qualified by <B>Section
12.4</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Disability</B>&rdquo;
shall be defined as that term is defined in the Participant&rsquo;s offer letter or other applicable employment agreement; or, if there
is no such definition, &ldquo;Disability&rdquo; means, as determined by the Company in its sole discretion and unless otherwise provided
in the applicable Award Agreement, the Participant is unable to perform each of the essential duties of such Participant&rsquo;s position
by reason of a medically determinable physical or mental impairment which is potentially permanent in character or which can be expected
to last for a continuous period of not less than 12 months; <I>provided</I>, <I>however</I>, that, with respect to rules regarding expiration
of an Incentive Stock Option following termination of the Participant&rsquo;s employment, &ldquo;Disability&rdquo; means &ldquo;permanent
and total disability&rdquo; as set forth in Code Section 22(e)(3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Effective
Date</B>&rdquo; means June 13, 2017, the date the Plan was approved by the Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Exchange
Act</B>&rdquo; means the Securities Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Fair
Market Value</B>&rdquo; means, as of any date, the value of the Common Stock as determined below. If the Common Stock is listed on any
established stock exchange or a national market system, including without limitation, the New York Stock Exchange or the NASDAQ Stock
Market, the Fair Market Value shall be the closing price of a share of Common Stock (or if no sales were reported the closing price on
the date immediately preceding such date) as quoted on such exchange or system on the day of determination. In the absence of an established
market for the Common Stock, the Fair Market Value shall be determined in good faith by the Board and such determination shall be conclusive
and binding on all persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Family
Member</B>&rdquo; means a person who is a spouse, former spouse, child, stepchild, grandchild, parent, stepparent, grandparent, niece,
nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother, sister, brother-in-law or sister- in-law, including adoptive
relationships, of the applicable individual, any person sharing the applicable individual&rsquo;s household (other than a tenant or employee),
a trust in which any one or more of these persons have more than 50% of the beneficial interest, a foundation in which any one or more
of these persons (or the applicable individual) control the management of assets, and any other entity in which one or more of these persons
(or the applicable individual) own more than 50% of the voting interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Grant
Date</B>&rdquo; means the latest to occur of (i) the date as of which the Board approves an Award, (ii) the date on which the recipient
of an Award first becomes eligible to receive an Award under <B>Section 6</B> or (iii) such other date as may be specified by the Board
in the Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Incentive
Stock Option</B>&rdquo; means an &ldquo;incentive stock option&rdquo; within the meaning of Code Section 422.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Incumbent
Directors</B>&rdquo; shall have the meaning set forth in <B>Section 15.2.2</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 44.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>New
Shares</B>&rdquo; shall have the meaning set forth in <B>Section 15.1</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Non-employee
Director</B>&rdquo; means a member of the Board or the board of directors of an Affiliate, in each case who is not an officer or employee
of the Company or any Affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Nonqualified
Stock Option</B>&rdquo; means an Option that is not an Incentive Stock Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 137.35pt 0pt 44.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Option</B>&rdquo;
means an option to purchase one or more Shares pursuant to the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 137.35pt 0pt 44.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Option
Price</B>&rdquo; means the exercise price for each Share subject to an Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Other
Share-based Awards</B>&rdquo; means Awards consisting of Share units, or other Awards, valued in whole or in part by reference to, or
otherwise based on, Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Participant</B>&rdquo;
shall mean a person who, as a Service Provider, has been granted an Award under the Plan; <I>provided</I>, <I>however</I>, that in the
case of the death or Disability of a Participant, the term &ldquo;Participant&rdquo; refers to the Participant&rsquo;s estate or other
legal representative acting in a fiduciary capacity on behalf of the Participant under applicable state law and court supervision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Performance
Award</B>&rdquo; means an Award made subject to the attainment of performance goals (as described in <B>Section 12</B>) over a performance
period established by the Committee, and includes an Annual Incentive Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 44.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Performance-Based
Compensation</B>&rdquo; means &ldquo;performance-based compensation&rdquo; under Section 162(m).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 44.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Plan</B>&rdquo;
means this Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 44.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Policy</B>&rdquo;
shall have the meaning set forth in <B>Section 3.2.2</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Prior
Plan</B>&rdquo; means the Anika Therapeutics, Inc. Second Amended and Restated 2003 Stock Option and Incentive Plan, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Purchase
Price</B>&rdquo; means the purchase price for each Share pursuant to a grant of Restricted Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 87.2pt 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Restricted
Stock</B>&rdquo; means restricted Shares, awarded to a Participant pursuant to <B>Section 10</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Restricted
Stock Unit</B>&rdquo; or &ldquo;<B>RSU</B>&rdquo; means a bookkeeping entry representing the equivalent of Shares, awarded to a Participant
pursuant to <B>Section 10</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>SAR
Exercise Price</B>&rdquo; means the per Share exercise price of a SAR granted to a Participant under <B>Section 9</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 45.25pt 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>SEC</B>&rdquo;
means the United States Securities and Exchange Commission.</P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Section
162(m)</B>&rdquo; means Code Section 162(m).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 277.15pt 0pt 44.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Section
409A</B>&rdquo; means Code Section 409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 277.15pt 0pt 44.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Securities
Act</B>&rdquo; means the Securities Act of 1933.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Separation
from Service</B>&rdquo; means the termination of the applicable Participant&rsquo;s employment with, and performance of services for,
the Company and each Affiliate. A Participant employed by, or performing services for, an Affiliate or a division of the Company or an
Affiliate shall not be deemed to incur a Separation from Service if such Affiliate or division ceases to be an Affiliate or division of
the Company, as the case may be, and the Participant immediately thereafter becomes an employee of (or service provider to), or member
of the board of directors of, the Company or an Affiliate or a successor company or an affiliate or subsidiary thereof. Approved temporary
absences from employment because of illness, vacation or leave of absence and transfers among the Company and its Affiliates shall not
be considered Separations from Service. Notwithstanding the foregoing, with respect to any Award that constitutes nonqualified deferred
compensation under Section 409A, &ldquo;Separation from Service&rdquo; shall mean a &ldquo;separation from service&rdquo; as defined under
Section 409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Service
Period</B>&rdquo; shall have the meaning set forth in <B>Section 10.1</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Service
Provider</B>&rdquo; means an employee, officer, Non-employee Director or Consultant of the Company or an Affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.0pt 0pt 44.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Share</B>&rdquo;
means a share of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 79.95pt 0pt 0.5in; text-indent: -0.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Stock
Appreciation Right</B>&rdquo; or &ldquo;<B>SAR</B>&rdquo; means a right granted to a Participant pursuant to <B>Section 9</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 79.95pt 0pt 0.5in; text-indent: -0.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Stockholders</B>&rdquo;
means the stockholders of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 44.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Subsidiary</B>&rdquo;
means any &ldquo;subsidiary corporation&rdquo; of the Company within the meaning of Code Section 424(f).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Substitute
Award</B>&rdquo; means any Award granted in assumption of or in substitution for an award of a company or business acquired by the Company
or an Affiliate or with which the Company or an Affiliate combines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Ten
Percent Stockholder</B>&rdquo; means an individual who owns more than 10% of the total combined voting power of all classes of outstanding
stock of the Company, its parent or any of its Subsidiaries. In determining stock ownership, the attribution rules of Code Section 424(d)
shall be applied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Termination
Date</B>&rdquo; means the date that is 10 years after the Effective Date, unless the Plan is earlier terminated by the Board under <B>Section
5.2</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<B>Voting
Securities</B>&rdquo; shall have the meaning set forth in <B>Section 15.2.2</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">3.</TD>
    <TD><FONT STYLE="font-size: 10pt">ADMINISTRATION OF THE PLAN</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><B>3.1.</B></TD>
    <TD><B>General</B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The
Board shall have such powers and authorities related to the administration of the Plan as are consistent with the Company&rsquo;s certificate
of incorporation and bylaws and applicable law. The Board shall have the power and authority to delegate its responsibilities hereunder
to the Committee, which shall have full authority to act in accordance with its charter, and with respect to the power and authority of
the Board to act hereunder, all references to the Board shall be deemed to include a reference to the Committee, unless such power or
authority is specifically reserved by the Board. Except as specifically provided in <B>Section 14 </B>or as otherwise may be required
by applicable law, regulatory requirement or the certificate of incorporation or the bylaws of the Company, the Board shall have full
power and authority to take all actions and to make all determinations required or provided for under the Plan, any Award or any Award
Agreement, and shall have full power and authority to take all such other actions and make all such other determinations not inconsistent
with the specific terms and provisions of the Plan that the Board deems to be necessary or appropriate to the administration of the Plan.
The Committee shall administer the Plan; <I>provided</I>, <I>however</I>, the Board shall retain the right to exercise the authority of
the Committee to the extent consistent with applicable law and the applicable requirements of any securities exchange on which the Common
Stock may then be listed. All actions, determinations and decisions by the Board or the Committee under the Plan or any Award Agreement,
or with respect to any Award, shall be in the sole discretion of the Board and shall be final, binding and conclusive on all persons.
Without limitation, the Board shall have full and final power and authority, subject to the other terms of the Plan, to:</P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">(i)</TD>
    <TD>designate Participants;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">(ii)</TD>
    <TD>determine the type or types of Awards to be made to Participants;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">(iii)</TD>
    <TD>determine the number of Shares to be subject to an Award;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">(iv)</TD>
    <TD STYLE="text-align: justify">establish the terms of each Award (including the Option Price of any Option, the nature
        and duration of any restriction or condition (or provision for lapse thereof) relating to the vesting, exercise, transfer or forfeiture
        of an Award or the Shares subject thereto and any terms or conditions that may be necessary to qualify Options as Incentive Stock Options);</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">(v)</TD>
    <TD STYLE="text-align: justify">subject to applicable law, delegate its authority and duties to the Chief Executive
        Officer with respect to the granting of Options to individuals who are not Covered Employees or &ldquo;insiders&rdquo; within the meaning
        of Section 16 of the Exchange Act. Any such delegation by the Board shall include a limitation as to the amount of Options that may be
        granted during the period of the delegation and shall contain guidelines as to the determination of the exercise price and the vesting
        criteria. The Board may revoke or amend the terms of a delegation at any time but such action shall not invalidate any prior actions of
        the Board&rsquo; delegate or delegates that were consistent with the terms of the Plan.;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">(vi)</TD>
    <TD>prescribe the form of each Award Agreement; and</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">(vii)</TD>
    <TD STYLE="text-align: justify">amend, modify or supplement the terms of any outstanding Award including the authority,
        in order to effectuate the purposes of the Plan, to modify Awards to foreign nationals or individuals who are employed outside the United
        States to recognize differences in local law, tax policy or custom.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><B>3.2.</B></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Separation from Service for Cause; Clawbacks</B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"></TD>
    <TD STYLE="width: 0.5in"><B>3.2.1.</B></TD>
    <TD><B>Separation from Service for Cause</B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The
Company may annul an Award if the Participant incurs a Separation from Service for Cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"></TD>
    <TD STYLE="width: 0.5in">3.2.2.</TD>
    <TD><FONT STYLE="font-size: 10pt">Clawbacks</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">All
awards, amounts or benefits received or outstanding under the Plan shall be subject to clawback, cancellation, recoupment, rescission,
payback, reduction or other similar action in accordance with the terms of any Company clawback or similar policy (the &ldquo;<B>Policy</B>&rdquo;)
or any applicable law related to such actions, as may be in effect from time to time. A Participant&rsquo;s acceptance of an Award shall
be deemed to constitute the Participant&rsquo;s acknowledgement of and consent to the Company&rsquo;s application, implementation and
enforcement of any applicable Policy that may apply to the Participant, whether adopted prior to or following the Effective Date, and
any provision of applicable law relating to clawback, cancellation, recoupment, rescission, payback or reduction of compensation, and
the Participant&rsquo;s agreement that the Company may take such actions as may be necessary to effectuate any such policy or applicable
law, without further consideration or action.</P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">3.3.</TD>
    <TD><FONT STYLE="font-size: 10pt">Deferral Arrangement</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The
Board may permit or require the deferral of any Award payment into a deferred compensation arrangement, subject to such rules and procedures
as it may establish and in accordance with Section 409A, which may include provisions for the payment or crediting of interest or dividend
equivalents as provided in <B>Section 17.10</B>, including converting such credits into deferred Share units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">3.4.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">No Liability</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">No
member of the Board or of the Committee shall be liable for any action or determination made in good faith with respect to the Plan, any
Award or Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">3.5.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Book Entry</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Notwithstanding
any other provision of the Plan to the contrary, the Company may elect to satisfy any requirement under the Plan for the delivery of stock
certificates through the use of book entry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">3.6.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">No Repricing</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Notwithstanding
any provision herein to the contrary, the repricing of Options or SARs is prohibited without prior approval of the Stockholders. For this
purpose, a &ldquo;repricing&rdquo; means any of the following (or any other action that has the same effect as any of the following):
(i) changing the terms or conditions of an Option or SAR to lower its Option Price or SAR Exercise Price; (ii) any other action that is
treated as a &ldquo;repricing&rdquo; under generally accepted accounting principles; and (iii) repurchasing for cash or canceling an Option
or SAR at a time when its Option Price or SAR Exercise Price is greater than the Fair Market Value of the underlying Shares in exchange
for another Award, unless the cancellation and exchange occurs in connection with a change in capitalization or similar change under <B>Section
15</B>. A cancellation and exchange under clause (iii) would be considered a &ldquo;repricing&rdquo; regardless of whether it is treated
as a &ldquo;repricing&rdquo; under generally accepted accounting principles and regardless of whether it is voluntary on the part of the
Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">4.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">STOCK SUBJECT TO THE PLAN</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in"><B>4.1.</B></TD>
    <TD STYLE="text-align: justify"><B>Authorized Number of Shares</B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Subject
to adjustment under <B>Section 15</B>, the total number of Shares authorized to be awarded under the Plan shall not exceed 5,5500,000
shares. The grant of any full value Award (i.e., an Award other than an Option or a SAR) shall be deemed, for purposes of determining
the number of Shares available for issuance under this <B>Section 4.1</B>, as an Award of two (2) Shares for each Share actually subject
to the Award. The grant of an Option or SAR shall be deemed, for purposes of determining the number of Shares available for issuance under
this <B>Section 4.1</B>, as an Award for one (1) Share for each such Share actually subject to the Award. Any Shares returned to the Plan
pursuant to <B>Section 4.2 </B>shall be returned to the reserved pool of Shares under the Plan in the same manner. In addition, Shares
underlying any outstanding award granted under a Prior Plan that, following the Effective Date, expires, or is terminated, surrendered
or forfeited for any reason without issuance of Shares shall be available for the grant of new Awards. As provided in <B>Section 1</B>,
no new awards shall be granted under the Prior Plan following the Effective Date. Shares issued under the Plan may consist in whole or
in part of authorized but unissued Shares, treasury Shares or Shares purchased on the open market or otherwise.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">4.2.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Share Counting</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 1in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in"><B>4.2.1.</B></TD>
    <TD STYLE="text-align: justify">Any Award settled in cash shall not be counted as issued Shares for any purpose under the Plan.</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 1in; text-align: justify"></TD>
    <TD STYLE="text-align: justify; width: 0.5in"><B>4.2.2.</B></TD>
    <TD STYLE="text-align: justify">If any Award expires, or is terminated, surrendered or forfeited, in whole or in part, the unissued Shares
        covered by such Award shall again be available for the grant of Awards.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 1in; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><B>4.2.3.</B></TD>
    <TD STYLE="text-align: justify">If Shares issued pursuant to the Plan are repurchased by, or are surrendered or forfeited to the Company at
        no more than cost, such Shares shall again be available for the grant of Awards.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 1in; text-align: right"></TD>
    <TD STYLE="width: 0.5in"><B>4.2.4.</B></TD>
    <TD STYLE="text-align: justify">If Shares issuable upon exercise, vesting or settlement of an Award, or Shares owned by a Participant (which
        are not subject to any pledge or other security interest), are surrendered or tendered to the Company in payment of the Option Price or
        Purchase Price of an Award or any taxes required to be withheld in respect of an Award, in each case, in accordance with the terms of
        the Plan and any applicable Award Agreement, such surrendered or tendered Shares shall not be available again for the grant of Awards.</TD>
        </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"></TD>
    <TD STYLE="width: 0.5in"><B>4.2.5.</B></TD>
    <TD>Substitute Awards shall not be counted against the number of Shares available for the grant of Awards.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">4.3.</TD>
    <TD><FONT STYLE="font-size: 10pt">Award Limits</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"></TD>
    <TD STYLE="width: 0.5in"><B>4.3.1.</B></TD>
    <TD><B>Incentive Stock Options</B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1in">Subject
to adjustment under <B>Section 15</B>, 5,550,000 Shares available for issuance under the Plan shall be available for issuance as Incentive
Stock Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"></TD>
    <TD STYLE="width: 0.5in">4.3.2.</TD>
    <TD><FONT STYLE="font-size: 10pt">Individual Award Limits for Section 162(m) -- Share-Based Awards</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1in">Subject
to adjustment under <B>Section 15</B>, the maximum number of each type of Award (other than cash-based Performance Awards) granted to
any Participant in any calendar year shall not exceed the following number of Shares: (i) Options and SARs: 400,000 Shares; and (ii) all
share-based Performance Awards (including Restricted Stock, RSUs and Other Share- based Awards that are Performance Awards): 400,000 Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"></TD>
    <TD STYLE="width: 0.5in">4.3.3.</TD>
    <TD><FONT STYLE="font-size: 10pt">Individual Award Limits for Section 162(m) -- Cash-Based Awards</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1in">The maximum
amount of cash-based Performance Awards intended to qualify as Performance-Based Compensation granted to any Participant in any calendar
year shall not exceed the following: (i) Annual Incentive Awards:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">$1,000,000; and (ii) all other cash-based Performance Awards:
$1,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"></TD>
    <TD STYLE="width: 0.5in">4.3.4.</TD>
    <TD><FONT STYLE="font-size: 10pt">Director Awards</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1in">The maximum
value of Awards granted during any calendar year to any Non-employee Director, taken together with any cash fees paid to such Non-employee
Director during the calendar year and the value of awards granted to the Non- employee Director under any other equity compensation plan
of the Company or an Affiliate during the calendar year, shall not exceed the following in total value (calculating the value of any Awards
or other equity compensation plan awards based on the fair market value as of grant date for financial reporting purposes): (i) $500,000
for the non-employee Chair or Lead Director of the Board and (ii) $425,000 for each Non-employee Director other than the Chair or Lead
Director of the Board; <I>provided, however</I>, that awards granted to Non-employee Directors upon their initial election to the Board
or the board of directors of an Affiliate shall not be counted towards the limit under this <B>Section 4.3.4</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">5.</TD>
    <TD><FONT STYLE="font-size: 10pt">EFFECTIVE DATE, DURATION AND AMENDMENTS</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><B>5.1.</B></TD>
    <TD><B>Term</B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The
Plan shall be effective as of the Effective Date, <I>provided </I>that it has been approved by the Stockholders. The Plan shall terminate
automatically on the 10-year anniversary of the Effective Date and may be terminated on any earlier date as provided in <B>Section 5.2</B>.</P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">5.2.</TD>
    <TD><FONT STYLE="font-size: 10pt">Amendment and Termination of the Plan</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The
Board may, at any time and from time to time, amend, suspend or terminate the Plan as to any Awards which have not been made. An amendment
shall be contingent on approval of the Stockholders to the extent stated by the Board, required by applicable law or required by applicable
securities exchange listing requirements. No Awards shall be made after the Termination Date. The applicable terms of the Plan, and any
terms applicable to Awards granted prior to the Termination Date, shall survive the termination of the Plan and continue to apply to such
Awards. No amendment, suspension or termination of the Plan shall, without the consent of the Participant, materially impair rights or
obligations under any Award theretofore awarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">6.</TD>
    <TD><FONT STYLE="font-size: 10pt">AWARD ELIGIBILITY AND LIMITATIONS</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><B>6.1.</B></TD>
    <TD><B>Service Providers</B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Subject
to this <B>Section 6</B>, Awards may be made to any Service Provider as the Board may determine and designate from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">6.2.</TD>
    <TD><FONT STYLE="font-size: 10pt">Successive Awards</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">An eligible
person may receive more than one Award, subject to such restrictions as are provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">6.3.</TD>
    <TD><FONT STYLE="font-size: 10pt">Stand-Alone, Additional, Tandem, and Substitute Awards</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Awards
may be granted either alone or in addition to, in tandem with, or in substitution or exchange for, any other Award or any award granted
under another plan of the Company, any Affiliate or any business entity to be acquired by the Company or an Affiliate, or any other right
of a Participant to receive payment from the Company or any Affiliate. Such additional, tandem or substitute or exchange Awards may be
granted at any time. If an Award is granted in substitution or exchange for another award, the Board shall have the right to require the
surrender of such other award in consideration for the grant of the new Award. Subject to the requirements of applicable law, the Board
may make Awards in substitution or exchange for any other award under another plan of the Company, any Affiliate or any business entity
to be acquired by the Company or an Affiliate. In addition, Awards may be granted in lieu of cash compensation, including in lieu of cash
amounts payable under other plans of the Company or any Affiliate, in which the value of Shares subject to the Award is equivalent in
value to the cash compensation (for example, RSUs or Restricted Stock).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">6.4.</TD>
    <TD><FONT STYLE="font-size: 10pt">Minimum Vesting</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Notwithstanding
any other provision of the Plan to the contrary, Share-based Awards granted under the Plan shall vest no earlier than the first anniversary
of the date the Award is granted, excluding, for this purpose, any (i) Substitute Awards, (ii) Shares delivered in lieu of fully vested
cash Awards, and (iii) Awards to Non-employee Directors that vest on the earlier of the one year anniversary of the date of grant or the
next annual meeting of stockholders (provided that such vesting period under this clause (iii) may not be less than 50 weeks after grant;
provided, that, the Board may grant Share-based Awards without regard to the foregoing minimum vesting requirement with respect to a maximum
of five percent (5%) of the available share reserve authorized for issuance under the Plan pursuant to Section 4.1 (subject to adjustment
under Section 15); and, provided further, for the avoidance of doubt, that the foregoing restriction does not apply to the Committee&rsquo;s
discretion to provide for accelerated exercisability or vesting of any Award, including in cases of retirement, death, disability or a
Change in Control, in the terms of the Award or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">7.</TD>
    <TD><FONT STYLE="font-size: 10pt">AWARD AGREEMENT</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The
grant of any Award may be contingent upon the Participant executing an appropriate Award Agreement, in such form or forms as the Board
shall from time to time determine. Without limiting the foregoing, an Award Agreement may be provided in the form of a notice which provides
that acceptance of the Award constitutes acceptance of all terms of the Plan and the notice. Award Agreements granted from time to time
or at the same time need not contain similar provisions but shall be consistent with the terms of the Plan. Each Award Agreement evidencing
an Award of Options shall specify whether such Options are intended to be Nonqualified Stock Options or Incentive Stock Options, and in
the absence of such specification such options shall be deemed Nonqualified Stock Options.</P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">8.</TD>
    <TD><FONT STYLE="font-size: 10pt">TERMS AND CONDITIONS OF OPTIONS</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><B>8.1.</B></TD>
    <TD><B>Option Price</B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The
Option Price of each Option shall be fixed by the Board and stated in the related Award Agreement. The Option Price of each Option (except
those that constitute Substitute Awards) shall be at least the Fair Market Value on the Grant Date; <I>provided</I>, <I>however</I>, that
in the event that a Participant is a Ten Percent Stockholder as of the Grant Date, the Option Price of an Option granted to such Participant
that is intended to be an Incentive Stock Option shall be not less than 110 percent of the Fair Market Value on the Grant Date. In no
case shall the Option Price of any Option be less than the par value of a Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">8.2.</TD>
    <TD><FONT STYLE="font-size: 10pt">Vesting</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Subject
to <B>Section 8.3</B>, each Option shall become exercisable at such times and under such conditions (including performance requirements)
as stated in the Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">8.3.</TD>
    <TD><FONT STYLE="font-size: 10pt">Term</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Each
Option shall terminate, and all rights to purchase Shares thereunder shall cease, upon the expiration of the Option term stated in the
Award Agreement not to exceed 10 years from the Grant Date, or under such circumstances and on such date prior thereto as is set forth
in the Plan or as may be fixed by the Board and stated in the related Award Agreement; <I>provided</I>, <I>however</I>, that in the event
that the Participant is a Ten Percent Stockholder, an Option granted to such Participant that is intended to be an Incentive Stock Option
at the Grant Date shall not be exercisable after the expiration of five years from its Grant Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">8.4.</TD>
    <TD><FONT STYLE="font-size: 10pt">Limitations on Exercise of Option</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Notwithstanding
any other provision of the Plan, in no event may any Option be exercised, in whole or in part, (i) prior to the date the Plan is approved
by the Stockholders as provided herein or (ii) after the occurrence of an event which results in termination of the Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">8.5.</TD>
    <TD><FONT STYLE="font-size: 10pt">Method of Exercise</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">An Option
that is exercisable may be exercised by the Participant&rsquo;s delivery of a notice of exercise to the Company, setting forth the number
of Shares with respect to which the Option is to be exercised, accompanied by full payment for the Shares. To be effective, notice of
exercise must be made in accordance with procedures established by the Company from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">8.6.</TD>
    <TD><FONT STYLE="font-size: 10pt">Rights of Holders of Options</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Unless
otherwise provided in the applicable Award Agreement, an individual holding or exercising an Option shall have none of the rights of a
Stockholder (for example, the right to direct the voting of the subject Shares) until the Shares covered thereby are fully paid and issued
to him or her. An individual holding an Option shall not have the right to receive cash or dividend payments or distributions attributable
to the subject Shares until the Option has been exercised and the Shares covered thereby are fully paid and issued to him or her. Except
as provided in <B>Section 15</B> or the related Award Agreement, no adjustment shall be made for dividends, distributions or other rights
for which the record date is prior to the date of such issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">8.7.</TD>
    <TD><FONT STYLE="font-size: 10pt">Delivery of Stock Certificates</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Subject
to <B>Section 3.5</B>, promptly after the exercise of an Option by a Participant and the payment in full of the Option Price, such Participant
shall be entitled to the issuance of a stock certificate which evidences, or electronic notice of a book entry which records, his or her
ownership of the Shares subject to the Option.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">8.8.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Limitations on Incentive Stock Options</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">An Option
shall constitute an Incentive Stock Option only (i) if the Participant of such Option is an employee of the Company or any Subsidiary
of the Company; (ii) to the extent specifically provided in the related Award Agreement; and (iii) to the extent that the aggregate Fair
Market Value (determined at the time the Option is granted) of the Shares with respect to which all Incentive Stock Options held by such
Participant become exercisable for the first time during any calendar year (under the Plan and all other plans of the Participant&rsquo;s
employer and its Affiliates) does not exceed $100,000. This limitation shall be applied by taking Options into account in the order in
which they were granted. No Option shall be treated as an Incentive Stock Option unless the Plan has been approved by the Stockholders
in a manner intended to comply with the stockholder approval requirements of Code Section 422(b)(1); <I>provided</I>, <I>however, </I>that
any Option intended to be an Incentive Stock Option shall not fail to be effective solely on account of a failure to obtain such approval,
but rather such Option shall be treated as a Nonqualified Stock Option unless and until such stockholder approval is obtained.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">9.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">TERMS AND CONDITIONS OF STOCK APPRECIATION RIGHTS (SARs)</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in"><B>9.1.</B></TD>
    <TD STYLE="text-align: justify"><B>Right to Payment</B></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">A SAR
shall confer on the Participant a right to receive, upon exercise thereof, the excess of (i) the Fair Market Value on the date of exercise
over (ii) the SAR Exercise Price, as determined by the Board. The Award Agreement for a SAR (except those that constitute Substitute Awards)
shall specify the SAR Exercise Price, which shall be fixed on the Grant Date as not less than the Fair Market Value on that date. SARs
may be granted alone or in conjunction with all or part of an Option or at any subsequent time during the term of such Option or in conjunction
with all or part of any other Award. A SAR granted in tandem with an outstanding Option following the Grant Date of such Option shall
have a grant price that is equal to the Option Price; <I>provided</I>, <I>however</I>, that the SAR&rsquo;s grant price may not be less
than the Fair Market Value on the Grant Date of the SAR to the extent required by Section 409A.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">9.2.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Other Terms</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The
Board shall determine at the Grant Date or thereafter, the time or times at which and the circumstances under which a SAR may be exercised
in whole or in part (including based on achievement of performance goals or future service requirements), the time or times at which SARs
shall cease to be or become exercisable following Separation from Service or upon other conditions, the method of exercise, whether or
not a SAR shall be in tandem or in combination with any other Award and any other terms of any SAR.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">9.3.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Term of SARs</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The
term of a SAR granted under the Plan shall be determined by the Board; <I>provided</I>, <I>however</I>, that such term shall not exceed
10 years.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">9.4.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Payment of SAR Amount</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Upon
exercise of a SAR, a Participant shall be entitled to receive payment from the Company (in cash or Shares, as set forth in the Award Agreement)
in an amount determined by multiplying:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">(i)</TD>
    <TD STYLE="text-align: justify">the difference between the Fair Market Value on the date of exercise over the SAR Exercise Price; by</TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">(ii)</TD>
    <TD STYLE="text-align: justify">the number of Shares with respect to which the SAR is exercised.</TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">10.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">TERMS AND CONDITIONS OF RESTRICTED STOCK AND RESTRICTED STOCK UNITS (RSUs)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><B>10.1.</B></TD>
    <TD><B>Restrictions (applicable to Restricted Stock and RSUs)</B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">At the
time of grant, the Board may establish a period of time (a &ldquo;<B>Service Period</B>&rdquo;) and any additional restrictions including
the satisfaction of corporate or individual performance objectives applicable to an Award of Restricted Stock or RSUs. Each Award of Restricted
Stock or RSUs may be subject to a different Service Period and additional restrictions. Neither Restricted Stock nor RSUs may be sold,
transferred, assigned, pledged or otherwise encumbered or disposed of during the Service Period or prior to the satisfaction of any other
applicable restrictions.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">10.2.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Delivery of Shares (applicable to Restricted Stock and RSUs)</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Subject
to <B>Section 3.5</B>, upon the expiration or termination of any Service Period and the satisfaction of any other conditions prescribed
by the Board, the restrictions applicable to Shares of Restricted Stock or RSUs settled in Shares shall lapse, and, unless otherwise provided
in the applicable Award Agreement, a stock certificate for such Shares shall be delivered, free of all such restrictions, to the Participant
or the Participant&rsquo;s beneficiary or estate, as the case may be.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">10.3.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Rights of Holders of Restricted Stock (applicable to Restricted Stock, not RSUs)</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Unless
otherwise provided in the applicable Award Agreement, holders of Restricted Stock shall have rights as Stockholders, including voting
and dividend rights; <I>provided</I>, <I>however</I>, any dividends with respect to the Restricted Stock shall be withheld by the Company
for the Participant&rsquo;s account, and interest may be credited on the amount of the dividends withheld at a rate and subject to such
terms as determined by the Committee. The dividends so withheld by the Committee and attributable to any particular share of Restricted
Stock (and earnings thereon, if applicable) shall be distributed to the Participant in cash or, at the discretion of the Committee, in
Shares having a Fair Market Value equal to the amount of such dividends, if applicable, upon the release of restrictions on such Share
and, if such Share is forfeited, the Participant shall have no right to such dividends.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">10.4.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Purchase of Restricted Stock (applicable to Restricted Stock, not RSUs)</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The
Participant shall be required, to the extent required by applicable law, to purchase the Restricted Stock from the Company at a Purchase
Price equal to the greater of (i) the aggregate par value of the Shares represented by such Restricted Stock or (ii) the Purchase Price,
if any, specified in the related Award Agreement. If specified in the Award Agreement, the Purchase Price may be deemed paid by services
already rendered. The Purchase Price shall be payable in a form described in <B>Section 11 </B>or, if so determined by the Board, in consideration
for past services rendered.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">10.5.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Restricted Stock Certificates (applicable to Restricted Stock, not RSUs)</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Subject
to <B>Section 3.5</B>, the Company shall issue, in the name of each Participant to whom Restricted Stock has been granted, stock certificates
or other evidence of ownership representing the total number of Shares of Restricted Stock granted to the Participant, as soon as reasonably
practicable after the Grant Date. The Board may provide in an Award Agreement that either (i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>the Secretary of the Company shall hold any stock certificates for the Participant&rsquo;s benefit until such time as the Restricted
Stock is forfeited to the Company or the restrictions lapse or (ii) such certificates shall be delivered to the Participant; <I>provided</I>,
<I>however</I>, that such certificates shall bear a legend or legends that comply with the applicable securities laws and regulations
and make appropriate reference to the restrictions imposed under the Plan and the Award Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">10.6.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Rights of Holders of RSUs (applicable to RSUs, not Restricted Stock)</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 1in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in"><B>10.6.1.</B></TD>
    <TD STYLE="text-align: justify"><B>Settlement of RSUs</B></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">RSUs may
be settled in cash or Shares, as set forth in the Award Agreement. The Award Agreement shall also set forth whether the RSUs shall be
settled (i) within the time period specified in Section 409A for short term deferrals or (ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT>otherwise within the requirements of Section 409A, in which case the Award Agreement shall specify upon which events such RSUs
shall be settled.</P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"></TD>
    <TD STYLE="width: 0.5in">10.6.2.</TD>
    <TD><FONT STYLE="font-size: 10pt">Voting and Dividend Rights</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">Unless
otherwise provided in the applicable Award Agreement, holders of RSUs shall not have rights as Stockholders, including voting or dividend
or dividend equivalents rights. Dividend equivalent rights may be granted with respect to RSUs pursuant to <B>Section 17.10</B>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 1in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">10.6.3.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Creditor&rsquo;s Rights</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">A holder
of RSUs shall have no rights other than those of a general creditor of the Company. RSUs represent an unfunded and unsecured obligation
of the Company, subject to the terms of the applicable Award Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">11.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">FORM OF PAYMENT FOR OPTIONS AND RESTRICTED STOCK</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in"><B>11.1.</B></TD>
    <TD STYLE="text-align: justify"><B>General Rule</B></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Payment
of the Option Price for the Shares purchased pursuant to the exercise of an Option or the Purchase Price for Restricted Stock shall be
made in cash or in cash equivalents acceptable to the Company, except as provided in this <B>Section 11</B>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">11.2.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Surrender of Shares</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">To the
extent the Award Agreement so provides, payment of the Option Price for Shares purchased pursuant to the exercise of an Option or the
Purchase Price for Restricted Stock may be made all or in part through the tender to the Company of Shares, which Shares shall be valued,
for purposes of determining the extent to which the Option Price or Purchase Price for Restricted Stock has been paid thereby, at their
Fair Market Value on the date of exercise or surrender. Notwithstanding the foregoing, in the case of an Incentive Stock Option, the right
to make payment in the form of already-owned Shares may be authorized only at the time of grant.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">11.3.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Cashless Exercise</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">With
respect to an Option only (and not with respect to Restricted Stock), to the extent permitted by law and to the extent the Award Agreement
so provides, payment of the Option Price may be made all or in part by delivery (on a form acceptable to the Company) of an irrevocable
direction to a licensed securities broker acceptable to the Company to sell Shares and to deliver all or part of the sales proceeds to
the Company in payment of the Option Price and any withholding taxes described in <B>Section 17.3</B>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">11.4.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Other Forms of Payment</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">To the
extent the Award Agreement so provides, payment of the Option Price or the Purchase Price for Restricted Stock may be made in any other
form that is consistent with applicable laws, regulations and rules, including the Company&rsquo;s withholding of Shares otherwise due
to the exercising Participant.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">12.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">TERMS AND CONDITIONS OF PERFORMANCE AWARDS</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in"><B>12.1.</B></TD>
    <TD STYLE="text-align: justify"><B>Performance Conditions</B></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The
right of a Participant to exercise or receive a grant or settlement of any Award, and the timing thereof, may be subject to such performance
conditions as may be specified by the Board. The Board may use such business criteria and other measures of performance as it may deem
appropriate in establishing any performance conditions, and may reduce the amounts payable under any Award subject to performance conditions,
except as limited under <B>Section 12.2 </B>in the case of Performance- Based Compensation.</P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">12.2.</TD>
    <TD><FONT STYLE="font-size: 10pt">Performance Awards Granted to Designated Covered Employees</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">If and
to the extent that the Board determines that a Performance Award to be granted to a Participant who is designated by the Board as likely
to be a Covered Employee should qualify as Performance-Based Compensation, the grant, exercise or settlement of such Performance Award
shall be contingent upon achievement of pre-established performance goals and other terms set forth in this <B>Section 12.2</B>. Notwithstanding
anything herein to the contrary, the Board may provide for Performance Awards to Covered Employees that are not intended to qualify as
Performance-Based Compensation.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 1in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">12.2.1.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Performance Goals Generally</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">The performance
goals for Performance Awards shall consist of one or more business criteria and a targeted level or levels of performance with respect
to each of such criteria, as specified by the Board consistent with this <B>Section 12.2</B>. Performance goals shall be objective and
shall otherwise meet the requirements of Section 162(m), including the requirement that the level or levels of performance targeted by
the Board result in the achievement of performance goals being &ldquo;substantially uncertain.&rdquo; The Board may determine that Performance
Awards shall be granted, exercised or settled upon achievement of any one performance goal or that two or more of the performance goals
must be achieved as a condition to grant, exercise or settlement of the Performance Awards. Performance goals may be established on a
Company-wide basis, or with respect to one or more business units, divisions, Affiliates or business segments, as applicable. To the extent
consistent with the requirements of Section 162(m), the Committee may determine at the time that goals under this <B>Section 12 </B>are
established the extent to which measurement of performance goals may exclude the impact of charges for restructuring, discontinued operations,
extraordinary items, debt redemption or retirement, asset write downs, litigation or claim judgments or settlements, acquisitions or divestitures,
foreign exchange gains and losses and other extraordinary, unusual or non-recurring items, and the cumulative effects of tax or accounting
changes (each as defined by generally accepted accounting principles and as identified in the Company&rsquo;s financial statements or
other SEC filings). Performance goals may differ for Performance Awards granted to any one Participant or to different Participants.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 1in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">12.2.2.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Business Criteria</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">One or
more of the following business criteria for the Company, on a consolidated basis, or specified Affiliates or business units of the Company
(except with respect to the total stockholder return and earnings per share criteria), shall be used exclusively by the Board in establishing
performance goals for Performance Awards: (i) cash flow; (ii) earnings per share, as adjusted for any stock split, stock dividend or other
recapitalization; (iii) earnings measures; (iv) return on equity; (v) total stockholder return; (vi) share price performance, as adjusted
for any stock split, stock dividend or other recapitalization; (vii) return on capital; (viii) revenue; (ix) income; (x) profit margin;
(xi) return on operating revenue; (xii) brand recognition or acceptance; (xiii) customer satisfaction; (xiv) productivity; (xv) expense
targets; (xvi) market share; (xvii) cost control measures; (xviii) balance sheet metrics; (xix) strategic initiatives; (xx) implementation,
completion or attainment of measurable objectives with respect to recruitment or retention of personnel or employee satisfaction; (xxi)
regulatory body approval for commercialization of a product; (xxii) implementation or completion of critical projects; or (xxiii) any
other business criteria established by the Board; <I>provided</I>, <I>however</I>, that such business criteria shall include any derivations
of business criteria listed above (<I>e.g.</I>, income shall include pre-tax income, net income and operating income).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 1in"></TD>
    <TD STYLE="text-align: justify; width: 0.5in">12.2.3.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Timing for Establishing Performance Goals</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">Performance
goals shall be established not later than 90 days after the beginning of any performance period applicable to Performance Awards, or at
such other date as may be required or permitted for Performance-Based Compensation.</P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"></TD>
    <TD STYLE="width: 0.5in">12.2.4.</TD>
    <TD><FONT STYLE="font-size: 10pt">Settlement of Performance Awards; Other Terms</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">Settlement of Performance Awards
may be in cash, Shares, other Awards or other property. The Board may reduce the amount of a settlement otherwise to be made in connection
with such Performance Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">12.3.</TD>
    <TD><FONT STYLE="font-size: 10pt">Written Determinations</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">All
determinations by the Board as to the establishment of performance goals, the amount of any Performance Award pool or potential individual
Performance Awards and the achievement of performance goals relating to Performance Awards, shall be made in writing in the case of any
Award intended to qualify as Performance-Based Compensation to the extent required by Section 162(m). To the extent permitted by Section
162(m), the Board may delegate any responsibility relating to Performance Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">12.4.</TD>
    <TD><FONT STYLE="font-size: 10pt">Status of Section 12.2 Awards under Section 162(m)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">It is
the intent of the Company that Performance Awards under <B>Section 12.2 </B>granted to persons who are designated by the Board as likely
to be Covered Employees within the meaning of Section 162(m) shall, if so designated by the Board, qualify as Performance-Based Compensation.
Accordingly, the terms of <B>Section 12.2</B>, including the definitions of Covered Employee and other terms used therein, shall be interpreted
in a manner consistent with Section 162(m). The foregoing notwithstanding, because the Board cannot determine with certainty whether a
given Participant will be a Covered Employee with respect to a fiscal year that has not yet been completed, the term Covered Employee
as used herein shall mean only a person designated by the Board, at the time of grant of Performance Awards, as likely to be a Covered
Employee with respect to that fiscal year. If any provision of the Plan or any agreement relating to such Performance Awards does not
comply or is inconsistent with the requirements of Section 162(m), such provision shall be construed or deemed amended to the extent necessary
to conform to such requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">13.</TD>
    <TD><FONT STYLE="font-size: 10pt">OTHER SHARE-BASED AWARDS</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><B>13.1.</B></TD>
    <TD><B>Grant of Other Share-based Awards</B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Other
Share-based Awards may be granted either alone or in addition to or in conjunction with other Awards. Other Share-based Awards may be
granted in lieu of other cash or other compensation to which a Service Provider is entitled from the Company or may be used in the settlement
of amounts payable in Shares under any other compensation plan or arrangement of the Company, including any other Company incentive compensation
plan. The Board shall have the authority to determine the persons to whom and the time or times at which such Awards will be made, the
number of Shares to be granted pursuant to such Awards, and all other terms of such Awards. Unless the Board determines otherwise, any
such Award shall be confirmed by an Award Agreement, which shall contain such provisions as the Board determines to be necessary or appropriate
to carry out the intent of the Plan with respect to such Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">13.2.</TD>
    <TD><FONT STYLE="font-size: 10pt">Terms of Other Share-based Awards</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Any
Common Stock subject to Awards made under this <B>Section 13 </B>may not be sold, assigned, transferred, pledged or otherwise encumbered
prior to the date on which the Shares are issued, or, if later, the date on which any applicable restriction, performance or deferral
period lapses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">14.</TD>
    <TD><FONT STYLE="font-size: 10pt">REQUIREMENTS OF LAW</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><B>14.1.</B></TD>
    <TD><B>General</B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The
Company shall not be required to sell or issue any Shares under any Award if the sale or issuance of such Shares would constitute a violation
by the Participant, any other individual exercising an Option or the Company of any provision of any law or regulation of any governmental
authority, including any federal or state securities laws or regulations. If at any time the Board determines that the listing, registration
or qualification of any Shares subject to an Award upon any securities exchange or under any governmental regulatory body is necessary
or desirable as a condition of, or in connection with, the issuance or purchase of Shares hereunder, no Shares may be issued or sold to
the Participant or any other individual exercising an Option pursuant to such Award unless such listing, registration, qualification,
consent or approval shall have been effected or obtained free of any conditions not acceptable to the Company, and any delay caused thereby
shall in no way affect the date of termination of the Award. Specifically, in connection with the Securities Act, upon the exercise of
any Option or the delivery of any Shares underlying an Award, unless a registration statement under such Act is in effect with respect
to the Shares covered by such Award, the Company shall not be required to sell or issue such Shares unless the Board has received evidence
satisfactory to it that the Participant or any other individual exercising an Option may acquire such Shares pursuant to an exemption
from registration under the Securities Act. The Company may, but shall in no event be obligated to, register any securities covered hereby
pursuant to the Securities Act. The Company shall not be obligated to take any affirmative action in order to cause the exercise of an
Option or the issuance of Shares pursuant to the Plan to comply with any law or regulation of any governmental authority. As to any jurisdiction
that expressly imposes the requirement that an Option shall not be exercisable until the Shares covered by such Option are registered
or are exempt from registration, the exercise of such Option (under circumstances in which the laws of such jurisdiction apply) shall
be deemed conditioned upon the effectiveness of such registration or the availability of such an exemption. The Committee may require
the Participant to sign such additional documentation, make such representations and furnish such information as it may consider appropriate
in connection with the grant of Awards or issuance or delivery of Shares in compliance with applicable laws, rules and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">14.2.</TD>
    <TD><FONT STYLE="font-size: 10pt">Rule 16b-3</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">During
any time when the Company has a class of equity security registered under Section 12 of the Exchange Act, it is the intent of the Company
that Awards and the exercise of Options will qualify for the exemption provided by Rule 16b-3 under the Exchange Act. To the extent that
any provision of the Plan or action by the Board or Committee does not comply with the requirements of Rule 16b-3, it shall be deemed
inoperative to the extent permitted by law and deemed advisable by the Board, and shall not affect the validity of the Plan. In the event
that Rule 16b-3 is revised or replaced, the Board may modify the Plan in any respect necessary to satisfy the requirements of, or to take
advantage of any features of, the revised exemption or its replacement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">15.</TD>
    <TD><FONT STYLE="font-size: 10pt">EFFECT OF CHANGES IN CAPITALIZATION</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><B>15.1.</B></TD>
    <TD><B>Adjustments for Changes in Capital Structure</B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Subject
to any required action by the Stockholders, in the event of any change in the Common Stock effected without receipt of consideration by
the Company, whether through merger, consolidation, reorganization, reincorporation, recapitalization, reclassification, stock dividend,
stock split, reverse stock split, split-up, split-off, spin-off, combination of shares, exchange of shares or similar change in the capital
structure of the Company, or in the event of payment of a dividend or distribution to the Stockholders in a form other than Shares (excepting
normal cash dividends) that has a material effect on the Fair Market Value, appropriate and proportionate adjustments shall be made in
the number and class of shares subject to the Plan and to any outstanding Awards, and in the Option Price, SAR Exercise Price or Purchase
Price per Share of any outstanding Awards in order to prevent dilution or enlargement of Participants&rsquo; rights under the Plan. For
purposes of the foregoing, conversion of any convertible securities of the Company shall not be treated as &ldquo;effected without receipt
of consideration by the Company.&rdquo; If a majority of the Shares which are of the same class as the Shares that are subject to outstanding
Awards are exchanged for, converted into, or otherwise become (whether or not pursuant to a Change in Control) shares of another corporation
(the &ldquo;<B>New Shares</B>&rdquo;), the Board may unilaterally amend the outstanding Awards to provide that such Awards are for New
Shares. In the event of any such amendment, the number of Shares subject to, and the Option Price, SAR Exercise Price or Purchase Price
per Share of, the outstanding Awards shall be adjusted in a fair and equitable manner. Any fractional share resulting from an adjustment
pursuant to this <B>Section 15.1 </B>shall be rounded down to the nearest whole number and the Option Price, SAR Exercise Price or Purchase
Price per share shall be rounded up to the nearest whole cent. In no event may the exercise price of any Award be decreased to an amount
less than the par value, if any, of the stock subject to the Award. The Board may also make such adjustments in the terms of any Award
to reflect, or related to, such changes in the capital structure of the Company or distributions as it deems appropriate. Adjustments
determined by the Board pursuant to this <B>Section 15.1 </B>shall be made in accordance with Section 409A to the extent applicable.</P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.0pt 0pt 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">15.2.</TD>
    <TD><FONT STYLE="font-size: 10pt">Change in Control</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"></TD>
    <TD STYLE="width: 0.5in"><B>15.2.1.</B></TD>
    <TD><B>Consequences of a Change in Control</B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">Subject
to the requirements and limitations of Section 409A if applicable, the Board may provide for any one or more of the following in connection
with a Change in Control, which such actions need not be the same for all Participants:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Accelerated Vesting</B>. The Board may provide in any Award Agreement, or in the event of a Change in Control may take such
actions as it deems appropriate to provide, for the acceleration of the exercisability, vesting or settlement in connection with such
Change in Control of each or any outstanding Award or portion thereof and Shares acquired pursuant thereto upon such terms, including
a Participant&rsquo;s Separation from Service prior to, upon, or following such Change in Control, to such extent as determined by the
Board.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Assumption, Continuation or Substitution</B>. In the event of a Change in Control, the surviving, continuing, successor or purchasing
corporation or other business entity or parent thereof, as the case may be (the &ldquo;<B>Acquiror</B>&rdquo;), may, without the consent
of any Participant, either assume or continue the Company&rsquo;s rights and obligations under each or any Award or portion thereof outstanding
immediately prior to the Change in Control or substitute for each or any such outstanding Award or portion thereof a substantially equivalent
award with respect to the Acquiror&rsquo;s stock, as applicable. For purposes of this <B>Section 15.2.1</B>, an Award denominated in Shares
shall be deemed assumed if, following the Change in Control, the Award confers the right to receive, subject to the terms of the Plan
and the applicable Award Agreement, for each Share subject to the Award immediately prior to the Change in Control, the consideration
(whether stock, cash, other securities or property or a combination thereof) to which a Stockholder on the effective date of the Change
in Control was entitled; <I>provided, however</I>, that if such consideration is not solely common stock of the Acquiror, the Board may,
with the consent of the Acquiror, provide for the consideration to be received upon the exercise or settlement of the Award, for each
Share subject to the Award, to consist solely of common stock of the Acquiror equal in Fair Market Value to the per Share consideration
received by Stockholders pursuant to the Change in Control. If any portion of such consideration may be received by Stockholders pursuant
to the Change in Control on a contingent or delayed basis, the Board may determine such Fair Market Value as of the time of the Change
in Control on the basis of the Board&rsquo;s estimate of the present value of the probable future payment of such consideration. Any Award
or portion thereof which is neither assumed or continued by the Acquiror in connection with the Change in Control nor exercised or settled
as of the time of consummation of the Change in Control shall terminate and cease to be outstanding effective as of the time of consummation
of the Change in Control.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Cash-Out of Awards. </B>The Board may, without the consent of any Participant, determine that, upon the occurrence of a Change
in Control, each or any Award or a portion thereof outstanding immediately prior to the Change in Control and not previously exercised
or settled shall be canceled in exchange for a payment with respect to each vested Share (and each unvested Share, if so determined by
the Board) subject to such canceled Award in (i) cash, (ii) stock of the Company or of a corporation or other business entity a party
to the Change in Control or (iii) other property which, in any such case, shall be in an amount having a Fair Market Value equal to the
Fair Market Value of the consideration to be paid per Share in the Change in Control, reduced by the exercise or purchase price per Share,
if any, under such Award. If any portion of such consideration may be received by Stockholders pursuant to the Change in Control on a
contingent or delayed basis, the Board may determine such Fair Market Value as of the time of the Change in Control on the basis of the
Board&rsquo;s estimate of the present value of the probable future payment of such consideration. In the event such determination is made
by the Board, the amount of such payment (reduced by applicable withholding taxes, if any) shall be paid to Participants in respect of
the vested portions of their canceled Awards as soon as practicable following the date of the Change in Control and in respect of the
unvested portions of their canceled Awards in accordance with the vesting schedules applicable to such Awards. For avoidance of doubt,
if the amount determined pursuant to this <B>Section 15.2.1(c) </B>for an Option or SAR is zero or less, the affected Option or SAR may
be cancelled without any payment therefore.</P>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.85pt 0pt 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"></TD>
    <TD STYLE="width: 0.5in">15.2.2.</TD>
    <TD><FONT STYLE="font-size: 10pt">Change in Control Defined</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">Unless
otherwise provided in the applicable Award Agreement, a &ldquo;<B>Change in Control</B>&rdquo; means the consummation of any of the following
events:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the acquisition, other than from the Company, by any individual, entity or group (within the meaning of Section 13(d)(3) or Section
14(d)(2) of the Exchange Act), other than the Company or any subsidiary, affiliate (within the meaning of Rule 144 promulgated under the
Securities Act) or employee benefit plan of the Company, of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the
Exchange Act) of more than 50% of the combined voting power of the then outstanding voting securities of the Company entitled to vote
generally in the election of directors (the &ldquo;<B>Voting Securities</B>&rdquo;); or</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>a reorganization, merger, consolidation or recapitalization of the Company (a &ldquo;<B>Business Combination</B>&rdquo;), other
than a Business Combination in which more than 50% of the combined voting power of the outstanding voting securities of the surviving
or resulting entity immediately following the Business Combination is held by the persons who, immediately prior to the Business Combination,
were the holders of the Voting Securities; or</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>a complete liquidation or dissolution of the Company, or a sale of all or substantially all of the assets of the Company; or</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>during any period of 12 consecutive months, the Incumbent Directors cease to constitute a majority of the Board; &ldquo;<B>Incumbent
Directors</B>&rdquo; means individuals who were members of the Board at the beginning of such period or individuals whose election or
nomination for election to the Board by the Stockholders was approved by a vote of at least a majority of the then Incumbent Directors
(but excluding any individual whose initial election or nomination is in connection with an actual or threatened proxy contest relating
to the election of directors).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Notwithstanding
the foregoing, if it is determined that an Award is subject to the requirements of Section 409A and payable upon a Change in Control,
the Company will not be deemed to have undergone a Change in Control for purposes of the Plan unless the Company is deemed to have undergone
a &ldquo;change in control event&rdquo; pursuant to the definition of such term in Section 409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">15.3.</TD>
    <TD><FONT STYLE="font-size: 10pt">Adjustments</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Adjustments
under this <B>Section 15</B> related to Shares or other securities of the Company shall be made by the Board. No fractional Shares or
other securities shall be issued pursuant to any such adjustment, and any fractions resulting from any such adjustment shall be eliminated
in each case by rounding downward to the nearest whole Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">16.</TD>
    <TD><FONT STYLE="font-size: 10pt">NO LIMITATIONS ON COMPANY</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The
making of Awards shall not affect or limit in any way the right or power of the Company to make adjustments, reclassifications, reorganizations
or changes of its capital or business structure or to merge, consolidate, dissolve or liquidate, or to sell or transfer all or any part
of its business or assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">17.</TD>
    <TD><FONT STYLE="font-size: 10pt">TERMS APPLICABLE GENERALLY TO AWARDS</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in"><B>17.1.</B></TD>
    <TD><B>Disclaimer of Rights</B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">No provision
in the Plan or in any Award Agreement shall be construed to confer upon any individual the right to remain in the employ or service of
the Company or any Affiliate, or to interfere in any way with any contractual or other right or authority of the Company or any Affiliate
either to increase or decrease the compensation or other payments to any individual at any time, or to terminate any employment or other
relationship between any individual and the Company or any Affiliate. In addition, notwithstanding anything contained in the Plan to the
contrary, unless otherwise provided in the applicable Award Agreement, no Award shall be affected by any change of duties or position
of the Participant, so long as such Participant continues to be a Service Provider. The obligation of the Company to pay any benefits
pursuant to the Plan shall be interpreted as a contractual obligation to pay only those amounts described herein, in the manner and under
the conditions prescribed herein. The Plan shall in no way be interpreted to require the Company to transfer any amounts to a third party
trustee or otherwise hold any amounts in trust or escrow for payment to any Participant or beneficiary under the terms of the Plan.</P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">17.2.</TD>
    <TD><FONT STYLE="font-size: 10pt">Nonexclusivity of the Plan</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Neither
the adoption of the Plan nor the submission of the Plan to the Stockholders for approval shall be construed as creating any limitations
upon the right or authority of the Board or its delegate to adopt such other compensation arrangements as the Board or its delegate determines
desirable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">17.3.</TD>
    <TD><FONT STYLE="font-size: 10pt">Withholding Taxes</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The
Company or an Affiliate, as the case may be, shall have the right to deduct from payments of any kind otherwise due to a Participant any
federal, state or local taxes of any kind required by law to be withheld (i) with respect to the vesting of or other lapse of restrictions
applicable to an Award, (ii) upon the issuance of any Shares upon the exercise of an Option or SAR or (iii) otherwise due in connection
with an Award. At the time of such vesting, lapse or exercise, the Participant shall pay to the Company or the Affiliate, as the case
may be, any amount that the Company or the Affiliate may reasonably determine to be necessary to satisfy such withholding obligation.
In addition, the Board may provide one or more Participants with the right to direct the Company to withhold, from the Shares otherwise
issuable upon the exercise of an Option or Stock Appreciation Right or upon the issuance of fully-vested Shares (whether pursuant to Restricted
Stock, RSUs, Other Share-based Awards, or otherwise), a portion of those Shares with an aggregate Fair Market Value equal to the percentage
of the applicable withholding taxes (not to exceed one hundred percent (100%)) designated by the Participant; <B><I>provided, however</I></B>,
that the amount of any Shares so withheld shall not exceed the amount necessary to satisfy the Company&rsquo;s required tax withholding
obligations using not more than the applicable maximum statutory withholding rates (or such other rates as required to avoid adverse accounting
treatment as determined by the Board). The Fair Market Value of the Shares used to satisfy such withholding obligation shall be determined
by the Company or the Affiliate as of the date that the amount of tax to be withheld is to be determined. A Participant who has made an
election pursuant to this <B>Section 17.3 </B>may satisfy his or her withholding obligation only with Shares that are not subject to any
repurchase, forfeiture, unfulfilled vesting or other similar requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">17.4.</TD>
    <TD><FONT STYLE="font-size: 10pt">Other Provisions; Legends</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Each
Award Agreement may contain such other terms not inconsistent with the Plan as may be determined by the Board. Any stock certificates
for any Shares issued under the Plan shall be subject to such stop-transfer orders and other restrictions as the Company in its sole discretion
may deem advisable under the rules, regulations and other requirements of the SEC, any securities exchange on which the Common Stock may
then be listed and any applicable federal or state securities law, and the Company in its sole discretion may cause a legend or legends
to be placed on such certificates to make appropriate reference to such restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">17.5.</TD>
    <TD><FONT STYLE="font-size: 10pt">Severability</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">If any
provision of the Plan or any Award Agreement shall be determined to be illegal or unenforceable by any court of law in any jurisdiction,
the remaining provisions hereof and thereof shall be severable and enforceable in accordance with their terms, and all provisions shall
remain enforceable in any other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">17.6.</TD>
    <TD><FONT STYLE="font-size: 10pt">Governing Law</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The
Plan shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts without regard to the
principles of conflicts of law thereof or principles of conflicts of laws of any other jurisdiction that could cause the application of
the laws of any jurisdiction other than the Commonwealth of Massachusetts. For purposes of resolving any dispute that arises directly
or indirectly in connection with the Plan, each Participant, by virtue of receiving an Award, shall be deemed to have submitted to and
consented to the exclusive jurisdiction of the Commonwealth of Massachusetts and to have agreed that any related litigation shall be conducted
solely in the courts of Middlesex County, Massachusetts or the United States District Court for the District of Massachusetts, where the
Plan is made and to be performed, and no other courts.</P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">17.7.</TD>
    <TD><FONT STYLE="font-size: 10pt">Section 409A</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The
Plan is intended to comply with Section 409A, and, accordingly, to the maximum extent permitted, the Plan shall be interpreted and administered
to be in compliance therewith. Any payments described in the Plan that are due within the &ldquo;short- term deferral period&rdquo; as
defined in Section 409A shall not be treated as deferred compensation unless applicable laws require otherwise. Notwithstanding anything
to the contrary in the Plan, to the extent required to avoid accelerated taxation and tax penalties under Section 409A, amounts that would
otherwise be payable and benefits that would otherwise be provided pursuant to the Plan during the six-month period immediately following
the Participant&rsquo;s Separation from Service shall instead be paid on the first payroll date after the six-month anniversary of the
Participant&rsquo;s Separation from Service (or the Participant&rsquo;s death, if earlier). Notwithstanding the foregoing, neither the
Company nor the Committee shall have any obligation to take any action to prevent the assessment of any excise tax or penalty on any Participant
under Section 409A and neither the Company nor the Board shall have any liability to any Participant for such tax or penalty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">17.8.</TD>
    <TD><FONT STYLE="font-size: 10pt">Separation from Service</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The
Board shall determine the effect of a Separation from Service upon Awards, and such effect shall be set forth in the applicable Award
Agreement. Without limiting the foregoing, the Board may provide in the Award Agreements at the time of grant, or any time thereafter
with the consent of the Participant, the actions that will be taken upon the occurrence of a Separation from Service, including accelerated
vesting or termination, depending upon the circumstances surrounding the Separation from Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">17.9.</TD>
    <TD><FONT STYLE="font-size: 10pt">Transferability of Awards</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"></TD>
    <TD STYLE="width: 0.5in"><B>17.9.1.</B></TD>
    <TD><B>Transfers in General</B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">Except
as provided in <B>Section 17.9.2</B>, no Award shall be assignable or transferable by the Participant to whom it is granted, other than
by will or the laws of descent and distribution, and, during the lifetime of the Participant, only the Participant personally (or the
Participant&rsquo;s personal representative) may exercise rights under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"></TD>
    <TD STYLE="width: 0.5in">17.9.2.</TD>
    <TD><FONT STYLE="font-size: 10pt">Family Transfers</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">If authorized
in the applicable Award Agreement, a Participant may transfer, not for value, all or part of an Award (other than Incentive Stock Options)
to any Family Member. For the purpose of this <B>Section 17.9.2</B>, a &ldquo;not for value&rdquo; transfer is a transfer which is (i)
a gift, (ii) a transfer under a domestic relations order in settlement of marital property rights or (iii) a transfer to an entity in
which more than 50% of the voting interests are owned by Family Members (or the Participant) in exchange for an interest in that entity.
Following a transfer under this <B>Section 17.9.2</B>, any such Award shall continue to be subject to the same terms as were applicable
immediately prior to transfer. Subsequent transfers of transferred Awards are prohibited except to Family Members of the original Participant
in accordance with this <B>Section 17.9.2</B> or by will or the laws of descent and distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">17.10.</TD>
    <TD><FONT STYLE="font-size: 10pt">Dividends and Dividend Equivalent Rights</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">If specified
in the Award Agreement, the recipient of an Award may be entitled to receive, currently or on a deferred basis, dividends or dividend
equivalents with respect to the Common Stock or other securities covered by an Award; <I>provided</I>, <I>however</I>, that no dividends
or dividend equivalents may be paid or granted with respect to an Option or SAR or the Shares subject thereto until such Award has been
exercised. The terms of a dividend equivalent right may be set forth in the Award Agreement. Dividend equivalents credited to a Participant
may be paid currently or may be deemed to be reinvested in additional Shares or other securities of the Company at a price per unit equal
to the Fair Market Value on the date that such dividend was paid to Stockholders. Notwithstanding the foregoing, in no event will dividends
or dividend equivalents on any Award that is subject to vesting conditions (including the achievement of performance criteria) be payable
before the Award has become vested.</P>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">17.11.</TD>
    <TD><FONT STYLE="font-size: 10pt">Data Protection</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">A Participant&rsquo;s
acceptance of an Award shall be deemed to constitute the Participant&rsquo;s acknowledgement of and consent to the collection and processing
of personal data relating to the Participant so that the Company and the Affiliates can fulfill their obligations and exercise their rights
under the Plan and generally administer and manage the Plan. This data shall include data about participation in the Plan and Shares offered
or received, purchased or sold under the Plan and other appropriate financial and other data (such as the date on which the Awards were
granted) about the Participant and the Participant&rsquo;s participation in the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">17.12.</TD>
    <TD><FONT STYLE="font-size: 10pt">Plan Construction</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In the
Plan, unless otherwise stated, the following uses apply: (i) references to a statute or law refer to the statute or law and any amendments
and any successor statutes or laws, and to all valid and binding governmental regulations, court decisions and other regulatory and judicial
authority issued or rendered thereunder, as amended, or their successors, as in effect at the relevant time; (ii) in computing periods
from a specified date to a later specified date, the words &ldquo;from&rdquo; and &ldquo;commencing on&rdquo; (and the like) mean &ldquo;from
and including,&rdquo; and the words &ldquo;to,&rdquo; &ldquo;until&rdquo; and &ldquo;ending on&rdquo; (and the like) mean &ldquo;to and
including&rdquo;; (iii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp; </FONT>indications of time of day shall be based
upon the time applicable to the location of the principal headquarters of the Company; (iv) the words &ldquo;include,&rdquo; &ldquo;includes&rdquo;
and &ldquo;including&rdquo; (and the like) mean &ldquo;include, without limitation,&rdquo; &ldquo;includes, without limitation&rdquo;
and &ldquo;including, without limitation&rdquo; (and the like), respectively; (v) all references to articles and sections are to articles
and sections in the Plan; (vi) all words used shall be construed to be of such gender or number as the circumstances and context require;
(vii) the captions and headings of articles and sections have been inserted solely for convenience of reference and shall not be considered
a part of the Plan, nor shall any of them affect the meaning or interpretation of the Plan or any of its provisions; (viii) any reference
to an agreement, plan, policy, form, document or set of documents, and the rights and obligations of the parties under any such agreement,
plan, policy, form, document or set of documents, shall mean such agreement, plan, policy, form, document or set of documents as amended
from time to time, and any and all modifications, extensions, renewals, substitutions or replacements thereof; and (ix) all accounting
terms not specifically defined shall be construed in accordance with GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; font-weight: bold; text-align: left; padding-left: 55.95pt">Adopted by the Board:</TD>
    <TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 49%; font-weight: bold">March 31, 2017</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 55.95pt">Approved by the Stockholders:</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">June 13, 2017</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 55.95pt">Amended by the Stockholders:</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">June 18, 2019</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 55.95pt">Amended by the Stockholders:</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">June 16, 2020</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 55.95pt"><U>Amended by the Stockholders:</U></TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold"><U>June 16, 2021</U></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 55.95pt">Scheduled Termination Date:</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">June 13, 2027</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.95pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.95pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55.95pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center; color: #2E5396"></P>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center; color: #2E5396"><FONT STYLE="font-size: 13pt"><B><I><A NAME="a_056"></A>Appendix
B</I></B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 57.25pt; text-align: center">ANIKA THERAPEUTICS, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 154.4pt 0pt 154.55pt; text-align: center"><B>2022 ANNUAL MEETING OF STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 154.4pt 0pt 154.55pt; text-align: center"><B>RULES OF CONDUCT AND PROCEDURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in">Welcome to the
2022 Annual Meeting of Stockholders (the &ldquo;<B>Annual Meeting</B>&rdquo;) of Anika Therapeutics, Inc. (the &ldquo;<B>Company</B>&rdquo;).
In the interest of providing a fair and informative Annual Meeting, participants are required to honor the following Rules of Conduct
and Procedures:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">1.</TD>
    <TD STYLE="text-align: justify">The Company&rsquo;s bylaws describe requirements for meetings of our stockholders, and
        the Annual Meeting will be conducted consistent with those requirements.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">2.</TD>
    <TD STYLE="text-align: justify">The Company&rsquo;s Chief Executive Officer will serve as the chair of the Annual Meeting
        (the &ldquo;<I>Chair</I>&rdquo;) and will have the authority and discretion necessary to preside over the Annual Meeting, including following
        adjournment of the formal business of the Annual Meeting. In the event of disorder, technical malfunction or any other issue that disrupts
        the Annual Meeting, the Chair may adjourn, recess or expedite the Annual Meeting or may take any other action that she determines is appropriate
        in light of the circumstances. In the event of any question of conduct or procedures that is not addressed expressly and clearly by these
        Rules of Conduct and Procedure, the Chair is authorized to address the question in the manner she determines, in her reasonable judgment,
        to be in the best interest of conducting a fair and informative Annual Meeting consistent with the purposes of the Annual Meeting.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">3.</TD>
    <TD STYLE="text-align: justify">The Annual Meeting is a virtual-only meeting. The live audio webcast of the Annual
        Meeting will be available for listening by the general public, but participation in the Annual Meeting, including voting shares and submitting
        questions, will be limited to stockholders.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">4.</TD>
    <TD STYLE="text-align: justify">Participants may access a live webcast of the Annual Meeting, and stockholders may
        submit questions and vote their shares, at <I>www.virtualshareholdermeeting.com/ANIK2022</I>.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">5.</TD>
    <TD STYLE="text-align: justify">Each stockholder of record as of 5:00 p.m., Eastern time, on April 13, 2022 may log
        into the webcast by entering the control number included on the Notice of Internet Availability of Proxy Materials or proxy card received
        from the Company. If you have voted your shares prior to the start of the Annual Meeting, your vote has been received by the Company&rsquo;s
        inspector of elections and there is no need to vote those shares during the Annual Meeting, unless you wish to revoke or change your vote.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify">The Meeting will begin at 9:00 a.m., Eastern time, on June 8, 2022. The only business
to be conducted at the Annual Meeting will consist of the consideration of, and voting on, the proposals set forth in the Proxy Statement.
These proposals will be considered sequentially at the Annual Meeting, in the order they are enumerated and set forth in the Proxy Statement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">7.</TD>
    <TD STYLE="text-align: justify">If a stockholder has a question about one of the agenda matters that is to be voted
        on at the Annual Meeting as set forth in the Proxy Statement, the question may be submitted in the field provided in the web portal at
        or before the time the matters are presented for consideration at the Annual Meeting. We will answer questions on any matters set forth
        in the Proxy Statement to be voted on by the stockholders at the Annual Meeting before voting is closed. During this period, the Company
        will not permit discussions or questions that are not relevant or pertinent to the agenda matter then being discussed, as determined by
        the Chair in her reasonable judgment.</TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 95; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">8.</TD>
    <TD STYLE="text-align: justify">Following adjournment of the formal business of the Annual Meeting, the Company will
        address appropriate general business-related questions as time allows from stockholders regarding the Company. The following rules will
        apply to this process:</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">a.</TD>
    <TD>To ensure that as many stockholders as possible are able to ask questions, each stockholder will be permitted
        to submit no more than two questions. Questions must be succinct and cover a single topic.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"></TD>
    <TD STYLE="width: 0.5in">i.</TD>
    <TD>Questions from multiple stockholders related to the same topic, or that are otherwise related, may be grouped
        and answered together.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"></TD>
    <TD STYLE="width: 0.5in">ii.</TD>
    <TD>Any second question from a stockholder will be deferred until such time as all appropriate first questions
        from stockholders have been addressed.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"></TD>
    <TD STYLE="width: 0.5in">iii.</TD>
    <TD>If more questions are presented than time permits to be answered, the Chair shall determine, in her discretion,
        which questions the Company will answer.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.5in">b.</TD>
    <TD>The views, questions and constructive comments of all stockholders are valued and welcomed. The purpose
        of the Annual Meeting must be observed, however, and the Company will not permit questions that:</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"></TD>
    <TD STYLE="width: 0.5in">i.</TD>
    <TD>are not relevant or pertinent to the business of the Company;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"></TD>
    <TD STYLE="width: 0.5in">ii.</TD>
    <TD>are related to material non-public information of the Company;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"></TD>
    <TD STYLE="width: 0.5in">iii.</TD>
    <TD>are related to pending or threatened litigation or investigations;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"></TD>
    <TD STYLE="width: 0.5in">iv.</TD>
    <TD>are in furtherance of a stockholder&rsquo;s personal or business interests;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"></TD>
    <TD STYLE="width: 0.5in">v.</TD>
    <TD>are repetitious of statements made by another stockholder;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"></TD>
    <TD STYLE="width: 0.5in">vi.</TD>
    <TD>are related to personal grievances;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"></TD>
    <TD STYLE="width: 0.5in">vii.</TD>
    <TD>include derogatory references to individuals or are otherwise in bad taste; or</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"></TD>
    <TD STYLE="width: 0.5in">viii.</TD>
    <TD>are out of order or not otherwise suitable for the conduct of the Annual Meeting as determined by the Chair
        in her reasonable judgment.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">9.</TD>
    <TD STYLE="text-align: justify">If there are any matters of individual concern to a stockholder and not of general
        concern to all stockholders, or if a question posed was not otherwise answered, such matters may be raised separately after the Annual
        Meeting by contacting Investor Relations at <I>investorrelations@anika.com</I>.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.</TD><TD STYLE="text-align: justify">Recording of the Annual Meeting is prohibited without the prior written permission
of the Company. A webcast playback of the Annual Meeting will be available at <I>https://ir.anika.com/annual-reports-and-proxies </I>within
approximately 24 hours after the completion of the Annual Meeting and will remain publicly available for ninety (90) days after the Annual
Meeting. The webcast playback will include each stockholder question addressed during the Annual Meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">11.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">A violation of any of the above conduct requirements will be cause for dismissal from the Annual Meeting.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>THANK YOU FOR YOUR COOPERATION
AND FOR JOINING THE ANNUAL MEETING.</B></P>

<P STYLE="margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 96; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE=" width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="proxy_01.jpg" ALT=""></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND  DATED. D80250 - P68617 1b. Glenn R. Larsen, Ph.D. 1a. Cheryl R. Blanchard, Ph.D. The Board of Directors recommends you vote FOR proposals 2, 3 and 4. 2. Approval of the amendment to the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan. 3. Ratification of Deloitte &amp; Touche LLP as the Company's independent registered public accounting firm. 4. Advisory vote on the compensation of the Company's named executive officers. NOTE: Such other business as may properly come before the meeting or any adjournment thereof. Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer. 1. Election of Directors Nominee: For Against Abstain ANIKA THERAPEUTICS, INC. The Board of Directors recommends you vote FOR the following: ANIKA THERAPEUTICS, INC. ATTN: DAVID COLLERAN 32 WIGGINS AVE. BEDFORD, MA 01730 ! ! ! ! ! ! For Against Abstain ! ! ! ! ! ! ! ! ! VOTE BY INTERNET Before The Meeting - Go to www . proxyvote . com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11 : 59 p . m . Eastern Time on June 7 , 2022 for shares held directly and by 11 : 59 p . m . Eastern Time on June 5 , 2022 for shares held in a Plan . Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form . During The Meeting - Go to www . virtualshareholdermeeting . com/ANIK 2022 You may attend the meeting via the Internet and vote during the meeting . Have the information that is printed in the box marked by the arrow available and follow the instructions . VOTE BY PHONE - 1 - 800 - 690 - 6903 Use any touch - tone telephone to transmit your voting instructions up until 11 : 59 p . m . Eastern Time on June 7 , 2022 for shares held directly and by 11 : 59 p . m . Eastern Time on June 5 , 2022 for shares held in a Plan . Have your proxy card in hand when you call and then follow the instructions . VOTE BY MAIL Mark, sign and date your proxy card and return it in the postage - paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717 . SCAN TO VIEW MATERIALS &amp; VOTE &#61531;&#61502;</P>

<!-- Field: Page; Sequence: 97 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="proxy_02.jpg" ALT=""></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: The Notice and Proxy Statement and Annual Report are available at www.proxyvote.com. D80251 - P68617 ANIKA THERAPEUTICS, INC. Annual Meeting of Stockholders  June 8, 2022, 9:00 AM This proxy is solicited on behalf of the Board of Directors The undersigned, having received notice of the Annual Meeting of Stockholders and the Proxy Statement furnished herewith, revoking all prior proxies, hereby appoints Dr . Cheryl R . Blanchard, Mr . David B . Colleran and Mr . Michael L . Levitz, and each of them, with full power of substitution, as proxies to represent and vote all shares of common stock which the undersigned would be entitled to vote, if personally present, at the 2022 Annual Meeting of Stockholders of Anika Therapeutics, Inc . (the "Company") to be held live via webcast at www . virtualshareholdermeeting . com/ANIK 2022 on Wednesday, June 8 , 2022 , at 9 : 00 a . m . , local time, and at any adjournment or postponement thereof, with respect to the matters set forth on the reverse side . Any proxy may be revoked by a stockholder by delivery of a written revocation or a subsequently dated proxy to the Secretary of the Company before the taking of the vote at the 2022 Annual Meeting, by properly casting a new vote via the Internet or Telephone at any time before the closure of the Internet or Telephone facilities . Attendance of the stockholder at the meeting or any adjournment or postponement thereof will not in and of itself constitute revocation of this proxy . This proxy, when properly executed, will be voted in the manner directed herein . If no such direction is made, this proxy will be voted "FOR" the election of each of the directors and "FOR" items 2 , 3 , and 4 , in each case, in accordance with the Board of Directors' recommendations, and voted in accordance with the discretion of the persons named as proxies on any other matters that may properly come before the Annual Meeting . Continued and to be signed on reverse side</P>
<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !N E(# 2(  A$! Q$!_\0
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M)<JS0I?W20F0*0"5W$9 R.GK51BY.T5=DRDHJ[V.FHKSW_AH;X8?]% \.?\
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MQ] 0@X''4C-6/V%_!TGBS]H[0)!'#+:Z/%-J4Z3@X*JNQ=O'W@\B$9]">U>
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MHS] PN,I8N'-39:HHHK@.T_'7]K!1_PTK\1>!_R%#V_Z9I76_L$J!^TYX?P
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MD/BQ\2]*^$/@'5_%>LLPL["/(2-2S2R$A8XP!W9B!Z#.3@5U]?F)^WE\?/\
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MY\_\%*O 6NW7C3PYXLMM.GNM"CTS[%+<P1LZP2+,S?O,#Y01(N">ISZ5XO\
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MQ_NL_7]$?"9__O$?0^__ /@EY_R+?Q"_Z_[3_P!%/7W#7P]_P2\_Y%OXA?\
M7_:?^BGK[AKX[./]_J^OZ(^GRO\ W.GZ!1117C'J!7Y\_P#!4#_D;/A]_P!>
M5Y_Z,BK]!J_/G_@J!_R-GP^_Z\KS_P!&15[V1_\ (PI_/\F>-F_^YS^7YGQ+
M7JFJ?M)>,;CX2:'\.-/O#H_AO3[1K>X2T.);XM(SDN_4+\V-JX!YSGMY77K&
MJ?LT^+[?X0Z'\2-,MCK/AR_LS<W1MQ^]L2)60ADSEEX!WKTYR !D_IV*^K<T
M/K%M]+]SX&A[>TO8]M;=CRA5:1U506=B !W))P!]<U]M?L\_\$];K5_LFO\
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M_P""H'_(U_#[_KRO/_1D5>]D?_(PI_/\F>-F_P#N<_E^9\2U^N?[%HW?LO>
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$H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>crb.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 crb.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ , "E P$1  (1 0,1 ?_$ '8   ,  @,!
M       &!P0% 0(( P$!                     !   0,# P,!!@,( @,!
M     0(#!!$%!@ A$C$3!T%187$B,D+!% B!D:'A4F(S%4,6T2,E%Q$!
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@+R[6QV'$.'IUT&TX^G38@$; ?LT!0<?I]_';KUT'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>dbc.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 dbc.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ ( "X P$1  (1 0,1 ?_$ &P  0 # 0$! 0
M       #! 8% @<( 0$                     $  " @$# @0%! ,! 0
M   ! @,$!0 1$B$&,4$B$U%A,A0'<4)2(X&1%20F$0$
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AS\FF(T%W'XJA0YFI76(R\?=?<L[<=]N3-R)VW^/GH/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>envelope.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 envelope.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  \ $P# 2(  A$! Q$!_\0
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M8.0"6Y.*^F_B,O[/W[.&G0^*_%.B^!_!OV5_-M+K^R;:.Z:1>1Y"I'YC./\
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MOJ[6O#6D>)4MDUC2K'54MIEN(%OK9)A%(OW77<#M8=B.:TJ /G3X3_L.^!O
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M0?\ 15/!7_A0VG_QRL/_ (8S^ __ $1_P7_X)8/_ (FC_AC/X#_]$?\ !?\
MX)8/_B: -S_AI?X0?]%4\%?^%#:?_'*/^&E_A!_T53P5_P"%#:?_ !RL/_AC
M/X#_ /1'_!?_ ()8/_B:/^&,_@/_ -$?\%_^"6#_ .)H W/^&E_A!_T53P5_
MX4-I_P#'*/\ AI?X0?\ 15/!7_A0VG_QRL/_ (8S^ __ $1_P7_X)8/_ (FC
M_AC/X#_]$?\ !?\ X)8/_B: /!_VU/B]X$\?7GP"L/#'C7P]XCOX_BIH4SVN
MDZI!=2K&&D!<JC$A0649Z9(]:^W:\IT']E#X,>%]:L=7TCX6>$M-U2QF6XM;
6RVTB!)89%.5=&"Y# \@CH17JU '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>phone.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 phone.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  \ % # 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4MM+110
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M+RV\?[6WP*5V8737 VJG0KYZY)SQC./?FOKJOCG]I[_D\SX"?]=/_;E*^QZ
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LKZ1-(FF#69+>.WLF:/:TJ06T,,9D*NR^8ZLP#$ C)KVJ@ HHIN[Y@* /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>laptop.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 laptop.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  \ #P# 2(  A$! Q$!_\0
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MK\2?_!;??_$5^I?_  KWPM_T+6C_ /@!%_\ $T?\*]\+?]"UH_\ X 1?_$T
M?EE)\4OAC)&R/^WG\2&1A@JVFWQ!'I]ROI__ ()-_:8_V59H&N+F[TF#Q)J,
M>DW%Q&8_-M-R%74'L7,I^I8=J^KO^%>^%O\ H6M'_P# "+_XFMJSLX-/M8[:
3U@CMK>,;4AA0(BCT ' % '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>p3a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 p3a.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ V@$] P$1  (1 0,1 ?_$ *4  0 " P$! 0
M       %!@0'" ," 0$!  ,! 0$               (#! 4!!A   0,# 04$
M! H&!PD       $" Q$$!08A,4$2!U%A(A-Q@9$4H;'!,D)28H(C".%RDJ)#
M%;(S4V.S)#31\=*#H\-T)181 0 " @$$ 0(%! ,!       ! A$#!"$Q01)1
M87&Q(C(3%)&A0@5B(S,5_]H # ,!  (1 Q$ /P#JD
M
M
M                  ^7R,C:KGN1K4WJJT01 CY\_81K1BK*OV4V>U2R-4RA
M.R&#+J6=?ZJ%K>]RJOQ4+(TPA.QX.S^25=CFM[D;_M)?M5>?N2H?5GJ/JW3E
MSAFXFYCB;=VTDMPCXF2<SFO1$W[MA?QN/2^<^%._=:N,*?9?F!U[ Y/>&V=V
MWBCHEC7VL<A?/!US\J8Y=UGQ'YDH5<C<QAG1HN^6TD1]/N2(W^D4W_U_Q*VO
M,^8; T[U3T/GW-CL\DR*Y=NMKG\"2O<CZ(OJ4R;.->O>&BF^ENTK9OVH4+@
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M\-W[OH,/+XWM^:O=KX^_'2>SH9%14JFU%W*<ET0
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MB&RE<0S6G,L<D\ +5B+!+6V17)^-)M>O9V)ZC+LMF5]*XAG%:8
M .=.NVA&8;,,S]A'RX_*/5+EC4\,=S2JKW)(FWTU.OPMWM'K/>'-Y6KUG,=I
M:L-K* ;P_+GJ5RMR.FYWU1G^<LFKP1RHV5J>OE7UG-Y^OM9NX=^]6[CFMP
M                   !B9:?R+"5R;'*G*WTNV$]<9E&\XA4C6S@&=AK5+B^
M;S)5D?C=ZMWPE>RV(2I&96HRM             $'K;3D.H]+Y#$2(G//$JV[
ME^C,WQ1N]3D+=.STM$J]M/:LPX_?')&]T<K>62-59(U=Z.:M%3VG?<=\@63I
MQFG8;7&'O>;DC6=L$Z_W<_X;J_M5*N13VI,+--O6\2ZZ. [
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MG\SO#4!O8P#J[I"Q6=-L$B[U@5?;(Y3A\K_TEUN/^B%P,ZX
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M,_'+1JKV)4]'7_3^R=9:(P=L_8YEG"KD[W,1R_&?/[[9O,_5V-48K"P%2P
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MR>.!O_,<C?E/+6Q$R]K&9P[0MX&6]O%!&E(XF-8Q.YJ40^=F<NU$/0\>@
M                 /.XA2:"2)=SVJWVGL3B7DQE3'-<QRL<E'-545.]#:S/
MP#TMIW6]PR9N]BUIVIQ0\F,QA[$XE<HI62QMD8M6/2J+Z3',8:8E]'@
M      #6O736#<-I9<5;OID,PBPHB+M9 G]:_P!?S4])LX6KVMGQ#-RMGK7'
MF7-9V7,#P;%Z$Z>7*:XCO7MK;XB-;AR\/-=X(D^%7>HR<W9ZTQ\M/%IF^?AT
MR<9TP                      !6L_:+%=^<B>";;]Y-YIU6S&%&R.J,+4
M"8P622)WNLJT8Y?PE7@J\/64[:9ZK-=O"P&=<          &#G,WC<)BKC*9
M&5(;2V:KY'+O7L:U.+G+L1"5*3:<0C:T5C,N2M9:JOM4:@N<O=U:DB\EM!6J
M10M^8Q/C7O.]JU12N(<C9LFTY0A8@*J(E5W(>CI[HGI%<#I".YN&<F0RRI=3
MHN]L:I^$Q?0W;Z5.+S-OM?'B'4XVOUK]VP#(T
M#'R%FV[M71+L=O8[L<FXE2V)1M&85!['L>YCTH]JT<G>AK9WX>@!/8C,HY&V
M]RZCMT<B\>Y>\S[-?F%M+^)312M        ,'-9O%X3'2Y'*7#;:TA2KY'KO
M7@UJ;W.7@B$J4FTXA&UHK&9<Q]2NI5_K'((R/FM\);.K:6B[W+N\V6GTEX)P
M.UQ^/&N/JYF[=-Y^BEFA0 7?I+H=VJ=3,]X8JXG'JV>^<J;'JBUCA^^J;>XS
M\K=Z5^LK^/J][?2'4Z(C41$2B)L1$W4.&ZH
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M;3B'6.B](X_2N @Q5FG,K/'<SJE'2S.^<]?D[$.%NVS>V9=;7KBD8A.E2P
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MW&JUJI<96Y1%O;VE*T_AQ_58WX=ZG%Y'(G9/T=33IBD?5<#.N
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MF#;S;VZ1TALU\6M>_5LAC&,8UC&HUC41&M:E$1$W(B(8VE^@
M                        (K):3TQDZ_S#%6ERJ[W20L5W[5*EE=MJ]IE"
MVNL]X0%QT;Z;SJJKA8XU7>L;Y6? CJ%L<O9'E7/'I\/)G1/ILUU?Y5S=RS34
M_I#^9L^3^-3X9UGTJZ>6;D?#@K97)QE1TO\ B*XC/)V3Y2C12/"QV>-QUBSD
MLK6&V9]6&-L:?NHA3-IGNLBL1V9!X]
M
M
M                                                        #__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>p3b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 p3b.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ V@$] P$1  (1 0,1 ?_$ *X  0 " @,!
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MGPAYTZV$'B&Z\BO1V^!3M^7FYJ>3;/%Z@:YKFAS3JUPU!]17C.Y]0$! 0$!
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MB02V2T1])QX,] 71>>RO;'.>?]'/2.^W=/*.7]5Q7.Z! 0$! 0$$=N+)R8K
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M 0$!!5=Y 8[(X;<4?NFK8;3NN^E5M'H/5^S)TD+?3QB:L-O"8LM2P;B @("
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MUE/W-_A^2/MZ_P#DOO\ ^;[:_P#=?_*F_M)]S;X?D?;5^/YOC>V.T =75Y9
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M"\#RL>Y.'I:?IA<5SM! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0- @:! T" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(
," @(" @(" @(/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>p3c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 p3c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ V@$] P$1  (1 0,1 ?_$ )8  0 " P$! 0
M       &!P0%" ,! @$! 0$! 0$!              4$ P(!!A   0," P()
M"08& P$       $" P0%$1(&(0<QT;(3<Y,4-#=!42*24W15"!AA<3(C5!>!
MD8*SM!5"4C5#$0$  0,!"0$! 0$          0(#!!01,4%1<3)",P5A%2$2
M_]H # ,!  (1 Q$ /P#JD
M          "LM0[]K+9+Y6VF:W5$LM%*L+Y&N:C7*B(N*8_>;;>%553$[=[+
M7E13,QL:[ZC]/_"JGUV'O^?5SAYUD<CZC]/_  JI]=@_GU<X-9'(^H_3_P *
MJ?78/Y]7.#61R/J/T_\ "JGUV#^?5S@UD<CZC]/_  JI]=@_GU<X-9'),= [
MQ*#6<59)24LE,E&YK7I(J+CG3'9@9[^/-O9MG>[6KT5[=B6F=V
M                           ')&\[Q"O_ +V[DH7L;UT]$B]WRC!V<@
M  7K\M?<[YTL7)4F_0\6["XKI)K<
M     .2-YWB%?_>W<E"]C>NGHD7N^48.SD    "]?EK[G?.EBY*DWZ'BW87%
M=)-;@                                    !R1O.\0K_[V[DH7L;UT
M]$B]WRC!V<@    7K\M?<[YTL7)4F_0\6["XKI)K<
M              !@WN:Y06N>6VQ)/6L:BQ1+Y=J8X;4Q7#' #0I<]73545P;
M"M+;GU45-%;9HV\\^%VR2HE?F_+5.%K4\VWA E@')&\[Q"O_ +V[DH7L;UT]
M$B]WRC!V<@    7K\M?<[YTL7)4F_0\6["XKI)K<
M             !J=64SZG3M="RI91YH\75$KE;&UJ*BNSN;@J-5$P7 "":8C
MI5OL"H^W21R2H^@@D2L:V%J)BY*-)FI'F7!7; +1 Y(WG>(5_P#>W<E"]C>N
MGHD7N^48.SD    "]?EK[G?.EBY*DWZ'BW87%=)-;@
M               -)K1:%--5JUTCHJ;!N>9B(JL7.F5RH[!%1KL%7'R :-M=
M)=JN@I+A?;1)#!41S(RC>BSS2Q+C&U$<Y49B[ARXKY )N!R1O.\0K_[V[DH7
ML;UT]$B]WRC!V<@    7K\M?<[YTL7)4F_0\6["XKI)K<
M                  !IM84\M1IRMCBIUJ9,K7-A1%55RN1VQJ?BPPQR^7@
MU3M26:IGMT-CYNKKI)XTGB; J.;#P2OD]%O-*WAV^78!+@.2-YWB%?\ WMW)
M0O8WKIZ)%[OE&#LY     O7Y:^YWSI8N2I-^AXMV%Q7236X
M                    #5:JCJ)+#5]GJF44K&I(VIE<K(VY'(Y<SF[4143
M"(TMXO-7/3P27>WOCK:^.HC[/-.^9(V/:JPM8C<4;Z.'IX)M L,#DC>=XA7_
M -[=R4+V-ZZ>B1>[Y1@[.0    +U^6ON=\Z6+DJ3?H>+=A<5TDUN
M                          U>J*%*ZPU=,K)'YFHJ-A?'&_%KD<F5TOY:
M<'_+8!"=,U"OO[GT=342U%5,V6N1M3:9,R,1&*KFQ-YS*B)M1@%E <D;SO$*
M_P#O;N2A>QO73T2+W?*,'9R    !>ORU]SOG2Q<E2;]#Q;L+BNDFMP
M                           &LU+:ZBZV.JM]/(V*6=J-1TB*K%P<BJUR
M)MRN1,% TTVG]1U<M V=ELIX:*HBFC?3,E25C8U])D>.")F;Z*_8!+ .2-YW
MB%?_ 'MW)0O8WKIZ)%[OE&#LY     O7Y:^YWSI8N2I-^AXMV%Q7236X
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M(5_][=R4+V-ZZ>B1>[Y1@[.0    +U^6ON=\Z6+DJ3?H>+=A<5TDUN
M                               ')&\[Q"O_ +V[DH7L;UT]$B]WRC!V
M<@    7K\M?<[YTL7)4F_0\6["XKI)K<
M         .2-YWB%?_>W<E"]C>NGHD7N^48.SD    "]?EK[G?.EBY*DWZ'B
MW87%=)-;@                                    !R1O.\0K_[V[DH7
ML;UT]$B]WRC!V<@    7K\M?<[YTL7)4F_0\6["XKI)K<
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MC<6JB\ &1IFV5]MM?9ZZ?GYG222-:BN<V)CW8MB:Y_I.:Q-B*H&U
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M3*COLQ ^VG4-JNRKV"59FHW.C\CVM5JKABUSD1%_@!L@
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M3CRXK(F;#AP7A ^:&M5RM=$RCK*22%T<3&NE=4\_&YS=GH,V9$ E
M                                                         #__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>p9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 p9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" %6 P,# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.X4LLGF&-R!M&<;._:O5OA1X[7XI?"WPUXF2V-DOB+2K75%MR^\P">%9=A;
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MLCZ@_;J\6ZGX%_8R^*.KZ-YO]I6/AB_D@>,'? ?(<&48Y&P$OGMMR>*^??\
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M^U=4Y47E\:"<)2BY;N2[6<=KW\TSGC&JL;*LU)*2CLE]SW_!GS/_ ,&]!/C
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MTC9[Z;ZVMY&-"&(I6JJF[PIJ-N[NOP/)?^"<7A?5?VT/^"GOCG]H^STJ71O
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M^*OAOX=G3OBLWP^;4K!H[;3F\)F\,!M4B509OM(#>;N!^Z-N,5YW_P %%/\
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MN;>V6P%Y]C\TRR!,F38^,9S]TYQCWKYVU'_@L?XD^%GASP9XI^)WP(UOP=X
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MYA8YX )9OA76<XU++VO-L]8\MNW7;YB66XCV2BX7_=\NZWYK]^FYXS_P2/\
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M[YYXYG^UZ4*;7M.:I[-KFL]7S)K=7T75V*_LVI*:?):'.GRZ:+EL]G;5]$>
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M<FK/=0-%J&IF6:.WA^SAC+OBBN9I/-9 ,A &R@KZSHH **** "BBB@ HHHH
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MG-W;"BBBM#,**** "BBB@#U']DS_ )'[5O\ L"W/\TK\'J_>']DS_D?M6_[
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MJCW)(%>7G&F$DWWC_P"E(]/)_P#>X_/_ -)9^"-%>@_%7]D_XF_ ZS-SXN\
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MLQO(FN4:YFEAC\R5Y%C9XHDK[!H **** "BBB@ HHHH **** "BBB@ HHHH
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MU<?E7?E=+VF+IP??\M3BS*I[/"SDNWYZ'S!1117ZB?F@4444 %%%% !1110
M5TGPS^%6K_%;6OLFEP95,&:X?(B@'JQ]?0=369X1\,77C3Q-9:59KNN;Z41)
MZ+GJQ]@,D^PK[?\ AYX!L/AKX5M]*T],10C+R$?-.Y^\[>Y_3@=J\3.,U^J0
M48:S>WEYGLY3E?UN;E/2*_'R//O!/[&OAC0+=&U4W&M70Y8NYAAS[*IS^;&O
M1?"G@#1? RRC2--M=/\ . $AA3!DQG&3U.,GKZUL45\)7QV(K?Q9M_E]VQ]M
M1P5"C_#@E^?W[D=U:QWUK)#-&DT,RE)(W4,KJ1@@@\$$=J^'?V^O^")?@?\
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M'7H'[.EV8O&-U%GY9;1CCU(9<?H37)CH\U"1TX65JJ/:**^:OVFOC?XOU?\
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MAZA>G_EYF6)?H@S_ #;]*PQTN6@S7"1O51Z11117S9[84444 %%%% !1110
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M\EKSKTW5J)+IIU"BBBO"/:"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /#OVT_AK_;/AJU\1VT>;C2_P!S=8'+0,?E
M)_W6/_CY/:OF2OT%U/38-9TVXM+F-9K:ZC:&6-NCHPP0?P-?$7Q@^&MQ\*O'
M5WI<H9H,^;:2G_EM"2=I^HZ'W!K[?AK'\]-X:>ZV]/\ @'QO$."<:GUF.SW]
M?^"<O1117U)\R%%%% !1110 4444 %;_ ,*_$_\ PAOQ'T74MVQ+6[0RG_IF
M3M?_ ,=)K HJ*D%.+A+9EPFX24UNCZ ^)>C_ -A>.M2@ POG&1!_LO\ ,/YX
M_"L.NB\5Z@/%?@OPKKXY:_T\6\Y'>6([7/YY_*N=KXZE=1M+=:?=H?:3:;YH
M[/7[]0HHHK0@*W/!OQ"U+P1<[K27= QR\$G,;_AV/N*PZ*F45)<LEH5&3B[H
M\Q_:X_X):?"_]N5;K6_"AMOAU\1Y1YDABB'V#4GYSYL2X&X]Y(\-U+*]?E'^
MTS^R1X^_9$\;G0O'6@W&ERN2;6[7][9WZ#^.&8?*X]1PRY^8 \5^U:.8G#*2
MK*<@@X(-=#K&L:%\8_!<WA#XBZ#9^+O#U\0KQ747F.K?PL.^X9X92''8UZ&!
MS;$X/W?CI]GNO1_HSBQ>6T,3[WPS[]'ZK]4?DK_P1Y_9$/[5?[7FF3:A;&;P
MMX(*:WJQ8?)*R-_H\!_WY "1W2.2OWPKR?\ 9#_8T\$_L4^ ]0T'P3;WB6NK
M:A)J-Q->R"6X=FP$C+[0=D:@*H/(Y))+,3ZQ7SN?YK]?Q//'X%HO\_F>UD^7
M?5*')+XGJPHHHKPSU0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#S?]J'X9_\ "Q/AK-)!'OU'2,W5O@?,Z@?O$'U4
M9QW*K7QW7Z&5\?\ [4'PA/PT\<-=6D>-(U=FF@P.(7ZO'^!.1[''8U]?PUCT
MKX6?JOU7Z_>?*<18%NV*AZ/]'^GW'F=%%%?8GR04444 %%%% !1110 4444
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MM)1<0M$8HUC$4B"-$"(%3Y:^:O W_!9ZR^(FC?">YL_!NE:2?B38ZC=N^O\
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M"[3],L%N[3PG'9>(=0AL]*-@;+^T5N#ML)I&:X>WDAE?=)(@F"E=@!T>F_\
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FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>blanchard.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 blanchard.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !X '@# 2(  A$! Q$!_\0
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MTS6OH^AR7EA%=QIO@D0.K#I@U))8M&<.I!KXVI4UL=/(<G-8L<C'?-95[:[
M<C&*[F:T5EZ#-8]]IF]<#!J8UG<.4X2:Y^S2%LXQ147BRU>SCD<#)HKTJ;YE
M<U5'F5T;%C_J?PK(U3YF:M2U;$?7M69J!R36ZW/'9CF/BLG5(U5"6.%QGFMW
M'%<[XJ25;&X @:5FC8)'M/S''/Y<5<5>21*5]#RWQ!KYO+YX('40)NVJIRN<
M\,WJ1CITKH/">DM+H*SK&SW=R72W'&1@C<S?YZFN"N+"\C9!);2Q+( 55XRN
M5]?I7>>%/$$/_"4:';A=UO'@?+ZCDDGOGFO=J+E@HP.W#I*7O'T#^RU\/[&;
MQG-#>1I(MDRJ0PW(SGDDYZGI^5?HWX;TFWMK=(!$@A& O':OAOX&VS:+'=:E
M8Z=<ZA<M/(\K!XXH]N?E52[ L?45]?\ PS^)FF^+(8[)DEL-4 Q)87(VS1\>
MG<'U%3&?-/78]*4.6&AZ,?!=G=6<D:QJJ2*58_7G/YU^>G[7GPM;X7^/K?7;
M>T2YMKYP\J)P2P(W2CG[PXXZG-?<?BCXTVG@O5X]+8Z?$S8WR7]T8@HQUX!X
MKR[]KSPRGQ?^!^NW>FP6USJNE0&_M)+:82QLT?+ $8."H88KT8<M]-S@ESI6
MELSY9^ ?Q DL_$EAX<O;E;[2-6!.GW#97RIBQ/E$GL0>A[XKU[QQIBV,I(4!
MO2OA+P/J6J>*-4\-Q:9&WVC4)XF06SL)-V\[L@\8# 9(&>.M??7CJ%T"Q3/Y
MLJ(JNPY!(&,_I7R^;X:G3GSK=E4ZK<;'E>I7OEY -9,.I>8^,YYK8UBU1E;B
MN8CM_+F)Z#->"HJQ',[B^(M/6\L&8+DX-%:ET!_9>3TQ17H4(^X$JDHNUSCK
M=L1GTQ6??\[LU:BDPAJA>R<FNKJ<+(XE1L"0'9WVCFN?\3:UEK?3=+YU&7B4
M)B0F,G R,<#DYY]/2LOXA>(O[%TM5#LIF^5@K[25],XK*\"W,5INN9DCM?.^
MXRMR$.2%W=V(QQZ=:Z:<'R^T9U8>/-+<O6_PWO-0M9M0U_4)HK&VWYM%) .3
MD ]=HZ$Y[9 -<7I^CWNO^/(HM&02W+OD(NT!0<8('\*@#OQQZUT7Q0\5ZO=?
M88;F*/3K*Y4?9TCD_P!4I(QO4'!+8!))ZD^F*U_@[X7?P[\2+#4(L,FH6TJ2
M%2.)%(./Q'/O7HQ4HP<I/6VB._EC4J1A%:75V?5OPS_8]O/$%M97]QK-PZQ$
M,8+=RL?3D$9&<\YS[5WN@Z:_@WX_:7<033RN9!;M',^Y0G/RCCH*Z;PO\3IO
M!_@!9+:$-=SQXB\PX5<\;F_SS7EO@G4M1A^(EGJEW!<ZM+).SR7B/OP2>%\L
M?= Z#%<\JKE"$+]3UEAX1G.71Z'T3\8/@#H/Q!U9=0UF$W=K</EX&8C:PZ $
M=O:NS\,_"_1/!?@^ZL]*L8;&UNHF5XHU^5R1@L1TR>^!5O79!K_AXS+=G2<H
M)$GN'"C<!T96[9ZUD>%?%FJZA9MI>H6H4H,"ZA;?!*IXW(P_D>:];FY9<K>G
M3U/+]GS1YNJT?H?EOX/\1#P?XFL9!IT=O?V-_(UH=V%5EF.<+NY!QGTR>W%?
M4FK>*K;Q/IZ7ENX.>'7^XXZK^%?"GC3QH)/BIKT4]J;'3O.\@A"X:%T8CS!D
M D<CC'.!7ING_%*/0]/MK;3KE+V\O'V?:)6)8$]"1WR"#DGTQFN',,-*O&YQ
MQE"2NNA[9>,)"_TK%:/<QXR,U/;W4K6<3S+LE*C<"<G\>.M5)+L*QXYKX]1:
M;1GU*VO7HM=,8=QFBN;\;7C+92#/5:*]3#KW#&H]2G"_RFJ=\WX5;A^Z:IWV
M._/X5KRF)X]\4-59M:BA1U 1$"Y^8!N3T_K5+2X[F.2&1B)UR&0,V4SZ^ZXH
M^+/A6:&];5(9-ZR*L.UNB =OY5V5O96;>%=!6]NXHYA")9%7"N8SD<[N%.WH
M,Y./R]>*C[&'+\SKH7;9Q'Q"U;4]7U#396D-NBIF#@9P3G<WL>V1TKI_"/Q#
MNO#GBOPM=WJJ^G[E5P@58PQP,J/X>",COU[U;T^'1=?U*[N-6:&WN(WV>2[=
M4W<*F!@?+C+>@P :Y7QKJ6E"1+#":E;-$;C_ $=2N)P#M&!R%Q@<5UKEJ6II
M:&SYJ-ZUS]!&TRQ\:> ]2\/7&VYA$L<]NQ/WHVS\F0<XR:A^%?P;>R3;;B$0
MP?(D5QOCD7_@:G+8]Z^2/A=\:O$'AO3;>UN%;Q!9VY6-+S2@TLD8(!$;*>7
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-9HHHKXNE\)])/<__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>conley.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 conley.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ > !X P$1  (1 0,1 ?_$ )H    ' 0$
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MT= Y"Z!0$@::4 %,=Z( DUC'=5A6**@I ']L4!(/MTAH(X55+,0  22>0 H
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M*X^9#?D0>%<G+I:#T6"Z=$R:GW3&G7Z'(RTBG].I0ZAEORX-_&GJUJ-4UFJ
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M>>_O^/(VO;1%N6W1Y$=I(Y$5E8=H(N*\\Z.3VZNH31(8^%'BPR2VT*%)8FP
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M>QXW6;M;['GO^NY-K*M,=OX.;+\H??\ Y,4ZG@DQ]U?'<W* -P-U&K]MN%K
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H&Q\=)U?PI,#UKMVU8D6_;GNT 99<^*"/( .H$P*R(? V8UD:1<C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>henneman.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 henneman.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !X '@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#S'1XPT1KG
M?$5L#=?C6OH,K>6 ?2J6N+NFS7Y@I>\?626AFM:J81]*YF^UJXTNZ"*<IFMZ
M:9T4XZ5Q^L%IKQ<^M=$))NS,))I'I=AG4[!'_B*UBW&W39'>XG6!>V]L$_04
M^Z\60^$M%M45//OKA?W,*C. .K'VK@+:ZNM2U?<95N-3N#O:9N3"N>BCH/\
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M^(Z>";"*,2>3=W"YC14+NW')"CL*Y;P;XV35KJ 7&NK=WMVOF16D\#6[;?\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>larsen.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 larsen.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !X '@# 2(  A$! Q$!_\0
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MLGX:7N=-M^?X17R7H\*QNAQWKZ8^&]TR:;!UZ"O)R^MJT;8ZEJF>X6NJK;Q
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MXM)6BD7Z,I!KZ9-GQ,J,;Z'[5?&1!)I-XY')4@J:_)KXM6L=EX^U:*+[GF9
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>4SDCHVBO(P69_K2;MM%%<994N&R<^AHHHK-@?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>richard.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 richard.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !X '@# 2(  A$! Q$!_\0
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MMX-ED_LRYC20/NBWAE.5([$'O7+:Q<>3.Z\EB:OZA]J^'O@&XE'DV%_N%O%
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MBPLO#+GLWX\BNV_X6TMOH.D65^D6G6Z3B.:Z"YF?LL,?H6(Z]@*\CFO$6W#
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M7'_$X* \I&!_6N)M;T"[N$SQN#C\1_B*_7LGA[+!4H^7YGQV+DY5I,TI(R[
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,[N,G8^IP?O44V?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>thompson.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 thompson.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !X '@# 2(  A$! Q$!_\0
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3<DT45+$2PL96R.%]:***8S__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>vogt.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 vogt.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !X '@# 2(  A$! Q$!_\0
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M*9"/,#%,MZ[1G';-?K)8LOE@'!R.1ZU^;_[5VC?\(+^U%:3;0EE<117%LO.
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B\)7 .T1ZK;$GV,BC^M%%%?)9Q%2J0;['TN5R<822[G__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>p26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 p26.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
M   !  $       #_[  11'5C:WD  0 $    /   _]L 0P " 0$" 0$" @("
M @(" @,% P,# P,&! 0#!0<&!P<'!@<'" D+"0@("@@'!PH-"@H+# P,# <)
M#@\-# X+# P,_]L 0P$" @(# P,& P,&# @'" P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@!5@*  P$B
M  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*"__$ +40
M  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A""-"L<$5
M4M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U155E=865IC
M9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2U
MMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$
M !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (! @0$ P0'
M!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6
M)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#
MQ,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1
M #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIK/@TAG - #Z*C%
MRIH^T+0!)148N%)H$ZL![TKH"2BF>>*#,H_E3 ?12(V]<TM !1110 4444 %
M%!.!4<MR$'O0!)36<"H'N-W'S!F&?_K_ $&1445RLP+*ZR!25)!Z,"01^!!'
MX57*%QNL:Q;Z/ILUU<2+'!;J7D8]@*^-_P!KO_@L7X;_ &=_#SMI&FVNJ:D[
M,D,=U<LJ@CN5C4D]OXA7TU\=?AUJ7Q5^%NJZ#I.JQZ)>:E$$2[>'SA%SDY7(
MZ_6OS%_:!_X(?_$#PGX.\2>,+GXE>']?31[.>_-E_9$D+S*JEV <N0IP/0\U
ME.IR[GBYE',)5%#"64>KNK_*Z9Q?BK_@N;\=/B'#;7FGKIWA#1;R[CMX[BT\
M/MME!(R$EN&<,<'M7T%_P41^+_Q'^"?[0O[.Z^'_ (C>+(M'\>7;0:K:FX5(
M9BODLO"*O4.P('M7,^.?"D/BS_@CE\([K[+;QM;ZOILN1& 0&F ZCI][FO0_
M^"H7PTU#QOK7[-VH:;:M,VCZV9)FZ+#&8X^3^*]*XI5)3]YGH87#2I1]Z3DW
M:]W^6Q]UQ:-(E]]HGNI[B10,+N*HIYR=H/-:$,@G3"'<O3*G(KB[7XF:9X%^
M$\GB7QAJUGHVD6[J);Z\?RHU\R18X^3W9W51W)85XO\ MT7WQ2T[P1KTFAZY
MHGP]\(Z"T(6XB$MS=ZY'(#YA9T4-:JAS\JJY;KO'2L<=CEA*#K<KE;HM_P#@
M+3=G;(^D-8BM=+L+VZOI_)MO*S,P^4(JC)/'M7R7\6_^"FTG@CQ%<Z3X9\+6
MLD-N^U-0U*^=XY0&&?W2[=ORY(8O@ '/H?3_ -GZVUOQ7^RAH>M>(YM6BUJX
MTI%N+;6$$7E #&TC R".0QY(//)-?(7QJ_9VUS6-=U6*/P_(EV) RE-4:**Y
M#LQ;"M S@*=N<$]0,XYKYO,LVQ\Z5.>%7(I).V[UMN]D?1\.9?A\3*4J^JC;
M=V7F;EW_ ,%5_B!J[S):2:';*C;?,%ACYN3L*LS<X&",YZGCI5&__P""L7Q$
M\.Q"5IM'N59L>5<6(?8N,Y+(5)&.F!D\CK7F>N_LL:CH-P%\S5V6-2]PNY)%
MB7D@(I* J3D9Z@@#^*N'\?? _P 0:7X6DU34(=0MIE_>"V>RC:26,G)X\P@'
MYN>RY!]<?-RQ^:P2G*I+7S/L(Y7EDJ<90A&TG9=^VVY]F?LN?\%9=7^,WQ&M
MO#&K>%-%DN+R%[F.YTV^DAVQJN<F*17Y;D@;P>*^CO%7[9W@/X;1Z>WBS4Y?
M"_\ :N5MWOH6,3,,9!=-P7J/O$5^._[/WCB[^$?Q7M=<73[JXOM+DN+2>$QL
MOV?_ $<?NV;E<8=2#QDGH*ZCXI_M&^(/&QCOM>O4NC&S?9( ^Y;<$YP/IP/P
MJEQIBL+2]G/WZE^O;3>Q\+Q/AJ.#Q2IP5DU>WS?J?M9H_B*Q\162W&GW=O?0
M-P);>59$]>JDCH:N"3/]:_!?_AJ_4? NE2:EI.H>)+#Q#J5]YUW/8WC0>4J+
MM4J5(W-CLW&!7I'PK_X+J_&;X)W]A_;VFZ3\4_"4S&.22\/]FZO$ ?O+-$AC
M;@]'BR<?>%?19+QE'$QMBZ;IR^^/RZ_>CYZC6]K4]G!=+G[1J<BEKPO]FS_@
MH%\/?VF='@DTV^N-%U"7 -AJR+;S!CT56#&-_P#@+9]J]P6;KZBOL,+C:&)A
MST)J2\C4DHIJR;C3JZ@"BBB@ HH)P*C-PH...?>@"2BF&< 9_K2?:!NQ0!)1
M3//4]_>D-PH_#WH DHJ/[0OK0+A2>H_.@"2BH_/YZ?K0)U+8_K0!)13//&*7
MS10 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** &./FKXB_;3_:=^.UM_P4%\*_!?X/ZI\/='_M
M[PA+XBEN?$^GS3QAXIY$<!HVR,J%P-IYS7V\PS7Q?^V-_P $K[/]M3]OCPSX
MW\<6.A:Y\+])\(RZ->:9)?7,&H27WGR212*(U"^6 _.9!_NFO6R6>&A7E+%V
MY>65KJ^MM-+J_P!Z/+S:&(G14<->_,KV=M.NNMON/F_Q!_P6C^*WC']G7X0Z
MOI=S\,? OB#Q-XUU?P7XCU?5D>X\/Q-91Q,MY')ORD#>9DD,XST)%>F>-_\
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MO+/3O#OA>Q^WWMQ=.(X8D1<L78]% 7)]>E5?A5X%CTCX=R:#:JJ1I=F.)>R
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M:&(G.\8-KNMN_P"*'?M0?M%^(/V+/C5I_B%K[Q7XRL_'D:2Z]X;U?61=:=#
M\J(3; QA;?RQ*H&%V' 5@V25]&^&G@[P)\>O#Y\2_"WQ?XCT2-8VM[F'3+_<
M;/+Y:.6TGWA1GCCY?0G->*_\%?M*?Q-X%NKN\94M]:U 6U_=N^T6-I%@VX3_
M &6F<NV#D\'G%>#_ ++>IWWA_P 'VMY::WJ']M:(US"^I),8[B1UE^;)7&1T
MX[\9%>M6S">'DX57S+\?7_@'ZKE>7SGA^:D^6=DGI>+\FOU/M;QK^S9\2->G
M6\M?BO;W5W&5$4>H>&8?)8 ,<2)#*F]3NZ8ZC\N#UO\ 9N^)%GH_V3^R/AQK
MSR1S(^UKK35B)& S!A.9$[A<J!Z'&:\[U+_@JA\2OAI81Q3:#X5\92''_'TT
MFG74@SU+P@KGW\NNL\%_\%G_  ?X@LK=?&/P\\7^$KJY<*C:==6^MV[#C,@&
M89-N<#[I-;1S#"UX?Q/D_P#@W1VXC#YI2I^SJT(RCW45^EG^%S@?AQ^PGXZF
M^(>IP>*--TO1?#^L2?Z3=:?JPNYK91G]XJ21*9"&VC!8$KP3P#7G7[6W[&?B
MG]F:[M;B2:+Q1X9OY?L]AJ<$)C"S!=PAFC))BD*@D<E6"G!SP/M_P-^UG\-?
MCKIU]?>'?&5C=1Z;.UM>B:TFMY+=CT#ET&#D'H2IQ5#X[_&+P?%\"?$6E:IX
MDT#5/.MHXK.VM[I;B::9'#(=B@[0""<G&.1SNKS<=3H.,IQ:<DFUJOEUZ['Q
M/%-.&.E[>NE"HDEU5['Y?:QX"UBZ\;:+!<P>39ZMA3M&2I^E>F>*/V/KKP'\
M&]6VWK^<\PN,E02!M/R\]!70>(]?TOQ3\7_!]O:I+&L1<OD?(#@5[?X^M)/$
MGPG\1F$KYEO@%R,@KM.17BY?B*U;$TX_9Y6WZZ_D?-8'"PIU%./5'E'P3^ >
MH>$?#]I?75TS6MPBL0#\O3/(KH_CK_P5B^(G[#;^#=+\(R:;XB^V7(@N=*UG
MS);9H<<A74AXFY&&4D#NK=*N_"+QV-3\.00WEQ'):P1K\@;DX']*^:_'?[.O
MCO\ :G_:Q^WZ7X9U"'PUI[XCNYQY<)Z'*\Y.?;THX1PV*6;.LYOW;[:)^374
MO!X:#F^;9'[?? +]JWPY\=-#L9H,Z5JUQ"LC:?<2!F4MV1\ /S]#[5ZI$^YO
MI7YC^(?V9_$5U!X/EM]6L;/3M'N1)J-O([[9T&.ZGJIP1[\UZ%H'_!17Q+^S
M9XZ71/$VFWWB_P 'LY07UHX?4-.0 $L-Q_?(H/*D[^X/&T_IU7BQX/'+#YA%
M1ISMRS6U[:J2W^:T,:U-1^$^^J*YGX5_%?0?C/X+M?$'A?6+/6]'O,^5<V[[
M@".JL.JL.ZL 1Z5TBG*<'\:^UIU(SBI0=T^ICY"N,K7SQXP_:+\3:3X8\?W%
MK_9OVGP]K\6F6.;<E?+?'WQN^8Y/7BOH9CLC.:^??&?[,?B/Q!X6\?6-O<:.
ML_B;78]2LF::3:D:X^_^[X;C@#(]Q7P7'T<X=&FLHYKVJ7Y;?R/EW_O6MYGL
MY.\*IMXJUKQM?_$K_A<TO"_[1]]XY^(/@^UL8[:WT_7-)N[B]B>/=+!=0DJT
M8;(QM88((Y!'2N%TW]L[Q!>? K7-0D33[?Q/I+0SQ@P'R9[:1]N\1[OX6RI.
M3U4]Z] L_P!FV\T+]HIO%6FW%FNBW$=Q+);L[B6&XF3:Y5=I4JQ"L3N!SGBN
M'\0_L3:YJOP8T/2[>\TFW\1:6L]K-()I!;7%M(Y<+N"9)4X(!7')YZ&OSG,(
M\=JG.5/F<X^U5E9*2M3C"4>S^*:7JCV\.\F<HJ5N5\KZZ:R;3[](M^C.V\5_
M$_QQXK^*'B+0O!ZZ)9P>%8(Y+F34(WD:Z>0%E"XX4?*P_#DCBJ/@+]IC5O%7
MB3P'<74-K:Z-XQMI[=T"'?!>Q-@@/G[K9& 1GD\\5I>+/A#XT\/_ !-\0:[X
M+NO#_D^*K>.&\CU/S%:VD0,%D3:"&X).#ZU#??LS7^E? +0?#ND7ULWB#PW=
MQZE:7DVY(C.'8MC 8A<,P'![5[$Z?%"Q5:M3]JW3<Y6;7+)*I%TXT_\ %3YD
M_.U]3EYLO]E"+Y=;+K=7B[N7I*UO+8JR_M':K_PBOQ&\1;;.32=#O/[,T)!&
M=US./E9F.?F&YEP!CH:G\,?$GQYX\^&ES)8R:!9>)O#>I36NL1W4#F%D12PV
M*I)#'*\Y]:K7_P"R[JEQ\-O!?A..^M;?3=+N6O-:N(9&6>:7DJ8?E()W$G+8
MZ"MCX=_ 36OAMXZ\33P:LVK:/XCTT1RRWLI:]-VH(5V(7!7:S#/7[O'%&%H\
M55,53CB545)QM-Q:34IJ4[KK[CY8)K2R95666QIR=+EYD[JZ>RM&SZ:J\K=V
MCC;3XY?$*W_9\O\ Q]=7'AMK6:U22PCBM7\V.0S!#Y@S@C;GH>M=1XC^)WC?
MQE\3[[PUX/.AV;:'I\%W>7.H1M)YTDHRB* >!U_+K39?V>M<D_9%A\!"XTT:
MU' L?F>8_P!E!$N_[VW=C _N_P"-3^(OA)XU\-?$J^\2>#;K0&DUJPAL[Z#4
MC(JQO$,+(A4'/?J!UZ&LWA.)*5&DJKK2@X474Y6G4YGS^T4==T^1-+IY7!U,
M#.4N7D3O/ENM+>[RW^7-;S.0U_\ ;$UJ/X;>#/$5II]KG5+BX74[4(7WI  7
M\HY^7C<<G=CWKT;X7_%VY^(/Q=\4:;#):S:'8V%C>:?*D>'D$ZLV6;//08X&
M*Y?P[^RSJ'AC3OAY9I>6-]#X8O+FZU0RAE^T"9"I6-<'(YQAB,CGVK4_9[_9
MZO\ X)>.?%%P;FWN='U"*&'30)&:>.-&D;:X*@# ? PQSBMLCAQ?',L.\=S.
MDW#GV]VU+5Z;J4G9]I171DXN65O#S5&RDKVWUO/3YI+3R?D>S4445^V'RH44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% "$<TW;S3Z*+ 1E6)]NU+M.*?10!'C_>HV[1PM244 1E2>U+@
MXI]% #4X%.HS44\X7Y<\T $L^T]J@9][%FX[U3U[51H>BWUX\4ETME;R3F*,
M?/*$4MM4>IQ@5XS^Q3XI\6>*/AKXB\2>--0CDMM8U>>[TZ'8B_8+8@%D+*3G
M#$@ DX XK>-']U*LVDHVW\S-U+35/JSW(JH/>C:OHU<]9>/K>[CLW0F-;V9(
MHE<9;YL$9YXR,UT ) ZKQZ5A3J1FKHTG3<79B30)+$R,N5<;2"< @^_:OYM_
MCQX4_P"%1?\ !0SXE:+X_P##]AX4USQ)K#:GHNEPV\3H\.^39#&8(UB65U,,
MR[5 9<C.XFOZ2"S+Z'L!CK7Y0?\ !8__ ())VMQ\3_!OQD\!:;XDU7Q-_P )
M7'J7B:^O-1>:STW3(8WFED;=N<N6"(F 5"Y7 X->3GF%^L8=KM<];(\9]7Q,
M9=]/OT/$/BE\</%&J^'=-\&Z??7!T:XE47,<-P8HR"H1I6QGH!C(!(!XKS;X
MJ>+;CP_'ILUQXKC\6::U_P"6VC3O<,ULVTE<1W,$9$2B,X>'Y4)Y WC,WC+Q
M1=?#)X]6>T@O;&Z=@J3'RV;!YVMR*]7_ ."?OP?TW]O3X^+I*6O_ !)]!ACU
MC6K2[F,7VVU$\4;0J5##<VX]2,JI ()!'YKE].=>JJ:7O/8_3L7B*>'HNM+X
M5Y;['Z$?\$V/V%O"_P"QS\%=0\2:5#<P>)OB-;QZYKKF26-7:5/-BB:)I&7=
M#YCJ&55/SMP,FOH&[\2V]E\+[N^O9EAM[*)C+*[ !0O.?RK1^(&HKIOAW5)-
MK2?)M 4=^@_"O*G\/?\ "<?!3Q3'?QO<"2T=?LY8[3E#7Z5*U*2IK;E:/R6I
M4=7FFMV[^6IT'PE^+>BZUX?U[Q#9W5O<:!HT#7,MQ&059@K,P!Z<*O\ X\*_
M/SQ%X'7X[?M%R0V=Q)=>(/%EW)>S1Q9D,!)WLQ'!(1%P%)Y"J,BL+X=^/V^"
M_P#P0CUN\@O+^UN/&WC5M(C)YG6,7:1/&OIF.VD7O]ZN@_X)V^#E^'/@'5/'
MWBN_FDUGQ:TMMI*-;[ELK%74N0K,I9I'4?,<@+"!_$:^'XNP+Q^(P^%E*U.*
MYI6Z]+?=U\S7*<//%8A83EYI-W;[);Z?\$^M=8\#6NA> (?#.F:+?:EI&E@D
M16^GQ7;?-RS2QP7:3M(3R6!SD<#@ ?$_[:?[-]UXGT^V\5?"W7]>\(^-M/G6
MU-K;:E<-%JY/SI9 R[+BVG=HSY<%PI61@5CD+?*^A\9?CAIK>(F6UU;3$NH7
MPAN+3[*<YS\MQ;G<I^O3Z<5SVL?MF>)M/T2^'B:Q;Q[X1CLVMM:T35+I9I%L
MS@F>RU&/$B%,!MLW 8*0RLH8>D\^P'*L)5I\D5HK;*VW2_W7/Z!RC@?'X:A'
M$8&:EWBM+^5FW&5_-Q]3Y*^*_P 9OC=_PRMJGQ0\'^*M+U+P+>6[S>)+;Q-'
M':VO]I&1FFTZRBE9ENV:,)(501D%V 13@UU'[(_QUL]%\ Z];ZW&FGGQ!Y>I
M60B)=(&=0&0$\D< \]\UZ=XB\?>"_@+H]YXVT/PTMYJ7B+4I%FU;4Y[FV;4)
M'18WDB\DM!#=.LF;N.6-E$@29 4F KX]^$EM]J^%^E;5:2S>!9[%2V[R8C_R
MSW<;L?*,\?2OG,_A04%&E:ZW:OU6C-'E]:GB/K&(BX^TO9.VC@[/1=KVUL_)
M'HGQ>N?$7V:\OH(+C4/#L@=98EF\NZV'C>H/RNIZ;<@UZU^R-I.D_M)M>27%
MN-#;P;807!TF&W"27LEPTOD18R/(5O*D=B0=JKD YR/G'X@_M5:E\)OA_JD>
MH:#'KFGV,8EML7'DS;,@,S-M(VY8$8&0,BO6OV!K^\'Q&UO5%DLETOQ5J]C)
M=W$-J]K&UP]I%:A"DCNY1(KB^F+L?F^RL=J[<#R,MRUU8VFK+6SON^OW7N9Y
MAC924J=%OFZ^5]K>MGL?7WP6^!:_!;X::AH\;1QW"SFXOR@ZR@$8^@))'M7E
MWB:P7Q7JLEK"J+<1ABQZ5[CX"^*\?QFT#4O$$9C@37)'G$8'^H!8[$/^T(VC
MS[YKIOAU\-_#.CP:E;ZI':SZG&BFXPX9X%89 8=5/U]:_*,5BGA<=7G).4(M
M*ZZ*[LV?AO$6$K_7ZE+$_'%Z_@?.%SX,AT1+'5&E25+<[=QZ XQUKW_]D/X+
M7G[0?PO\<1Q23*XN5M8N2$ ,>>?SKR#X\^%5^'EC-HD-Y"K3.MY%:EOWL<!;
M;D^GKCTKZ7_X)K?'7PS\-2O@W4;C[+JOCR^DFTKH5D$,0#!N>"<G'KBOV#A3
M KV]!S3M.+>NZNM+G"H2IPBXKH? ?C_Q O[/]EXDBO(9/,TH/ 74\97(S7B7
MP2_X+@^/#>3:7K4]OI^EV:_NFMHOWLJ\]3CV[5]&_P#!2KX<6B>"?$L*Z^&\
M5^)-<DBM--C7<L-N& DEF/\ #RPVCO@U\I?M ?L#^&OV??@SI>R^OM2\<:CF
MXPB 6\-JH.[<?XF9BF,>E>YD^6J,*DIIIR;MKT3.K X63M*6S9[_ .'?^"D%
MI\8/ >JW]G)J4RZ>VXM.[!6([8_6ND_9_P#VH9OVE?A'XR\1111V6J:6/LD5
MJ/F;Y@V7 ]"!Z5YG^QI^P]H_Q!^%G@'PC:ZC)9^)O&L$^IZA=MS%:Q9Q'$JG
M^+CJ:]8_9J_91T/X7>&?B1JFE"^V>$]8CTV\M99P7O=JG<R_5@<?6N3B+AN&
M,PR5/XX-.+>O5-KYAB<-.M3=+9O^D>-?L>_MU?$S]E_XLV.L>%7N-.TZXEV7
MMA<Y>QU=$X*7$8P<X)VR#YU[$C(/[P_LI?MC>%?VLO":W6BS"SU:WC62_P!)
MEE#7%IGC<#QYD><@. .V0#Q7X[^&?!K2_LC>-?C9#X=L9/-U&?1K"WD8M%8X
MPH?'][)_.N5^"W[2OB+P?\5O!=OX9U?^Q;I9);E[Z#'F%A']SG@KGJK<$<&O
MI<GK5\)%0DO=UT3O:W9FF!R.FL*X.7OIK7=7?0_H0)&*:,FOE'_@FC_P4UTG
M]N/P:UGK%M:^'/B!ISR17.FI+NAU)8^L]J6Y*XY:,_,A]5(8_5PFW\#TS7V=
M.I&I'F@[H\6I1G3ER35F Z]*4*<_UI]%:&9'LYI3]#TI]% $>S/X&@H<U)10
M!&R_+TI=N>W6GT4 1[2<4H7(I]%*P!1113 **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+?M.>''^"_\ P3T^'>DR:?;R22>-=2N8X78;!))+?/$2?<..><9SVP<"]_;
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MIF9[?< VXG/S-TZYK2G@,:THSJ]$MNJW?S1BZT4G;72/Y[GZ'77QA\"^%?\
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M/)V26N5CD^?#\.N2""<'FKI_QQF\0>(;72-'FM]6\V^\JW@O[;R/M4;-OVR
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M'PUU;PCXR\-V.K>'=<@\B\LF7:D@'*L/[CJ?F5UPRD9!%?D5\9_^#130='\
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M^$WQ!N/#.I>&/B-)J$-V]G UMX?+PZA(JAF^SG>#* &!RHHP^6XJO_!@WO\
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M?$-8_"^MW5Y9W%Y->1>1*B7#>7M^=$\P,"'#$M^[XY;J>WC_ (N\:VFF0?\
M"/Z+96-K;Z"IFPJ[Y/,VID+R"%)0*5&#Z'N/I'7?@CI.F6U]<QF.ZMK=#NDE
ME+M," -RD[&4LW)3^$(N2<[1YA\2O!/VRSAN8M$TO2]!@<OB!$W.W!VJ['?R
MB*-Q;KD8YP?.RC,*$JWLEL_/RTT.C/<'C*=/VU1O1K2U[J_?H>:_%GQ=IOC3
M4[74-&TY=%DAC\\R0RLI);#+L&<Q!<XP#Q@?4])\-_V__C9\*K<6^D?$SQ0]
MJH 6WU.==35 .  ;A78#V#"N7\1^$)M(G?S+6&U@8+%#%$1MC5< # [#<,'O
MS7&W5LUK<NC?>5BOZ\U[M; X>M%1KP4O\23_ #.[+<=4IQ_V>;CZ.Q]10?\
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M]=:/-+'<:7<FTU"RG(6XL)1T#@<$-SAAP<$=0<=:#@]?S-?CNG_!1:3]G/\
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MS[8_&OI KY@96Y%0PZ5;6\\LL<$4<LY!D=%VM(1T)(Y./>OA<;EZQ%>C6O\
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MU '^E?*\;3<<EK6[+_TI'T?"M-_VI2OW?Y,_3&(<4N,GI1%]S\OY4ZOYY/W
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MIU5S1C[WXL_I2_X(B:VVK?\ !*OX-QM)>L]EH[6^+F;SF5!/+LVGM'MP$'8
MK_#7Z&?!2!H_ L.[^*5V_7%?F'_P;Y&^/_!,GPO;:@S276DZKJ6CY\S>J16]
MR_EHA]%\Q\>[5^I'PGM_L_@'3N.9(S(>?[S$UMCIWP\6NO\ D<N%IM8J:?3_
M #.DHHHKQ3U@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI<EW\'O!OAZ1I)$\*WT<C,' #O"6V @Y!7D$C'<U\7Q5AZ.'QF#Q^SC.S?\
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M+J,$.C2W&DZE;+?://\ -'&X#&-3_=^GYCM7O9'Q#7RR;4'>#W7ZKLSYW/\
MAW#YE!.22G'9_H^Z/D6Z\*6WC+X3^'M)AM[I&T%)MN5W$)(P8@Y[ CIT&37
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M?</FVL 4!^BX/_ C7\^O_!N+^SQ-^UAI/@?PS<1O-X>\-W$^M^(,_<^RK/\
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M]FGQ1CUJYW]=3QZG"^7O:G;TT/$?%/[$=_XHCC6Z\:-;J@P0D1?\LL*/!/\
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M 5$1=JH/0 =*G4;1754K2GN8T,-"EMN&****S.@**** "BBB@ HHHH ****
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M#;?]HSXTZUMO/"MAX!T5IPIU+Q->K#*%Q\Q2UA:29MO3G8"3PV.GZ+?LQ_\
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M*O(FT4ZBN@S#%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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=** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>p59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 p59.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@!. 'T P$1  (1 0,1 ?_$ +<  0 " P$! 0
M       %!@,$!P(!" $! 0$! 0$               ,$ @$%$  !! $# P$#
M!P@( P4& PD" 0,$!0 1$@8A$P<Q02(446$RE!56%W'10M(CLW0W@;(S)#5U
M%@B14K2QX6)#D_"A\7*"HL%C.%-SPS14)28V&!$!  (  P8$!00" @,!
M  $"$0,4,9$24F($(4$R,U%A<2(3@<&"0T)R\#2AX2/1_]H # ,!  (1 Q$
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M'MNK0H&FJF:+[J=<CEY%KQ,QY*WS:UF(GS0,/S=PJ33S[92D,Q8+P1T%QO\
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MPT556C_M[D.)%:WOP)$AX]J:D\!'M<5?^8=J:+[,C>TZC]5*UC\/Z*3=G,_
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M9$4F,-DN\C-F\3CMA?<RM!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@<ZL_ O
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M8?U\:?JJ:CIL?B<_]U+SZL/Z^-/U5-1TV/Q.?^ZEY]6']?&GZJFHZ;'XG/\
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M9<TMA+1EYD7C&$KG#LP&!0N97]W9WK?#.,._#S3!'K>S1-4BL+Z(*I_YA_\
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M;_R3S:EA\8X]"EU?(>8\LE.A L6 -NN;BMIJ3R@+CA'L^8NO7 V:CG_.^/\
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M7TCJ8J3@:#T,$P.D\=\L<'OH%O.C32BM4*K]KA.:<BN1QT4A-P'4%4$A%53
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M=25$^3 V<"ES/"_BJ9+>F2N,07I,@R=?=-O4C,UU(EZ^JJN!A_ SQ#]U*_\
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MY?3J&#CGFCR%9\*YN]6Q&.0WW&'V&Z^1'BOQTD,R$55<*&2]W<T@DNU--?\
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M6_-/-"H6*!?AOQ$3DJ<>D#VOV79W*[\4C.[78K">ORX'?$UT37U]N P& P&
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M 8# 8# 8&M$LZV83@1);,@FET=%IP345^0D%5T_IP/3$^!(<5IB2TZX@HXH
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M:KFGNXQM%O*T,W:SA6:^=97W,K48# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M421%%?E1<#[@:-/>U%RR^]5R@E-1I#L1\V]=!?8+:ZVNNG42Z+@;V P& P&
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M42TUT]"%4P/M)=U5Y5L6M3)&77R4)6) :[2024"TU1%Z$*I@;N P& P& P&
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M[NTZ?(F!TGR)QGE0\ YHCEW+O?C:N8$&J^%CBH&8JH"W\.V+IJB>ZB+KK^7
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MH+57/:<?9CG(U?U!Q 46WQ1=N\"UZ+\^!I7]E1WO"Z<+?BUW4\N@0$^Q953
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MZ8'(^#V_Q'V([0W$^7Y <Y(\U:P$DRGV?LH9K@O?$LD1,-MBP@J):(NNFG7
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M3EMN$GN^JX'1F>)NL>(EX_<O/RY0UA_:+_><1XY"@KSJHZ)(?]JJZ:+Z=/3
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MG%.,),G34J8?Q=FWVK&1V&]\AM>B@\6FIHNGH6!@<X+PMRG:I7** =0P2FQ
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>@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>proxy_01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 proxy_01.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_X0YG17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  +<;    G
M$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,C(Z,#0Z
M,C,@,3@Z-#$Z-#0      Z !  ,    !  $  * "  0    !   #!: #  0
M   !   #Z          & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $   TQ
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M'0.-O(I\TSJ1!_4P2X"?<T:S_P"9)C0-H'V,$-^B-P[_ .Y)3(T.($XF.8T
MW<-&O^@3?9R9G$Q]0=WNYG_K'YR8TM#21AR2#[2YO?\ -^E^<B5FRII;5C;6
M\QN:-4E,@<IH#6TUAH$- L( C_K2.H5N>YLO9L/[L@_D4TE*22224I4VUN^Q
MUM]"J0]I-<^P>_Z3?Y7YW]=7$$8>,*6T"L>DQP<UNNA!]2?\])2#.:8R';&1
M]F>/4_/GW>S_ (M-_P!XG_H+_P"BT3.IK]#(OV_I?0>S=_)@NV_YR'_WB?\
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MLP^Q?9-VGI>EOC7Z.S="2G__V?_M$PI0:&]T;W-H;W @,RXP #A"24T$)0
M    $                      X0DE- ^T      ! !+     $  0$L
M 0 !.$))300F       .             #^    X0DE-! T       0    >
M.$))3009       $    'CA"24T#\P      "0           0 X0DE-! H
M      $  #A"24TG$       "@ !          (X0DE- _4      $@ +V9F
M  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M      $ -0    $ +0    8       $X0DE- _@      '   /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z   .$))300(       0     0   D    )      #A"24T$
M'@      !      X0DE-!!H      TT    &              /H   #!0
M  P < !R &\ > !Y %\ 4 !A &< 90!? #$    !
M      $              P4   /H                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    !/_         X0DE-!!0
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MC]"_MJW_  WYJE5B8SW-M9A8Q:_W"UFTR'?2>T^E[MV[]Y%_9?3?^XE&FO\
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M4CQ24NDFD);@>X24NDF2!!X,I*7232/%.DI!G?T+(_XI_P#U)0/^\3_T%_\
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M-T)*?__9 #A"24T$(0      50    $!    #P!! &0 ;P!B &4 ( !0 &@
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M4D="                  #VU@ !     -,M2% @(
M                                            $6-P<G0   %0
M,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8
M    %&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0
M  +$    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE
M87,   0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (
M#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE
M='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V
M+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                                  !865H@
M    \U$  0    $6S%A96B                      6%E:(        &^B
M   X]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X0
M +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H
M   6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                 &1E<V,         +DE%0R V,3DV
M-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M    +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@
M<U)'0@                            !D97-C         "Q2969E<F5N
M8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M   L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N
M,0                                  =FEE=P      $Z3^ !1?+@ 0
MSQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M      $                        "CP    )S:6<@     $-25"!C=7)V
M        !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0
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MBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW____N  Y!9&]B90!D0
M  '_VP"$  (" @(" @(" @(# @(" P0# @(#! 4$! 0$! 4&!04%!04%!@8'
M!P@'!P8)"0H*"0D,# P,# P,# P,# P,# P! P,#!00%"08&"0T*"0H-#PX.
M#@X/#PP,# P,#P\,# P,# P/# P,# P,# P,# P,# P,# P,# P,# P,# P,
M#/_  !$( ^@#!0,!$0 "$0$#$0'_W0 $ &'_Q &B    !P$! 0$!
M   $!0,"!@$ !P@)"@L!  (" P$! 0$!          $  @,$!08'" D*"Q
M @$# P($ @8' P0"!@)S 0(#$00 !2$2,4%1!A-A(G&!%#*1H0<5L4(CP5+1
MX3,68O D<H+Q)4,T4Y*BLF-SPC5$)Y.CLS875&1TP]+B"":#"0H8&82414:D
MM%;352@:\N/SQ-3D]&5UA96EM<75Y?5F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G
M]SA(6&AXB)BHN,C8Z/@I.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ$0 "
M @$" P4%! 4&! @# VT!  (1 P0A$C%!!5$382(&<8&1,J&Q\!3!T>$C0A52
M8G+Q,R0T0X(6DE,EHF.RP@=STC7B1(,75),("0H8&28V11HG9'15-_*CL\,H
M*=/C\X24I+3$U.3T976%E:6UQ=7E]4969G:&EJ:VQM;F]D=79W>'EZ>WQ]?G
M]SA(6&AXB)BHN,C8Z/@Y25EI>8F9J;G)V>GY*CI*6FIZBIJJNLK:ZOK_V@ ,
M P$  A$#$0 _ /OYBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BK__T/OYBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BK__T?OYBKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK__TOOYBKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK__T_OYBKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK__U/OYBKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK__
MU?OYBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BK__UOOYBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BK\5/\ GYM^?_YZ?EE^:_Y<>3_RJ\^:SY2TN^\J2:O?
M66AHGK7%R][- 7D81N[*B1"@Z#<]\640_/[0O^<J/^<HKI[<>8_^<@OS/T1'
MU&VANFLM+-^8]/=9#<W2@FWY21,$"Q;<PQ/->-&4T&0>=_\ G)S\^],@TYOR
M]_YR?_-SSE<S22+JD&K^6_T(MO&%!C:-UN+WU2QJ"*+3K4XK3%/+W_.8?_.8
M.F^8_+EY>_G#YRDM8]6L1-!J<:O:2JUPBF*99;<*RN"003OVQ30?U;XM;L5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_]?[^8J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J_._SY_\
M),OR*_\ -/Z]_P!1EQBGH_1#%#L5? /_ #\J_P#69V_\#?RE_P!U6'%(??V*
M'8J[%5*>>&VAFN;B5(+>W1I)YY&"(B(*LS,=@ !4DXJ_.C4?^?I?_.+6GZY?
M:;'/YNU30M.F,-WY[L=#DET=:=7#F1;@IX$0[C<5&*>$OJO\UO\ G(W\G_R5
M\CZ5^8'YA>;H='T'S!$DOEN%(Y)KW4O4C695M+1%,KD(P9CQ 0'XRN*T^:_R
M^_Y^6?\ ..GYA><O+/DFVM/.7ES4?.6H6^E^5]0UK1O2L[RZNY!% B2V\TY
M=F4!F4**[D8KPOI7\^O^<A/RX_YQO\H6/G3\R[N\M]*U/4HM)T^VTZW^MW4U
MS+')+1(0RDJJ1,S&NP^>*@6G?Y+_ )S>1?S[\@Z;^9'Y=WT]YY=U.:YM@EW"
M;>Z@GM93%+%/"22C @&E=U(/?%!%/,/RB_YS#_)'\ZOS$\U?E7Y0UB_MO.WE
M*2[CNM)U>T-G];^H7#VUT;)V9A-Z3+5@-^)Y4I4A33)!_P Y*_EJW_.0+?\
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MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OSO\^?_ "3+\BO_ #3^O?\
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M_P#.4_Y,_FAK7FK2_-OY'.-.U?\ -G2O^54_G->1G@UOY>OY?4@UY>)4F?3
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MLWF+R_;7;6%QKNGP7R>KSLY+J)91Z$27$U4+!AZ<4B2-MLK!CL0<520_F/\
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MF6D8J06CXBA:JJJ.L_D=%J%Q?"V\QV^GB[6XM;2,6HYVEK+J=AJ<=M!QE6B
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M /./FF65MH%C-K\U_9:!<Z?=I'-;1EKA[.33':.X8L0\+?HQ.$=/W9:M6X(
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MFO[6V*KKSS;Y6TZUM[[4/,NEV%G=6]S>6UW<WD$4<EO9QF:YF5W< I#&"\C
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MIVAO''?S/-"70>F\H2E:E@P JK458 W_ #D_^3:6/EC4'\QSQ0></*&J^=M
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M1V8*1T;P=3\F4]"#BJCK'YA^3=#X+?>8+032W/U**".178W'H37 C8@\4K'
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MV+RIK'EK0-4N=-_2T>CPBXEX.D8TB6)DE$4:QJTTB1T>5@6:B<B510%6K_\
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MEQ^;2+V*RBT2[@::WTY[F\^MS66FK+!PB:.34)+AHD)D%644"!44);_RJ_\
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MO"-68]3P W.*MZ7_ ,J1OUEUG2S&TF@I"YO5:Y]6"&6_OHBZ\B2$^LW5TDA
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M7FC\ZA@-L59OK'EO4O-6A7^C:_=VMN)=7M[NS>RC9P+2POH;JWCE$I^)Y%A
MDIL.1 K2I5>9'_G'[2WM(]/E\SZD;$QO979BI#<2:<E]:75K9K<1LKHL$-C#
M;<A\3(&)^)B<5=+_ ,X]Z&]Q'<KK]_--I5UJ.I>5+R_"WUWI>H:E=Z??RW,5
MQ<%G;_2;%G*FE5ED2O&F*LY\J_EY_@[6=1U'1M9>.P\P:AJVJ>9=&>!?1NKS
M4KV2[BN4(8&.6%9/19A42H%Y+R56"KS?3?\ G'^?1);B^T;S58Z?JJZM'JEA
M=1Z*JQ2&._NKZNI1QW2->3?Z4T:R\X^*]%JS54VSH?EC+)=O%=Z\LWEV]UBW
M\R:SH"683U]6@:*;DDS3/PMWGA69H2K-RK^]X_#BA!3_ )32ZCY:M_(NN^88
MM9\DZ9/I+Z-I4NGHERD&DWD-U%#<7*2A)1QA6-66*-E #59Q7%44WY;ZQ>:C
MY+NM9\WC58_)-X]W8W[6"QZO, 9!'%)?I, $>)ECN (OWP6IXU(Q5CGF'\BK
M3S#YF\Y^8)M:MK0>;K:^B9H-,B%_&U]HL>B/'-?&0M/;*B"98"BCU>+%CQ&*
M;5K3\FKN"&&P?7-&M]$N_+MQY7\R:'INAFQM[BPGFGE)M%2^;ZK+_I#\F/J!
MC\7$8H3/5/RHO=?T[7UUSS?-<>8M2TN#2=$\QVEHML^G1V=P+RVN%B,D@DG%
MPJ2.U55BBA405JJGGEG\M-+\K>:+WS'I]W+]7DT2PT73-$*((;-+15CFE1@
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MF GUO]'Z#H^K7%_IDG!3]4]2]FL[>1?4;9Z0GCVY8H>)+YL_YS9XKR_)C\J
MU!R \[:J17_N XIV>H?EAK'Y\ZG?:M'^;_D;R?Y2TZ*")M%N/+.O7>L2S3EB
M)$F2YTZR$:A:$$,U3V&*&&>9O,O_ #EM;>8=:M_*7Y4_EMJOE>&[D30-3U+S
M=J-I>3VH/[N2XMX]&F2)R.JK(P'B<4[(GR?YC_YRLO/,VCVWGK\KORZT3RC-
M,PUW5M(\UZA?7T$7IL5:"VFT>W21BX4$&1=B37:F*[,B_,W6O^<@]-UFPA_*
M/R#Y+\V:#)9!]2OO,OF&\TBYCO/4<&..&VTV]5T],*>1<&I(X[5*KS@^:_\
MG-BAI^3/Y45[?\[MJG_>!Q79[9^8>H_FMI_ENPN?RN\K>7?,WFN2ZA74M+\P
MZK<:791VQC<RO'<V]G=NSK(%"J8P""344H5#Q3_%?_.:_P#Y9G\J?_"VU3_O
M XIV>UZ)J/YK3?ES<:CY@\K>7;#\TUM+U[7RO9:K<7&C-=(TGU.-M1>SCF"2
M (9&%N2E30-3=0\3_P 5_P#.;'?\F?RIK_X&VJ?]X'%.SUK\KM6_.S4_TW_R
MN'R9Y4\HF$V_^'_\,:W=:Q]8#>IZ_P!8^LV%EZ7"B<>/+E4UI3=0\WUCS/\
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MC=_EQY6\N>8O.TDUL-1T77-5N--T^.)D8W#1W<%G=2,R/0(#$.0W)&*'B?\
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MS)JUQI%M%:^FY,D4UM9WK._J!1Q* 4)-=J%0\6_Q7_SFO_Y9G\J?_"VU3_O
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MMY!7\PSI7Y=7_G63R7YLM/)^CVEA>Q13ZS?)I!UW6VMXWB8JFEV2EG/Q<V'
M<32JFGL6C?G1I/F#\U=&_+?1[#Z_I^O_ )=1?F-I7F^.X4P36<]\EG%"L/"I
MYK() _.E-J=\5I\^>7O^<R]>\X66AWOE+\E+G76O?RZF_,C6-+CUV"*]BL+?
M5[K2I+6RCDM!'<SUM3( TD0(/$'E2JM/<?,'_.07E73_ ,J_R_\ S1\N:=>^
M;8/S9N-#L?RU\OP&*VN=1O?,(5K.%WG81P!4+/*S$\%1S1B "K3Q[SY_SF;;
M_EM9:A!YI_++4!YN\L>>=(\H>=O*VGW\5W]6LM7TZXU:'6K&=85-W;_5;65@
MC1Q2<D=2JD;JTRW2O^<I],UG\P=-\C6/E1Y[?5OS*OOR\LO,46H1R0R+9^5X
M_,R:DB+%\4<L<@B5 W^7R(^'%:5?R^_YR<3\P//NF_E=:>0[O3?/VEWNO6_Y
MLZ)/>*R^5K;1W6*UNY)1"/K*:HTT36G$)SC9WV$;#%:8GY\_YS*T[R!<:Y8:
MEY N[K4_+7YF'R-KFGPWZ"2#1UTZWU5_,9!@WA6VND8Q=:U'.N*TGR_\Y:^6
MK7SKH'ESS#H]MY6\N>8O.GG+R?9>>=4U:WMK(-Y.MXVFNF]5$6EQ=-);HGJ5
M!3E4\N(5IA^@?\YIVWFK4?RST[1_*.A:;_RLJR\QW^GZEYC\V0Z79"/R_P"8
M3H CMYQ8W'UF:[-)XD4"JU6II4JTB/*O_.:^B^9YAIY\@WVEZT/S:MORR;3;
MB]3X[2]O+ZP@UZ%Q"/4A,^G3QF*@*NA4OT)5I[!KOY[0Z;^>^C?D59Z'9MJM
M]HEMK]WJNKZM'I1FM;FYEMRFCVTD,CZC+!Z#/.B,@C4K\1+4Q6GF7E[_ )R\
MC\X6/E.#RQY!$WF?S%:>8=8U:RU36K?3M*T31?+^MSZ$U_J&IO Y7ZS<0_N8
MT@8GXN1 4MBM(/S'_P YGZ3Y5\W_ )@^3]6\C3+=>2ORU7S[IVJV^J0SV.JW
M@TR?59-$AN(XF19?0MI7CE!99%1V4?#0JTR3RA_SE"?./YCZ]Y"M/+6B:6/+
MFFZ1J5VVH^98X=6NTU;0(]>_W':4+)FN5@63TI&]5:4+]!3%:6?E#_SE+<?F
M)>_E':^:/RWN?(T'YZ^7;CS%^66K0ZG%JUI<BS@6ZN;&Z806LEO<I WJ!?3:
M-E#<9"01BI#*O,O_ #D9HWEO\_/*WY(2>7Y[N#7+:V76_/27*+9Z3JFIQWLV
MD:9<0E"QEOH].G*$,*404/,8K3RWRU_SFQHOF*ZNM,/D&^TW6;7\V[+\LOJ$
M]ZA$UG?ZC=Z9#KT$@A'.+ZQ8SQM%2JLA4ON"5:3W\M_^<KY_.%S^6,_F;\L[
MGR?Y7_.35M8T'R!YJM]3BU.$ZGH\MXAM-0B]"VDMGN$L)GA*B5#3BS*V*TFG
MYC_\Y+:QY#\Z_F9Y=T_\J[KSAH?Y0>5=*\X>>-7L=4BAOQINI->\VLM/E@"7
M#6Z6,DCJ;A"1L@9ML5I4US_G*GR_9_FA^7OY=^7_ "_)YBT[S]HECJ0\\?6U
MMK#3KO7H+N;R[97:^E)(&U/ZE*J,!\'P_"W,#%:81J?_ #EQYMT#RA^<WG+7
MORCTRST[\EO,MMY0UQ8?-32_6=5N9],C#1M)I,*I;*FIJ[2O\0X$>G^UBM,F
MO/\ G)7S<WF#RSY6\K_EEHOY@ZUKWE'6?.DA\M>;H;NR>QT;48=.>#3[Q]/B
MCNKB1I@0K>DJD,A>HQ6GT%^6?YA>7_S8\@>4OS'\K&?] ><=.BU+3H[N/TKB
M)9!\44T=2%DC8%' ) 8'<XH9UBKL5=BKL5=BKL5?+GG[RY-J'GOSG+:^4-1O
MO-NHZ9H*?ESYO@LI/2T^[MI;MGE.I4"01P.RR31EP94^'A)RXE2QC3_R[@US
MR?YMTO6/(=G>ZX//4-[6X\M2VEQ):R>9WE>5[ZY:1+[_ $-F)DBX@1,4(H:8
MJC+/R_\ FK#JGF[5=*\IMY>M?/\ HVK:7IHM;_C)9#3T*^7 UF$A2R/U5)8V
M993QED2O395EXT1Y]1\B2?E=Y7D\A_HW7[J7S/+J^AW"1$MHUU#ZEQ&L]HUT
MQ=D3UA,ZEOVGZXH0,^@>=[O\E?(WD&3RY)JVJ:]Z5EYYMYKB334CT^(R3W@:
MX'KO$;C@L*#XFI)U^$L%7FUWY=_-HZ7YBUV]\O:M<>8YO+^@>4/,VF03/,E_
M]5NKN$ZC:,?3$C0NR7#.%4M%+(".2J I>D>0?+TMMYMTFYTORAJ/E_6;'S!Y
MIG_,#S'/9R6-OJ&GW=Y?M:1-*X07SR2/;S1NH<1HC#FG+BRKSCS%^7WG*%/S
M5O/\-"XC\T/KLEC]3TV266Y0>8K295U2))B]_P [5>5JJ<*1>M%U8$JLMU/\
MKK;6&U34_+GD;3K'4[[\MM0L=*U.WT7] A=6DE:.-8X+BLUK(R$A>;5"&G+C
MBJ'_ #"\M>:OS+U*XUCR_P"67%A<W-C#:67FK3)A$9=/T3S#ZDDEG-) T8]>
M^MXXICL):. ZH*JA0\O>5_.VE:UY?N[?1O,$^A^:O/MOJ.L0ZBY>YT[ZEIY2
M*]N:O]BXB00S<103(C ?O&.*LN_,7\N1=:U^;6O^7_*%N=?U;\ODM=#UR"SC
M]>759'U))0DB<',K1M$'(8%EXKRI2BA(]7\H>=[SSGYQF\V37EUI%]I5[$VO
M>6].N(D]-['3U1(;)[B]>5^<<BE 2)!R7CN:JIWK'ECS'YM_+/\ +C1#Y3TG
M298/,\!O=%GTAFTJ+3K9KM8KF?2/7A:))8Q'+Z#2UB=@K$E<4H:S\DZKHNIV
MFD/I^JZYYNTO7="/E7\P9XWDX>7;%-/CO8Y;ZH6/U(XKE9("P,KOS"MRY!5Y
M_P"6?RBU%O*TNE^;/(EG?W,]WY-U&RA33E6$(NM$ZF;B.5YBUZ("_P!;FJ!+
M#Z8XCBPQ6V6S^4[VWO?,\?F'R;J.MZ#<2ZU!Y%TVSMFE%EJ+WLCV]Q$(ZBV]
M2'T1!<?"L(1AS3ENH0&C^4OS'T/7-)EO;#4=7B\R^?K"[\V7$;$Q6UQIVGPJ
MVJ(I84MKH1-$]!0.D1I\;G%+.O-^@:M=^:_,,@T.\O?,][J>D3_EGYJ2%Y;?
M2K.!+5;Q&N0"ML!(L\DJ,5]='" 2?9"AXY_A3S_Y;L/)U@/+OF"_T.S-UYB=
MH$DN9[&277=,GO-/>-&:5RP62XA4 U5I$ HB@J7T!Y6\NW=S^8FHZ^'U6+R4
M;&#7_+.C7\$UL+?6]6:ZM]28I,5D4K%"CB)T 1KB5OVUX*'MV*NQ5V*O_]?[
M^8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%7S?YN_P"<<-$\W1?\Y(17/F;4+,?\Y(:/I^CZX8HH6_1B
M:?IKZ:LEKR'QLROS/.HK[8IM(_.?_.*'E?SCYGB\S/YDOM(ECTSR9IC6-I;V
MXB=?)FO?IV"0U6O*XD_=2>"_9WQ6V:^4?R.MO+_YO>9?SHU?S1<>8O-FN:,?
M+EF%L;+3HH=,-V+P)<?4XD:\F5E1%EF)*HM%4<F+*VP.[_YQ$\B7/Y;?G!Y
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M36]-\R:?Y;M[&R]8ZGI,_P!8@DBU-HS=6Z.X03)&PYJO'DJLX90\QL/^</M
MT/1-'MO+OGG5-+\Q:9IOF+0K[79;.QO+?5-'\R:O/K4UCJ&GW$312+;W%P3
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M?.G_ #C=^7?E/R%^5,=]+:^6M:\V$/?ZBL#E'8&1V1B"*/PAX*U4$CLK8LJ
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M ,Y1_FUY9\U^:+V?5]/G\B>3T_,QO-,?U&'U[.TT;S'^@]&OU9=V6QDDA^L
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MV6@6MMIRV6FZ#?>7HX?T6LYC,S6NH2LT_J?;$8$8B018K;T?4O\ G'^WO/R
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M_P" -K'_ %#/BD<TG_YP>_\ 62/R"_\  2M/UOBIYOJK%#3,JJ68A5459CL
M!W.*M(ZNJNC!T<!D=34$'<$$8JNQ5!WVHZ?ID(N=2OK?3[<L$$]S*D2<CT7D
MY J:=,55H;B"Y5GMYHYT5WC9XV# .C%74D5W4@@CL<57R21Q+SED6-*A>3$
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MZ?\ ..OFO7?//Y$_E+YO\SW@U'S%Y@\KZ=>:UJ 18_K%R\"^I*40!5+GXB%
M%3L -L4%[/BKL5?)_P"8&FZW^8O_ #D+8?EI-Y^\U>3?*.B_EY_B?ZKY2U)M
M(N+K4;G56LN=S<PJ972.**B1A@M69B":44IM^1,FNZ'Y]_/;\L[_ ,W:YYRT
M'R%JNA2>5[_S)=?7]2ACU?28KNX@DO&57EC6:K)SJRABO+C0!4OIK%#L5?.G
M_.2&I:_%H_Y8^6-"\R:EY3C_ #$_,/1O+.OZWHTJV^HQZ=<175S.EI<E7,#R
M&V5"ZCD%+<2#0A2&&Z?Y>UG\I/SY_*?RSI7YD>=/-GES\Q]&\T#S%HWF[5Y-
M:C2;1X[&>TGM6G7U('!G=6XMQ93NM0"%7U[BAV*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OR?_P"<NO\ UOS_ )P5_P"8B[_ZB!BR
M')^L&+%V*NQ5_]7[^8J[%7S;_P YB?\ K*__ #D!_P" -K'_ %#/BD<TG_YP
M>_\ 62/R"_\  2M/UOBIYOJK%#L5=BKL523S%H%AYHT>ZT34_5%E=M"\OHMP
M>L$J3)1J']I!7VQ5@VF?E#Y;TCSGJ/GNQOM237M1-]65WMW$2ZE-:SW**[0&
M5U+6B!%E=Q&I98N"T 5>J8JQ'S#Y0M]=O;35;?6=3\MZU9026D>KZ3)"LK6T
MSH[PR)<0SPNI9 06C++OP9>3558QK7Y.>3=?L6L-2CNIH?5U2XC+2(_"?5M2
MM]6FEX21NC%+JVC9 ZE:#BRL"1BJ3:S^2VD7'EB_\LZ5,88M?N-(77;V016S
M+;:9*'9[:*QA@BCED4%3P1$^(DBE5*K.CY"T%M/U'3")S::GK\'F2Y0N#_IE
MO=P7J 56@C]2W2JTZ5'?%49HOE+3M T<^7[">Z_0HAG@M]/ED#K!'/-+*4B8
MKS"H)?30%B%154#:I5>;I^0?E(Z.=)O-8U[49/J TQ-7FNH4NEM([,V,$(]"
M"*+C%$32L9Y$MZOJ D8IM&Z+^1GD;1-.UK2X4N[FT\PWME?:O%,T*)++8ZA+
MJ:*(H(8HD1YIG#(B!>/P@ 8H1L?Y0Z"=/FTV_P!9UG6+9M&NO+UJ;R>$O;Z9
M=/ _U>-XH(RWI_5U"O)S>E>3-7%4KT_\AO(^G^9Y_-G/4;W4IY[V9TN98F0K
M?M=M-%(R0I+,O^FRA3,[N!1>7%0 K:<^6_RQC\HWJWNB^:M8F:8:;9Z@NI-#
M=<M*TB*Z2TL(*1Q")5:YJTE&D8+\3%CRQ5/;OR'H-[)K\LPG$GF35M+UK4G6
M0 _6=(-H;8(:;)6RCY+W^+I7%4OU#\MM+O=)DTBWU?5-)B.MOYB@N;1[<S0Z
MB^HMJ9F0SP3*1ZK%>+*R\#2E=\53WRWY5L_+$,D5E?7MV]W+-=:K=7LBS37M
MW.4YW,[\ >85 BA.**E%5 JJ JR?%78J[%78J[%78J[%78J[%78J[%78J[%7
MRW%^2?YM^6+WSC;_ )9_GC8>5O*OFW7M5\QIHNJ^4XM8NK&\UJ9KJ]$-X-1M
M T?KR.\8DB8K7B2R@8IM[=^6WD73?RR\@>3OR]T>YN+W3/)FD6FD6=[=E3/,
MMK&(_5DXA5Y.1R(  %=A3%#-L5=BKP;S_P#E+YNUK\P--_,[\N?S&A\@^:8/
M+\GEC6$U'14UVQO-/-T+R&D)NK)XI8I2U'$A#*Q#+LI"E-?RI_*[6/(FH>>_
M,_FSSF//7G;\Q=0M+SS!K,&G)I-FD6GVD=E:6]M9)-<% D:$LS2NS,2=A0!0
M]DQ5V*O*?S=_+2Y_,S0]!MM*\S2>3_,OE#S#8^9_*?F$6J7\4&H6'J(HN+21
MXQ/$\<TB,H=#O565@#BK#_+'Y0>?C^8OES\Q?S1_-2T\]7GDO3=3L/*6DZ3Y
M>30;>!]8]!;N>X8WM\\[>G;JB*&15JQ(8THIM]#8H=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK\G_P#G+K_UOS_G!7_F(N_^H@8L
MAR?K!BQ=BKL5?__6^_F*NQ5\V_\ .8G_ *RO_P Y ?\ @#:Q_P!0SXI'-)_^
M<'O_ %DC\@O_  $K3];XJ>;ZJQ0[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J_)_\ YRZ_];\_YP5_YB+O_J(&+(<GZP8L78J[%7__U_OYBKL5?-O_
M #F)_P"LK_\ .0'_ ( VL?\ 4,^*1S2?_G![_P!9(_(+_P !*T_6^*GF^JL4
M.Q5V*NQ5)-?\QZ'Y6L%U3S#J<.E6#W-O:)<SF@:>ZE6&"-0*DL[N  !^&*J^
MF:SINLB_.FW(N?T7>S:??45EX7-N0)8_B KQ)&XVQ5-,58UYA\W^7_*QM$UF
M]DCN+\2-9V%K;7%[=2I"4$LB6]K'+*4CYKS?CQ7D.1%1BJ8Z=K6FZM)J<5A=
M">31[PZ?J*\67T[E8HYC'\0%?@E4U%1OBJ9\E%3R%!UWZ8JQCS1YR\N>3+:R
MNO,5])90ZA.]O9^E;7%T[O'#)<2'A;1RL%2*%W9B.*JI+$#%4SO=<TG3]-BU
MB[OXHM+G>V2"^!YQNUY*D-OQ9:U]1Y5 (VWQ5-*BM*BO6F*M<EH3R%!U-<5;
MJ*TJ*^&*L,\S?F'Y/\GWMK8>8]8&F7%W;R7<9:">2)((Y$B,DTT<;1PJ9)$1
M3(R\F8*M6-,53N7S!H\'E^7S3->K%H$.GG59M096"K9K%ZYE*TY4$?Q4I7VQ
M5 >6?.?ESS>EX=!OWN)=.,8U"RN+>XL[J#UEYQ&6VNHXIE6102A*485H33%6
M48J[%78J[%78J[%78J[%78J[%78J[%78J[%78J^4;'\T/S_\]77G;4_RR\C>
M0SY1\J>9-8\LV+>9]=U*UU*^N-"N'L[J8Q6>F7,,*23Q.(P9&/$!FI7B%+W#
M\J_/EM^:/Y;^1_S%M-/ETB#SIHMGJZZ5.ZR26QNHE=H6=:!N#$CD *]:#IBA
MGV*NQ5\^^?\ \R?S'A_,S3ORI_*ORQY=U77O\,OYLUW5_-6I7=A90V9O/J,$
M$"V5I>2R2O('9BP555>I+;*4U_*3\Q_-GFW6/S%\E^?_ "]I>@^=?RTU"QM=
M5?0;V:_TN[M]4LH[ZUFMY;FWM9E8*Y21'CV9:AB#LJ]MQ0[%7D'YS?F-K7Y=
MZ)Y8'E?0K3S#YL\\^9]/\I^6++4KI[+3X[N_$LGKWD\44\BQ110.Q$<;,QHH
M K4*AA_ES\ROS:TC\SO*?Y=?FWY4\IV2^?\ 3-7O?*^M^4=5OKY8Y]%^K/<0
MWD-_8VA421W(*/&S;J0R[@XI?1^*'8J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J_)__G+K_P!;\_YP5_YB+O\ ZB!BR')^L&+%V*NQ
M5__0^_F*NQ5\V_\ .8G_ *RO_P Y ?\ @#:Q_P!0SXI'-)_^<'O_ %DC\@O_
M  $K3];XJ>;ZJQ0[%78J[%6'^??+ESYL\K:AH5G-#;W-W+:213S@E%^KW,4[
M5X@FI5"![XJ\HT'\J/,&B?F+J_G**WT&,7.N:MK$>JV\MPFI7]OJ-M%;Q:;>
MU@95AA=/6JKL"RI2-3R=E+Z'Q0\F\^>3O-&J:E=:SY3O+=;S4O+]QY?O;>ZO
MKO37@#R":"[M+RSBFDBDC<MS4)^\'#XEX[JO,;[\B?,U_P"8M#UJ_P#,*:A%
M9ZBM[?"*Y^I3+-Z>E!K^)WLKP^N6T^0%4:(E'X^L 7!51.C_ /./=M92^3;7
M4+?1KWR_I%EI9\TZ*87:#4M3L[#5[6>\EC=>,K2/?PMREJU(]_LIBMLE\S?E
M)J_FGR/^7/E6\\QR6NH>4;$P:KK5M/<)+/<?H2YTWU%9&1Y%,TP=TD-'2H:M
M:8JR[S/Y;\R:WY!70;6#1[37;.71[BSMTEFATYFTRZM+MHPRP.\*,8&1:(_$
M<3ON,5>/>=?R<_,3SYYBO];U"_T#1H[_ $VZTV2"QE=G-I=Z8]JUG-.MA!<3
MJEVQF#M,%(( @1TYLI6^:/R%US5GURST9=&T?RO=:W#JMKY9@F6/ZY2TN[63
MZQ<R:7<B)$]>)X83#<+$T?[MXU*+&H91H'Y6ZMY$U6+S3HUO#KFL?6=7&J W
M#+>ZE!J5Q:BS6[O)E'J"U2)G8L#O4HO)CBEDWGO\K(?._F-=8OYP]C;^6[S2
MK733/<11/>S7$-Q!+<Q1,L<\<;1!@L@8!MPN*&.:3^4&H^7_ ";YU\GZ(VEV
M=CYK\L6^CP01&6&""^32Y;*>[9%C/(SRF,NWVBHY,2P *K-?+'EWS7#YBN?-
M?F2/2K>_NM-LM$32M,N;B>&"TM&GF:9IYK>$S2R2S4"^D@1:_$Q.ZKT[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%7QAY.\P?F/\ DZOYD^4KG\A?.GGC
M])^>/-/F/R_YB\MS:')IUW9Z]J$VH6H+7NJ6DT4B>OZ<JM%\)4D%E(Q2]P_(
M#R9KGY>?DE^5GD?S*D,7F'ROY:T^PUJ"WD$L4=U%"HEC60 !PC57D-C2HVQ0
M7K^*NQ5\M>?D\Z^2/SZL?S4TC\M==_,GRSJOD(^5+JV\LRZ=]>LKZWU0WR/-
M#J-Y9*T,L<A 9'8AEHRT8'%*;?DAI7FZ\\[?G;^9GF;R;J'D&R_,75-%'ESR
MWK4MI)J8M]'TN*RDGN4L;BZAC$LH;@HE9N(JU*@8J7T?BAV*OG[_ )R&\O\
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MNQ5V*O\ _]'[^8J[%7S;_P YB?\ K*__ #D!_P" -K'_ %#/BD<TG_YP>_\
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ML^8="_*S1WUV^TOR!/YNNM6N[2:2+1H[&'4[SU"]_&T\-]<(CR.L0=4+,K%
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MZ_\ 6_/^<%?^8B[_ .H@8LAR?K!BQ=BKL5?_U/OYBKL5?-O_ #F)_P"LK_\
M.0'_ ( VL?\ 4,^*1S2?_G![_P!9(_(+_P !*T_6^*GF^JL4.Q5V*NQ5V*NQ
M5V*NQ5V*NIBKJ#%78JZF*NQ5V*NIBKJ8JZF*NQ5V*I-JOEWR_KLVD7.MZ'8:
MQ<:!>+J.A3WMM%</97B*56XMVD5C'(H8@.M"*]<53F@Q5V*NQ5V*NQ5V*H6^
ML;+4[*\TW4K.#4-.U&"2VO["YC66&>&92DD4L;@JZNI(8$4(V.*JEM;6]G;P
M6EI!':VMK&L-M;1*$CCC0!41%4 *J@4 '3%4)J.D:3JXLUU73+34UTZ[AO\
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MI#_%4#KOUQ52O?+GE[4IXKG4="T[4+F"0S0W%S:Q2NDC(L1=6=20Q10M1O0
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MYB+O_J(&+(<GZP8L78J[%7__U/OYBKL5?-O_ #F)_P"LK_\ .0'_ ( VL?\
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M\ H>3>:OS<_,*=[*VTF[T*S@EAN;6*YMI9#'J.IV.NZ-:^I97+*];5X+UTD
M5F4B0;\ Q59'<?GQYFM=<T_R\?)]K>7UL]['YAN(;R.&&4V>I3Z<YL?K+Q,W
MIB#UW6C,%*H 68,5*;>9OS"\VVWDK\FO,[7>@^6]6\YZW:#4H;N\D324@OM)
MO[J.&6X>-9'XE8SL$Y.H^R#BJ5VW_.0ES?Z)92VND:3!YHU.]:UL/+]YJB6_
MJ0CRZ=:%X'E5/W#2J8T<A59*-R4F@50TWYY:Y/)--Y9T[3-7@CT277;R]O+B
M>W@:&PT^"ZN$MH1"SJTCR,@YL0*<]_LE5J'_ )R!\P7EOYMU.+RK9:7HN@7#
M*NH:C?0+);P6UZUK.UQ:I+ZSR/&C311JJU44!=N(96GHN@_FS8WNC_F+K&LW
M6G6</D4SWDXM&FNDCTSTY);6XEDC1N32I$S,B+S3[#(&&ZAB/Y>?GE?^;O,U
MEY?U:QTK3%DO+_2/K%O<^O+=ZC:0B[ AAC>0PQ_5R6Y.S D,O)6 5E*EJ_YR
M^=-/U+S"8/+6BS:'HC>8)HF>]G6[EM?+-Q:PW=5]#@))_K8],5XKQ)8GE154
M#_T,8!J_F>&#3+75M$T<POI^J6LCQO(+VYO=.LH9(7Y2+)+?VT<%65!64$ @
M<F59;^8?YKZSY)\P:5HB6>AN6T"77M3CO;V2"XNC;W=O;/9:;&(SZLTGK_N^
M1W;@O'XZJH2"Q_.WS'(NDW-_HFCVT=Z+2Z_14=W*]]>VNH:C-IT$6G(T:":>
M'T?5G6E '1 ?V\4L1@_YR5\QRZ%I-]'Y?T+4[[S';:5>6$NEZEZUCIZZC;7U
MP;749Y_JZK./J7%15>1?H.%'5I/+C\XO,Z:CI?F/5].@\O\ EK2KO7$US2$N
MO7E%AI<=H;RYNG1#'SM1)(X6)F4JA/,\A10]&UG\Q-:L=*\@R"TTK0]2\\5D
M>[UNX>'3[)%B%P+=Y%"E[B1& 1-@2LAK\%"JPM?SM\QW9C@TW1='GOM9N[*#
M2;1[J;EI@NM4BTTPZRJ1LT5P/4,BQJ/B*2)4<.958W=?\Y$^;K/3M+,WDW39
M-5U^&UN]+]&^I:0PRIJ7-+F:Y^K@.\FF,L=& _>"M2AYJ:9=^9/YG>8/*.M>
M2KZUDTK3(=1\H:]K.J>7-=OA )IK&329!;V\D*R"2Y"SR1IQ/'XB:-MBK#HO
MS@\]^>K_ ,OV^F:(/*>BR><[*SU)Y;E!J#644FH"6QEABD>6*X<V*N0RHM"8
MB30EE62Z5^=WF35[_P O:=8Z%I%[/YCEMKL-:W<TPT^RFLM0OI+*Z58R?TA&
MM@5]+X5)8UX\/B54]/\ SA\[>:/R=_,3SSI6@Z?Y?UK0M&?5/+4MS<1WMJ0U
MG];].XCMY7D$D JKA@O(T/$"H"J3WGYT>;?*'^,=3OK&Q\V:(VN7ECY=:TNB
M)$EATZRNJEF01BT4R2,6YE@OQDTV56GI#?F-YKE\C>4]:MO+^G0>9?-&NQZ%
M':W5V&L5#SS1"\$EHUP2K)%ZBQ\N0KP9@03BAYE=_P#.1/FZTTW0W;R5ITVJ
M^9;&QUC2XX;\+:Q6MY;7LZV\\]U]643N]@R(:\:-RWX,&4TB-0_/'SS?ZEJ5
MII/E[3O+FG:-YHT[2M2U+5[F*1X+;]-6VF72SPQ3<T:=9B\3\0BJ*EFY(<53
M'3OSO\Q S7?^&K>^T"QN_P!'R1I=O+JMQ=36]Y=1B)?12*@^K*E":GGVX_&H
M3SRU^<^H:EH'YB:K>V.C:O/Y&L;"^0>7+Y[RWE_2%J;H12RM&O#T13FP#?!^
M\H/L!5,?)WYG>8?,OG*W\I-9:)<V]C;7USKGF;3;J6>SN1;BS](:=\!#_%>!
M)2[_  -&RCE7X56*:A^?FHOYQU3R?Y;TW2]6E>^BL=%U">:6"..1-7@T>\6Z
M0!I28I9BR\456XT5B#S"FF9>1_S7OO->MZ?Y<N='M[/59+>ZO]0]&=I(TL;.
M633WFC+(I)>_A=%4T/#XCOMBA@\__.0D\WFO4_+&D0Z+)!)=I#H_F:^N)+6Q
MMHX[NXL[GZ^&K*K"6V:.,\45W95!*D.5+%_)WY\^8?\ "EE<W8TV]OX]-;5[
MW6=3ORMG>QPVMM=-9V$B0IRN)A= 1 CXE0O3?B%6>7OY[W+PVUGHVE:=)YFN
MGU"*30+Z\:&:R>W\RZ?H-M]<CCCDDC]1+[UF''JO%:@\L5I3NOSB\ZVMV;0^
M7=$E?5M8O=#\LM]<N%'K:?Y@L="FFN_W)XJYO?558^1'#B2>5558]>?\Y!^;
M]-L[6.\\I:6^IZO,8-,FM[QOJD!M[J_L[A[I[@0!0\M@?2 8?WBJ3R7XE41Y
MH_.G\PH- \U7^E^7M'T6>VM;VTT47MR]W/;ZG:>6D\Q.URL"^B\:CU(0(W/)
M@K\N)("K(_S;\^>;?+]AH#Z)J^D6^GZYY3\SWE]J$3%I)+^RTGZU8MITIY(1
MZG)QR#$J*T-,526X_/#SGI.O:9Y-N_*%CJ7F!;M8]3N;2]2*UFB:'3)EBMGO
M&MZW!74MP=OW=>/Q_ JH+^?_ )L35-.M7\C0:C;W<%QJ30:=>(;F6Q2^O+)$
MMEN6MS+<(+,S2(BMLZ1K5B&95$V'YD^;_-?G/\N]*CO=&@T4ZG)=>8[[1;N:
M:VNH9=)NKRVM%GXK^\MVBK.AV(,3;!BH4/J".2.6-)8G62*10\<B$%64BH((
MV((Q5?BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?D__P Y=?\ K?G_
M #@K_P Q%W_U$#%D.3]8,6+L5=BK_]'[^8J[%7S;_P YB?\ K*__ #D!_P"
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MKL5=BK\G_P#G+K_UOS_G!7_F(N_^H@8LAR?K!BQ=BKL5?__2^_F*NQ5\V_\
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M ;G5)[95NM2U&'3;40))8>H5YW".YD5&"A@%8\:J6I_^<BM99M;AM/(,\O\
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M;S](Z]/):PV\5GY,MFOK>.RLA<+*8?55^*%%J[-R!4D8JG6K_G5^6BZOI?\
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MR:/ILR^=O--O86,(M[>&YN+>UM)EEN6GE,KVY"(G-156?TPVRJ>>3_//DO\
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M(DFNS/Z[@&>0'DYY!BK57;%6[_\ +GR7J=SIMU?:%'<'1K>&UTBU,LPM;6.
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M #@K_P Q%W_U$#%D.3]8,6+L5=BK_]+[^8J[%7S;_P YB?\ K*__ #D!_P"
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MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK%_.G_ "BVM_\
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M_]7[^8J[%7S;_P YB?\ K*__ #D!_P" -K'_ %#/BD<TG_YP>_\ 62/R"_\
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ML5=BKL5=BKL5=BK%_.G_ "BVM_\ ,.?UC%648J[%78J[%78JQF?_ )3'3/\
MMC7_ /U$6F*LFQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*J%U_O-<?\8G_X
MB<52?RI_RB_EO_ME6?\ R83%4_Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*L8\K?[S:Q_VVM1_ZB'Q5D^*NQ5V*NQ5B_G3_ )1K
M4?G!_P GX\5#*,5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK\G_^<NO_ %OS
M_G!7_F(N_P#J(&+(<GZP8L78J[%7_]?[^8J[%7S;_P YB?\ K*__ #D!_P"
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M .%_K_\ V58K;U3\H_\ G&GR!^2^OZEYD\JZSYQU74M4T\Z9.OF7S)J6MPI
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M((Y'@EN$DB=98949&%1Q!/VJ!1;*O^A"OR<_ZG#\U?\ PO\ 7_\ LJQ6W?\
M0A7Y.?\ 4X?FK_X7^O\ _95BMN_Z$*_)S_J</S5_\+_7_P#LJQ6W?]"%?DY_
MU.'YJ_\ A?Z__P!E6*V[_H0K\G/^IP_-7_PO]?\ ^RK%;=_T(5^3G_4X?FK_
M .%_K_\ V58K;O\ H0K\G/\ J</S5_\ "_U__LJQ6W?]"%?DY_U.'YJ_^%_K
M_P#V58K;O^A"OR<_ZG#\U?\ PO\ 7_\ LJQ6W?\ 0A7Y.?\ 4X?FK_X7^O\
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M6":KZNH2:G^]NYM8C$=S<7(6((\@ _=T4+'^PH%!BM%0;\]_^<$9M';0KO\
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MO^AX/^<2/_+_ 'E+_I,/_-.*T7?]#P?\XD?^7^\I?])A_P":<5HN_P"AX/\
MG$C_ ,O]Y2_Z3#_S3BM%W_0\'_.)'_E_O*7_ $F'_FG%:+O^AX/^<2/_ "_W
ME+_I,/\ S3BM%W_0\'_.)'_E_O*7_28?^:<5HN_Z'@_YQ(_\O]Y2_P"DP_\
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M )&_[@]M_P TXK;O^A.?^<5__8?_ "-_W![;_FG%;=_T)S_SBO\ ^P_^1O\
MN#VW_-.*V[_H3G_G%?\ ]A_\C?\ <'MO^:<5MW_0G/\ SBO_ .P_^1O^X/;?
M\TXK;O\ H3G_ )Q7_P#8?_(W_<'MO^:<5MW_ $)S_P XK_\ L/\ Y&_[@]M_
MS3BMN_Z$Y_YQ7_\ 8?\ R-_W![;_ )IQ6W?]"<_\XK_^P_\ D;_N#VW_ #3B
MMN_Z$Y_YQ7_]A_\ (W_<'MO^:<5MW_0G/_.*_P#[#_Y&_P"X/;?\TXK;O^A.
M?^<5_P#V'_R-_P!P>V_YIQ6W?]"<_P#.*_\ [#_Y&_[@]M_S3BMN_P"A.?\
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M^<5__8?_ "-_W![;_FG%;=_T)S_SBO\ ^P_^1O\ N#VW_-.*V[_H3G_G%?\
M]A_\C?\ <'MO^:<5MW_0G/\ SBO_ .P_^1O^X/;?\TXK;O\ H3G_ )Q7_P#8
M?_(W_<'MO^:<5MW_ $)S_P XK_\ L/\ Y&_[@]M_S3BMN_Z$Y_YQ7_\ 8?\
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M )&_[@]M_P TXK;O^A.?^<5__8?_ "-_W![;_FG%;=_T)S_SBO\ ^P_^1O\
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0=BKL5=BKL5=BKL5=BK__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>proxy_02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 proxy_02.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_X1"K17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  +<;    G
M$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,C(Z,#0Z
M,C,@,3@Z-#$Z,S@      Z !  ,    !__\  * "  0    !   #!: #  0
M   !   #Z          & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $   ]U
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 #_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M?#VL_,_TB2F_D/S&.K^S5,M:3%F^PL($M]S(KMW_ )_[B"W(ZH[1^%6 0?\
M#S_9=^A5457$D!I#G& YU=H 'YT_K+OI>WWIQ7[=CF.<P&-HKLT#A[F^[(=[
MMFSW)*8Y./U-_P#,8E6.YA.U]5K YP(<W:[U<*]K=R';TWJ+BV&2!8YT^M6T
MP/3]-T?8MOTF675_Z.W^O^A,:G%_N:]S70#M99.T%K=I>W(V^ZMGTOZB84/.
ML'<XETMKL;$\_1RO;_924B?@=4=+PS:XM #&WMVLD[OT)=@N_FVUL:W_ (VU
M6**L^@-8,*EYKEOKNN'J.#0178_;C,_2VPSU/W-ZBZLO#B6.]PU_1OT)+C;Z
MGZQ[]]GZ6O\ T3$[:"&/(:X/>TC<&6 "=S=KF_:=W[OY_P#U:2FP;^K@D?9*
M7#2"+R)T&[G'_>5FAUSJ@Z]@KL,[F-=O UT]^VO\W^0LWTG026PYQ:)-5D<E
M_P!'[3[G>I[VI&FQVUNQPB2"66<.][:R[[5].MWTO_ TE.LDLH5Q6 :W[WD$
M'99I.\;7?K'_ *,46U!S1MK?P=Q].S4[OS/UCV?RDE.NL3_UFOG_ .CE:PJR
MW(#MKFD!S7.+'@$"-K?TEUNSW>_Z*J_^LU\__1R2G__6])R/^4\3^I=_Z*6>
M&8LB-@> 1QB[CJ[CW?G.<M#(_P"4\3^I=_Z*50W.:(=:/=H)M=H"2QKMWV7<
MUWM24Q(H$$-:T/:T"P#&$Z[H^G_)W?\ 6E%@P7>V*@(W 1C?1 ^E[7.]K9]=
MW_%HK;GFP;;=8 #0\P7@\;?LO^$_PCTF7N<'%MFI;I-CNPWEQW8OZ/C:])2(
MG&99HUK;6G>#&*#)VNU_2?RO43[*:VN,- ;[' MQ1,:;?I;?T7[B(VY[MFUP
M(AI -CA((;5M>W[)]%Z7K.%0-=F[N7&QW$-_/^S._.N_.24A>W'=67G983[6
MR,63I^].S:SV-_[XI>EBOL+ UA.XAUC6XVI<[:-WO<_U/=L^@IF]^T/=:1,D
M18[4$['>W[+^:[^;]OO3BZSTA^E&Z2T?I#!&D^_[)]*MW\W[/\(])2.,<';:
M6N( < X8LPX[MG+?H_33-&*9>W96007@#%T!=N;8YT_FN_1(M=CW%TV!S3[?
MI[OI'\UGV0?1_,_D)FY!#9-P@@;=SSH#._Z6)N9^D_\ /:2D;!C0Z?2#;(;,
M8WEKH[W-_-_MI_3Q1 V,#S+R ,:1M'IV?G?F^FYVY6Q1FES=P&V"U_Z6=#NU
MV_9O>[W)?9L[:==3M(_3=PW:_P#[3_O?YZ2FL[[/8YS(81(L#?U<[G$-WZ.<
M]WJ;=[G6/_E_\&G<<:XR]C'N$.=8YN.Z YF_W?I/H>_?_P"H58%&:9#AK!@^
MK_)>V ?L[7-]WIN_]5^FF&/G@B"7#D[KAR#]#^C?024PP74G(8&[3#7!@_02
MT3^;]G=OVN5?_P!9KY_^CEH44Y3;PZR P3P\.DDD[MOH5?\ GQ9__K-?/_T<
MDI__U_2<C_E/$_J7?^BE3'4>H08((DN!=AY33L =+=GNWV_S>W^W^C5S(_Y3
MQ/ZEW_HI4W?5\$/$8@%GT_U1NI#GV,<[])_@]_L_E_I/STE+?M+J3J@X-]-[
M0=[78N0[=.XU&OTW?N?SK/\ !V?HT]G4>J"'LKFISG!L8]Q> '!C=U;GUN_.
MW_I/28I'H8W>H/LHMT=ZGV9L[R[=;;_.?3L;_P"33?L!GJ;B,4LV-9L&*S3:
MPUMVNWEVW^1_H_T?\M)2SNH]3!(+0TMAC@,;(>-\>ZQCF?SE'J-?MV_F>FG;
MU#J+@S2"'GU/U3(^A(=[-SF^[TV7>_>__ ^G_HTAT)T!MC\=S&AVQHQ6 -+A
M[G5^]WTG>]_[ZB/J[7#06XCH,NG$:) VQ]&QNUWM=_GI*4[J75/2EC07M!W?
MJN1!(]VYC7.8[9[F,V_SGJ>I_@_TBD>I9OJ$ $L:'3^IY&NX;Z2QV[_!M_GV
M;?ZBB.@/#7-8[$8U[0UP;B- ,'U&->/5VNJ:]K?T?_34G] 8XZ#%#6B*0<5I
M+-IFKW>I[MB2E-S^IEX9 <7-<6@8N0T2&V%NZRUS*F>^OZ#W?^?*U%O4.J;0
MY[=K6O%;S]DO))+=^ZNIMKW[/S=_\W_PBD>@ES(+\<N$;7'%9QN=:YCF[MKF
M.=8F'0&LW-J^RLJ=IL^RM^C(>UD[QNV;*]N[_1I*9MS>I%CG.+8+';8QKY#H
M<]KG5.=O<S]&]OI_GV>FF/4.H.U8W:TN=[G8M\[9?Z?Z.=^[]#9O_KT?Z5#_
M .;S@PM:_%T:]C-V'7 8\O/HNV.KW4_I7[F-V>I^D_?5QO1.E;6[L2@N: )%
M8 _LCW;6_P E)35/4>I0YP@-+R& X>23M,ENYK?=]';NLVL]_P#@U*W/ZB 6
MLVAX+A+L7)</:6U[AZ?\MMNW_25>DK3ND=,<2XXM6XAX+MH#OTF[UO>/=^DW
MOW)-Z/TIKMS<2H$ B0P<$%CO\YCMJ2D.%G9=^2T/]M1;JQV-?4X. &[]-=^A
MV;]VU5O_ %FOG_Z.6A1TKIN/:+J,:NNULP]K0")^EK_*6?\ ^LU\_P#T<DI_
M_]#TG(_Y3Q/ZEW_HI7%4RZ,EU]&1C;"^D/:66$@$/#=0]@=[FN9^XFW=7_T>
M/_GO_P#222FXDJ>[J_\ H\?_ #W_ /I)+=U?_1X_^>__ -))*;B2I[NK_P"C
MQ_\ /?\ ^DE4R.FY&38;+\;&>YW)-MHF([!FW\QJ2G726(>BO+7,.+CEKXW?
MIKM8W@?F_P#"O4STJXDDXN-)#VF+;0(L.ZQL!GYSDE.PDL5G1K*XVXN/I DW
MW$^T[V^YS?WV_P!M2'2KP\6#&QP\.W ^M=S._P#<_>24["2R\/"S,)KVXN/C
MUBP[G#U;3)C;/OK<K&[J_P#H\?\ SW_^DDE-Q)4]W5_]'C_Y[_\ TDENZO\
MZ/'_ ,]__I))3<6)_P"LU\__ $<K^[J_^CQ_^W'_ /I)#_9MO['^P^HWUMOT
MX.S?N]7Z,[O3WI*?_]G_[1324&AO=&]S:&]P(#,N,  X0DE-!"4      !
M                    .$))30/M       0 2P    !  $!+     $  3A"
M24T$)@      #@             _@   .$))300-       $    'CA"24T$
M&0      !    !XX0DE- _,       D           $ .$))300*       !
M   X0DE-)Q        H  0         ".$))30/T       2 #4    ! "T
M   &       !.$))30/W       <  #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      --    !@             #Z    P4    , '  <@!O
M '@ >0!? %  80!G &4 7P R     0                         !
M          ,%   #Z                      !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   #Z     !29VAT;&]N9P   P4    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   ^@
M    4F=H=&QO;F<   ,%     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     3_P        .$))3001       ! 0 X
M0DE-!!0       0    !.$))300,      ^1     0   'P   "@   !=
MZ(    ]U !@  ?_8_^  $$I&248  0(  $@ 2   _^T #$%D;V)E7T--  /_
M[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5
M$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.
M#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,
M# P,# P,# P,# P,# S_P  1" "@ 'P# 2(  A$! Q$!_]T !  (_\0!/P
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MO]+_  WYRT$DE.?]GZKSNQ/^VG]QM_TW[J7V?JH_.Q-(_P $_MHW_#+03$@
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MW-Q*@0")#!P06._SF.VI*0X6=EWY+0_VU%NK'8U]3@X ;OTUWZ'9OW;56_\
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M &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
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MN?\ G*GSM'8_FSIREO,+:Y;SW366@WLGI1K%97[DI432%RH0HE>6=?\ *_\
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M-*3S/<:]]4MN0_*[]&#4X;8LL'#XKMUL#)3U/\KEOD%_YSU\JWOFK\[/R/\
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M58417J&4.>)ZCEU&&DGESR]+HJ^6Y="T^3R\L20+H+VL360BC(*(+<KZ?%2
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MR,12F)>6;G_G+QO,.C+YRT?\H8?*C72#S!+HVH:])J"VN_,VJ7%FD32=*!V
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M/-]YJ]O>B\]1^8C6PMIHS%PX4)/*O+:E,Y^+K_G."HKH?Y'TJ*TU/S)6G?\
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M^9]/7\RM*_*RV\F%9OTK-Y:OM;FU,-Z3>CZ*7EK%"09./+DP^&M-\&_F)/\
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M-FS9_]#[^9L(O,_F31_)WEO7_-GF&[6PT+RSI]SJFL7K;B*VM(FFE>G>BJ:
M=<^57E[_ )R+_P"<\_\ G)JVU3SG_P XX_E[Y4\A_E5'?2VOEK6O-;!K_4%@
M<HS R.R,011^$7!6J@D=E;#KZK_S]K_ZN7Y8?\#;?]4<WU7_ )^U_P#5R_+#
M_@;;_JCF^J_\_:_^KE^6'_ VW_5'-]5_Y^U_]7+\L/\ @;;_ *HYOJO_ #]K
M_P"KE^6'_ VW_5'-]5_Y^U_]7+\L/^!MO^J.;ZK_ ,_:_P#JY?EA_P #;?\
M5'-]5_Y^U_\ 5R_+#_@;;_JCF^J_\_:_^KE^6'_ VW_5'-]5_P"?M?\ U<OR
MP_X&V_ZHYOJO_/VO_JY?EA_P-M_U1S?5?^?M?_5R_+#_ (&V_P"J.;ZK_P _
M:_\ JY?EA_P-M_U1S?5?^?M?_5R_+#_@;;_JCF^J_P#/VO\ ZN7Y8?\  VW_
M %1S?5?^?M?_ %<ORP_X&V_ZHYOJO_/VO_JY?EA_P-M_U1S?5?\ G[7_ -7+
M\L/^!MO^J.;ZK_S]K_ZN7Y8?\#;?]4<WU7_G[7_U<ORP_P"!MO\ JCF^J_\
M/VO_ *N7Y8?\#;?]4<WU7_G[7_U<ORP_X&V_ZHYOJO\ S]K_ .KE^6'_  -M
M_P!4<WU7_G[7_P!7+\L/^!MO^J.;ZK_S]K_ZN7Y8?\#;?]4<WU7_ )^U_P#5
MR_+#_@;;_JCF^J_\_:_^KE^6'_ VW_5'-]5_Y^U_]7+\L/\ @;;_ *HYOJO_
M #]K_P"KE^6'_ VW_5'-]5_Y^U_]7+\L/^!MO^J.;ZK_ ,_:_P#JY?EA_P #
M;?\ 5'-]5_Y^U_\ 5R_+#_@;;_JCF^J_\_:_^KE^6'_ VW_5'-]5_P"?M?\
MU<ORP_X&V_ZHYOJO_/VO_JY?EA_P-M_U1S?5?^?M?_5R_+#_ (&V_P"J.;ZK
M_P _:_\ JY?EA_P-M_U1S?5?^?M?_5R_+#_@;;_JCF^J_P#/VO\ ZN7Y8?\
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M8?\  VW_ %1S?5?^?M?_ %<ORP_X&V_ZHYOJO_/VO_JY?EA_P-M_U1S?5?\
MG[7_ -7+\L/^!MO^J.;ZK_S]K_ZN7Y8?\#;?]4<WU7_G[7_U<ORP_P"!MO\
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M_P"J.;ZK_P _:_\ JY?EA_P-M_U1S?5?^?M?_5R_+#_@;;_JCF^J_P#/VO\
MZN7Y8?\  VW_ %1S?5?^?M?_ %<ORP_X&V_ZHXY;7_G[4&0G4?RO8!@2I%O0
M@'<&D0-#[9T?_G'S_G++\T[W\Y;K_G&O_G)_R'8^1?S7ELWU#RCK6CEOT9K$
M$2/*P0-+,*M'&[(Z2%6X.C*CKQ/T/S9L_]'[^9L\X?\ .8(K_P XM?G[7?\
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MG\Y^6//T_P"7'F/\H9]6F\OW5MIMKJ,,@U>T2RF22"Y(2BQ*0M.Y]L(?-'Y
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M!Y=U?S5K?EF\U:VT^/1M.T/4'TJZ!NVCE6>66\C:.W4*JO\ :=XUW'0_)?\
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MT50!3.EYLV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9L^4__ #EM_P"M[?\
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M^7;LS><]:N);N_CMM$N].]*'EISO\+N)IBHXGTXP2V>Q?RS_ .<DOS:U-_\
MG&KSYYG\P>7M?\L_\Y+ZKJFG7/Y;:9IWH7?EF*SM;NZ2>WO!<227'U3ZKPO?
M639C\'"E##H_^<K?S5@N+[4+'S/_ (C\L>?ORN\^^=_R]U;4/+^GZ0+>7RU:
MBXL+NPMXM2O+N6TDJ587\4;N0&78L@':9^>?Y]ZYK/D7RMYC_-/R7Y-C\X?E
M!-^;]YJ]YH@%K+!-%###H<32W<998%YW-U..+_'1%1%&'_Y%?F9J'Y.?\^T?
M*GYGZ'H\6M:GY.\E7NH:;I;\OJ[2_7YT1YBG%O1B+^I)2AX*W0XIYI_,;\XE
M;\S_ ,F-;_,S2/-MQKOY'WWYC:7^86@:1#:R:0Z2>C/8R0K<RQO;W<3'ZK*:
M2@<B2Y ;#O\ )?RY+Y:_Y]U2*][;78UK\H=0UB VMA;Z>(8[S06=87^K@>NZ
M 4:=_CDZMOG ?(NE^2?(4O\ S[SO_P GIH-#_-CS_:Z-#^9?EK0)N*ZQY:FT
M0S:O?:Q90L48P2A72>1.7.OQ;;'WY"?F[^;?F";_ )Q[_+;R+J/E/\OM,_,.
MR_,?5O,;V/EVW6W@'E_S5Z(DL[*W>",331,R,6;B6D:9@[@*3_RQ_P Y6_\
M.0]_8:O^;'_*O[W7ORZBM?.<VJ>7/T?IMK:Z0/+L5^UBMMJ,>K2WUU,9;18K
MM);1:<RT:J$^,N_.S7?SSU'_ )QM_*7\P;S\_H3>_F-YP\A7DL7EG2H+"UM8
M->N[<"UCG2X>6>WAD>I$K?O>)23X302SS_\ \Y#_ )U>7+3_ )R+\TZ;YO\
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M;_G!K_F(N_\ J(&?5C-FS__0^_F;/.'_ #F!_P"LM_G[_P" /K'_ %#/A/\
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M@PV[O]9>X9%XP_N0 _[QOAPH\R_E-^87F+\RM*_.:SN-%\O>=/+'EVWTS0=
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M6[UHW@@@22&>99Y)A;%BM%6%4+.].11=OSN\K_I30_+\>CZ_-YGUS4[S1_\
M#2V-+JTO+"W@N[A;HM(L2(+>X299!(8W0C@S$J#(/./YE:+Y+UORIY:N],U?
M6=>\ZB^_P]IFDVGUEY3IT<<MQZCEDCB 24$-(RKVK6@,<M_SX\AWE[:6EF=2
MN+>;RVWFW4=6-HT5IINE127,,\M]),8S"\,MK)&\7$R!A3B:-Q5E_.SRM:6=
M_>:II'F'1_J&F)KWU2\TV1)YM&,\<$NHQ1J6)CM_55YT:DL2D%XQ45 '\Z_*
M3ZDFI+KDT/E2VT7S)J,DWZ/>:*_BT&\T^UFO;.YBD9GC62Y,42I$QN"W*,T5
M?4,9OSH\N0):VS:+KO\ B2]UA=#M_)C6D<>IFZ>QDU):K),D(0VD3RAS+0\2
M@_> IG6X9/6ABFX/%ZJ*_IR#BZ\A6C#L1WSSW^7GYU1:I?ZOHGFF*^BN?^5@
M^9/*&BZ^;+T=->>POKOZE8B:M6D^JP#X^/!G!3GZGP8<W?\ SD#Y"L=!U;S+
M=Q:U!HNGZ8=;T^[?3I@=4TQ;F.S:[T^/[<J"6:,4*JY5T=5*.C,=M^;WEV#4
MK?2[[2]:TZX#Z=%K<L]F#!I,^KR>EI\-_-&[HCSL5V0MP#(9?3#K7G/D7\_;
M:7RS>7OG*PUA[NVUOSAIUMJ]OIC):7LOEZ^U)A8VI4@O,ME9[$J$D9'5'9PR
MCMVC^==!U_6;C1='N&OYK71].UR:\B6MN+756G%I22OVY%MW?C39:$_:&1G7
MOS<\N>5KC5X?,>GZMHL>F:;JVJVEW<VZ"/48-#B,]\+,+(SLR1_&H=4YK\2<
M@"1'+K_G(?R'I_EZ^\R:K9Z_I-G9Z=IFL6]G=:7,MY>:=JUW'8VMS:VR\I''
MK2JKQT$J57E&.2<C[_E<7EA8+M+BPUFTU^UU2VT8>3I;,_I26]O;<W=JD42L
MT;+) CR>IZG!523FR&-PL<UG\\O+&GO8ZG-J%_I=EI4'F67S7Y;GTMGOHY/+
M]@E]<PR/ZJB%XXG61.(D6967@W$AB"\V_P#.0>F:%Y*\Y>9-+\JZS>ZYY8\O
M0^9K/RQJ$4=A->:;=,\<-XADD-(N2$2*?WJ?M1@E:]%T3\Q;#7?,U_Y4M-"U
MB+4=%BMCYDFFB@$&FW%Y;"\AM+ATG8F1H65JQ!XQ4*7Y;9$]5\P?F1JWYC^<
M_*7D_5= TJV\I^7-#U6SAU;3KB[%Y=:M-JD;)--!>0&*-18I0JC$<B:-LN;R
M5^>&B^<+OREH4.A:HOF?S%HIUC4[&VC2XM--2"[FT^[$]YS1"(KN!XQ0<WV8
M)]KC*_S%\X:AY5L?+]GH5C!J'FCSIK4/E_RQ!=LR6B7,L,]U)/<E/C]."WMI
M92J_$W$(""W(0;\Q_-?G;\LO)EOYAUG7K/7)7\W>6+%VTK19HY?J&I:O:65W
M;I;?6;QI9'25A&4HP)'4BN28?F_Y<-LZ_HS63YACUO\ PY)Y+6T#:J-2^IC4
M?2*+(80OU1A/ZOJ^EP_;KMA+>?\ .0'D>W9_JEGKFL16WEC_ !AJES96#%++
M2DEN8)9+GU6C*212VDB/#0R C9#1N*GF'\S1_P K(_+WR7Y=NQ-'>ZXMKYOF
M$2R0M;W?E_6-3M(8IJ[2<K&.5N/1&7L^0[\Y/S>U[R+YP&@Z;YB\M^7H8_)M
MYYATVWURW>>;5]4AO8;6VTRWX7=NW*<RA (U=RS+Q4_9/H_2[JYOM,TZ]O+&
M32[N\M89[K3)65WMY)$#/"S+524)*DC;;/+5A^=OF:?S[>Z"FL>7-4EC_,:;
MR='^75M;N-;&E11Q-)JHE%XQ MU<S2EH GI@@$,5K*_)/YR30_E=Y=\Z>>;.
M_NHKB&]N?,GF:QM(UL+"W@OY[837'[Q2%1$!81J[ 5<BE3DKA_.GRE-KNH:*
M;/6((=+\SIY.O_,$MF5TZ/6IEB:WM?6Y%CZQG15<(4YL$9E8@&&_F=^=C:1Y
M \U^:?*5CJ:6?EVZLD3S=)8";3[E4UFTL;Z*T3DTT[%)) A6+BY!,;,0,Z-I
M_P"9NFZI#KL=EY?UV77O+ES;6VK>4C;1IJ,1O8A-;2$-,(?3D0U#F7B"&5BK
M*R@FMOSP\F7NI:!I=E#JES<:[IVHZK-*+4)#IUKHUX+#4WU":5T2$VMP2CBI
M)(/#E3"+RU^;LGG#\V/+OEK2K+4]-\MZKY$U+S.D>JZ>UJ]V!?Z9#8W4$C5/
M Q7$O*-J.M5]1%^&LI_.SS9YJ\D_EOK&O^2+:PO/-BWNCZ?H5MJBR/://J>J
M6E@!*(I(VI2X-"&%#0[C;(%^9'YX7VC^0?(_F;R19VMUJWG&ZTRXEL]25W2S
MTMKZSMM4:58WC82PM=);@5^&9UY @$9UOR=Y]TOSQ/YC31M.U.*T\LZM?:'=
MZK>6X@MY[[3;N:SNX[8LY>01R0GX^/$U%&)Y!89K>O\ YB:E^9GF'R9Y/U;0
MM'MO+WE/2-<A_2VFW%[]:N]3O-4MS'))#>6QCC5;%*%5)JQ.^PQ^F_G+9MY!
MTSSSK7ES4K:U2WOW\X/IZQWEKI$FCSR6FIM+-SC,D<,L,A'!3(R*6]/8@*^8
M_P X_*NG^7-9O[?4+FTN[;4-7T*&06?UJ2"^TRPN-1DG-OZD?J1+;0&X4\P'
M0I0@N,@/YI_GQ'Y9_+KS%?>66U#4?,FCZ+I5W<>8(=+:6PLKK5A&UH+M.3\#
M*K\RHYB)64R,JLI:??G!YYU'R5_RKR"RU[1O*UOYO\SG1M5\QZY%ZMM:6ZZ5
MJ-^& -Q:J'>6T1 6>E&.U:8<_E-YPU/SUY*M/,.JQVKRS7M_;6>K6$;Q6.J6
M=K=RPVNI6:222LL-W"BRI5VV;9F6C$OU3S3YIUWSYJOD'R7<Z;HX\KZ79:EY
MI\QZE;27I634WN%L[2UM8YK8%N-J\DCN]%!155BQ*&FK^?K?RM/IOE[4K6_\
MU^;#I9U/5++R[I[N4M82(Y;PPO*WIHTE1''ZCR.05C$A5LXO#^<FNZO^8^FZ
M?H&K6M[Y+UGS=Y<LM*F6W%9M*U;RIJ.L,0[@."\\$;@D @57N<GUY_SD%Y"L
M-&O/,%U!K<>DQV\-]I%U^C9B=5LYK^#3!<Z?&!SE07%U$""JL5='561T9I;J
M'YC6.CMHK:YY?UO1;+6)+"WEU2Z@A^K65UJ<RVUI;W+QSN0[S.D9,8=59EYL
MM:X4>7_SF\J^8]3T_3[:QUBQ@U?6M5\NZ-K5]9&"RN]5T62ZCO+2*0L6Y 64
MS(S*$<*>#%@5$E\Y>>=/\CV<FJ:MI>IW&C65M+>ZUK-G LEOI]I;T,T]P6D1
MN*+5BL:N_$$A: Y&6_.CRFFO:MHK6>L+;Z#Y@L?*^L>8S9G]&0:IJ<5I+90F
M?E5A-]=A0.BE59@'*5%8KK/YSQWGG;\KO+GEB#4%TSS/YRU/0M0UV>P8Z??Q
M:5I>JR7<5K<FO%H[NT0!B%$@5_3+J&(&^=OS/UWRG^<7Y>^41:V3^2/,&E7<
M_F>_=)#>6UU+>V>GZ:\;AP@B:XN5BD#(361&! 4@Q[S-^?A\I_F5YIL-5MHO
M^59>3/*&IZIK.J6L$ESJ,FK:;<Z4)XH%CD(:..#58P5X<S)4 _#0^B-)U!]5
MTZUU!].N]):Z4O\ HZ_5$N8Q4@>HD;R!20*TY5 .]#49PK\N?SCU#6-2_-ZU
M\])I^DV?D;6=:G\O7]JLB+-Y?TF[GL99)Q([\IH);1S*5HO%X_A%=X[^7GYY
MZKJW*Z_,:XL_*KVEQYUFN]&MK&5T33?+\]@T3W%R9W,<UM#>*LJJC"5RQ7@$
M 8Z\P?G)K%CYZ_*_3;;RGYBM=+\WIK\4OE^?3HAJ-]+96UG<VTL0,U((U623
MF9VCH1Q8!N(,\N?S<\LQ^4=/\]V=EJVK>4[NQGU.^UBTM?@T^TM#2ZDNTE>.
M1&A(;G&JM(.+T0\3BX_-7RM-YA/ERW^NREKY='3S"MLWZ+.J26HO8[(7)(#2
M-"000"G(B/GZGP9SR'\T?,]G_P XV>4/S3E^IW_FK5-"\MWM^TT16VDGU6:S
MBN&]*)DXBD[%0#0&G;/1V<]M/->HS_FMYA\CO%;C2=*\IZ-KMO.%;US<ZA?:
MG;2JS<N)0)9(5 6M2U2=J1[4/SR\E:8NL7%U#JRZ9I U/AK0L7%I>-HC%=46
MT=B#(;4*[-L RQR-$9!&U'Z]^:6F6GG33?*NFW%W=W]M=30:AI5M8I.+^<Z-
M<ZK%9PW4D\*0R+#$LI)!!Y(AX\^0C&C?G]ZWY6^3/S,UW\O/,5E;>:]-L;M[
M.Q%C=&.?4&BCM[>%3>1RS-/)*JQ!$+M7=5.V>A@:@$BE>Q[9R/S!^='E?RG!
MYEN/,VFZUHB>6]%U#S#QN+0&2^TW2GCCO)K...1W?TFFC^!PCD.I52#7%G_.
M/RO;1:RNI6&LZ3JVC/I:'RW=V174+K]-SO;:8;:)&<.+F6)T'Q H5;U1'Q:@
M3\J?/VH>>]5_-D7<%S96?E/S:FB:5IE[:_5+JUC71M,NIHIEWYGZQ<2LK@E6
M4KQ9EH<,]$_-KRQY@GGATRTU:57L;W4M G>QD1-9MM/E6"YDT[EO+QD=0 0I
M<,KIRC8/C%_-SRV+>_6>PU:WU[3M6M]$F\GFV675&OKNW%W;QI'!))&PDMZS
M<Q)P5%8NR\&IS>U_/<Z5Y[_,BP\V:5K&G^6?+&F>7=3D)T]&_0=OJ<=PL\NI
M30R.I'J1@D1M(44%Z>F"V=R\U>;=+\H6EA<:A%=7ESJ]['INB:380F>ZO;R5
M'D6&% 0*\(W=F=E155F9E4$YQ3S/^<6H:EYA_*[RYY-T_6+0^9O-EYHOG&8V
MEI];TUM*T^:_FLI8;R50K2 1N9%#@P%FB9F9#GI/-GRG_P"<MO\ UO;_ )P:
M_P"8B[_ZB!GU8S9L_]/[^9L\X?\ .8'_ *RW^?O_ ( ^L?\ 4,^$_P#SA#_Z
MR7^0G_@)VOZWSU/D&_,?R:WG[RC>^5UU$:4;N\TVZ^NF+UN/Z/O[>]X\.25Y
M^AQK7:M=Z4R!WWY)Z;<?F+JGG86_E[4K3S#J.G:KK%CK.CB]O(;S38(H$EL;
ML7$8CY+;0$"2-^#H77=J O'Y"P\O.\G^)#%<:UK>G:SY(N$LT/Z#_1FI/K<,
M/!G(N$.HSSR./@K&RQBA0/A9YO\ ^<=XOS)FEOOS"UZWU>\U+6=#OM7M;&SD
ML[46/E^*^^I6MK2Y>>*5;B_DN!.92RO3B%XK1NL?D+YB\R6VH+YC_,3]+ZG=
M>7+3RTNM2:<J3RP6&LC5+>XN5CF5&F:-1%(45%9JR*J ^F#+S[^6S0^9-9_,
MVWUBYCU=;[RY?>7X+;2)]5%I<Z/'J-G(T]M:OZT\4\&IRHXC"L@^,$TPQ_(_
MRUYITWR_Y^OO-D]Q#JGGGSAJ^N6T[6JV%PEK.D-K;N+4O/Z%5M^<:2,SJA3U
M?WG+.;P?\XKR"UD6X\W62WY\N6?ER74[72/3GO\ ZIJUGJC:EJ4[W4DMQ=3F
MTXN2_$%BR@;@];F\C7?EK\L/S0T&TF?7KWS'+YOUBS@AA*.TFNSWEZEJJAG+
M,AN!&"/M$5H*TSENE_D5YI\U_E]Y5L_.?F]5UC3?(VF^6](4:4+>2S1I],OK
MY[Q/7;U)W;3H8CP]-%XDA*M0=&\Q?D[-K/G35_/=EYC73M;>Z\O:AY;#VGKP
MVEUH<6I6[^NGJH9H[F#4Y8V53&RC=7Y4HS1OR>O+/S[IOYCZMYDBU#S#]>U.
M_P!?CM[+ZO;S->Z=9Z;;PVZF:1HX[>&S7=V=G9F)*BBA#\R?+WG/5/S8_)S6
M/*4RZ>F@V'FG]*:I=6+7M@!=16"16]R$E@=/5*ED*R*>4?=>0)?I7_./.E6E
MIYCTO4]?GU73?-ODJ?RIY@I D$\MQ?ZAJ6I7]^C!F1#+-J3E8^!"4&[8/U7\
MI_.'F.3Z[YA_,""35X-"F\KZ?J6G:6+4Q:;J5Q:R:O.5DN)_]+NHK1(T=2(X
M3\2QL=LC$W_.-%C<:0/*DGF%4\GZ1Y=UWROY,TD6GJ/INFZE>Z5?Z?"SR3,L
MR:=)IHCC5EH\7!'W0LY]<_DK+/Y/UKR[%8^0[*_\Q7:OJU_;>6YHH6CAA:.W
MG2-=1]5;F!V,D<GJ_!]E0I^/.D>1+?S?86^J:/YG;ZS8:!+9Z7Y5UFXD$NH:
MI:6UA;+-J%\Z.R^K/=&;8*IX@$BIR%+^39^H:18OKX==,_,C4?/[M]6IZJ:A
M=WUR;&GJ[<1>\?4[\:\17:#67_.,UG8>3=4\EVUWY>M(SI=MHV@^:+70O0U=
M+.WO(+GT[R<7166J6L2-P2/FR^HPK11-M6_)/3+_ /,34O._U;R]J=KYBNM+
MO-?T[7-'^OW"7&EQK"DME<BXB$9>.&$<9(W",GJ+N2,+-&_)S4?+_P"AH]<\
MX?XA\H>3O-.N>=],TF/22M\;O4YK^X2W>2&60RQ6QOY"BI%ZDC! 2:%6%_\
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MZC+^3KR6>MVO^( /TQ^96G?F"'^K?W8L+NQNOJ5/5WY_4N/J;4Y5XFFY;/\
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M2MK:V_Q9):I)YSUG7]?$5KMJ&AZ[J/Z2O=#D!E^%))(H T@W(0_".1HG=_\
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M-5VWF-_,^FVNEQ1:U<P>5X;=_4DDTJ%8TAGN"'=?4F<2. *<4* J&#9YK?\
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M'"/)GEE([9%MWBL)-.)>\6+ZS(CQ2%G0R49P"U0..1RQ_P"<>?+L&@CRW?\
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MT8U,AM@T@>(L@=#&:CB[2JQ\SG\JO^<<]-\T:HUL=0TSRY;3PB2YFDAN-2U
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M_)7\OS1KO3;C4Y9K76K35;B^NIYY-07S!';1:B]X[/61I([2)%.W!5"IQ4
M%#^1?D6.YU^^NI-<U/4_,MCIFG:CJ][K%]+=K#HMS)=Z<;><3*\#V\LI97C*
ML3\3%F))E5C^7VC6>I^6];N+W5-8UGRK%J<.EZIJ5Y)<2\-6:$W(DK16'[A
M@  4#8;G-Y?_ "]T'0-5UC75GU#6]9URUBTZ]U/6+I[V46%O)-+#9IZFRQ(]
MQ(:4JW+XBU!2.6_Y,>0;2WETQTO[JSET6]\O:)IUYJ-Q.FF:7?1K%<VVG)(Y
M]%2BJO(595"HK! %R7W7DC0+RR\HZ;<P2RV/DFZM;W1+4RMP]:R@>WMS,*_O
M!&'Y -MS"MU484^8?RM\G>9M;L/,.HV,T>IZ?'91(]K/) DB:;J=OK%H)HT(
M5_1NK966HV#2+T=@0^I_E7Y)U#6;S7K^"8:CJNK-JL\GUJ1%>]DT1_+Q*KR
MWL9&4*/VOC^UA*GY"_EW!;26ME97NG0R6NC1.MK>31?Z5Y?,7Z,U+9J?7(!
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MIDVD#4K62VAF]5;.XEEDC,<CO$V_%BO)=C0=,S9\I_\ G+;_ -;V_P"<&O\
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M"HZ/+ K+"64U53Q.Q.YO:?EUY/M-*U;0_P!%/?:1KB)'JFGZC=W6H12)'7@
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MCS2A-<4\S_E_Y,\YRPS>:/+MIK4D-K/8UN%)$EG=<?7M9@I E@DXJ6BDY(2
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M)9([Z[N+.6R0W4DSO(Z1)*61.7$,$V^!<Z-FSY3_ /.6W_K>W_.#7_,1=_\
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MX@#EL*4R:QZ/I$1MC%I=G&;.YFO;,K!&/2N;GU/6FCHOPO)ZK\F&[<FJ?B.
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MUN#Z_JX CE,T\.@PQ3APA*&YD<?$N1W\R=6\W2W=O%^4UW-Y[T71_/7E:?\
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M&&%%MVYB1:UB<+54IM1\_"#\T?,>IZUKME=6GG3RQHGF*"RNKB2WT'0KG2-
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M,WEJUL;R]MOJESY7T]K-H;*V21YK)-2>YY1QQO&LS*W$",E3_P#)VV\PW/\
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M-8DU'RG-;^0_)%EY)U%_+VK:G+I&HVBL=1C!M+J&*SN#,%$QN(PKPT5W9$=
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MWQ#3/S(\C:QK'G#0K#S/I\VJ>094B\VVYF1?J9>%)ZR%B!Q5)%Y-T5JJ2&!
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M'U6>$UA?;D : 4RO)GYH?E!)!^7?D[R?YFTQ8?,7EM+[R)HT4PY-I5BEO"B
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M9UD_GO>>7KF!&\H^588OS'YJX?T_,/F"S?2#;2)4T*FVO;NO=IP<=^</E?\
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MA(XT "JH%  !L !C\V;"ZQTC2=+EU";3=,M=/FU6X:[U26VA2)KFX8 &68H
M7<@ <FJ<,<"7]A8ZI97>FZG9PZAIU_$\%]8W,:RPS12#B\<D;@JRL#0@BAQ6
MWMX+2""UM8([:UMHUBMK:)0D<<: *J(J@   4 '3%LV;-FS9LV?*?_G+;_UO
M;_G!K_F(N_\ J(&?5C-FS__2^_F;/.'_ #F!_P"LM_G[_P" /K'_ %#/A/\
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M^<MO_6]O^<&O^8B[_P"H@9]6,V;/_]7[^9L\X?\ .8'_ *RW^?O_ ( ^L?\
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MDT337GBT]= 6\.DZ@9'C:WC697<SQ-+(30*6C:N=BT?_ )S8_+[7=$36]/\
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MB;HWYD77_.0EU=><]0TH_P#.0.C^6=(U-(+:&0:8GEIR\<D',_O#-6C!^G;
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M=HA]9]0R.BK12*>[=1O!I^GWU^8Q*+&WEN#$72(-Z2%Z>I(51:TZL0!W-,\
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MYD?F-9>8-0O?)^IZS#IUGH]MY8OCIFH27.HK!<&0-=@1P>G >=:MP .-O_\
MG-[RAI_YJO\ E[+H]C^CK'SE;>0-7U#].VHUB/6;AHX6G@T3T_6EL(;B00R7
M'J*P(+"(HI;/<.;/E/\ \Y;?^M[?\X-?\Q%W_P!1 SZL9LV?_]#[^9L\X?\
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MT;2O,&MW%F));/7FA:=)XK.TMHF,8MT$955(WY<B:X&@_P"<9?RR@_(W1_\
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M\CASH_\ SCK^6^D?E3YX_)D0:AJ/DC\PKK7KOS';WEURN&?S%/+<7@BF14*
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MI(P!9:YWG-GRG_YRV_\ 6]O^<&O^8B[_ .H@9]6,V;/_T?OYFSSA_P Y@?\
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M<,IZ9PC_ )R5_P"<B_-7Y0WVL1>2QY:UZ;R;Y3E\W^:?*UW9:YJ&IR6D4DH
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M7_G$'_G'JS\Z#S[#Y"*^8(/,@\WZ<OZ3U(6-EK?J":2^M+ 70M89)7 :3C&
M]!R! IGI;-GRG_YRV_\ 6]O^<&O^8B[_ .H@9]6,V;/_T_OYFSSA_P Y@?\
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M6@BXL?JRVRL8V6( 2FLC_'GHGS3_ ,Y)_G9^53?\Y'^5=?O=%\\Z_P#EM'Y
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MVG^4=#U+6)O*UEY4\X^:VTNWAN=>M+6W6WD%ZH#<EGH6D0DAB?BY=<FGF?\
M)S\J/.FAZ%Y:\U_ESY=\P:!Y7CCA\MZ1>Z=;RP6$4:+&L5LA2D2<$5"BT4J.
M)!&V<R\\_P#.+OY>?F%^8_DCSCYDTW3=0\I^2O*.I^48/RSN-,MY-,E@U":V
MECE6I A-N+<*BHG0[$9T3S-^2/Y/^<](T#0?-7Y9^6M=T7RK"+;RSIEWIMN\
M-A;A57T+9>'[N,JB@HM%( !!&21O('D9O\3<O)^C-_C2SAT[S?6Q@_W*6EO
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M4!2J4!&Q!&V2:V\C^3++4-!U6S\J:1::EY5L)-*\LW\%E!'+IUC-P$EK:.J
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M;_G!K_F(N_\ J(&?5C-FS__7^_F;/.'_ #F!_P"LM_G[_P" /K'_ %#/A/\
M\X0_^LE_D)_X"=K^M\]3YLV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-
MFS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9L
MV;-GRG_YRV_];V_YP:_YB+O_ *B!GU8S9L__T/OYFSSA_P Y@?\ K+?Y^_\
M@#ZQ_P!0SX3_ /.$/_K)?Y"?^ G:_K?/4^;-FS9LV;-FS9LV;-FS9LV;-FS9
MLV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9LV;-
MFS9LV;-FS9LV;-FS9\I_^<MO_6]O^<&O^8B[_P"H@9]6,V;/_]'[^9L\X?\
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M^<MO_6]O^<&O^8B[_P"H@9]6,V;/_]3[^9L\X?\ .8'_ *RW^?O_ ( ^L?\
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MM5]1T5).<1Y?NV:G0T.V33-FS9LV;-FS9LV;-FS9LV;-FS9LV;-FS9L^4_\
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MEW7]6TOS+9>8]3\NV$]_:B!(+* :/:W-QJ&H?%ZD%LQ6,KS)60T \JW'F/\
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M_)^8?GV^O]9_YRGUOR'?^6[^]NI](3RE-=WL1@-A*I3TU]%6CF;^[V",%H,
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M$'*X)\ X+2/^[%!\.U-O#;'8T*J@A5"@DD@"FYZG,JJBA44(HZ*!0#Z,RHB
MA%" DD@"FYZG.":I_P X[>4/,/G_ $OS[YI\R>;?-:^7]<_Q+Y;\DZMK$D_E
M_3M65"D5W;V/!36$,3$KNR(2650=\[[C>"\N?$<Z<>=-Z>%<RHJ5"*%!)) %
M*D]3F*JQ4LH8J:J2*T/B,=FQK(K<>2AN)JM16A\1CL;P7D7XCF10O3>GA7,R
M*].2AN)Y+45H1W&8HK%690S(:H2*D?+,R*].2AN)#+45H1T(RV4,"K ,K"A4
M[@C,  .( "@4"]J92JJ*%10JKL% H!]&.S9LV;-FS9LV;-FS9LV;-FS9LV;-
MFS9LV?*?_G+;_P!;V_YP:_YB+O\ ZB!GU8S9L__0^_F;.-_\Y$>3M8_,'\B?
MS=\D^7HUFU[S/Y3U73]'@8T$MS+;.(HZ[4YM103XYX,_YPO_ .<SOR+\J?D7
MY3_*W\TO-MO^5GGS\K('\O:YH?F)9;5I#;2NJR1LR4Y4/&2,T='# KQHQ]9?
M]#M_\XF_^7[\I_\ 26?^:<W_ $.W_P XF_\ E^_*?_26?^:<W_0[?_.)O_E^
M_*?_ $EG_FG-_P!#M_\ .)O_ )?ORG_TEG_FG-_T.W_SB;_Y?ORG_P!)9_YI
MS?\ 0[?_ #B;_P"7[\I_])9_YIS?]#M_\XF_^7[\I_\ 26?^:<W_ $.W_P X
MF_\ E^_*?_26?^:<W_0[?_.)O_E^_*?_ $EG_FG-_P!#M_\ .)O_ )?ORG_T
MEG_FG-_T.W_SB;_Y?ORG_P!)9_YIS?\ 0[?_ #B;_P"7[\I_])9_YIS?]#M_
M\XF_^7[\I_\ 26?^:<W_ $.W_P XF_\ E^_*?_26?^:<W_0[?_.)O_E^_*?_
M $EG_FG-_P!#M_\ .)O_ )?ORG_TEG_FG-_T.W_SB;_Y?ORG_P!)9_YIS?\
M0[?_ #B;_P"7[\I_])9_YIS?]#M_\XF_^7[\I_\ 26?^:<W_ $.W_P XF_\
ME^_*?_26?^:<W_0[?_.)O_E^_*?_ $EG_FG-_P!#M_\ .)O_ )?ORG_TEG_F
MG-_T.W_SB;_Y?ORG_P!)9_YIS?\ 0[?_ #B;_P"7[\I_])9_YIS?]#M_\XF_
M^7[\I_\ 26?^:<W_ $.W_P XF_\ E^_*?_26?^:<W_0[?_.)O_E^_*?_ $EG
M_FG-_P!#M_\ .)O_ )?ORG_TEG_FG-_T.W_SB;_Y?ORG_P!)9_YIS?\ 0[?_
M #B;_P"7[\I_])9_YIS?]#M_\XF_^7[\I_\ 26?^:<W_ $.W_P XF_\ E^_*
M?_26?^:<W_0[?_.)O_E^_*?_ $EG_FG-_P!#M_\ .)O_ )?ORG_TEG_FG-_T
M.W_SB;_Y?ORG_P!)9_YIS?\ 0[?_ #B;_P"7[\I_])9_YIS?]#M_\XF_^7[\
MI_\ 26?^:<W_ $.W_P XF_\ E^_*?_26?^:<W_0[?_.)O_E^_*?_ $EG_FG-
M_P!#M_\ .)O_ )?ORG_TEG_FG-_T.W_SB;_Y?ORG_P!)9_YIS?\ 0[?_ #B;
M_P"7[\I_])9_YIS?]#M_\XF_^7[\I_\ 26?^:<W_ $.W_P XF_\ E^_*?_26
M?^:<W_0[?_.)O_E^_*?_ $EG_FG-_P!#M_\ .)O_ )?ORG_TEG_FG-_T.W_S
MB;_Y?ORG_P!)9_YIS?\ 0[?_ #B;_P"7[\I_])9_YIS?]#M_\XF_^7[\I_\
M26?^:<W_ $.W_P XF_\ E^_*?_26?^:<W_0[?_.)O_E^_*?_ $EG_FG-_P!#
MM_\ .)O_ )?ORG_TEG_FG-_T.W_SB;_Y?ORG_P!)9_YIS?\ 0[?_ #B;_P"7
M[\I_])9_YIS?]#M_\XF_^7[\I_\ 26?^:<W_ $.W_P XF_\ E^_*?_26?^:<
MW_0[?_.)O_E^_*?_ $EG_FG-_P!#M_\ .)O_ )?ORG_TEG_FG-_T.W_SB;_Y
M?ORG_P!)9_YIS?\ 0[?_ #B;_P"7[\I_])9_YIS?]#M_\XF_^7[\I_\ 26?^
M:<W_ $.W_P XF_\ E^_*?_26?^:<W_0[?_.)O_E^_*?_ $EG_FG-_P!#M_\
M.)O_ )?ORG_TEG_FG-_T.W_SB;_Y?ORG_P!)9_YIS?\ 0[?_ #B;_P"7[\I_
M])9_YIS?]#M_\XF_^7[\I_\ 26?^:<W_ $.W_P XF_\ E^_*?_26?^:<W_0[
M?_.)O_E^_*?_ $EG_FG-_P!#M_\ .)O_ )?ORG_TEG_FG-_T.W_SB;_Y?ORG
M_P!)9_YIS?\ 0[?_ #B;_P"7[\I_])9_YIS?]#M_\XF_^7[\I_\ 26?^:<W_
M $.W_P XF_\ E^_*?_26?^:<W_0[?_.)O_E^_*?_ $EG_FG-_P!#M_\ .)O_
M )?ORG_TEG_FG-_T.W_SB;_Y?ORG_P!)9_YIS?\ 0[?_ #B;_P"7[\I_])9_
MYIS?]#M_\XF_^7[\I_\ 26?^:<W_ $.W_P XF_\ E^_*?_26?^:<W_0[?_.)
MO_E^_*?_ $EG_FG-_P!#M_\ .)O_ )?ORG_TEG_FG-_T.W_SB;_Y?ORG_P!)
M9_YIS?\ 0[?_ #B;_P"7[\I_])9_YIS?]#M_\XF_^7[\I_\ 26?^:<W_ $.W
M_P XF_\ E^_*?_26?^:<W_0[?_.)O_E^_*?_ $EG_FG-_P!#M_\ .)O_ )?O
MRG_TEG_FG-_T.W_SB:?_ "O?E+_I+/\ S3GAJ7S[H'_.8'_.?GY-ZS^4T5SK
MWY=_\X]Z?=WOFCSTL4D5G+<2B1XEB+JIXM-Z:)R ,E)&4<%Y'[%9LV?_T?OY
MFS9QKSC_ ,X[_D3^86LR>8?._P"47E/S/KLR\9]8U#2K:6YE Z>I*4Y/2FQ8
MG(K_ -"??\XM?^6"\C_]P>V_YHS?]"??\XM?^6"\C_\ <'MO^:,W_0GW_.+7
M_E@O(_\ W![;_FC-_P!"??\ .+7_ )8+R/\ ]P>V_P":,W_0GW_.+7_E@O(_
M_<'MO^:,W_0GW_.+7_E@O(__ '![;_FC-_T)]_SBU_Y8+R/_ -P>V_YHS?\
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M)]_SBU_Y8+R/_P!P>V_YHS?]"??\XM?^6"\C_P#<'MO^:,W_ $)]_P XM?\
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MM?\ E@O(_P#W![;_ )HS?]"??\XM?^6"\C_]P>V_YHS?]"??\XM?^6"\C_\
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M^6"\C_\ <'MO^:,W_0GW_.+7_E@O(_\ W![;_FC-_P!"??\ .+7_ )8+R/\
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7-FS9LV;-FS9LV;-FS9LV;-FS9LV?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
